var images_info;if (!images_info) images_info =[]; images_info["59"]={"59000":{"type":"graphic_picture","displayName":"Xanthogranulomatous PN Light","title":"Xanthogranulomatous PN light","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xanthogranulomatous PN light</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/NEPH/59000_Xanthogranulomatous_PN_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in xanthogranulomatous pyelonephritis showing an interstitial infiltrate composed of neutrophils, mononuclear cells, and, most characteristically, lipid-laden macrophages (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 59000 Version 1.0</div></div></div>"},"59002":{"type":"graphic_picture","displayName":"PDR traction retinal detachment 2","title":"Severe traction retinal detachment in proliferative diabetic retinopathy: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe traction retinal detachment in proliferative diabetic retinopathy: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:396px; height:295px;\" src=\"images/ENDO/59002_PDR_traction_retin_detach-2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph of extremely severe traction retinal detachment in proliferative diabetic retinopathy, with elevation and distortion of the macula due to overgrowth and contraction of neovascular proliferations.</div><div id=\"graphicVersion\">Graphic 59002 Version 3.0</div></div></div>"},"59006":{"type":"graphic_diagnosticimage","displayName":"ACC prev resect pulm mets","title":"Pulmonary metastases from previously resected adenoid cystic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary metastases from previously resected adenoid cystic carcinoma</div><div class=\"cntnt\"><img style=\"width:396px; height:320px;\" src=\"images/ONC/59006_ACC_prev_resect_pulm_mets.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of James R Jett, MD.</div><div id=\"graphicVersion\">Graphic 59006 Version 2.0</div></div></div>"},"59008":{"type":"graphic_table","displayName":"Inherited causes RTA","title":"Inherited primary causes of renal tubular acidosis (RTA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inherited primary causes of renal tubular acidosis (RTA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\"><span style=\"color: #ff0000;\"></span>&nbsp;</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Gene location</td> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">Features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Type 1 (distal) RTA</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive with deafness</td> <td><em>ATP6V1B1</em></td> <td>2p13</td> <td>B1 subunit of H-ATPase</td> <td>Presents in infancy with severe metabolic acidosis, poor growth, rickets, and nephrocalcinosis</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive without deafness</td> <td><em>ATP6V0A4</em></td> <td>7q33-q34</td> <td>a4 subunit of H-ATPase</td> <td>Presents in infancy with severe metabolic acidosis, poor growth, rickets, and nephrocalcinosis</td> </tr> <tr> <td class=\"indent1\">Autosomal dominant</td> <td><em>SLC4A1</em></td> <td>17q21-q22</td> <td>Chloride-bicarbonate exchanger</td> <td>Presents later in life (eg, adolescence and adulthood) with mild/moderate metabolic acidosis, hypercalciuria, nephrolithiasis or nephrocalcinosis, osteomalacia, and erythrocytosis; may be associated with hereditary spherocytosis and&nbsp;ovalocytosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Type 2 (proximal) RTA</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive</td> <td><em>SLC4A4</em></td> <td>4q21</td> <td>Sodium bicarbonate cotransporter</td> <td>Severe hypokalemic, hyperchloremic, metabolic acidosis, growth retardation, and ocular abnormalities (glaucoma, cataracts, and band keratopathy)</td> </tr> <tr> <td class=\"indent1\">Autosomal dominant</td> <td>Unknown</td> <td>Unknown</td> <td>Unknown</td> <td>Short stature and metabolic acidosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Type 3 (mixed) RTA</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive</td> <td>Carbonic anhydrase II</td> <td>8q22</td> <td>Carbonic anhydrase II</td> <td>Mixed RTA, osteopetrosis, cerebral calcification, and mental retardation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59008 Version 4.0</div></div></div>"},"59009":{"type":"graphic_table","displayName":"Noninvasive methods hibernation","title":"Approaches to identifying viability in hibernating myocardium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approaches to identifying viability in hibernating myocardium</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\" colspan=\"1\">A. Assessment\nof regional myocardial function using radionuclide methods,\nechocardiography, or magnetic resonance imaging during or after:</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>1. Nitroglycerin </td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td> 2. Postextrasystolic potentiation </td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td> 3. Catecholamine (dobutamine) infusion </td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td> 4. Exercise </td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td> 5. Synchronized diastolic coronary venous retroperfusion </td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\" colspan=\"1\">B. Assessment\nof perfusion, membrane integrity, and metabolism</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\"> 1. Thallium-210 scintigraphy</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"> a. Rest: early redistribution-late distribution</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"> b. Exercise: redistribution-reinjection</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td> 2. Technetium-99m sestamibi</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\"> 3. Positron emission tomography</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"> a. Flow: rubidium-8, N-ammonia</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"> b. Metabolism: fluorine-18-fluorodeoxyglucose,\ncarbon-11-acetate</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td> 4. Magnetic resonance spectroscopy</td>\n\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Castro, PF, Bourge, RC, Foster, RE. Am J Med 1998; 104:69.</div><div id=\"graphicVersion\">Graphic 59009 Version 1.0</div></div></div>"},"59010":{"type":"graphic_diagnosticimage","displayName":"Triquetrum fracture difficult identification","title":"Difficulty identifying Triquetrum fracture on plain radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Difficulty identifying Triquetrum fracture on plain&nbsp;radiograph</div><div class=\"cntnt\"><img style=\"width:288px; height:384px;\" src=\"images/EM/59010_Triquetral_fracture_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The difficulty of identifying a fracture of the triquetrum using standard anterior-posterior radiographs of the wrist is apparent in this image, in which the superimposed shadow of the pisiform obscures the fracture. Note the small density (arrow) near the ulnar styloid which could represent a fracture fragment or a possible concomitant lunate fracture.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 59010 Version 6.0</div></div></div>"},"59011":{"type":"graphic_figure","displayName":"Salter I fracture reduction","title":"Salter I fracture reduction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Salter I fracture reduction</div><div class=\"cntnt\"><img style=\"width:346px; height:418px;\" src=\"images/EM/59011_SalterIfxreduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acceptable method of closed reduction of distal physeal fractures of the radius. Panel A) Position of the fracture fragments as finger trap traction with countertraction is applied (arrows). Panel B) Often with traction alone the fracture will reduce without external pressure (arrows). Panel C) If the reduction is incomplete, simply applying direct pressure over the fracture site in a distal and volar direction with the thumb often completes the reduction while maintaing traction. This technique theoretically decreases the shear forces across the physis during the reduction process.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59011 Version 13.0</div></div></div>"},"59012":{"type":"graphic_table","displayName":"Entecavir versus lamivudine I","title":"Selected virologic, biochemical, and serologic endpoints at week 48, nucleoside-naive patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected virologic, biochemical, and serologic endpoints at week 48, nucleoside-naive patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"34%\"></colgroup><colgroup span=\"4\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">(HBeAg-positive)</td> <td class=\"subtitle1\" colspan=\"2\">(HBeAg-negative)</td> </tr> <tr> <td class=\"subtitle2\">Entecavir 0.5 mg<br /> (n = 354)</td> <td class=\"subtitle2\">Lamivudine 100 mg<br /> (n = 355)</td> <td class=\"subtitle2\">Entecavir 0.5 mg<br /> (n = 325)</td> <td class=\"subtitle2\">Lamivudine 100 mg<br /> (n = 313)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">HBV DNA*</td> </tr> <tr> <td class=\"sublist1\">Proportion undetectable (&#60;300 copies/mL)</td> <td class=\"sublist_other\">67 percent<sup>&#182;</sup></td> <td class=\"sublist_other\">36 percent</td> <td class=\"sublist_other\">90 percent<sup>&#182;</sup></td> <td class=\"sublist_other\">72 percent</td> </tr> <tr> <td class=\"sublist1\">Mean changes from baseline (log10 copies/mL)</td> <td class=\"sublist_other\">-6.86<sup>&#182;</sup></td> <td class=\"sublist_other\">-5.39</td> <td class=\"sublist_other\">-5.04<sup>&#182;</sup></td> <td class=\"sublist_other\">-4.53</td> </tr> <tr> <td>ALT normalization (&#8804;1 X ULN)</td> <td>68 percent<sup>&#182;</sup></td> <td>60 percent</td> <td>78 percent<sup>&#182;</sup></td> <td>71 percent</td> </tr> <tr> <td>HBeAg seroconversion</td> <td>21 percent</td> <td>18 percent</td> <td>NA</td> <td>NA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Roche COBAS Amplicor PCR assay (LLOQ = 300 copies/mL).<br />¶ p&lt;0.05.</div><div id=\"graphicVersion\">Graphic 59012 Version 4.0</div></div></div>"},"59015":{"type":"graphic_picture","displayName":"Kiwi vacuum device","title":"Kiwi vacuum device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kiwi vacuum device</div><div class=\"cntnt\"><img style=\"width:432px; height:484px;\" src=\"images/OBGYN/59015_Kiwi_vacuum_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of James Greenberg, MD.</div><div id=\"graphicVersion\">Graphic 59015 Version 1.0</div></div></div>"},"59016":{"type":"graphic_diagnosticimage","displayName":"CT fluoroscopic guidance","title":"CT fluoroscopic guidance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT fluoroscopic guidance</div><div class=\"cntnt\"><img style=\"width:432px; height:257px;\" src=\"images/ONC/59016_CT_fluoroscopic_guidance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 77-year-old woman with biopsy-proven 1.8 cm left lower lobe adenocarcinoma (stage IA NSCLC) who was not considered a surgical candidate due to chronic obstructive pulmonary disease and cardiac risk factors. Axial CT fluoroscopy image with patient in the prone position shows the RF electrode positioned within the left lower lobe lung cancer. Pleural thickening where local anesthetic was administered (arrow).</div><div class=\"graphic_reference\">Courtesy of Schirmang, T, MD and Dupuy, D, MD.</div><div id=\"graphicVersion\">Graphic 59016 Version 2.0</div></div></div>"},"59018":{"type":"graphic_diagnosticimage","displayName":"Segond fracture","title":"Segond fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Segond fracture</div><div class=\"cntnt\"><img style=\"width:202px; height:504px;\" src=\"images/EM/59018_Segond_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiographs cannot be used to diagnose anterior cruciate ligament tears. In some cases, an avulsion fracture of the anterolateral tibial plateau (ie, Segond fracture) is identified at the site of attachment of the lateral capsular ligament.</div><div class=\"graphic_reference\">Courtesy of Ryan P Friedberg, MD.</div><div id=\"graphicVersion\">Graphic 59018 Version 3.0</div></div></div>"},"59019":{"type":"graphic_table","displayName":"Management of adults with hypocalcemia after thyroid surgery","title":"Management of adults with hypocalcemia after thyroid surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of adults with hypocalcemia after thyroid surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Postoperative day</td> <td class=\"subtitle1\">Serum tests</td> <td class=\"subtitle1\">Therapy</td> </tr> <tr class=\"divider_bottom\"> <td>Night of surgery</td> <td>Calcium in the evening (approximately 8 PM)</td> <td><strong>Ca &#60;7.5 mg/dL:</strong> Calcitriol 0.5 mcg three times daily x three days and calcium gluconate 3 g/L D5 1/2 normal saline IV at 100 mL/hour</td> </tr> <tr class=\"divider_bottom\"> <td>Day 1</td> <td>Calcium and phosphorus in the morning (approximately 6 AM); if Ca &#60;7.5 mg/dL, add magnesium</td> <td> <p><strong>Ca &#60;7.5 mg/dL:</strong> Calcitriol 0.5 mcg twice daily x three days and adjust depending upon calcium response and calcium gluconate 3 g/L D5 1/2 normal saline IV at 100 mL/hour and calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses depending upon calcium response</p> <p><strong>Ca 7.5 to 8.0 mg/dL:</strong> Calcitriol 0.5 mcg twice daily x three days and adjust depending upon calcium response and calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses depending upon calcium response</p> <p><strong>Ca &#62;8.0 mg/dL:</strong> Calcium carbonate (1 g elemental calcium) by mouth twice daily</p> <strong>Mg &#60;2 mg/dL:</strong> Magnesium sulfate 4 g in 100 mL normal saline IV at 33 mL/hour and magnesium oxide 400 mg by mouth twice daily x one month</td> </tr> <tr> <td>Day 2 to 4</td> <td>If day 1 Ca &#8804;8.0 mg/dL, total calcium and phosphorus</td> <td> <p><strong>Ca &#60;7.5 mg/dL and symptomatic:</strong> Calcitriol 0.25 mcg three times daily and calcium gluconate 3 g/L D5 1/2 normal saline IV at 100 mL/hour and calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses and modify based upon calcium response</p> <p><strong>Ca &#60;7.5 mg/dL and asymptomatic:</strong> Calcitriol 0.25 mcg three times daily and calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses and modify based upon calcium response</p> <p><strong>Ca 7.5 to 8.4 mg/dL or P &#8805;4.5 mg/dL:</strong> Calcitriol 0.25 mcg daily and calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses and modify based upon calcium response</p> <p><strong>Ca 8.5 to 9.4 mg/dL and P &#8804;4.5 mg/dL:</strong> Calcium carbonate (1 to 4 g elemental calcium) by mouth daily in divided doses and modify based upon calcium response</p> <strong>Ca &#8805;9.5 mg/dL:</strong> No therapy</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">To convert serum calcium to mmol/L, divide by 4. To convert serum phosphorus to mmol/L, divide by 3.1.</div><div class=\"graphic_footnotes\">Ca: calcium; IV: intravenous; Mg: magnesium; P: phosphorus.</div><div id=\"graphicVersion\">Graphic 59019 Version 7.0</div></div></div>"},"59020":{"type":"graphic_picture","displayName":"Seborrheic keratosis","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:396px; height:270px;\" src=\"images/PC/59020_Seborrheic_keratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several scaly, well-circumscribed lesions that have a &quot;stuck on&quot; appearance are present.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 59020 Version 2.0</div></div></div>"},"59022":{"type":"graphic_waveform","displayName":"Normal rhythm strip","title":"Normal rhythm strip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"59025":{"type":"graphic_picture","displayName":"Cryptococcosis skin","title":"Cutaneous lesions of disseminated cryptococcosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous lesions of disseminated cryptococcosis</div><div class=\"cntnt\"><img style=\"width:418px; height:320px;\" src=\"images/DERM/59025_Cryptococcosis_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the resemblance of these papules to those of molluscum contagiosum.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59025 Version 2.0</div></div></div>"},"59027":{"type":"graphic_picture","displayName":"Dermatitis zinc defic","title":"Dermatitis in zinc deficiency","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Dermatitis in zinc deficiency</div><div class=\"cntnt\"><img style=\"width:518px; height:188px;\" src=\"images/PEDS/59027_Dermatitis_zinc_defic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perianal dermatitis in a child with zinc deficiency, which developed because of total parenteral nutrition with insufficient zinc supplementation. The second panel shows dramatic improvement in the dermatitis after only seven days of systemic zinc supplementation.</div><div class=\"graphic_reference\">Courtesy of William J Klish, MD.</div><div id=\"graphicVersion\">Graphic 59027 Version 1.0</div></div></div>"},"59028":{"type":"graphic_figure","displayName":"Incidence of sudden death in men and women increases with age","title":"Incidence of sudden death in men and women increases with age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incidence of sudden death in men and women increases with age</div><div class=\"cntnt\"><img style=\"width:386px; height:248px;\" src=\"images/CARD/59028_Incidence_SCD_by_age_gender.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a 38-year follow-up of subjects in the Framingham Heart Study, the annual incidence of sudden death increased with age in both men and women. However, at each age, the incidence of sudden death is higher in men than women.</div><div class=\"graphic_reference\">Data from Kannel WB, Wilson PWF, D'Agostino RB, et al. Am Heart J 1998; 136:205.</div><div id=\"graphicVersion\">Graphic 59028 Version 4.0</div></div></div>"},"59030":{"type":"graphic_picture","displayName":"Candida albicans vaginitis","title":"<em>Candida albicans</em> vaginitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Candida albicans</em> vaginitis</div><div class=\"cntnt\"><img style=\"width:248px; height:360px;\" src=\"images/PC/59030_Candida_albicans_vaginitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power micrograph of hyphal elements seen on 10%&nbsp;potassium hydroxide examination of a patient with <EM>C. albicans</EM> vaginitis.</div><div class=\"graphic_reference\">Courtesy of Jack D Sobel, MD.</div><div id=\"graphicVersion\">Graphic 59030 Version 4.0</div></div></div>"},"59031":{"type":"graphic_table","displayName":"World recs alcohol consump","title":"Worldwide recommendations on alcohol consumption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Worldwide recommendations on alcohol consumption</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Country</td> <td class=\"subtitle1\" rowspan=\"2\">Authority</td> <td class=\"subtitle1\" rowspan=\"2\">Standard unit</td> <td class=\"subtitle1\" colspan=\"3\">Men</td> <td class=\"subtitle1\" colspan=\"4\">Women</td> </tr> <tr> <td class=\"subtitle2\">Advice</td> <td class=\"subtitle2\">Max, g/day</td> <td class=\"subtitle2\">Max, g/week</td> <td class=\"subtitle2\">Advice</td> <td class=\"subtitle2\">Max, g/day</td> <td class=\"subtitle2\" colspan=\"2\">Max, g/week</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Australia</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>National Health and Medical Research Council</em></td> <td>10 g</td> <td>For a healthy man, four standard drinks per day with two alcohol-free days per week is regarded as low risk</td> <td>40</td> <td>&nbsp;</td> <td>For a healthy woman, two standard drinks per day with two alcohol-free days per week is regarded as low risk</td> <td>20</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Austria</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"6\"><em>Bundesministerium f&#252;r Gesundheit und Konsumentenschutz</em></td> <td class=\"divider_bottom\" rowspan=\"6\">See right</td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"6\">Standard drinks per week</td> </tr> <tr> <td class=\"subtitle2_left\">Definition</td> <td class=\"subtitle2_left\" colspan=\"2\">Men</td> <td class=\"subtitle2_left\" colspan=\"4\">Women</td> </tr> <tr> <td class=\"sublist_other\">Low risk</td> <td class=\"sublist_other\" colspan=\"2\">Up to 21</td> <td class=\"sublist_other\" colspan=\"4\">Up to 14</td> </tr> <tr> <td class=\"sublist_other\">Moderate risk</td> <td class=\"sublist_other\" colspan=\"2\">21 to 50</td> <td class=\"sublist_other\" colspan=\"4\">15 to 35</td> </tr> <tr> <td class=\"sublist_other\">High risk</td> <td class=\"sublist_other\" colspan=\"2\">Over 50</td> <td class=\"sublist_other\" colspan=\"4\">Over 35</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist_other\" colspan=\"7\">Trinkeinheiten - standard drinks - are defined as 125 mL of wine, 300 mL of beer, or 20 mL of spirits. This equates to approximately 12 g of beer or wine, or 6 g of spirits.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Canada</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">&nbsp;</td> <td><em>Committee of Health and Welfare</em></td> <td>13.5 g*</td> <td>No more than seven drinks per week</td> <td>&nbsp;</td> <td>94.5*</td> <td>No more than seven drinks per week</td> <td>&nbsp;</td> <td colspan=\"2\">94.5*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><em>Addiction Research Foundation (endorsed by Royal College of Physicians and Surgeons of Canada, Canadian Medical Association and others)</em></td> <td class=\"divider_bottom\" rowspan=\"6\">13.6 g</td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"6\">Amount of alcohol per week</td> </tr> <tr> <td class=\"subtitle2_left\">Definition</td> <td class=\"subtitle2_left\" colspan=\"2\">Standard drinks per week</td> <td class=\"subtitle2_left\" colspan=\"4\">As g of pure alcohol</td> </tr> <tr> <td class=\"sublist_other\">Low risk</td> <td class=\"sublist_other\" colspan=\"2\">1 to 14</td> <td class=\"sublist_other\" colspan=\"4\">182</td> </tr> <tr> <td class=\"sublist_other\">Moderate risk</td> <td class=\"sublist_other\" colspan=\"2\">15 to 34</td> <td class=\"sublist_other\" colspan=\"4\">195 to 442</td> </tr> <tr> <td class=\"sublist_other\">High risk</td> <td class=\"sublist_other\" colspan=\"2\">35+</td> <td class=\"sublist_other\" colspan=\"4\">455</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist_other\" colspan=\"7\">\"As a general guideline, persons should not drink more than two standard drinks in any day.\" A standard drink is defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of spirits.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Czech Republic</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"2\"><em>National Institute of Public Health</em></td> <td class=\"divider_bottom\" rowspan=\"2\">None</td> <td>0 to 24 g of alcohol per day is \"comparatively safe\"</td> <td>24</td> <td>&nbsp;</td> <td>0 to 16 g of alcohol per day is \"comparatively safe\"</td> <td>16</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"7\">The recommendations are for adults over 18 without any disease which \"could deteriorate because of alcohol (eg, epilepsy),\" not engaged in risky behaviors, and not taking medicines interacting with alcohol.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Denmark</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"2\"><em>Sundhedsstyrelsen</em></td> <td class=\"divider_bottom\" rowspan=\"2\">12 g</td> <td class=\"divider_bottom\" colspan=\"2\">No more than 21 drinks per week</td> <td>252</td> <td>No more than 14 drinks per week</td> <td>&nbsp;</td> <td colspan=\"2\">168</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"7\">Advises: \"Skip the drinks on every day/Save them for weekends or special days!\"</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Finland</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>Oy Alko AB</em></td> <td>11 g</td> <td colspan=\"2\">No more than 15 drinks per week</td> <td>161</td> <td>No more than 10 drinks per week</td> <td>&nbsp;</td> <td colspan=\"2\">110</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">France</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>Academy of Medicine</em></td> <td><strong>12 g</strong></td> <td>Maximum of&nbsp;five drinks per day</td> <td>60</td> <td>&nbsp;</td> <td>Maximum of&nbsp;three drinks per day</td> <td>36</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Germany</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>No official guidelines</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Hungary</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>17 g</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Iceland</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>9.5 g</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Ireland</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"2\"><em>An Roinn Slainte (Department of Health)</em></td> <td class=\"divider_bottom\" rowspan=\"2\">8 g</td> <td>Three units per day</td> <td>24</td> <td>&nbsp;</td> <td>Two units per day</td> <td>16</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"7\">Advises: \"Less Is Better\" (1996).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Israel</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>Ministry of Health</em></td> <td>None</td> <td colspan=\"7\">\"No advice in relation to sensible levels of drinking.\"</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Italy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"3\"><em>Ministero della Sanit&#224;/Societ&#224; Italiana di Nutrizione Umana</em></td> <td class=\"divider_bottom\" rowspan=\"3\">10 g</td> <td>40 g per day, but 30 g for&nbsp;older adult&nbsp;men, which must not exceed 10% of the caloric intake</td> <td>40</td> <td>&nbsp;</td> <td><strong>30 g per day, but 25 g for&nbsp;older adult&nbsp;women, which must not exceed 10% of the caloric intake</strong></td> <td>30</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td colspan=\"7\">The Ministero della Sanit&#224; publishes guidance tables as part of LARN (National Recommended Energy and Nutrient Intake Levels).</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"7\">The tables give alcohol consumption limits for a range of body weights in men and women and for wine at 10%, 11%, and 12% ABV, and for spirits (superalcoholico) plus 11% ABV wine.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Japan</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>Ministry of Health and Welfare</em></td> <td>19.75 g</td> <td>Two drinks (go's) of sake per day at the most</td> <td>39.5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Netherlands</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>Ministrie van Welzijn, Volksgezondheid en Cultuur</em></td> <td>9.9 g</td> <td colspan=\"7\">The Dutch government adheres to the advice of the World Health Organisation that \"less is better\" and suggests \"two or three units a few times a week.\"]</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">New Zealand</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>Alcohol Advisory Council of New Zealand (ALAC)</em></td> <td>10 g</td> <td>No more than 21 standard drinks per week and no more than six on any one occasion</td> <td>&nbsp;</td> <td>210</td> <td>No more than 14 standard drinks per week and no more than four on any one occasion</td> <td>&nbsp;</td> <td colspan=\"2\">140</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Portugal</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>Conselho Nacional de Alimentacao e Nutricao (CNAN)</em></td> <td>14 g*</td> <td>Wine only. Estimates based on 150 mL serving. (Source: ARISE.)</td> <td>37.3</td> <td>261.1</td> <td>&nbsp;</td> <td>18.6</td> <td colspan=\"2\">130.6</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Romania</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>Health Ministry</em></td> <td>&nbsp;</td> <td>Up to 32.5 g as beer or 20.7 g as wine per day</td> <td>20.7 to 32.5</td> <td>&nbsp;</td> <td>Up to 17.3 g as beer or 10.8 g as wine per day</td> <td>10.8 to 17.3</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Spain</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> <td><em>INESIBA</em></td> <td><strong>10 g*</strong></td> <td>40-44 g per day</td> <td>40-44</td> <td>&nbsp;</td> <td>40-44 g per day</td> <td>40-44</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><em>Ministry of Health &#38; Consumption</em></td> <td class=\"divider_bottom\" rowspan=\"2\"><strong>10 g*</strong></td> <td>30 g per day</td> <td>30</td> <td>&nbsp;</td> <td>20 g per day</td> <td>20</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"7\">Moderate drinking is considered to be 100-420 g of alcohol per week.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Basque Country</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>Department of Health &#38; Social Security</em></td> <td>&nbsp;</td> <td>Maximum of 1 g per kg of body weight per day</td> <td>70<sup>&#182;</sup></td> <td>&nbsp;</td> <td>Maximum of 0.5 g per kg of body weight per day</td> <td>28<sup>&#916;</sup></td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Catalonia</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><em>Central Authority</em></td> <td>8 to 10 g</td> <td colspan=\"7\">Advises not exceeding 40 to 50 g per day.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Sweden</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"9\"><em>Systembolaget</em></td> <td class=\"divider_bottom\" rowspan=\"9\">&nbsp;</td> <td class=\"subtitle2\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"6\">Amount of alcohol per week</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Men</td> <td class=\"subtitle2_left\" colspan=\"3\">Women</td> </tr> <tr> <td class=\"subtitle3_left\">Definition</td> <td class=\"subtitle3_left\">As 40% spirits</td> <td class=\"subtitle3_left\">As mL pure alcohol</td> <td class=\"subtitle3_left\">As g of pure alcohol</td> <td class=\"subtitle3_left\">As 40% spirits</td> <td class=\"subtitle3_left\">As mL pure alcohol</td> <td class=\"subtitle3_left\">As g of pure alcohol</td> </tr> <tr> <td class=\"sublist1\">Not dangerous</td> <td class=\"sublist_other\">Up to 15 cL<sup>&#9674;</sup></td> <td class=\"sublist_other\">60</td> <td class=\"sublist_other\">47</td> <td class=\"sublist_other\">Up to 12 cL<sup>&#167;</sup></td> <td class=\"sublist_other\">48</td> <td class=\"sublist_other\">38</td> </tr> <tr> <td class=\"sublist1\">Low risk</td> <td class=\"sublist_other\">Up to 40 cL</td> <td class=\"sublist_other\">160</td> <td class=\"sublist_other\">126</td> <td class=\"sublist_other\">Up to 30 cL</td> <td class=\"sublist_other\">120</td> <td class=\"sublist_other\">95</td> </tr> <tr> <td class=\"sublist1\">Intermediate risk</td> <td class=\"sublist_other\">Up to 75 cL</td> <td class=\"sublist_other\">300</td> <td class=\"sublist_other\">237</td> <td class=\"sublist_other\">Up to 55 cL</td> <td class=\"sublist_other\">220</td> <td class=\"sublist_other\">174</td> </tr> <tr> <td class=\"sublist1\">High risk</td> <td class=\"sublist_other\">Up to 125 cL</td> <td class=\"sublist_other\">500</td> <td class=\"sublist_other\">395</td> <td class=\"sublist_other\">Up to 95 cL</td> <td class=\"sublist_other\">380</td> <td class=\"sublist_other\">300</td> </tr> <tr> <td class=\"sublist1\">Very high risk</td> <td class=\"sublist_other\">Over 125 cL</td> <td class=\"sublist_other\">Over 500</td> <td class=\"sublist_other\">Over 395</td> <td class=\"sublist_other\">Over 95 cL</td> <td class=\"sublist_other\">Over 380</td> <td class=\"sublist_other\">Over 300</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist_other\" colspan=\"7\"> <p>NOTES:</p> <p>&#9674; Or&nbsp;five bottles of beer, or two-thirds of a bottle of wine.</p> &#167; Or&nbsp;four bottles of beer or half a bottle of wine.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">United Kingdom</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"3\"><em>Department of Health</em></td> <td class=\"divider_bottom\" rowspan=\"3\">8 g</td> <td>\"Maximum health advantage\" for men over 40 lies between one and two units a day</td> <td>8 to 16 g</td> <td class=\"divider_bottom\" rowspan=\"3\">Advice on weekly consumption is avoided</td> <td>\"Maximum health advantage\" for postmenopausal women lies between one and two units a day</td> <td>8 to 16 g</td> <td class=\"divider_bottom\" rowspan=\"3\" colspan=\"2\">Advice on weekly consumption is avoided</td> </tr> <tr> <td>Regular consumption of between three and four units a day for men of all ages \"will not accrue significant health risk\"</td> <td>24 to 32 g</td> <td>Regular consumption of between two and three units a day by women of all ages \"will not accrue any significant health risk\"</td> <td>16 to 24 g</td> </tr> <tr class=\"divider_bottom\"> <td>Consistently drinking four or more units a day is \"not advised as a sensible drinking level\"</td> <td>32 g+</td> <td>Consistently drinking three or more units a day is \"not advised as a sensible drinking level\"</td> <td>24 g+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">United States</td> </tr> <tr> <td rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\"><em>Department of Agriculture/Department of Health and Human Services</em></td> <td rowspan=\"3\">14 g<sup>&#165;</sup></td> <td>No more than two drinks per day</td> <td>28 g</td> <td>&nbsp;</td> <td>No more than one drink per day</td> <td>14 g</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td colspan=\"7\">A standard drink is defined as 12 ounces of regular beer (one bottle); a 5-ounce glass of wine; or 1.5 ounces of 80-proof distilled spirits.</td> </tr> <tr> <td colspan=\"7\">Advises: \"If you drink alcoholic beverages, do so in moderation, with meals, and when consumption does not put you or others at risk.\"</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Approximate/unofficial figure.<br />&para; For a 70 Kg man.<br />&Delta; For a 56 Kg woman.<br />&yen; Wine Institute suggests 12 g for wine.</div><div class=\"graphic_reference\"><a href=\"http://www.drinkingandyou.com/#\" spellcheck=\"true\" target=\"_blank\">www.drinkingandyou.com/#</a></div><div id=\"graphicVersion\">Graphic 59031 Version 3.0</div></div></div>"},"59033":{"type":"graphic_picture","displayName":"HEp-2 cells stained speckled","title":"Anti-Sm antibodies stain the nuclei of HEp-2 cells in a coarse nuclear speckled pattern","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Anti-Sm antibodies stain the nuclei of HEp-2 cells in a&nbsp;coarse nuclear&nbsp;speckled pattern</div><div class=\"cntnt\"><img style=\"width:512px; height:511px;\" src=\"images/RHEUM/59033_HEp2_cells_stained_speckled.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Human serum containing anti-Sm antibodies stain the nuclei of HEp-2 cells in a coarse nuclear speckled pattern (A and C). DAPI staining in panels B and D indicate the location of nuclei. In contrast to anti-DNA antibodies, in dividing cells (indicated by white arrow in C and D) anti-Sm antibodies do not stain the chromosomes. The anti-Sm antibody reference serum was obtained from the Centers for Disease Control repository of ANA standards.</div><div class=\"graphic_footnotes\">ANA: antinuclear antibody.</div><div id=\"graphicVersion\">Graphic 59033 Version 3.0</div></div></div>"},"59035":{"type":"graphic_table","displayName":"Causes of microcytic anemia","title":"Causes of microcytic anemia (mean corpuscular volume less than 80 fL)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of microcytic anemia (mean corpuscular volume less than 80 fL)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hereditary disorders</td> </tr> <tr> <td class=\"sublist1_start\">Defects of globin synthesis</td> </tr> <tr> <td class=\"sublist1\"><span style=\"color: #ff0000;\">Thalassemia syndromes</span></td> </tr> <tr> <td class=\"sublist1\">Thalassemic hemoglobinopathies (eg, hemoglobin [Hb]E, Hb Lepore)</td> </tr> <tr> <td class=\"sublist1_start\">Defects of iron metabolism</td> </tr> <tr> <td class=\"sublist1\">Iron refractory iron deficiency anemia (IRIDA)*</td> </tr> <tr> <td class=\"sublist1\">Divalent metal transporter (DMT)1 mutations*</td> </tr> <tr> <td class=\"sublist1\">Atransferrinemia*</td> </tr> <tr> <td class=\"sublist1\">Sideroblastic anemia</td> </tr> <tr> <td class=\"subtitle1_single\">Acquired disorders</td> </tr> <tr> <td><span style=\"color: #ff0000;\">Iron deficiency anemia</span></td> </tr> <tr> <td class=\"sublist1_start\">Myelodysplastic syndrome (MDS) with acquired thalassemia*</td> </tr> <tr> <td>Sideroblastic anemias due to drugs or toxins (lead poisoning, alcohol, drugs)</td> </tr> <tr> <td>Copper deficiency (some cases)</td> </tr> <tr> <td>Zinc deficiency</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The two most common causes of microcytosis are shown in <span style=\"color: #ff0000;\">red</span> type.</div><div class=\"graphic_footnotes\">* Very rare cause of microcytosis.</div><div id=\"graphicVersion\">Graphic 59035 Version 5.0</div></div></div>"},"59036":{"type":"graphic_diagnosticimage","displayName":"Bronchogenic carcinoma CT","title":"Bronchogenic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchogenic carcinoma</div><div class=\"cntnt\"><img style=\"width:398px; height:259px;\" src=\"images/PULM/59036_Bronchogenic_carcinoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of a bronchogenic carcinoma shows a mass in lingula, measuring 5.5 cm in diameter (arrow), with dystrophic calcification and hilar lymph node enlargement (arrowhead). A small left pleural effusion proved to be benign, and therefore did not affect staging of the tumor.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59036 Version 3.0</div></div></div>"},"59037":{"type":"graphic_diagnosticimage","displayName":"Septic embolization PA","title":"Septic embolization in an intravenous drug user with tricuspid valve endocarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Septic embolization in an intravenous drug&nbsp;user with tricuspid valve endocarditis</div><div class=\"cntnt\"><img style=\"width:336px; height:316px;\" src=\"images/PULM/59037_Septic_embolization_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows multiple ill-defined nodular opacities, some with cavitation. This is an example of multifocal patchy opacification.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59037 Version 4.0</div></div></div>"},"59038":{"type":"graphic_diagnosticimage","displayName":"Adult proximal humerus fracture 2","title":"Displaced (two-part) proximal humerus fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced (two-part) proximal humerus fracture</div><div class=\"cntnt\"><img style=\"width:319px; height:468px;\" src=\"images/EM/59038_Adult_proximal_humerus_fx_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows a signficantly displaced fracture of the humerus at the surgical neck. In the Neer classification system this is categorized as a two-part fracture. The superior displacement of the distal fragment was clinically apparent as shortening of the upper arm.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 59038 Version 3.0</div></div></div>"},"59041":{"type":"graphic_figure","displayName":"Bennett fracture of the thumb","title":"Bennett fracture of the thumb","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bennett fracture of the thumb</div><div class=\"cntnt\"><img style=\"width:442px; height:439px;\" src=\"images/SURG/59041_Bennett_fx_thumb_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Bennett fracture of the thumb is an oblique, intra-articular fracture of the thumb metacarpal base. The smaller proximal fragment of the metacarpal shaft includes the palmar and ulnar corner of the metacarpal base and is fixed to the base of the index finger metacarpal and the trapezium by virtue of the anterior oblique ligament. The larger fragment of the metacarpal shaft is displaced radially, proximally and dorsally by the pull of the abductor pollicis longus (APL) that inserts on the dorsal radial corner of the metacarpal base. This is an unstable fracture pattern that requires fixation after reduction of the fracture.</div><div id=\"graphicVersion\">Graphic 59041 Version 4.0</div></div></div>"},"59043":{"type":"graphic_figure","displayName":"Plasmapheresis in myeloma","title":"Figure showing reduction in circulating light chains after plasmapheresis in a patient with multiple myeloma and acute kidney injury","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Figure showing reduction in circulating light chains after plasmapheresis in a patient with multiple myeloma and acute kidney injury</div><div class=\"cntnt\"><img style=\"width:468px; height:252px;\" src=\"images/NEPH/59043_Plasmapheresis_in_myeloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum protein electrophoresis before (left panel) and after (right panel) four consecutive daily plasma exchanges in a patient with multiple myeloma and acute renal failure. The monoclonal peak representing the circulating light chains (arrow) has essentially disappeared.</div><div class=\"graphic_reference\">Courtesy of Andre Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 59043 Version 4.0</div></div></div>"},"59044":{"type":"graphic_table","displayName":"Dystonia syndromes","title":"Dystonia syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dystonia syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Isolated dystonias</td> </tr> <tr> <td class=\"subtitle2_left\">Early-onset generalized isolated dystonia</td> </tr> <tr> <td class=\"sublist_other\">Description: dystonia with focal-onset beginning in childhood that often progresses to generalized involvement; cases may be sporadic, familial, genetically defined or without known cause</td> </tr> <tr> <td class=\"indent1\">Early-onset generalized dystonia (DYT-TOR1A)</td> </tr> <tr> <td class=\"indent1\">Adolescent-onset dystonia of mixed type (DYT-THAP1)</td> </tr> <tr> <td class=\"subtitle2_left\">Focal or segmental isolated dystonia with onset in adulthood</td> </tr> <tr> <td class=\"sublist_other\">Decription: focal or segmental isolated dystonias usually begin after age 30 years; most are sporadic without identifiable cause, and rarely progress to generalized dystonia, but can extend to contiguous body regions</td> </tr> <tr> <td class=\"indent1\">Adult-onset segmental dystonia (DYT-GNAL)</td> </tr> <tr> <td class=\"indent1\">Cervical dystonia</td> </tr> <tr> <td class=\"indent1\">Blepharospasm</td> </tr> <tr> <td class=\"indent1\">Writer's cramp</td> </tr> <tr> <td class=\"indent1\">Oromandibular dystonia</td> </tr> <tr> <td class=\"indent1\">Laryngeal dystonia (spasmodic dysphonia)</td> </tr> <tr> <td class=\"indent1\">Limb dystonia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other syndromes of late adult-onset focal isolated dystonia</td> </tr> <tr> <td class=\"subtitle1_single\">Combined dystonias</td> </tr> <tr> <td class=\"subtitle2_left\">Dystonia-parkinsonism</td> </tr> <tr> <td class=\"sublist_other\">Description: disorders that combine dystonia and parkinsonian features, sometimes accompanied by pyramidal tract involvement, and/or nonmotor features, including cognitive decline; many are inherited</td> </tr> <tr> <td class=\"indent1\">Dopa-responsive dystonia (DYT-GCH1, DYT-TH, and DYT-SPR)</td> </tr> <tr> <td class=\"indent1\">Wilson disease</td> </tr> <tr> <td class=\"indent1\">Early-onset parkinsonism (PARK-PARKIN)</td> </tr> <tr> <td class=\"indent1\">Early-onset parkinsonism (PARK-PINK1)</td> </tr> <tr> <td class=\"indent1\">Early-onset parkinsonism (PARK-DJ1)</td> </tr> <tr> <td class=\"indent1\">X-linked dystonia-parkinsonism/Lubag (DYT-TAF1)</td> </tr> <tr> <td class=\"indent1\">Rapid-onset dystonia-parkinsonism (DYT-ATP1A3)</td> </tr> <tr> <td class=\"sublist2_start\">Neurodegeneration with brain iron accumulation:</td> </tr> <tr> <td class=\"sublist2\">Pantothenate kinase-associated neurodegeneration (PANK2 gene)</td> </tr> <tr> <td class=\"sublist2\">Infantile neuroaxonal dystrophy (PLA2G6 gene)</td> </tr> <tr> <td class=\"sublist2\">Mitochondrial membrane protein-associated neurodegeneration (C19ORF12 gene)</td> </tr> <tr> <td class=\"sublist2\">Beta-propeller protein-associated neurodegeneration, also known as static encephalopathy of childhood with neurodegeneration in adulthood (WDR45 gene)</td> </tr> <tr> <td class=\"sublist2\">Fatty acid hydroxylase-associated neurodegeneration (FA2H gene)</td> </tr> <tr> <td class=\"sublist2\">Kufor-Rakeb syndrome (PARK-ATP13A2)</td> </tr> <tr> <td class=\"sublist2\">Neuroferritinopathy (FTL gene)</td> </tr> <tr> <td class=\"sublist2\">Aceruloplasminemia (ceruloplasmin gene)</td> </tr> <tr> <td class=\"sublist2\">Woodhouse-Sakati syndrome (DCAF17 gene)</td> </tr> <tr> <td class=\"subtitle2_left\">Myoclonus-dystonia</td> </tr> <tr> <td class=\"sublist_other\">Description: disorders in which there is a combination of dystonia and myoclonus; dystonia may be mild, and myoclonus generally predominates</td> </tr> <tr> <td class=\"indent1\">Myoclonus-dystonia (DYT-SGCE)</td> </tr> <tr> <td class=\"subtitle2_left\">Paroxysmal dyskinesia with dystonia</td> </tr> <tr> <td class=\"sublist_other\">Description: disorders characterized by episodes of spontaneous or induced dyskinesia with dystonia</td> </tr> <tr> <td class=\"indent1\">Paroxysmal nonkinesigenic dyskinesia (DYT-MR1)</td> </tr> <tr> <td class=\"indent1\">Paroxysmal kinesigenic choreoathetosis (DYT-PRRT2)</td> </tr> <tr> <td class=\"indent1\">Paroxysmal exertion-induced dyskinesia (DYT-SLC2A1)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28:863.</li>&#xD;&#xA;    <li>Klein C. Genetics in dystonia. Parkinsonism Relat Disord 2014; 20 Suppl 1:S137.</li>&#xD;&#xA;    <li>Marras C, Lohmann K, Lang A, Klein C. Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples. Neurology 2012; 78:1016.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 59044 Version 4.0</div></div></div>"},"59047":{"type":"graphic_waveform","displayName":"ECG left lateral WPW III","title":"12-lead electrocardiogram (ECG) showing a left lateral atrioventricular accessory pathway in a patient with Wolff-Parkinson-White (WPW) syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing a left lateral atrioventricular accessory pathway in a patient with Wolff-Parkinson-White (WPW) syndrome</div><div class=\"cntnt\"><img style=\"width:390px; height:246px;\" src=\"images/CARD/59047_LeftlateralWPWIII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram during sinus rhythm from a patient with a left lateral accessory pathway. Panel A: Normal PR interval and a fairly normal QRS complex. Panel B: With pacing from the coronary sinus at a site close to the accessory pathway, the QRS complexes are maximally preexcited.</div><div id=\"graphicVersion\">Graphic 59047 Version 4.0</div></div></div>"},"59048":{"type":"graphic_table","displayName":"Cutaneous vasculitis types","title":"Types of cutaneous vasculitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of cutaneous vasculitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"12\" width=\"8%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">PAN</td> <td class=\"subtitle1\">c-PAN</td> <td class=\"subtitle1\">NV</td> <td class=\"subtitle1\">GP<br /> (WG)</td> <td class=\"subtitle1\">EGP<br /> (CSS)</td> <td class=\"subtitle1\">MPA</td> <td class=\"subtitle1\">CV</td> <td class=\"subtitle1\">RV</td> <td class=\"subtitle1\">IgA<br /> (HSP)</td> <td class=\"subtitle1\">UV</td> <td class=\"subtitle1\">CSVV</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vessel size</strong></td> <td>Medium</td> <td>Medium</td> <td>Medium</td> <td>Medium and small</td> <td>Medium and small</td> <td>Medium and small</td> <td>Medium and small</td> <td>Medium and small</td> <td>Small</td> <td>Small</td> <td>Small</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cutaneous findings</strong></td> <td>Nodules, ulcers, livedo racemosa, infarcts</td> <td>Nodules, ulcers, livedo racemosa</td> <td> <p>Nodules, ulcers</p> <p>Lower extremity edema</p> </td> <td> <p>Nodules, ulcers, livedo racemosa, infarcts, palpable purpura</p> <p>Saddle nose deformity</p> <p>Strawberry gums</p> </td> <td>Nodules, ulcers, livedo racemosa, infarcts, palpable purpura</td> <td>Nodules, ulcers, livedo racemosa, infarcts, palpable purpura</td> <td>Nodules, ulcers, livedo racemosa, infarcts, palpable purpura</td> <td>Nodules, ulcers, livedo racemosa, infarcts, palpable purpura</td> <td>Urticarial papules, purpura, petechiae</td> <td>Urticarial papules, purpura, petechiae</td> <td>Urticarial papules, purpura, petechiae</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Systemic symptoms/involvement</strong></td> <td> <p>Weight loss, myalgia, fatigue, neuropathy, hypertension</p> <p>Decreased renal perfusion</p> </td> <td>Weight loss, myalgia, fatigue, neuropathy</td> <td>Tuberculosis</td> <td> <p>Weight loss, myalgia, fatigue, neuropathy</p> <p>Glomerulonephritis</p> <p>Necrotizing granulomatous inflammation of respiratory tract</p> </td> <td> <p>Weight loss, myalgia, fatigue, neuropathy</p> <p>Allergies</p> <p>Asthma</p> <p>Heart and GI involvement (esp if pANCA -)</p> <p>Glomerulonephritis and neuropathy (esp if pANCA +)</p> </td> <td> <p>Weight loss, myalgia, fatigue, neuropathy</p> <p>Alveolar hemorrhage</p> <p>Glomerulonephritis</p> </td> <td> <p>Weight loss, myalgia, fatigue, peripheral neuropathy</p> <p>Membranoproliferative glomerulonephritis</p> </td> <td> <p>Weight loss, myalgia, fatigue, neuropathy</p> <p>Deforming arthritis</p> </td> <td>Arthritis, abdominal pain, renal involvement</td> <td>Fever, angioedema, athralgias, abdominal pain, Raynaud's phenomenon, uveitis, obstructive lung disease</td> <td>Fatigue</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Helpful lab/study findings</strong></td> <td>NEGATIVE ANCAs</td> <td>NEGATIVE ANCAs</td> <td> <p>PPD</p> <p>CXR</p> </td> <td> <p>+c-ANCA</p> <p>+PR3</p> </td> <td> <p>+p-ANCA</p> <p>+MPO</p> <p>Eosinophilia</p> </td> <td> <p>+p-ANCA</p> <p>No eosinophilia</p> </td> <td> <p>Hepatitis C+ plus cryoglobulins</p> </td> <td>High titer rheumatoid factor</td> <td>Urinalysis looking for renal involvement</td> <td>Low complement levels</td> <td>No systemic involvement</td> </tr> <tr> <td><strong>DIF</strong></td> <td>Negative</td> <td>Negative</td> <td>Negative</td> <td>Negative</td> <td>Negative</td> <td>Negative</td> <td>+IgM</td> <td>+IgM</td> <td>IgA</td> <td>IgG, C3, fibrin, can also be seen along DEJ</td> <td>C3, IgM, IgA, IgG</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PAN: polyarteritis nodosa; c-PAN: cutaneous polyarteritis nodosa;&nbsp;NV: nodular vasculitis; GP (WG): granulomatosis with polyangiitis (Wegener's granulomatosis); EGP (CSS): eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome); MPA: microscopic polyangiitis; CV: cryoglobulinemic vasculitis: RV: rheumatoid arthritis; IgA (HSP): IgA vasculitis (Henoch-Schönlein purpura); UV: urticarial vasculitis; CSVV: cutaneous small vessel vasculitis; DEJ: dermal-epidermal junction; ANCA: antineutrophil cytoplasmic antibodies; DIF: direct immunofluorescence.</div><div class=\"graphic_reference\">Data from: Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology; 56:3-23.</div><div id=\"graphicVersion\">Graphic 59048 Version 9.0</div></div></div>"},"59049":{"type":"graphic_table","displayName":"Medically relevant spiders by geographic location","title":"Medically relevant spiders by geographic location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medically relevant spiders by geographic location</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Geographical location</td> <td class=\"subtitle1\">Common name and species </td> <td class=\"subtitle1\">Appearance</td> <td class=\"subtitle1\">Typical habitat</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Widows</td> </tr> <tr> <td class=\"indent1\">Southeastern United States (Maryland, southern Ohio, and lower states)</td> <td> <p>Southern black widow</p> <p><em>L. mactans</em></p> </td> <td rowspan=\"2\">Shiny black spider with some form of red on body</td> <td rowspan=\"6\"> <p>Clutter surrounding homes (eg, gardens, sheds, garages)</p> <p>Rarely indoors</p> </td> </tr> <tr> <td class=\"indent1\">Western half of the United States from Canada to Mexico</td> <td> <p>Western black widow</p> <p><em>L. hesperus</em></p> </td> </tr> <tr> <td class=\"indent1\"> <p>New Zealand (coastal areas)</p> <p>Australia (coastal areas)</p> <p>Japan (Osaka prefecture)</p> </td> <td> <p>Australian red back</p> <p><em>L. hasselti</em></p> </td> <td>Shiny black body with dorsal red stripe</td> </tr> <tr> <td class=\"indent1\">South America</td> <td><em>L. curacaviensis</em></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Mediterranean</td> <td> <p>Black hag, black wolf</p> <p><em>L. tredecimguttatus</em></p> </td> <td>Smattering of 13 red dots on dorsal abdomen, <strong>no</strong> red hour glass</td> </tr> <tr> <td class=\"indent1\">Worldwide and in United States (from South Carolina to Texas and California)</td> <td> <p>Brown widow (can bite humans, but envenomation is usually&nbsp;mild)</p> <p><em>L. geometricus</em></p> </td> <td>White stripes on a tan abdomen with&nbsp;orange hourglass, abdomen color can vary from cream to almost black</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">False Black Widows</td> </tr> <tr> <td class=\"indent1\"> <p>United States: Southeast, Pacific coast, and Colorado</p> <p>Canada: British Columbia</p> <p>Australia</p> </td> <td> <p>False black widow</p> <p><em>S. grossa</em></p> </td> <td rowspan=\"2\"> <p>Similar shape to widows</p> <p>Chocolate brown color with tan stripes or markings on abdomen</p> <p><strong>Do not</strong>&nbsp;have red markings</p> </td> <td rowspan=\"2\"> <p>Clutter surrounding homes</p> <p>Also indoors (in cupboards and undisturbed places)</p> </td> </tr> <tr> <td class=\"indent1\">Europe</td> <td> <p><em>S. paykulliana</em></p> <p><em>S. grossa</em></p> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">Recluses</td> </tr> <tr> <td class=\"indent1\">United States: Midwest and southern states extending westward </td> <td> <p>Brown recluse</p> <p><em>L. reclusa</em></p> </td> <td rowspan=\"4\"> <p>Non-descript brown spiders</p> <p>Recluses have&nbsp;three pairs of eyes (six total), monochromatic abdomen and legs, and very fine hairs on legs</p> </td> <td rowspan=\"4\"> <p>Mostly inside homes: attics, basements, cupboards</p> <p>Outdoors: in rock piles and under tree bark, <strong>not</strong>&nbsp;in live vegetation</p> </td> </tr> <tr> <td class=\"indent1\">Worldwide infestations of buildings</td> <td> <p>Mediterranean recluse</p> <p><em>L. rufescens</em></p> </td> </tr> <tr> <td class=\"indent1\">South America (Brazil, Chile, others)</td> <td rowspan=\"2\"> <p>Chilean recluse</p> <p><em>L. laeta</em></p> <p><em>L. intermedia</em></p> <p><em>L. gaucho</em></p> </td> </tr> <tr> <td class=\"indent1\">Isolated reports in South Africa, Australia</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">Phoneutria</td> </tr> <tr> <td class=\"indent1\">South America</td> <td> <p>Brazilian wandering spider</p> <p><em>P. nigriventer</em></p> <p><em>P. keyserlingi</em></p> <p><em>P. fera</em></p> </td> <td>Large, extensively-haired spider (up to 95 mm leg span)</td> <td> <p>Forage at night and may enter homes to take refuge under household items during the day.</p> <p>Found in urban environments in piles of clutter, vegetation, or rubbish.</p> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">Australian Funnel Web</td> </tr> <tr> <td class=\"indent1\">Australia - Southeastern coastal regions (including Sydney and Brisbane)</td> <td> <p>Australian funnel web spider</p> <p><em>Atrax robustus</em></p> <p>Five species of <em>Hadronyche</em></p> </td> <td>Large spider (25 mm body length), shiny black coloration on body</td> <td>Moist areas such as basements</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59049 Version 14.0</div></div></div>"},"59051":{"type":"graphic_table","displayName":"Bleeding risk index warfarin","title":"Index for predicting risk of bleeding with warfarin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Index for predicting risk of bleeding with warfarin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">This index was derived from a retrospective analysis of the incidence of bleeding in 556 outpatients treated with warfarin. There are four adverse risk factors. One point is given for the presence of each of these risk factors, for a total potential score from&nbsp;0 to 4.</td> </tr> <tr> <td class=\"sublist1\">Age &#8805;65 years</td> </tr> <tr> <td class=\"sublist1\">History of stroke</td> </tr> <tr> <td class=\"sublist1\">History of gastrointestinal bleeding</td> </tr> <tr> <td class=\"sublist1\">One or more of the following comorbid conditions:</td> </tr> <tr> <td class=\"sublist2\">Recent myocardial infarction</td> </tr> <tr> <td class=\"sublist2\">Hematocrit &#60;30%</td> </tr> <tr> <td class=\"sublist2\">Serum creatinine concentration &#62;1.5 mg/dL (&#62;133 micromol/L)</td> </tr> <tr> <td class=\"sublist2\">Diabetes mellitus</td> </tr> <tr> <td>In the prospective validation portion of this study, the cumulative incidence of major bleeding after 48 months of treatment with warfarin in 264 outpatients was as follows:</td> </tr> <tr> <td><strong>Low risk</strong> (no risk factors present, point score 0): 3%</td> </tr> <tr> <td><strong>Intermediate risk</strong> (point score 1 to 2): 12%</td> </tr> <tr> <td><strong>High risk</strong> (point score 3 to 4): 53%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.&nbsp;Am J Med 1998; 105:91.</div><div id=\"graphicVersion\">Graphic 59051 Version 4.0</div></div></div>"},"59052":{"type":"graphic_figure","displayName":"Translation RNA to protein","title":"Translation","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Translation</div><div class=\"cntnt\"><img style=\"width:488px; height:665px;\" src=\"images/PC/59052_Translation_RNA_to_protein.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59052 Version 4.0</div></div></div>"},"59054":{"type":"graphic_picture","displayName":"Achilles tendon US exam","title":"Achilles tendon sonographic technique","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Achilles tendon sonographic technique</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/59054_Achilles_tendon_US_exam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows proper sonographic technique for examination of the Achilles tendon. The Achilles tendon should be stretched as much as possible by pointing the big toe towards the examination bench.</div><div class=\"graphic_reference\">Reproduced with permission from Bruyn GA, Schmidt WA. Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist. Bohn Stafleu &amp; Van Loghum, 2006. Copyright &#169;2006 Bohn Stafleu &amp; Van Loghum.</div><div id=\"graphicVersion\">Graphic 59054 Version 2.0</div></div></div>"},"59055":{"type":"graphic_waveform","displayName":"12-lead ECG right posteroseptal WPW III","title":"12-lead electrocardiogram (ECG) of a right posteroseptal accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a right posteroseptal accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:515px; height:316px;\" src=\"images/CARD/59055_Posteroseptal_accessory_pat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12 lead ECG during rapid atrial pacing shows QRS complexes that are maximally preexcited; the complexes have a pattern suggesting an AV accessory pathway located in the right posteroseptal area. At the time of ablation, the pathway was localized to the midseptal region.</div><div id=\"graphicVersion\">Graphic 59055 Version 3.0</div></div></div>"},"59056":{"type":"graphic_picture","displayName":"Small bowel polyp","title":"Small bowel polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel polyp</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/GAST/59056_Small_bowel_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel polyp detected during double balloon enteroscopy.</div><div class=\"graphic_reference\">Courtesy of Hiroto Kita, MD, PhD.</div><div id=\"graphicVersion\">Graphic 59056 Version 1.0</div></div></div>"},"59057":{"type":"graphic_picture","displayName":"Squamous cell carcinoma - lip","title":"Squamous cell carcinoma on the lip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma on the lip</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/59057_Squa_cell_carc_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This erythematous, crusted nodule on the lip represents a squamous cell carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59057 Version 3.0</div></div></div>"},"59061":{"type":"graphic_figure","displayName":"Fortification spectra","title":"Fortification spectra","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fortification spectra</div><div class=\"cntnt\"><img style=\"width:412px; height:306px;\" src=\"images/NEURO/59061_Fortification_spectra.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59061 Version 1.0</div></div></div>"},"59062":{"type":"graphic_table","displayName":"Guidelines for opioid rotation","title":"Guidelines for opioid rotation<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for opioid rotation<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Step 1:</td> </tr> <tr> <td class=\"indent1\">Consider opioid rotation as a strategy to address the scenario of poor opioid responsiveness following dose titration.</td> </tr> <tr> <td class=\"indent1\">The decision about the drug to which the patient is switched is empirical, based on prior experience of the patient and physician, availability, cost, and other factors.</td> </tr> <tr> <td class=\"indent1\">When the new drug is selected, calculate the equianalgesic dose from an equianalgesic dose table.</td> </tr> <tr> <td class=\"indent1\">If switching to any opioid other than methadone or fentanyl, identify an \"automatic dose reduction window\" equal to a reduction of 25 to 50 percent below the calculated equianalgesic dose.</td> </tr> <tr> <td class=\"indent1\">If switching to methadone, the \"automatic dose reduction window\" should be a 75 to 90 percent reduction below the calculated equianalgesic dose. Great caution should be exercised in converting to methadone at doses of 100 mg or greater per day; consider inpatient monitoring, including serial EKG monitoring. Some have recommended that regardless of the oral morphine equivalent dose, methadone should be initiated at no more than 30 mg per day<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\">If switching to transdermal fentanyl, do not do an automatic dose reduction and use the calculated equianalgesic dose included in the FDA-approved manufacturer's labeling for these formulations.</td> </tr> <tr> <td class=\"sublist2_start\">Select a dose closer to the lower boundary (25 percent reduction) or the upper boundary (50 percent reduction) of the \"automatic dose reduction window\" on the basis of a clinical judgment that the equianalgesic dose table is relatively more or less applicable, respectively, to the specific characteristics of the opioid regimen or patient:</td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Select a dose closer to the upper boundary (50 percent reduction) of the reduction if the patient is receiving a relatively high dose of the current opioid regimen, is not Caucasian, or is elderly or medically frail. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\"> <ul> <li>Select a dose closer to the lower boundary (25 percent reduction) of the reduction if the patient does not have these characteristics or is undergoing a switch to a different route of systemic drug administration using the same drug. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Step 2:</td> </tr> <tr> <td class=\"indent1\">Before finally selecting the starting dose of the new opioid, perform a second assessment of pain severity and other medical or psychosocial characteristics to determine whether to apply an additional increase or decrease of 15 to 30 percent to enhance the likelihood that the initial dose will be effective for pain, or conversely, unlikely to cause withdrawal or opioid-related side effects.</td> </tr> <tr> <td class=\"indent1\">After the initial doses, assess response and titrate the dose of the new opioid regimen to optimize outcomes.</td> </tr> <tr> <td class=\"indent1\">If a supplemental \"rescue dose\" is used for titration, calculate this at 5 to 15 percent of the total daily opioid dose and administer at an appropriate interval; an exception are the oral transmucosal fentanyl formulations, which should be initiated at one of the lower available doses irrespective of the baseline opioid dose.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EKG: electrocardiogram; FDA: Food and Drug Administration.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fine PG, Portenoy RK; Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing \"best practices\" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 2009; 38:418.</li>&#xD;&#xA;    <li>Chaham MS, Dodds A ES, Svengsouk JS, Juba KM. Dose ratios between high dose oral morphine or equivalents and oral methadone. J Palliat Med 2013; 16:947.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 59062 Version 5.0</div></div></div>"},"59063":{"type":"graphic_waveform","displayName":"Hypocalcemia tutorial","title":"Hypocalcemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypocalcemia</div><div class=\"cntnt\"><img style=\"width:420px; height:87px;\" src=\"images/CARD/59063_Hypocalcemia_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">QT interval prolongation is the hallmark of hypocalcemia. In this example, the corrected QT interval is &gt;0.6 seconds (normal ≤0.44 seconds).</div><div id=\"graphicVersion\">Graphic 59063 Version 2.0</div></div></div>"},"59065":{"type":"graphic_picture","displayName":"Villous lymphocytes of SMZL","title":"Splenic marginal zone lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Splenic marginal zone lymphoma</div><div class=\"cntnt\"><img style=\"width:392px; height:287px;\" src=\"images/HEME/59065_Villous_lymphocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced peripheral smear shows small lymphoid cells with dark round nuclei, lightly basophilic cytoplasm, and bipolar surface villous processes (arrows).</div><div class=\"graphic_reference\">From Warnke RA, Weiss LM, Chan JK, Cleary ML, Dorfman RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 59065 Version 3.0</div></div></div>"},"59066":{"type":"graphic_figure","displayName":"Telomeric regions of chromosomes 4q and 10q","title":"Telomeric regions of chromosomes 4q and 10q","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Telomeric regions of chromosomes 4q and 10q</div><div class=\"cntnt\"><img style=\"width:517px; height:364px;\" src=\"images/PEDS/59066_Telomeric4q10q.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagrammatic representation of the hierarchical genetic organization of the telomeric regions of chromosomes 4q and 10q. Patients with facioscapulohumeral dystrophy have fewer than 10 copies of the D4Z4 repeat on chromosome 4, whereas 11 to 100 copies are normally present. The presence of a restriction site for BInI in the 10q repeats allows these two chromosomal repeats to be differentiated. Double digestion of genomic DNA with EcoRI and BInI eliminates the chromosome 10 EcoRI fragment containing D4Z4 repeats and thus allows measurement of size of the chromosome 4 EcoRI fragment, which results in almost 100 percent accurate diagnosis of FSHD.</div><div class=\"graphic_footnotes\">B: BInI; E: EcoRI; K: KpnI restriction sites; CEN: centromere; TEL: telomere.</div><div class=\"graphic_reference\">Reproduced with permission from: Orrell RW, Darras BT, Griggs RC. Facioscapulohumeral dystrophy, scapuloperoneal syndromes, and distal myopathies. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, Jones HR, De Vivo DC, Darras BT (Eds). Butterworth Heinemann, Philadelphia 2003. p.701. Copyright © 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 59066 Version 3.0</div></div></div>"},"59067":{"type":"graphic_picture","displayName":"Branchial cleft cyst","title":"Branchial cleft cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Branchial cleft cyst</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/59067_Branchial_cleft_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cystic papule is located on the lower neck, anterior to the sternocleidomastoid muscle.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59067 Version 4.0</div></div></div>"},"59068":{"type":"graphic_algorithm","displayName":"Otorrhea no inflammation","title":"Otorrhea without external auditory canal inflammation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Otorrhea without external auditory canal inflammation</div><div class=\"cntnt\"><img style=\"width:386px; height:348px;\" src=\"images/EM/59068_Otorrhea_no_inflammation.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AOM: acute otitis media; CSF: cerebrospinal fluid.<br>* Concurrent bacterial otitis exterra may be present.<br>&#8226; Often associated with a periauricular mass, chronic ear drainage, and a normal tympanic membrane.</div><div id=\"graphicVersion\">Graphic 59068 Version 1.0</div></div></div>"},"59069":{"type":"graphic_table","displayName":"Comprehensive diabetic foot exam","title":"Key components of the diabetic foot exam","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key components of the diabetic foot exam</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inspection </td> </tr> <tr> <td class=\"subtitle2_single\">Dermatologic </td> </tr> <tr> <td class=\"indent1\">Skin status: color, thickness, dryness, cracking </td> </tr> <tr> <td class=\"indent1\">Sweating </td> </tr> <tr> <td class=\"indent1\">Infection: check between toes for fungal infection </td> </tr> <tr> <td class=\"indent1\">Ulceration </td> </tr> <tr> <td class=\"indent1\">Calluses/blistering: hemorrhage into callus? </td> </tr> <tr> <td class=\"subtitle2_single\">Musculoskeletal </td> </tr> <tr> <td class=\"indent1\">Deformity, eg, claw toes, prominent metatarsal heads, Charcot joint </td> </tr> <tr> <td class=\"indent1\">Muscle wasting (guttering between metatarsals) </td> </tr> <tr> <td class=\"subtitle1_single\">Neurological assessment </td> </tr> <tr> <td class=\"subtitle2_single\">10 g monofilament +&nbsp;one of the following four</td> </tr> <tr> <td class=\"indent1\">Vibration using 128 Hz tuning fork </td> </tr> <tr> <td class=\"indent1\">Pinprick sensation </td> </tr> <tr> <td class=\"indent1\">Ankle reflexes </td> </tr> <tr> <td class=\"indent1\">VPT </td> </tr> <tr> <td class=\"subtitle1_single\">Vascular assessment </td> </tr> <tr> <td>Foot pulses</td> </tr> <tr> <td>ABI, if indicated</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ABI: ankle brachial index; VPT: vibration-perception threshold.</div><div class=\"graphic_reference\">Reprinted with permission from: Boulton AJM, Armstrong DG, Albert ST, et al. Comprehensive Foot Examination and Risk Assessment: A report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008; 31:1679. Copyright © 2008 American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 59069 Version 3.0</div></div></div>"},"59070":{"type":"graphic_algorithm","displayName":"Enteral tube feeding algorithm","title":"Enteral tube decision tree","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Enteral tube decision tree</div><div class=\"cntnt\"><img style=\"width:502px; height:567px;\" src=\"images/GAST/59070_Enteral_tube_feeding_algori.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PEG: percutaneous endoscopic gastrostomy; PEJ: percutaneous endoscopic jejunostomy; TPN: total parenteral nutrition.<BR>* Enteral feeding should also be given since it is trophic for enteric mucosa.</div><div id=\"graphicVersion\">Graphic 59070 Version 2.0</div></div></div>"},"59074":{"type":"graphic_picture","displayName":"Syphilis of the placenta","title":"Syphilis of the placenta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Syphilis of the placenta</div><div class=\"cntnt\"><img style=\"width:327px; height:587px;\" src=\"images/OBGYN/59074_Syphilis_of_the_placenta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chronic villitis.<br />(B) Onion skin placental villi.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 59074 Version 3.0</div></div></div>"},"59076":{"type":"graphic_figure","displayName":"CDC head circumference-for-age girls 0 to 36 months","title":"Head circumference-for-age percentiles, girls 0 to 36 months, CDC growth charts","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Head circumference-for-age percentiles, girls 0 to 36 months, CDC growth charts</div><div class=\"cntnt\"><img style=\"width:559px; height:756px;\" src=\"images/PEDS/59076_Head_circumference_by_age_g.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59076 Version 3.0</div></div></div>"},"59077":{"type":"graphic_diagnosticimage","displayName":"ICE mitral stenosis 2","title":"Intracardiac echocardiography mitral stenosis 2","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Intracardiac echocardiography mitral stenosis 2</div><div class=\"cntnt\"><img style=\"width:504px; height:203px;\" src=\"images/CARD/59077_ICE_mitral_stenosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracardiac examination shows a severely deformed mitral valve with extreme thickening of valve leaflets and subvalvular apparatus.</div><div id=\"graphicVersion\">Graphic 59077 Version 3.0</div></div></div>"},"59079":{"type":"graphic_picture","displayName":"Leiomyoma uterus B","title":"Bivalved hysterectomy specimen showing intramural and subserosal leiomyomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bivalved hysterectomy specimen showing intramural and subserosal leiomyomas</div><div class=\"cntnt\"><img style=\"width:360px; height:334px;\" src=\"images/OBGYN/59079_Leiomyoma_uterus_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright © Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 59079 Version 2.0</div></div></div>"},"59080":{"type":"graphic_table","displayName":"Distribution of skin lesions","title":"Distribution of common skin dermatoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of common skin dermatoses</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Flexural distribution</td> </tr> <tr> <td>Acanthosis nigricans</td> </tr> <tr> <td>Atopic dermatitis</td> </tr> <tr> <td>Bullous pemphigoid</td> </tr> <tr> <td class=\"subtitle1_single\">Extensor distribution</td> </tr> <tr> <td>Psoriasis</td> </tr> <tr> <td>Atopic dermatitis (infants)</td> </tr> <tr> <td>Dermatitis herpetiformis</td> </tr> <tr> <td>Xanthomas</td> </tr> <tr> <td class=\"subtitle1_single\">Feet/hands</td> </tr> <tr> <td>Eczema</td> </tr> <tr> <td>Tinea infections and \"id\" reactions</td> </tr> <tr> <td>Erythema multiforme</td> </tr> <tr> <td class=\"subtitle1_single\">Wrists/ankles</td> </tr> <tr> <td>Lichen planus</td> </tr> <tr> <td>Scabies</td> </tr> <tr> <td>Contact dermatitis</td> </tr> <tr> <td>Eczema</td> </tr> <tr> <td class=\"subtitle1_single\">Photodistributed</td> </tr> <tr> <td>Lupus erythematosus</td> </tr> <tr> <td>Photodrug eruption</td> </tr> <tr> <td>Dermatomyositis</td> </tr> <tr> <td>Pellagra</td> </tr> <tr> <td>Porphyria cutanea tarda</td> </tr> <tr> <td>Polymorphous light eruption</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Mouth</td> </tr> <tr> <td>Mucous cysts</td> </tr> <tr> <td>Leukoplakia</td> </tr> <tr> <td>Fordyce spots</td> </tr> <tr> <td>Pyogenic granuloma</td> </tr> <tr> <td>Skin cancers</td> </tr> <tr> <td>Kaposi's sarcoma</td> </tr> <tr> <td class=\"subtitle1_single\">Axillae</td> </tr> <tr> <td>Acanthosis nigricans</td> </tr> <tr> <td>Hidradenitis suppurativa</td> </tr> <tr> <td>Impetigo</td> </tr> <tr> <td>Hailey-Hailey disease</td> </tr> <tr> <td>Achrocordon</td> </tr> <tr> <td>Folliculitis</td> </tr> <tr> <td>Erythrasma</td> </tr> <tr> <td>Contact dermatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Buttocks/anal</td> </tr> <tr> <td>Folliculitis</td> </tr> <tr> <td>Psoriasis</td> </tr> <tr> <td>Hidradenitis suppurativa</td> </tr> <tr> <td>Lichen sclerosus et atrophicus</td> </tr> <tr> <td>Streptococcal cellulitis</td> </tr> <tr> <td>Kawasaki disease</td> </tr> <tr> <td class=\"subtitle1_single\">Scalp</td> </tr> <tr> <td>Seborrhea</td> </tr> <tr> <td>Contact dermatitis</td> </tr> <tr> <td>Tinea capitis and kerion</td> </tr> <tr> <td>Discoid lupus</td> </tr> <tr> <td>Psoriasis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59080 Version 3.0</div></div></div>"},"59081":{"type":"graphic_table","displayName":"Histologic features DIP","title":"Histologic features of desquamative interstitial pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic features of desquamative interstitial pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Key histologic features</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Uniform involvement of lung parenchyma.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prominent accumulation of alveolar macrophages (may show fine granular positivity with iron stains).</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Mild to moderate fibrotic thickening of alveolar septa.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mild interstitial chronic inflammation (lymphoid aggregates).</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Pertinent negative findings</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dense and extensive fibrosis: inconspicuous or absent.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Smooth muscle proliferation: inconspicuous or absent.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Honeycomb fibrosis absent.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fibroblastic foci and organizing pneumonia: inconspicuous or absent.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Eosinophils: inconspicuous, absent, or only focal.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 59081 Version 1.0</div></div></div>"},"59082":{"type":"graphic_table","displayName":"Radiographic patterns in ILD","title":"Helpful radiographic patterns in the differential diagnosis of interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Helpful radiographic patterns in the differential diagnosis of interstitial lung disease</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Normal*</td></tr>\n\t\t\t\t\t\t<tr><td>Hypersensitivity pneumonitis (common in population studies, rare in isolated chronic cases)</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Sarcoidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Connective tissue disease</td></tr>\n\t\t\t\t\t\t<tr><td>Bronchiolitis obliterans</td></tr>\n\t\t\t\t\t\t<tr><td>IPF (especially early \"cellular\" stage)</td></tr>\n\t\t\t\t\t\t<tr><td>Asbestosis</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphangioleiomyomatosis</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Airspace opacities</td></tr>\n\t\t\t\t\t\t<tr><td>Pulmonary hemorrhage</td></tr>\n\t\t\t\t\t\t<tr><td>Chronic or acute eosinophilic pneumonia</td></tr>\n\t\t\t\t\t\t<tr><td>Bronchiolitis obliterans with organizing pneumonia</td></tr>\n\t\t\t\t\t\t<tr><td>Alveolar proteinosis</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Reticular or linear opacities</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Peripheral lung zone predominance</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Bronchiolitis obliterans with organizing pneumonia</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Eosinophilic pneumonia</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Upper zone predominance</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2_start\">Granulomatous disease</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Sarcoidosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Pulmonary Langerhans cell histiocytosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Chronic hypersensitivity pneumonitis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Chronic infectious diseases (eg, tuberculosis, histoplasmosis)</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2_start\">Pneumoconiosis </td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Silicosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Berylliosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Coal miners' pneumoconiosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Hard metal disease</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2_start\">Miscellaneous</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Rheumatoid arthritis (necrobiotic nodular form)</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Ankylosing spondylitis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Radiation fibrosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Drug-induced (amiodarone, gold)</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Lower zone predominance</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Idiopathic pulmonary fibrosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Rheumatoid arthritis (associated with usual interstitial pneumonia)</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Asbestosis</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n    \n\n    \n\n    \n\n    \n\n    \n\n    \n    \n\n    \n    \n    \n    \n    \n\n    \n\n    \n\n    \n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* The HRCT scan is abnormal in most of these cases.</div><div id=\"graphicVersion\">Graphic 59082 Version 1.0</div></div></div>"},"59083":{"type":"graphic_picture","displayName":"Virtual Iraq Humvee scenario","title":"Virtual Iraq Humvee scenario from two user perspectives","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Virtual Iraq Humvee scenario from two user perspectives</div><div class=\"cntnt\"><img style=\"width:473px; height:191px;\" src=\"images/PSYCH/59083_Humvee_PTSD.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Skip Rizzo.</div><div id=\"graphicVersion\">Graphic 59083 Version 3.0</div></div></div>"},"59084":{"type":"graphic_picture","displayName":"Positioning for puncture of subacromial-subdeltoid bursa","title":"Positioning for ultrasound-guided puncture of subacromial-subdeltoid bursa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Positioning for ultrasound-guided puncture of subacromial-subdeltoid bursa</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/59084_Pos_punc_subacr_subdel_burs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient and needle positioning for puncture of subacromial-subdeltoid bursa.</div><div class=\"graphic_reference\">Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &#169; 2012.</div><div id=\"graphicVersion\">Graphic 59084 Version 2.0</div></div></div>"},"59085":{"type":"graphic_figure","displayName":"Calcitonin prevents osteoporosis","title":"Calcitonin prevents osteoporosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcitonin prevents osteoporosis</div><div class=\"cntnt\"><img style=\"width:410px; height:362px;\" src=\"images/ENDO/59085_CT_prevents_osteoporosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean change in lumbar bone mineral content in 39 postmenopausal women treated for two years with intranasal salmon calcitonin or placebo. Bone mineral content was stable with calcitonin but fell in the placebo group (p&lt;0.001 at two years).</div><div class=\"graphic_reference\">Data from: Overgaard K, Riis BJ, Christiansen C, et al. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989; 299:477.</div><div id=\"graphicVersion\">Graphic 59085 Version 3.0</div></div></div>"},"59086":{"type":"graphic_table","displayName":"Phys class causes dys","title":"Physiologic classification of causes of dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic classification of causes of dyspnea</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\n<tr>\n\t<td class=\"container\">\n\t<table cellspacing= \"0\">\n\t\n\t\n<tr>\t\n<td class=\"subtitle1_single\">Increased ventilatory demand</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Increased physiologic dead space</td>\n</tr>\n\n\t\n<tr>\n<td class=\"indent1\">Pulmonary embolism</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Extrinsic compression of pulmonary artery </td>\n</tr>\n\n\t\n<tr>\n<td class=\"indent1\">Emphysema</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Metabolic</td>\n</tr>\n\n\t\n<tr>\n<td class=\"indent1\">Exercise</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Altered pCO<sub>2</sub> set point</td>\n</tr>\n\n\t\n<tr>\n<td class=\"indent1\">Early metabolic acidosis due to deconditioning</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Neurohumeral</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Pain</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Anxiety</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Depression</td>\n</tr>\n\n</table>\n</td>\n\n\n\n\n<td class=\"container\">\n<table cellspacing= \"0\">\n\n<tr>\n<td class=\"subtitle1_single\">Impaired Mechanical Response</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Airway Obstruction</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Chronic bronchitis</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Tumor</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Decreased Chest Wall Compliance</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Post-thoracotomy </td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Obesity</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Decreased parenchymal elasticity</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Pulmonary fibrosis</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Pulmonary vessel congestion secondary to left heart failure</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Inspiratory muscle weakness</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Neuromuscular disease</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Cachexia due to cancer</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Steroid myopathy</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Electrolyte imbalance</td>\n</tr>\n\n\n</table>\n</td>\n</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 59086 Version 1.0</div></div></div>"},"59093":{"type":"graphic_figure","displayName":"Construction of a double barrel loop colostomy - colotomy","title":"Construction of a double barrel loop colostomy - colotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of a double barrel loop colostomy - colotomy</div><div class=\"cntnt\"><img style=\"width:360px; height:312px;\" src=\"images/SURG/59093_Double-barrel-loop-colostomy-colotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a colotomy being made on the antimesenteric surface of the colon with electrocautery.</div><div id=\"graphicVersion\">Graphic 59093 Version 1.0</div></div></div>"},"59094":{"type":"graphic_figure","displayName":"Anterior-apex paddle position","title":"Anterior/apex position of electrode paddles with a supine patient","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Anterior/apex position of electrode paddles with a supine patient</div><div class=\"cntnt\"><img style=\"width:536px; height:398px;\" src=\"images/EM/59094_Antapexpaddleposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior/apex position is most practical in the emergency setting and is typically used. The paddle or electrode pad held in the rescuer's left hand is placed to the right of the sternum below the clavicle. The paddle or electrode pad held in the rescuer's right hand is placed in the left midaxillary line, lateral to breast tissue, at the level of the nipple. If paddles are used, they must be applied with considerable, firm and steady pressure.</div><div class=\"graphic_reference\">Reproduced with permission from: Scarfone RJ, Cho CS. Cardioversion and Defibrillation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59094 Version 12.0</div></div></div>"},"59095":{"type":"graphic_diagnosticimage","displayName":"Garden type IV hip fracture","title":"Garden type IV hip fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Garden type IV hip fracture</div><div class=\"cntnt\"><img style=\"width:396px; height:374px;\" src=\"images/EM/59095_HipfxGarden4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Garden type IV fracture, there is complete displacement between fragments and the shaft translates proximally. The head is free to realign itself within the acetabulum, and the primary compressive trabeculae of the head and acetabulum realign (white lines).</div><div class=\"graphic_reference\">Reproduced with permission from: Baumgaertner MR, Higgins TF. Femoral neck fractures. In: Rockwood and Green's Fractures in Adults, 5th ed,&nbsp;Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59095 Version 12.0</div></div></div>"},"59096":{"type":"graphic_table","displayName":"Premedication prophylaxis for acute contrast reaction","title":"Premedication prophylaxis for patients with previous acute reaction to iodinated contrast","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Premedication prophylaxis for patients with previous acute reaction to iodinated contrast</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Nonurgent oral premedication:</td> </tr> <tr> <td class=\"subtitle2_single\">Glucocorticoid-preferred regimen:</td> </tr> <tr> <td class=\"indent1\"> <p>Adult: Oral prednisone 50 mg at 13, 7, and 1 hour prior to contrast administration </p> </td> </tr> <tr> <td class=\"indent1\">Pediatric: Prednisone 0.5 to 0.7 mg/kg oral (maximum 50 mg per dose) at 13, 7, and 1 hour prior to contrast administration.</td> </tr> <tr> <td class=\"subtitle2_single\">Glucocorticoid-alternate: </td> </tr> <tr> <td class=\"indent1\">Adult: Methylprednisolone&nbsp;32 mg IV at 12 and 2 hours prior to contrast administration.</td> </tr> <tr> <td class=\"indent1\">Pediatric: Methylprednisolone&nbsp;1 mg/kg IV (maximum&nbsp;32 mg per dose) at&nbsp;12 and 2&nbsp;hours prior to contrast administration.</td> </tr> <tr> <td class=\"indent1\"><strong>AND</strong></td> </tr> <tr> <td class=\"subtitle2_single\">H1 antihistamine:</td> </tr> <tr> <td class=\"indent1\">Adult: Diphenhydramine 50 mg oral, IM, or IV&nbsp;1 hour prior to contrast administration.</td> </tr> <tr> <td class=\"indent1\">Pediatric: Diphenhydramine 1.25 mg/kg oral, IM, or IV (maximum 50 mg)&nbsp;1 hour prior to contrast administration.</td> </tr> <tr> <td class=\"subtitle1_single\">Urgent intravenous premedication (eg, inpatients, emergency department):*</td> </tr> <tr> <td class=\"indent1\"><em></em> <p>Hydrocortisone 200 mg IV 5 and 1 hour prior to contrast administration and 50 mg IV diphenhydramine 1 hour prior to contrast administration. </p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously; IM: intramuscularly.<br />* Premedication regimens less than four to five hours in duration (oral or IV) have not been shown to be effective. </div><div id=\"graphicVersion\">Graphic 59096 Version 10.0</div></div></div>"},"59097":{"type":"graphic_diagnosticimage","displayName":"Anterior shoulder dislocation with greater tuberosity fracture","title":"Anterior shoulder dislocation with a displaced fracture of the greater tuberosity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior shoulder dislocation with a displaced fracture of the greater tuberosity</div><div class=\"cntnt\"><img style=\"width:432px; height:344px;\" src=\"images/EM/59097_Shoulder_DL_tuber_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This AP radiograph clearly shows a fracture of the greater tuberosity, which is completely avulsed from the humeral head (arrow).</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div id=\"graphicVersion\">Graphic 59097 Version 3.0</div></div></div>"},"59098":{"type":"graphic_figure","displayName":"Tubes for closed suction drainage","title":"Tubes for closed suction drainage","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Tubes for closed suction drainage</div><div class=\"cntnt\"><img style=\"width:532px; height:416px;\" src=\"images/SURG/59098_Closed_suction_drainage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Many sizes are available.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 59098 Version 2.0</div></div></div>"},"59099":{"type":"graphic_table","displayName":"Parapneumonic effusion drainage","title":"Categorizing risk for poor outcome in patients with parapneumonic effusions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categorizing risk for poor outcome in patients with parapneumonic effusions</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Pleural space anatomy</td>\n\n\n      <td class=\"subtitle1\">&nbsp;</td><td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Pleural fluid bacteriology</td>\n\n\n      <td class=\"subtitle1\">&nbsp;</td><td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Pleural fluid chemistry*</td>\n\n      <td class=\"subtitle1\">Category</td>\n\n      <td class=\"subtitle1\">Risk of poor outcome</td>\n\n      <td class=\"subtitle1\">Drainage</td>\n\n    </tr>\n\n    <tr>\n\n      <td>A0</td>\n\n      <td>Minimal, free flowing (&#60;10 mm on lat decub film)&yen;</td>\n\n      <td>AND </td><td>Bx </td>\n\n      <td>Culture and Gram AND stain results unknown</td>\n\n      <td>AND</td><td>Cx</td>\n\n      <td>pH unknown</td>\n      <td>1</td>\n\n      <td>Very low</td>\n\n      <td>No**</td>\n\n    </tr>\n\n    \n\n    <tr>\n\n      <td>A1</td>\n\n      <td>Small to moderate free flowing effusion (&#62;10 mm and &#60;1/2 hemithorax)</td>\n      <td>AND</td><td>B0</td>\n\n      <td>Neg culture and Gram stain&yen;&yen;</td>\n      <td>AND</td><td>C0</td>\n\n      <td>pH &#8805;7.20</td>\n      <td>2</td>\n\n      <td>Low</td>\n\n      <td>No&#8224;&#8224;</td>\n\n    </tr>\n\n    \n\n    <tr>\n\n      <td rowspan=\"2\">A2</td>\n\n      <td rowspan=\"2\">Large, free flowing (&#8805;1/2 hemithorax)***, loculated effusion&#8224;&#8224;&#8224;, or effusion with thickened parietal pleura&yen;&yen;&yen;</td>\n      <td rowspan=\"2\">OR</td><td>B1</td>\n\n      <td>Positive culture or Gram stain</td>\n\n      <td rowspan=\"2\">OR</td><td rowspan=\"2\">C1</td>\n\n      <td rowspan=\"2\">pH &#60;7.20</td>\n      <td>3</td>\n\n      <td>Moderate</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>B2</td>\n\n      <td>&nbsp;pus</td>\n\n      \n\n      \n      <td>4</td>\n\n      <td>High</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=67227&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Parapneumonic_effusion_drai.htm</title></head></div><div class=\"graphic_footnotes\">* pH is the preferred pleural fluid chemistry test, and pH must be determined by a blood gas analyzer. If a blood gas analyzer is not available, pleural fluid glucose should be used (P0 = glucose ≥60 mg/dL; P1 = glucose &lt;60 mg/dL). The expert panel cautions that the clinical utility and decision thresholds for pH and glucose have not been well-established.<br> ¥ Clinical experience indicates that effusions of this size do not require thoracentesis for evaluation, but will resolve.<br> ** If thoracentesis were performed in a patient with A0 category pleural anatomy and P1 or B1 status found, clinical experience suggests that the P1 or B1 findings might be false-positive. Repeat thoracentesis should be considered if effusion enlarges and/or clinical condition deteriorates.<br> †† If clinical condition deteriorates, repeat thoracentesis and drainage should be considered.<br> ¥¥ Regardless of prior antibiotic use.<br> *** Larger effusions are more resistant to effective drainage, possibly because of the increased likelihood that large effusions will also be loculated.<br> ††† Pleural loculations suggest a worse prognosis.<br> ¥¥¥ Thickened parietal pleura on contrast-enhanced CT suggests presence of empyema.</div><div class=\"graphic_reference\">Adapted from Colice, GL, Curtis, A, Deslauriers, J, et al, Chest 2000; 118:1158.</div><div id=\"graphicVersion\">Graphic 59099 Version 2.0</div></div></div>"},"59100":{"type":"graphic_diagnosticimage","displayName":"RLL BAC CT","title":"Bronchioloalveolar carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchioloalveolar carcinoma</div><div class=\"cntnt\"><img style=\"width:385px; height:335px;\" src=\"images/PULM/59100_RLL_BAC_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with the consolidative form of bronchioloalveolar carcinoma in the right lung. CT scan shows a mass in the posterobasal and laterobasal segments of the right lower lobe.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59100 Version 4.0</div></div></div>"},"59101":{"type":"graphic_figure","displayName":"Ventilation in pregnancy","title":"Changes in ventilation during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Changes in ventilation during pregnancy</div><div class=\"cntnt\"><img style=\"width:492px; height:258px;\" src=\"images/PULM/59101_Ventilation_pregnancy_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time course of % increases in minute ventilation, oxygen uptake, and basal metabolism during pregnancy.</div><div class=\"graphic_reference\">Modified from: Prowse CM, Gaensler EA. Respiratory and acid-base changes during pregnancy. Anesthesiology 1965; 26:381.</div><div id=\"graphicVersion\">Graphic 59101 Version 4.0</div></div></div>"},"59102":{"type":"graphic_figure","displayName":"Pregnancy rate by age of donor oocyte","title":"Percentages of transfers that resulted in live births for ART cycles using fresh embryos from own eggs and ART cycles using donor eggs, by age of woman, 2012","html":"<div class=\"graphic\"><div style=\"width: 714px\" class=\"figure\"><div class=\"ttl\">Percentages of transfers that resulted in live births for ART cycles using fresh embryos from own eggs and ART cycles using donor eggs, by age of woman, 2012</div><div class=\"cntnt\"><img style=\"width:694px; height:356px;\" src=\"images/ENDO/59102_Preg_rate_age_donor_oocyte.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ART: assisted reproductive technology.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. 2012 Assisted Reproductive Technology National Summary Report. Section 4: ART Cycles using donor eggs. Available at: <a href=\"http://www.cdc.gov/art/pdf/2012-report/slides/art-2012-graphs-charts-figure-39.pdf\" target=\"_blank\">www.cdc.gov/art/pdf/2012-report/slides/art-2012-graphs-charts-figure-39.pdf</a> (Accessed May 26, 2015).</div><div id=\"graphicVersion\">Graphic 59102 Version 4.0</div></div></div>"},"59103":{"type":"graphic_table","displayName":"Guidelines for spacing live and inactivated antigens","title":"Guidelines for spacing of live and inactivated antigens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for spacing of live and inactivated antigens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antigen combination</td> <td class=\"subtitle1\">Recommended minimum interval between doses</td> </tr> <tr> <td>Two or more inactivated*<sup>&#182;</sup></td> <td>May be administered simultaneously or at any interval between doses</td> </tr> <tr> <td>Inactivated and live<sup>&#916;</sup></td> <td>May be administered simultaneously or at any interval between doses</td> </tr> <tr> <td>Two or more live injectable<sup>&#916;</sup></td> <td>28 days minimum interval, if not administered simultaneously</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MCV-4: meningococcal conjugate vaccine; PCV-13: pneumococcal conjugate vaccine (13-valent); PPSV23: pneumococcal polysaccharide vaccine.<br />* Certain experts suggest a 28-day interval between tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine and tetravalent meningococcal conjugate vaccine if they are not administered simultaneously.<br />¶ In&nbsp;persons with functional or anatomic asplenia, MCV-4 and PCV13 should not be administered simultaneously and should be spaced by four weeks. Likewise for persons with immunosuppressive high-risk conditions indicated for PCV13 and PPSV23, PCV13 should be administered first, and PPSV23 should be administered no earlier than 8 weeks later. For persons 65 years old or older indicated for PCV13 and PPSV23, PCV13 should be administered first and PPSV23 should be administered 6 to 12 months later.<br />Δ The live oral vaccines Ty21a typhoid vaccine and rotavirus vaccine may be administered simultaneously with or at any interval before or after inactivated or live injectable vaccines.</div><div class=\"graphic_reference\">Reproduced with permission of the American Academy of Pediatrics, from: Active Immunization. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), Copyright © 2015; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 59103 Version 4.0</div></div></div>"},"59104":{"type":"graphic_picture","displayName":"Seborrheic dermatitis face 2","title":"Facial seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Facial seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:644px; height:270px;\" src=\"images/DERM/59104_Seborrheicdermattsfc2E1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intense erythema and scaling involving the central face and nasolabial folds.</div><div id=\"graphicVersion\">Graphic 59104 Version 4.0</div></div></div>"},"59105":{"type":"graphic_picture","displayName":"Gram stain CSF 5A with answer","title":"Listeria monocytogenes in cerebrospinal fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Listeria monocytogenes in cerebrospinal fluid</div><div class=\"cntnt\"><img style=\"width:360px; height:322px;\" src=\"images/ID/59105_Gram_stain_CSF_5A_with_answ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and small, gram-positive rods and coccobacilli. Culture of this specimen revealed moderate sized, beta-hemolytic colonies composed of small, motile gram-positive rods, confirmed to be <EM>Listeria monocytogenes</EM>.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 59105 Version 3.0</div></div></div>"},"59106":{"type":"graphic_picture","displayName":"Nodule of onchocerciasis","title":"Onchocerciasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Onchocerciasis</div><div class=\"cntnt\"><img style=\"width:243px; height:348px;\" src=\"images/ID/59106_Nodule_of_onchocerciasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A painless subcutaneous nodule (arrow) inhabited by the adult filarilal worms of <EM innerHtml>Onchocerca volvulus</EM>, which is transmitted by the black fly. The female adult worms give rise to the microfilariae that produce the dermal and ocular manifestations of onchocerciasis.</div><div class=\"graphic_reference\">Courtesy of Krotoski WA. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp;Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 59106 Version 6.0</div></div></div>"},"59108":{"type":"graphic_picture","displayName":"H and E subtypes MPM","title":"H&E subtypes MPM","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">H&amp;E subtypes MPM</div><div class=\"cntnt\"><img style=\"width:263px; height:593px;\" src=\"images/ONC/59108_H_and_E_subtypes_MPM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrographs of hematoxylin and eosin (H&amp;E)-stained sections of three different histologic subtypes of malignant peritoneal mesothelioma, photographed at 400x magnification. (A) epithelioid, (B) sarcomatoid, and (C) tubulopapillary.</div><div class=\"graphic_reference\">Courtesy of Dr. H Richard Alexander, Jr., as published for the National Institutes of Health.</div><div id=\"graphicVersion\">Graphic 59108 Version 1.0</div></div></div>"},"59110":{"type":"graphic_table","displayName":"Surfactant products","title":"Surfactant products for neonatal respiratory distress syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surfactant products for neonatal respiratory distress syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Surfactant</td> <td class=\"subtitle1\">Origin</td> <td class=\"subtitle1\">Concentration of phospholipids</td> <td class=\"subtitle1\">Concentration of protein</td> <td class=\"subtitle1\">Initial dose*</td> <td class=\"subtitle1\">Repeat dosing schedule*</td> </tr> <tr class=\"divider_bottom\"> <td>Poractant alfa (Curosurf)</td> <td>Porcine lung minces, lipid extraction with purification using liquid-gel chromatography.</td> <td>76 mg PL per mL</td> <td>1 mg per mL (contains 0.45 mg/mL of SP-B and 0.59 mg/mL of SP-C)</td> <td>2.5 mL/kg (contains 190 mg/kg PL)</td> <td>1.25 mL/kg (95 mg/kg PL) every 12 hours as needed up to two total doses.</td> </tr> <tr class=\"divider_bottom\"> <td>Calfactant (Infasurf)</td> <td>Calf lung lavage, lipid extraction.</td> <td>35 mg PL per mL</td> <td>0.7 mg per mL (contains 0.26 mg/mL of SP-B and 0.44 mg/mL of SP-C)</td> <td>3 mL/kg (contains 105 mg/kg PL)</td> <td>3 mL/kg (105 mg/kg PL) every 12 hours as needed up to three total doses.</td> </tr> <tr class=\"divider_bottom\"> <td>Beractant (Survanta)</td> <td>Bovine lung minces, lipid extraction. Supplemented with DPPC, palmitic acid, and tripalmitin.</td> <td>25 mg PL per mL</td> <td>&#60;1 mg per mL (contains both SP-B and SP-C)</td> <td>4 mL/kg (contains 100 mg/kg PL)</td> <td>Repeat same dose every six hours as needed for total of four doses.</td> </tr> <tr class=\"divider_bottom\"> <td>Bovine lipid extract surfactant<br /> (BLES, available in Canada)</td> <td>Extract of natural bovine lung surfactant.</td> <td>27 mg PL per mL</td> <td>0.2 to 0.5 mg per mL (contains both SP-B and SP-C)</td> <td>5 mL/kg (contains 135 mg/kg PL)</td> <td>Repeat same dose as needed up to a maximum of four doses within the first five days of life.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PL: phospholipid; DPPC: dipalmitoylphosphatidylcholine; POPG: palmitoyloleoyl-phosphatidylglycerol; SP-B: surfactant-associated protein B; SP-C: surfactant-associated protein C; KL<SUB>4</SUB>: sinapultide.<br />* mL of surfactant per kg of birth weight for intratracheal administration.<br /></div><div class=\"graphic_reference\">Data from:&nbsp;<br /><OL>&#xD;&#xA;<LI>United States Prescribing Information. National Library of Medicine, DailyMed. <A spellcheck=true href=\"http://dailymed.nlm.nih.gov/dailymed/index.cfm\" target=_blank>http://dailymed.nlm.nih.gov/dailymed/index.cfm</A> (Accessed on August 20, 2015).</LI>&#xD;&#xA;<LI>Canadian Product Monograph. Health Canada. <A spellcheck=true href=\"http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp\" target=_blank>http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp</A> (Accessed on&nbsp;August 20, 2015).</LI></OL></div><div id=\"graphicVersion\">Graphic 59110 Version 9.0</div></div></div>"},"59113":{"type":"graphic_picture","displayName":"AIRTRAQ pediatric sizes","title":"AIRTRAQ pediatric sizes","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">AIRTRAQ pediatric sizes</div><div class=\"cntnt\"><img style=\"width:514px; height:389px;\" src=\"images/EM/59113_AIRTRAQ_pediatric_sizes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Airtraq laryngoscopes come in a variety of sizes (A), including (B) infant (gray), and (C) pediatric (pink).</div><div class=\"graphic_reference\">Reproduced with permission from: Airtraq LLC. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 59113 Version 2.0</div></div></div>"},"59114":{"type":"graphic_figure","displayName":"Location of retropubic midurethral sling","title":"Retropubic midurethral sling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retropubic midurethral sling</div><div class=\"cntnt\"><img style=\"width:373px; height:390px;\" src=\"images/OBGYN/59114_Loc_retropub_midureth_sling.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59114 Version 3.0</div></div></div>"},"59116":{"type":"graphic_picture","displayName":"Tuberculosis verrucosa cutis histopathology","title":"Tuberculosis verrucosa cutis","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Tuberculosis verrucosa cutis</div><div class=\"cntnt\"><img style=\"width:514px; height:264px;\" src=\"images/DERM/59116_Tubrc_verr_cutis_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This specimen from a lesion of tuberculosis verrucosa cutis demonstrates epidermal acanthosis, intraepidermal abscess formation, and a&nbsp;lichenoid&nbsp;lymphohistiocytic infiltrate in the dermis (A). A multinucleated giant cell is visible at higher magnification (B).</div><div class=\"graphic_reference\">Courtesy of the Research Institute for Tropical Medicine, Philippines.</div><div id=\"graphicVersion\">Graphic 59116 Version 1.0</div></div></div>"},"59117":{"type":"graphic_figure","displayName":"TWAR equation","title":"Equation for computing T wave alternans ratio","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Equation for computing T wave alternans ratio</div><div class=\"cntnt\"><img style=\"width:280px; height:91px;\" src=\"images/CARD/59117_TWAR_equation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59117 Version 1.0</div></div></div>"},"59118":{"type":"graphic_picture","displayName":"TMEP III","title":"Telangiectasia macularis eruptive perstants (TMEP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Telangiectasia macularis eruptive perstants (TMEP)</div><div class=\"cntnt\"><img style=\"width:396px; height:300px;\" src=\"images/ALLRG/59118_TMEP_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cem Akin, MD, PhD.</div><div id=\"graphicVersion\">Graphic 59118 Version 3.0</div></div></div>"},"59119":{"type":"graphic_table","displayName":"Bedside tests of attention","title":"Bedside tests of attention","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bedside tests of attention</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Test</td>\n\n      <td class=\"subtitle1\">Directions</td>\n\n      <td class=\"subtitle1\">Scoring</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Digit span</td>\n\n      <td>Ask the subject to listen carefully and repeat a series of\nrandom numbers. Begin with a string of 2 digits, then increase. Read\neach number in a normal tone of voice at a rate of one digit per\nsecond, taking care not to group digits in pairs or sequences that\ncould aid repetition; eg, 3 - 52 - 8 - 18 - 4 - 9 - 36 - 3 - 8 - 5 - 15\n- 7 - 2 - 9 - 4 - 68 - 1 - 9 - 2 - 7 - 5 - 6</td>\n\n      <td>Inability to repeat a string of at least five digits indicates probable impairment.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Vigilance \"A\" test</td>\n\n      <td>Read a list of 60 letters, among which the letter \"A\" appears\nwith greater than random frequency. The subject is required to indicate\n(eg, by tapping on the desk) whenever the target letter is spoken by\nthe examiner. The letter list is read in a normal tone at a rate of one letter per second; eg, L T P E A O A I C T D A L A A N I A B F S A M R A E O Z\nD P A K A L U C J T A E O</td>\n\n      <td>Count errors of omission and commission. More than two errors is considered abnormal.</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 59119 Version 1.0</div></div></div>"},"59121":{"type":"graphic_figure","displayName":"IPF static deflation volume","title":"Relationship of the static deflation volume and pressure in a patient with idiopathic pulmonary fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relationship of the static deflation volume and pressure in a patient with idiopathic pulmonary fibrosis</div><div class=\"cntnt\"><img style=\"width:373px; height:367px;\" src=\"images/PULM/59121_IPF_static_deflation_volume.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lung volume (as a percent of predicted TLC) is plotted against the static transpulmonary pressure (cmH2O) for a patient with ILD. In general, the compliance, maximum static transpulmonary pressure, and the coefficient of retraction (the maximum transpulmonary pressure to TLC) tend to correlate with the extent of parenchymal lung involvement observed on lung biopsy.</div><div id=\"graphicVersion\">Graphic 59121 Version 1.0</div></div></div>"},"59123":{"type":"graphic_figure","displayName":"Severity restrictive disease","title":"Interpretation of office spirometry: Restrictive pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interpretation of office spirometry: Restrictive pattern</div><div class=\"cntnt\"><img style=\"width:376px; height:308px;\" src=\"images/PULM/59123_Severity_restrictive_dz_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spirometry interpretation flow chart for the detection of a restrictive ventilatory defect.</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second; FVC: forced vital capacity; LLN: lower limit of normal.<br />* The fifth percentile LLN, as calculated by most spirometers, should be used to detect airway obstruction, rather than the absolute value of the FEV<SUB>1</SUB>/FVC ratio.<br />¶ Measurement of lung volumes is needed to confirm restriction (ie, total lung capacity below fifth percentile of predicted). A reduced FVC by itself does not prove restriction.</div><div id=\"graphicVersion\">Graphic 59123 Version 3.0</div></div></div>"},"59124":{"type":"graphic_picture","displayName":"Port wine stain - V2 infant","title":"Port wine stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Port wine stain</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/59124_Port_wine_stain_V2_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A port wine stain in the V2 distribution is present on the face of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59124 Version 4.0</div></div></div>"},"59125":{"type":"graphic_figure","displayName":"HBV replication cycle","title":"Replication cycle of HBV","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Replication cycle of HBV</div><div class=\"cntnt\"><img style=\"width:372px; height:390px;\" src=\"images/GAST/59125_HBV_replication_cycle.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the replication cycle of hepatitis B virus (HBV). The replication cycle of HBV begins with attachment of the virion to the hepatocyte membrane, a process that may be mediated through the pre-S1 region of the virion envelope. The virion is uncoated in the hepatocyte cytoplasm and the viral genome enters the hepatocyte nucleus. Inside the hepatocyte nucleus, synthesis of the plus strand HBV DNA is completed and the viral genome is converted into a covalently closed circular DNA (ccc DNA). The pregenomic RNA, nucleocapsid, and polymerase proteins are encapsidated in the virus core particle inside which reverse transcription takes place. A new minus strand HBV DNA is produced followed by the synthesis of a new plus strand HBV DNA. Nucleocapsids with the partially double stranded HBV DNA can reenter the hepatocyte nucleus to produce more ccc DNA or be secreted as complete virions after coating with envelope proteins.</div><div id=\"graphicVersion\">Graphic 59125 Version 1.0</div></div></div>"},"59127":{"type":"graphic_figure","displayName":"Focal distribution of HAT","title":"The focal distribution of human African trypanosomiasis","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">The focal distribution of human African trypanosomiasis</div><div class=\"cntnt\"><img style=\"width:514px; height:294px;\" src=\"images/ID/59127_Focal_distribution_of_HAT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left of the red line: <EM>Trypanosoma brucei gambiense </EM>foci in West and Central Africa. Right of the red line: <EM>Trypanosoma brucei rhodesiense </EM>foci in Eastern and South Africa.</div><div class=\"graphic_reference\">Report of the Scientific Working Group meeting on African trypanosomiasis Geneva, 4 to 8 June 2001. Reproduced with permission from the World Health Organization. Copyright © 2001 World Health Organization.</div><div id=\"graphicVersion\">Graphic 59127 Version 3.0</div></div></div>"},"59131":{"type":"graphic_figure","displayName":"Achieving hemostasis after cone","title":"Achieving hemostasis after cervical (uterine cervix) conization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Achieving hemostasis after cervical (uterine cervix) conization</div><div class=\"cntnt\"><img style=\"width:413px; height:336px;\" src=\"images/OBGYN/59131_Achieving_hemostasis_after.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A surgical hemostatic pack (Surgicel) is placed into the unsutured cone bed and then secured in place by tying across with lateral cervical sutures.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 59131 Version 2.0</div></div></div>"},"59132":{"type":"graphic_table","displayName":"Body art information","title":"Resources for information about tattoos and body piercing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for information about tattoos and body piercing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Tattoos</td> </tr> <tr> <td class=\"subtitle2_single\">Websites</td> </tr> <tr> <td class=\"indent1\">Alliance of Professional Tattooists, Inc.<br /> www.safe-tattoos.com</td> </tr> <tr> <td class=\"indent1\">About.com<br /> Tattoos<br /> www.tattoo.about.com</td> </tr> <tr> <td class=\"indent1\">US Food and Drug Administration<br /> Think before you ink: Are tattoos safe?<br /> <a href=\"http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048919.htm\" target=\"_blank\">www.fda.gov</a></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">US National Library of Medicine<br /> Piercing and Tattoos<br /> <a href=\"https://www.nlm.nih.gov/medlineplus/piercingandtattoos.html\" target=\"_blank\">www.nlm.nih.gov</a></td> </tr> <tr> <td class=\"subtitle2_single\">Books</td> </tr> <tr> <td class=\"indent1\">Why People Get Tattoos and Other Body Art by Jeanne Nagle (Rosen Publishing)</td> </tr> <tr> <td class=\"indent1\">Tattoo Art Around the World by Diane Bailey (Rosen Publishing)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Erasing the Ink: Getting Rid of Your Tattoo by Frank Spalding (Rosen Publishing)</td> </tr> <tr> <td class=\"subtitle1_single\">Body piercing</td> </tr> <tr> <td class=\"subtitle2_single\">Websites</td> </tr> <tr> <td class=\"indent1\">Association of Professional Piercers<br /> <a href=\"http://www.safepiercing.org/\" target=\"_blank\">www.safepiercing.org</a></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">US National Library of Medicine<br /> Piercing and Tattoos<br /> <a href=\"https://www.nlm.nih.gov/medlineplus/piercingandtattoos.html\" target=\"_blank\">www.nlm.nih.gov</a></td> </tr> <tr> <td class=\"subtitle2_single\">Books</td> </tr> <tr> <td class=\"indent1\">DeBoer S. Body Piercing Removal: Healthcare Professionals Handbook (includes DVD), Peds-R-Us Medical Education, LLC, Dyer, IN 2013.<br /> Available at www.Peds-R-Us.com</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59132 Version 12.0</div></div></div>"},"59133":{"type":"graphic_figure","displayName":"Stage-based survival in patients with RCC","title":"Stage-based survival in patients with renal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Stage-based survival in patients with renal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:525px; height:442px;\" src=\"images/ONC/59133_Stage-based-survival-RCC.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 59133 Version 11.0</div></div></div>"},"59134":{"type":"graphic_figure","displayName":"Modified vasectomy forceps","title":"Modified vasectomy forceps","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Modified vasectomy forceps</div><div class=\"cntnt\"><img style=\"width:497px; height:185px;\" src=\"images/OBGYN/59134_ModifiedvasectforcepPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The forceps used in vasectomy operations are ideal for removing deeply placed contraceptive implants. The forceps are modified so that the diameter of the circular grasper is reduced to slightly less than 2 mm.</div><div class=\"graphic_reference\">Reproduced with permission from: Speroff L, Darney PD. A Clinical Guide for Contraception, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59134 Version 6.0</div></div></div>"},"59135":{"type":"graphic_picture","displayName":"Pseudoxanthoma elasticum neck 2","title":"Pseudoxanthoma elasticum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudoxanthoma elasticum</div><div class=\"cntnt\"><img style=\"width:432px; height:347px;\" src=\"images/DERM/59135_PXE_neck_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Symmetric, confluent, yellow papules and redundant skin folds are present in this 38-year-old woman. The characteristic plucked chicken skin changes on the neck of patients with pseudoxanthoma elasticum are seen. An eye examination showed the characteristic angioid streaks.</div><div class=\"graphic_reference\">Copyright © Rakhesh SV, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 59135 Version 7.0</div></div></div>"},"59139":{"type":"graphic_diagnosticimage","displayName":"Brain images of K. pneumoniae","title":"Brain images of Klebsiella pneumoniae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain images of Klebsiella pneumoniae</div><div class=\"cntnt\"><img style=\"width:369px; height:442px;\" src=\"images/ID/59139_K_pneum_brain_images.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panels A and B) A 64-year-old diabetic woman with K. pneumoniae liver abscess and meningitis developed relapsing K. pneumoniae meningitis one month later. CT (panel A) and MRI (panel B) of the brain demonstrate mild internal hydrocephalus and ventriculitis.<br />(Panels C and D) A 62-year-old diabetic man with fever, vomiting, altered mental status and seizure. CT of the brain demonstrates obliteration of right-sided cortical sulci (panel C). MRI of the brain demonstrates right subdural effusion (panel D, arrows). Culture from subdural empyema obtained at surgery grew K. pneumoniae.</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Wen-Liang Yu, MD and Yin-Ching Chuang, MD.</div><div id=\"graphicVersion\">Graphic 59139 Version 5.0</div></div></div>"},"59140":{"type":"graphic_figure","displayName":"Circadian pattern UAP nonQ MI","title":"Circadian variation in unstable angina and non-Q wave myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Circadian variation in unstable angina and non-Q wave myocardial infarction</div><div class=\"cntnt\"><img style=\"width:537px; height:297px;\" src=\"images/CARD/59140_CircadianpatternUAPnonQ.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prospective analysis of patients entered into the TIMI III registry shows that there is a circadian variation in the onset of pain in patients with unstable angina and non-Q wave myocardial infarction; the greatest number of patients experience the onset of pain between 6&nbsp;AM and 12 PM.</div><div class=\"graphic_reference\">Redrawn from Cannon, CP, McCabe, CH, Stone, PH, et al, for the TIMI III Registry and TIMI IIIB Investigators, AM J Cardiol 1997; 79:253.</div><div id=\"graphicVersion\">Graphic 59140 Version 2.0</div></div></div>"},"59141":{"type":"graphic_picture","displayName":"Bell palsy photos","title":"Bell's palsy: Idiopathic facial nerve (cranial nerve VII) palsy","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Bell's palsy: Idiopathic facial nerve (cranial nerve VII) palsy</div><div class=\"cntnt\"><img style=\"width:508px; height:519px;\" src=\"images/NEURO/59141_Bells_palsy_photos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Man with idiopathic peripheral facial nerve (cranial nerve VII) palsy, or Bell's palsy.<br />(A) Demonstrates inability to raise the left eyebrow or generate wrinkles on the left side of forehead;<br />(B) Demonstrates difficulty closing the left eye and inability to raise the left corner of mouth;<br />(C) Demonstrates drooping at the left corner of mouth, loss of the left nasolabial fold, and inability to completely close the left eye.</div><div class=\"graphic_reference\">Reproduced with permission from: Charles Goldberg, MD and The University of California, San Diego. Copyright &copy; 2005 The Regents of the University of California. http://medicine.ucsd.edu/clinicalimg/neuro-central-CN7-palsy2.html.</div><div id=\"graphicVersion\">Graphic 59141 Version 4.0</div></div></div>"},"59142":{"type":"graphic_figure","displayName":"Hayman stitch","title":"Hayman stitch","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Hayman stitch</div><div class=\"cntnt\"><img style=\"width:514px; height:382px;\" src=\"images/OBGYN/59142_Hayman_stitch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hayman described a modification of the B-Lynch suture that is performed without a hysterotomy. Two to four vertical compression sutures are placed, as needed, but in contrast to the B-Lynch technique, these sutures pass directly from the anterior uterine wall to the posterior uterine wall. A transverse cervicoisthmic suture can also be placed if needed to control bleeding from the lower uterine segment.</div><div class=\"graphic_reference\">Hayman, RG, Arulkumaran, S, Steer, PJ. Uterine compression sutures: surgical management of postpartum hemorrhage. Obstet Gynecol 2002; 99:502.</div><div id=\"graphicVersion\">Graphic 59142 Version 3.0</div></div></div>"},"59143":{"type":"graphic_diagnosticimage","displayName":"Cyclopia","title":"Cyclopia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cyclopia</div><div class=\"cntnt\"><img style=\"width:254px; height:365px;\" src=\"images/PEDS/59143_Cyclopia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph shows the single orbital cavity of cyclopia in holoprosencephaly.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 59143 Version 2.0</div></div></div>"},"59144":{"type":"graphic_diagnosticimage","displayName":"Proximal phalanx condylar fracture AP radiograph","title":"Condylar fracture of the proximal phalanx: AP view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Condylar fracture of the proximal phalanx: AP view</div><div class=\"cntnt\"><img style=\"width:334px; height:544px;\" src=\"images/EM/59144_Prox_phal_condylar_fx_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anterior-posterior (AP)&nbsp;radiograph shows a condylar fracture at the head of the proximal phalanx. These fractures most often involve one condyle and are unstable.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 59144 Version 3.0</div></div></div>"},"59145":{"type":"graphic_diagnosticimage","displayName":"Ulceration in Barretts","title":"Esophageal ulceration in Barrett's metaplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal ulceration in Barrett's metaplasia</div><div class=\"cntnt\"><img style=\"width:226px; height:376px;\" src=\"images/GAST/59145_Ulceration_in_Barretts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium swallow in a patient with gastroesophageal reflux and Barrett's metaplasia shows a granular appearance of the mucosa and a large proximal esophageal ulceration.</div><div class=\"graphic_reference\">Courtesy of Anita E Spiess, MD and Peter J Kahrilas, MD.</div><div id=\"graphicVersion\">Graphic 59145 Version 2.0</div></div></div>"},"59146":{"type":"graphic_figure","displayName":"Intrauterine pressure in dysmenorrhea with and without NSAIDs","title":"Intrauterine pressure in dysmenorrhea with and without NSAID therapy","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Intrauterine pressure in dysmenorrhea with and without NSAID therapy</div><div class=\"cntnt\"><img style=\"width:475px; height:276px;\" src=\"images/OBGYN/59146_Uterine_pressure_after_NSAI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In women with primary dysmenorrhea, treatment with meclofenamate produces a decrease in mean intrauterine pressure as recorded by an intrauterine microtransducer (blue line). Placebo treatment did not decrease intrauterine pressure (red line). A reduction in intrauterine pressure was associated with a decrease in reported dysmenorrhea.</div><div class=\"graphic_reference\">Data adapted from: Smith, RP, the dynamics of nonsteroidal anti-inflammatory therapy for primary dysmenorrhea. Obstet Gynecol 1987; 70:785.</div><div id=\"graphicVersion\">Graphic 59146 Version 2.0</div></div></div>"},"59147":{"type":"graphic_picture","displayName":"Multicystic dysplastic kidney","title":"Multicystic dysplastic kidney: gross pathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multicystic dysplastic kidney: gross pathology</div><div class=\"cntnt\"><img style=\"width:432px; height:400px;\" src=\"images/PEDS/59147_Multicystic_dysplastic_kidn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross pathologic features observed in the multicystic dysplastic kidney. Poorly defined renal archectiture, loss of corticomedullary differentiation, and multiple cysts are evident.</div><div id=\"graphicVersion\">Graphic 59147 Version 3.0</div></div></div>"},"59149":{"type":"graphic_table","displayName":"Rapid vancomycin desensitization protocol","title":"Rapid vancomycin desensitization protocol","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid vancomycin desensitization protocol</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Premedication:</strong> Diphenhydramine 50 mg IV and hydrocortisone 100 mg IV 15 minutes prior to initiation of protocol, then every six hours throughout protocol</td> </tr> <tr> <td class=\"subtitle1\">Infusion number</td> <td class=\"subtitle1\">Dilution</td> <td class=\"subtitle1\">Vancomycin dose (mg)</td> <td class=\"subtitle1\">Concentration (mg/mL)</td> </tr> <tr> <td>1</td> <td>1:10,000</td> <td>0.02</td> <td>0.0002</td> </tr> <tr> <td>2</td> <td>1:1000</td> <td>0.2</td> <td>0.002</td> </tr> <tr> <td>3</td> <td>1:100</td> <td>2</td> <td>0.02</td> </tr> <tr> <td>4</td> <td>1:10</td> <td>20</td> <td>0.2</td> </tr> <tr> <td>5</td> <td>Standard</td> <td>500</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Preparation</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">1. Prepare a standard bag of 500 mg vancomycin in 250 mL NS or D5W; label as infusion number 5, vancomycin 2 mg/mL.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">2. Draw up 10 mL of the standard vancomycin 2 mg/mL preparation and place in 100 mL bag of NS or D5W; label as infusion number 4, vancomycin 0.2 mg/mL.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">3. Draw up 10 mL of the 0.2 mg/mL solution and place in a 100 mL bag of NS or D5W; label as infusion number 3, vancomycin 0.02 mg/mL.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">4. Draw up 10 mL of the 0.02 mg/mL solution and place in a 100 mL bag of NS or D5W; label as infusion number 2, vancomycin 0.002 mg/mL.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">5. Draw up 10 mL of the 0.002 mg/mL solution and place in a 100 mL bag of NS or D5W; label as infusion number 1, vancomycin 0.0002 mg/mL.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Infusion rate directions</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Initiate infusion rate at 0.5 mL/minute (30 mL/hour) and increase by 0.5 mL/min (30 mL/hour) as tolerated every five minutes to a maximum rate of 5 mL/minute (300 mL/hour). If pruritus, hypotension, rash, or difficulty breathing occurs, stop infusion and reinfuse the previously tolerated infusion at the highest tolerated rate. This step may be repeated up to three times for any given concentration.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Upon completion of infusion number 5, immediately administer the required dose of vancomycin in the usual dilution of NS or D5W over two hours. Decrease rate if patient becomes symptomatic or, alternatively, increase rate if patient tolerated dose. Administer diphenhydramine 50 mg orally 60 minutes prior to each dose.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; NS: sodium chloride 0.9% solution; D5W: dextrose 5% in water.</div><div class=\"graphic_reference\">Reproduced with permission from: Wazny LD, et al. Desensitization protocols for vancomycin hypersensitivity. The Annals of Pharmacotherapy 2001; 35:1458. Copyright &copy; 2001 Harvey Whitney.</div><div id=\"graphicVersion\">Graphic 59149 Version 6.0</div></div></div>"},"59150":{"type":"graphic_picture","displayName":"Molluscum penis 2","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/DERM/59150_Molluscum_penis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has a &quot;giant&quot; molluscum lesion on the shaft of his penis as well as other scattered smaller lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59150 Version 2.0</div></div></div>"},"59152":{"type":"graphic_picture","displayName":"Peaked pupil","title":"Clinical photo of a patient with a small corneal laceration with uveal prolapse plugging the wound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical photo of a patient with a small corneal laceration with uveal prolapse plugging the wound</div><div class=\"cntnt\"><img style=\"width:351px; height:111px;\" src=\"images/EM/59152_Peaked_pupil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peaked pupil indicates the incarceration of the iris.</div><div id=\"graphicVersion\">Graphic 59152 Version 2.0</div></div></div>"},"59155":{"type":"graphic_picture","displayName":"Bergmeister papilla","title":"Bergmeister papilla","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bergmeister papilla</div><div class=\"cntnt\"><img style=\"width:377px; height:271px;\" src=\"images/PEDS/59155_Bergmeister_papilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A white glial remnant overlies the central portion of the disc, obscuring the retinal vessels.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 59155 Version 1.0</div></div></div>"},"59157":{"type":"graphic_diagnosticimage","displayName":"SCFE radiograph","title":"Slipped capital femoral epiphysis (SCFE)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Slipped capital femoral epiphysis (SCFE)</div><div class=\"cntnt\"><img style=\"width:504px; height:309px;\" src=\"images/PEDS/59157_SCFE_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the posterior displacement of the femoral epiphysis on the left, which appears like ice-cream slipping off a cone (arrow).</div><div class=\"graphic_reference\">Courtesy of Andrew Kienstra, MD and Charles G Macias, MD.</div><div id=\"graphicVersion\">Graphic 59157 Version 3.0</div></div></div>"},"59158":{"type":"graphic_table","displayName":"Norton scale for predicting risk of pressure-induced injury","title":"Norton scale for predicting risk of pressure-induced injury*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Norton scale for predicting risk of pressure-induced injury*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n <tbody>\n\n <tr>\n\n  <td class=\"subtitle1\">Physical condition</td>\n  <td class=\"subtitle1\">Mental condition</td>\n  <td class=\"subtitle1\">Activity</td>\n  <td class=\"subtitle1\">Mobility</td>\n  <td class=\"subtitle1\">Incontinent</td>\n\n </tr>\n\n <tr>\n\n  <td>4 = Good</td>\n  <td>4 = Alert</td>\n  <td>4 = Ambulant</td>\n  <td>4 = Full</td>\n  <td>4 = Not</td>\n\n </tr>\n\n <tr>\n\n  <td>3 = Fair</td>\n  <td>3 = Apathetic</td>\n  <td>3 = Walk/help</td>\n  <td>3 = Slightly limited</td>\n  <td>3 = Occasional</td>\n\n </tr>\n\n <tr>\n\n  <td>2 = Poor</td>\n  <td>2 = Confused</td>\n  <td>2 = Chairbound</td>\n  <td>2 = Very limited</td>\n  <td>2 = Usually/urine</td>\n\n </tr>\n\n <tr>\n\t\n\t<td>1 = Very bad</td>\t\n\t<td>1 = Stupor</td>\n\t<td>1 = Bed</td>\n\t<td>1 = Immobile</td>\n\t<td>1 = Doubly</td>\n\t\n</tr>\n\n <tr>\n\t\n\t<td><strong>Score:</strong> __________</td>\t\n\t<td><strong>Score:</strong> __________</td>\n\t<td><strong>Score:</strong> __________</td>\n\t<td><strong>Score:</strong> __________</td>\n\t<td><strong>Score:</strong> __________</td>\n\t\n</tr>\n\n </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=60091&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Norton_scale.htm</title></head></div><div class=\"graphic_footnotes\">* Calculated as the sum of the scores in all five areas. A score less than 14 indicates a high risk of pressure ulcer development.</div><div class=\"graphic_reference\">Adapted from: Norton D. Calculating the risk: reflections on the Norton Scale. Decubitus 1989; 2:24.</div><div id=\"graphicVersion\">Graphic 59158 Version 5.0</div></div></div>"},"59159":{"type":"graphic_table","displayName":"Secondary causes of short QT interval on ECG","title":"Secondary causes of short QT interval on ECG","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary causes of short QT interval on ECG</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Hyperkalemia</td> </tr> <tr> <td>Hypercalcemia</td> </tr> <tr> <td>Hyperthermia</td> </tr> <tr> <td>Acidosis</td> </tr> <tr> <td>Effect of catecholamine</td> </tr> <tr> <td>Activation of ATP-sensitive potassium current</td> </tr> <tr> <td>Activation of acetylcholine-sensitive potassium current</td> </tr> <tr> <td>Effects of drugs like digitalis</td> </tr> <tr> <td>Myocardial ischemia</td> </tr> <tr> <td>Increased vagal tone</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59159 Version 1.0</div></div></div>"},"59160":{"type":"graphic_figure","displayName":"Time velocity CM pericarditis","title":"Medial mitral annular time-velocity plots","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Medial mitral annular time-velocity plots</div><div class=\"cntnt\"><img style=\"width:486px; height:283px;\" src=\"images/CARD/59160_Time_velocity_CM_pericardit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The medial mitral annular time-velocity plots are derived from color-coded tissue Doppler M-mode echocardiogram. Shown are the plots from a patient with constrictive pericarditis (panel A) and a restrictive cardiomyopathy (panel B).</div><div class=\"graphic_footnotes\">E: peak early diastolic velocity; A: peak atrial velocity.</div><div id=\"graphicVersion\">Graphic 59160 Version 1.0</div></div></div>"},"59161":{"type":"graphic_diagnosticimage","displayName":"Oblique fracture of the fifth metatarsal shaft","title":"Oblique fracture of the fifth metatarsal shaft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique fracture of the fifth metatarsal shaft</div><div class=\"cntnt\"><img style=\"width:319px; height:406px;\" src=\"images/EM/59161_5th_metatarsal_oblique_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An oblique fracture (arrow) of the distal shaft of the fifth metatarsal is seen in two plain radiographs, one using an anteroposterior view (left side image) and the other an oblique view (right side image) of the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: Eiff MP, Hatch RL, Calmbach WL. Fracture management for primary care, 2nd ed. Chapter 2: General principles of fracture care. Saunders, Philadelphia 1998. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 1998 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 59161 Version 3.0</div></div></div>"},"59163":{"type":"graphic_figure","displayName":"Pharyngeal swallow timeline","title":"Timing of events within the pharyngeal swallow","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Timing of events within the pharyngeal swallow</div><div class=\"cntnt\"><img style=\"width:480px; height:318px;\" src=\"images/GAST/59163_Pharyn_swallow_timeline_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time line showing volume-induced modifications in the timing of events within the pharyngeal swallow. Each horizontal bar depicts the period during which one of the oropharyngeal valves is in a swallowing configuration as opposed to a respiratory configuration. Events at the onset and offset of pharyngeal reconfiguration bear a fixed time relationship to each other, regardless of swallow bolus volume. The stereotypy of these phases is demonstrated by referencing of onset events from time 0 counting forward and of offset events from time 0 counting forward or backward. This timing scheme defines the volume-dependent middle portion of the time line (black), which has a value of 0 for 1-mL swallows and 0.2 seconds for 20-mL swallows.</div><div class=\"graphic_reference\">Reprinted with permission. Adapted from: Cook IJ, Kahrilas PJ. AGA: Technical review: Management of oropharyngeal dysphagia. Gastroenterology 1999; 116:455.</div><div id=\"graphicVersion\">Graphic 59163 Version 3.0</div></div></div>"},"59164":{"type":"graphic_picture","displayName":"St Johns wort","title":"St. John's wort","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">St. John's wort</div><div class=\"cntnt\"><img style=\"width:324px; height:487px;\" src=\"images/PC/59164_St_Johns_wort.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Martin Wall/herbslides.com.</div><div id=\"graphicVersion\">Graphic 59164 Version 1.0</div></div></div>"},"59165":{"type":"graphic_table","displayName":"Indicator success NPPV","title":"Potential indicators of success in noninvasive positive pressure ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential indicators of success in noninvasive positive pressure ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Younger age</td> </tr> <tr> <td>Lower acuity of illness (APACHE score)</td> </tr> <tr> <td>Able to cooperate, better neurologic score</td> </tr> <tr> <td>Less air leaking, intact dentition</td> </tr> <tr> <td>Moderate hypercarbia (PaCO<sub>2</sub> &#62;45 mmHG, &#60;92 mmHG)</td> </tr> <tr> <td>Moderate acidemia (pH &#60;7.35, &#62;7.10)</td> </tr> <tr> <td>Improvements in gas exchange and heart respiratory rates within first&nbsp;two hours</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: International Concensus Conferences in Intensive Care Medicine: Noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 2001; 163:288. Copyright © 2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 59165 Version 4.0</div></div></div>"},"59166":{"type":"graphic_diagnosticimage","displayName":"NSCLC RUL mass","title":"Chest CT of lung cancer with paratracheal adenopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest CT of lung cancer with paratracheal adenopathy</div><div class=\"cntnt\"><img style=\"width:432px; height:350px;\" src=\"images/PULM/59166_NSCLC_RUL_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 54-year-old man presented with shortness of breath. CT chest demonstrated a right upper lobe mass with bronchial obstruction and right paratracheal adenopathy.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 59166 Version 4.0</div></div></div>"},"59168":{"type":"graphic_picture","displayName":"Wrist drop","title":"Wrist drop in vasculitic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wrist drop in vasculitic neuropathy</div><div class=\"cntnt\"><img style=\"width:262px; height:432px;\" src=\"images/RHEUM/59168_Wrist_drop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient has suffered bilateral peripheral nerve infarction, leading to a complete wrist drop on the left and significant dorsiflexion weakness on the right. The patient's underlying diagnosis is eosinophilic granulomatosis with polyangiitis (Churg-Strauss).</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 59168 Version 2.0</div></div></div>"},"59170":{"type":"graphic_picture","displayName":"NASH liver biopsy","title":"Nonalcoholic steatohepatitis liver biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonalcoholic steatohepatitis liver biopsy</div><div class=\"cntnt\"><img style=\"width:360px; height:255px;\" src=\"images/GAST/59170_NASH_liver_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy showing steatosis, hepatocyte balloon degeneration, mixed acute and chronic inflammation, and pericellular fibrosis.</div><div class=\"graphic_reference\">Courtesy of Marshall M. Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 59170 Version 1.0</div></div></div>"},"59173":{"type":"graphic_diagnosticimage","displayName":"Normal fetal nasal bone","title":"Normal fetal nasal bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal fetal nasal bone</div><div class=\"cntnt\"><img style=\"width:432px; height:352px;\" src=\"images/OBGYN/59173_Normal_fetal_nasal_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the fetal profile is viewed in the midsagittal plane, the nasal bone synostosis appears as a thin echogenic line within the bridge of the nose. The nasal bone is considered present if this line is more echogenic than the overlying skin, and absent if it is not visualized, or less echogenic, than the overlying skin.</div><div class=\"graphic_reference\">Courtesy of Beryl R Benacerraf, MD.</div><div id=\"graphicVersion\">Graphic 59173 Version 2.0</div></div></div>"},"59174":{"type":"graphic_picture","displayName":"SCCA columella","title":"SCCA of the columella","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">SCCA of the columella</div><div class=\"cntnt\"><img style=\"width:396px; height:329px;\" src=\"images/ONC/59174_SCCAcolumella.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Parsons JT, Stringer SP, Mancuso AA, Million RR. Nasal vestibule, nasal cavity, and paranasal sinuses. In: Million RR, Cassisi NJ (Eds). Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: J.B. Lippincott Company, 1994. Copyright © 1994 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59174 Version 13.0</div></div></div>"},"59176":{"type":"graphic_diagnosticimage","displayName":"Pulmonary paragonimiasis","title":"Pulmonary paragonimiasis","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Pulmonary paragonimiasis</div><div class=\"cntnt\"><img style=\"width:582px; height:353px;\" src=\"images/ID/59176_Pulmonary_paragonimiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Chest&nbsp;radiograph and computed tomography (CT) on admission.<br />(A) Multiple mass-like opacities are shown in the right lung (arrow).<br />(B) Multiple nodules with adjacent areas of ground glass opacity, suggestive of hemorrhagic metastasis, are observed in both lungs (arrows).<br />(C) Fluorodeoxyglucose-positron emission tomography (FDG-PET) CT showing increased FDG uptake (max SUV: 3.1) (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Kim KU, Lee K, Park HK, et al. A pulmonary paragonimiasis case mimicking metastatic pulmonary tumor. Korean J Parasitol 2011; 49:69. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 59176 Version 2.0</div></div></div>"},"59177":{"type":"graphic_figure","displayName":"Culdocentesis","title":"Culdocentesis","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Culdocentesis</div><div class=\"cntnt\"><img style=\"width:511px; height:392px;\" src=\"images/OBGYN/59177_Culdocentesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted with permission from: Mann, WJ, Stovall, TG. Gynecologic Surgery. Churchill Livingstone, New York 1996. Copyright &#169; 1996 Elsevier.</div><div id=\"graphicVersion\">Graphic 59177 Version 1.0</div></div></div>"},"59178":{"type":"graphic_figure","displayName":"FAO metabolism overview","title":"Fatty acid oxidation metabolism overview","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Fatty acid oxidation metabolism overview</div><div class=\"cntnt\"><img style=\"width:534px; height:696px;\" src=\"images/NEURO/59178_Carnitinecycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure illustrating the carnitine cycle. The mitochondrial membrane is not permeable to long-chain fatty acids; a multistep process is therefore required for these compounds to be used by mitochondria. In the muscle cytoplasm, long-chain fatty acids are first activated by long-chain acyl-CoA synthetase (ACS) to their CoA thioesters. The CoA thioesters are subsequently linked with carnitine by the enzyme carnitine palmitoyltransferase&nbsp;1 (CPT 1) located on the inner side of the outer mitochondrial membrane. The acylcarnitine form of the long-chain fatty acid, palmitoylcarnitine, is then transferred across the inner mitochondrial membrane by carnitine:acylcarnitine translocase. Once in the mitochondrial matrix, it is converted back to free acyl-CoA derivative and carnitine by carnitine palmitoyltransferase&nbsp;2 (CPT 2) on the inner side of the inner mitochondrial membrane. Once carnitine is released, the long-chain acyl-CoA derivative enters the beta-oxidation pathway. With every complete cycle, a two-carbon fragment is cleaved, and an acetyl-CoA molecule is released.</div><div class=\"graphic_footnotes\">ACS: acyl-CoA synthetase; CPT 1: carnitine palmitoyltransferase 1; CACT: carnitine-acylcarnitine translocase; CPT 2: carnitine palmitoyltransferase 2; VLCAD: very-long-chain acyl-CoA dehydrogenase; TFP: trifunctional protein; LCHAD: long-chain 3-hydroxyacyl-CoA dehydrogenase; MCAD: medium-chain acyl-CoA dehydrogenase; SCAD: short-chain acyl-CoA dehydrogenase; M/SCHAD: medium/short-chain 3-hydroxyacyl-coenzyme A dehydrogenase; FADH<SUB innerHtml>2</SUB>: flavin adenine dinucleotide; ETF: electron transfer flavoprotein; ETFDH: electron transfer flavoprotein dehydrogenase; NADH: nicotinamide adenine dinucleotide.</div><div id=\"graphicVersion\">Graphic 59178 Version 8.0</div></div></div>"},"59179":{"type":"graphic_diagnosticimage","displayName":"Normal intraoperative cholangiogram after cholecystectomy","title":"Normal intraoperative cholangiogram after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal intraoperative cholangiogram after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:430px; height:430px;\" src=\"images/SURG/59179_Normal_cholangiogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Nathaniel J Soper, MD, FACS.</div><div id=\"graphicVersion\">Graphic 59179 Version 4.0</div></div></div>"},"59180":{"type":"graphic_table","displayName":"Adjustments in SCIT dosing for gaps in treatment","title":"Adjustments in subcutaneous immunotherapy dosing for gaps in treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjustments in subcutaneous immunotherapy dosing for gaps in treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Build-up phase</td> </tr> <tr> <td class=\"indent1\">Up to 7 days late</td> <td>Continue build-up as scheduled</td> </tr> <tr> <td class=\"indent1\">8 to 13 days late</td> <td>Repeat previous dose</td> </tr> <tr> <td class=\"indent1\">14 to 21 days late</td> <td>Reduce dose 25%</td> </tr> <tr> <td class=\"indent1\">21 to 28 days late</td> <td>Reduce dose 50%</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Maintenance phase</td> </tr> <tr> <td class=\"indent1\">2 to 4 weeks late</td> <td>Reduce dose 75%</td> </tr> <tr> <td class=\"indent1\">&#62;4 weeks late</td> <td>Reduce by one or more dilutions depending on length of time and patient sensitivity</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59180 Version 5.0</div></div></div>"},"59184":{"type":"graphic_figure","displayName":"Knee splint","title":"Knee splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Knee splint</div><div class=\"cntnt\"><img style=\"width:344px; height:188px;\" src=\"images/PEDS/59184_Knee_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the knee placed in full extension, 6-inch plaster rolls extend from the buttocks posteriorly to 3 inches above the malleoli.</div><div id=\"graphicVersion\">Graphic 59184 Version 2.0</div></div></div>"},"59186":{"type":"graphic_picture","displayName":"Glucocorticoid-induced acne","title":"Systemic glucocorticoid-induced acneiform eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Systemic glucocorticoid-induced acneiform eruption</div><div class=\"cntnt\"><img style=\"width:335px; height:501px;\" src=\"images/DERM/59186_Glucocorticoid-induced_acne.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Drug-induced acneiform eruption. This patient was taking prednisone for sarcoidosis. B) This patient is taking systemic glucocorticoids for severe asthma.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59186 Version 3.0</div></div></div>"},"59189":{"type":"graphic_figure","displayName":"Electromagnetic spectrum and medical laser wavelengths","title":"Electromagnetic spectrum and medical laser wavelengths","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Electromagnetic spectrum and medical laser wavelengths</div><div class=\"cntnt\"><img style=\"width:516px; height:232px;\" src=\"images/PULM/59189_Laser_light_characteristics.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59189 Version 3.0</div></div></div>"},"59192":{"type":"graphic_movie","displayName":"Abnormal leukocyte movement in LAD II","title":"Abnormal leukocyte movement in leukocyte-adhesion deficiency II","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abnormal leukocyte movement in leukocyte-adhesion deficiency II</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/59192_lddstimconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:305px; height:224px;\" src=\"images/CARD/59192_lddstim.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Amos Etzioni, MD.</div><div id=\"graphicVersion\">Graphic 59192 Version 5.0</div></div></div>"},"59194":{"type":"graphic_diagnosticimage","displayName":"CT scan signs of CVT","title":"Signs of cerebral venous thrombosis on head CT scan","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Signs of cerebral venous thrombosis on head CT scan</div><div class=\"cntnt\"><img style=\"width:486px; height:212px;\" src=\"images/NEURO/59194_CT_scan_signs_of_CVT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Noncontrast head CT shows a hyperdense thrombosed cortical vein (arrow).<br />(B) Noncontrast head CT shows a hyperdensity in the torcula (small arrowhead) and the straight sinus (large arrowhead), a direct sign of dural sinus thrombosis (the dense triangle sign).<br />(C) Head CT shows non-filling of the confluent sinus after contrast injection (the empty delta sign).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 59194 Version 4.0</div></div></div>"},"59195":{"type":"graphic_picture","displayName":"Lichen simplex chronicus3","title":"Vulvar lichen simplex chronicus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar lichen simplex chronicus</div><div class=\"cntnt\"><img style=\"width:432px; height:304px;\" src=\"images/OBGYN/59195_Lichen_simplex_chronicus3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 59195 Version 3.0</div></div></div>"},"59197":{"type":"graphic_picture","displayName":"Normal human metamyelocyte","title":"Normal human metamyelocyte","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal human metamyelocyte</div><div class=\"cntnt\"><img style=\"width:395px; height:259px;\" src=\"images/HEME/59197_Normal_human_metamyelocyte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear shows a normal human metamyelocyte. The cytoplasm resembles the mature neutrophil and band forms; granules are small, fine blue-black or grey, and dispersed homogeneously throughout the cytoplasm. The nucleus is indented like a bean and the nuclear chromatin is coarse, clumped, and condensed peripherally.</div><div class=\"graphic_reference\">Courtesy of Robert L Baehner, MD.</div><div id=\"graphicVersion\">Graphic 59197 Version 1.0</div></div></div>"},"59200":{"type":"graphic_diagnosticimage","displayName":"Multilevel spinal stenosis","title":"Multilevel spinal stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multilevel spinal stenosis</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/NEURO/59200_Multilevel_spinal_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted sagittal MRI of the lower thoracic, lumbar, and sacral spine demonstrates spinal stenosis at multiple levels.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Seward Rutkove, MD and Andrew Tarulli, MD.</div><div id=\"graphicVersion\">Graphic 59200 Version 2.0</div></div></div>"},"59201":{"type":"graphic_table","displayName":"Dose and admin of LAI antipsychotic for schizophrenia","title":"Dosage and administration of long-acting injectable antipsychotics for schizophrenia in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosage and administration of long-acting injectable antipsychotics for schizophrenia in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"11\" width=\"9%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Aripiprazole extended release</td> <td class=\"subtitle1\">Aripiprazole lauroxil&nbsp;</td> <td class=\"subtitle1\">Flupentixol decanoate*</td> <td class=\"subtitle1\">Fluphenazine decanoate</td> <td class=\"subtitle1\">Haloperidol decanoate</td> <td class=\"subtitle1\">Olanzapine pamoate</td> <td class=\"subtitle1\">Paliperidone palmitate<br /> (4-week)</td> <td class=\"subtitle1\">Paliperidone palmitate<br /> (12-week)</td> <td class=\"subtitle1\">Pipotiazine palmitate*</td> <td class=\"subtitle1\">Risperidone microspheres</td> <td class=\"subtitle1\">Zuclopenthixol decanoate*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Trade (brand) name</strong></td> <td>Abilify Maintena</td> <td>Aristada</td> <td>Fluanxol Depot (Canada)</td> <td>Generic</td> <td>Haldol Decanoate</td> <td>Zyprexa Relprevv</td> <td>Invega Sustenna</td> <td>Invega Trinza</td> <td>Piportil L<sub>4</sub> (Canada)</td> <td>Risperdal Consta</td> <td>Clopixol Depot (Canada)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Generation</strong></td> <td>Second</td> <td>Second</td> <td>First</td> <td>First</td> <td>First</td> <td>Second</td> <td>Second</td> <td>Second</td> <td>First</td> <td>Second</td> <td>First</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Injection interval</strong></td> <td>4 weeks</td> <td> <p>4 weeks (441, 662, 882&nbsp;mg)</p> <p>6 weeks (882 mg only)</p> <p>8 weeks (1064 mg only)</p> </td> <td>2 to 4 weeks</td> <td>2 to 4 weeks</td> <td>4 weeks</td> <td>2 to 4 weeks</td> <td>4 weeks</td> <td>12 weeks (three months)</td> <td>3 to 4 weeks</td> <td>2 weeks</td> <td>2 to 4 weeks</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Available dosage strengths</strong></td> <td> <p>300 mg</p> 400 mg</td> <td> <p>441 mg</p> <p>662 mg</p> <p>882 mg</p> <p>1064 mg</p> </td> <td> <p>20 mg/mL</p> <p>100 mg/mL</p> (variable dose)</td> <td> <p>25 mg/mL</p> (variable dose)</td> <td> <p>50 mg/mL</p> <p>100 mg/mL</p> (variable dose)</td> <td> <p>210 mg</p> <p>300 mg</p> 405 mg</td> <td> <p>39 mg</p> <p>78 mg</p> <p>117 mg</p> <p>156 mg</p> 234 mg</td> <td> <p>--</p> <p>273 mg</p> <p>410 mg</p> <p>546 mg</p> 819 mg</td> <td> <p>25 mg/mL</p> 50 mg/mL</td> <td> <p>12.5 mg</p> <p>25 mg</p> <p>37.5 mg</p> 50 mg</td> <td> <p>200 mg/mL</p> (variable dose)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dose range (adult)</strong><sup>&#182;</sup></td> <td>200 to 400 mg</td> <td>441 to&nbsp;1064 mg</td> <td>10 to 50 mg</td> <td>12.5 to 100 mg</td> <td>20 to 450 mg</td> <td>150 to 405 mg</td> <td>39 to 234 mg</td> <td>273 to 819 mg</td> <td>75 to 200 mg</td> <td>12.5 to 50 mg</td> <td>100 to 400 mg</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Maximum recommended dose</strong></td> <td>400 mg every 4 weeks</td> <td>882 mg every&nbsp;4 weeks</td> <td>100 mg every 2 weeks</td> <td>100 mg every 2 weeks</td> <td>450 mg every 4 weeks</td> <td>300 mg every 2 weeks</td> <td>234 mg every 4 weeks</td> <td>819 mg every 12 weeks</td> <td>250 mg every 3 weeks</td> <td>50 mg every 2 weeks</td> <td>600 mg every 2 weeks</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Conversion from oral tablets</strong></td> <td> <p>Initiate LAI at 400 mg.</p> Overlap oral aripiprazole 10 or 20 mg daily (or other oral antipsychotic) for 14 days concurrent with first LAI injection.</td> <td> <p>If stable on oral&nbsp;10 mg daily, then 441 mg LAI every 4 weeks.</p> <p>If&nbsp;stable on oral 15 mg daily then 662 mg LAI every 4 weeks, or 882 mg LAI every 6 weeks, or 1064 mg LAI every 8 weeks.</p> <p>If stable on&nbsp;oral &#8805;20 mg daily, then 882 mg LAI every 4 weeks.</p> <p>Oral aripiprazole should be continued for 21 days after the first dose of LAI.</p> </td> <td>Initiate LAI at 4 times daily oral dose every two weeks or 8 times daily oral dose every 4 weeks. For first week, overlap with oral treatment.</td> <td>1 mg of oral daily &#8776; 1.25 mg LAI every 3 weeks.</td> <td>Initiate LAI at 10 to 20 times daily oral dose, up to 100 mg. If initial conversion requires &#62;100 mg, follow by balance in 3 to 7 days. Then administer at 4-week intervals.</td> <td> <p>If stable on oral 10 mg daily, then 210 mg LAI every 2 weeks or 405 mg LAI every 4 weeks for first 8 weeks, then 150 mg IM LAI every 2 weeks or 300 mg every 4 weeks.</p> <p>If stable on oral 15 mg daily, then 300 mg LAI every 2 weeks for first 8 weeks, then 210 mg LAI every 2 weeks or 405 mg LAI every 4 weeks.</p> If stable on oral 20 mg daily, then 300 mg LAI every 2 weeks.</td> <td>Conversion from oral extended release: If stable on oral 12 mg daily, then 234 mg LAI; if 6 mg oral daily, then 117 mg LAI; if 3 mg oral daily, then 39 to 78 mg LAI.</td> <td> <p>Conversion from oral tablets is <strong>not</strong> available.</p> Conversions from various doses of paliperidone palmitate 4-week LAI, once it has been established as adequate treatment, are shown in the footnote.<sup>&#916;</sup></td> <td>Discontinue oral treatment. Initiate at 50 to 100 mg LAI every 3 weeks. Individualize dose and interval in 25 mg increments based on response no more frequently than every 2 to 3 weeks.</td> <td>Initiate LAI at 25 mg every 2 weeks. For first 3 weeks overlap with full-dose oral treatment.</td> <td> <p>If stable on oral dose up to 20 mg daily, then 100 mg LAI every 2 weeks.</p> <p>If stable on 25 to 40 mg oral daily, then 200 mg LAI every 2 weeks.</p> <p>If stable on 50 to 75 mg oral daily, then 300 mg LAI every 2 weeks.</p> If stable on more than 75 mg daily, then 400 mg LAI every 2 weeks.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Injection site</strong></td> <td>Deltoid or gluteal</td> <td> <p>Deltoid (441 mg only)</p> <p>Gluteal (441, 662, 882, or 1064&nbsp;mg)</p> </td> <td>Gluteal or lateral thigh<sup>&#9674;</sup></td> <td>Gluteal<sup>&#167;</sup></td> <td>Gluteal<sup>&#167;</sup></td> <td>Gluteal only</td> <td> <p>Deltoid only (load)</p> Deltoid or gluteal (maintenance)</td> <td>Deltoid or gluteal</td> <td>Gluteal</td> <td>Deltoid or gluteal</td> <td>Gluteal or lateral thigh<sup>​&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Injection technique</strong></td> <td>Standard</td> <td>Standard</td> <td>Z-Track</td> <td>Z-Track</td> <td>Z-Track</td> <td>Standard</td> <td>Standard</td> <td>Standard</td> <td>Z-Track</td> <td>Standard</td> <td>Z-Track</td> </tr> <tr> <td><strong>Solubilization and vehicle</strong></td> <td>Low solubility particles in aqueous suspension</td> <td>Low solubility particles in aqueous suspension</td> <td>Ester in medium chain triglycerides or coconut oil</td> <td>Ester in sesame seed oil</td> <td>Ester in sesame seed oil</td> <td>Nanoparticles in aqueous suspension</td> <td>Nanoparticles in aqueous suspension</td> <td>Nanoparticles in aqueous suspension</td> <td>Ester in sesame seed oil</td> <td>Microsphere matrix in aqueous suspension</td> <td>Ester in low viscosity vegetable oil</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Long-acting preparations are administered by deep INTRAMUSCULAR (IM) administration only and NEVER given intravenously. Subcutaneous administration is not recommended due to variable absorption and increased risk of local site reaction. Details shown are specific to the preparations and forms available in the United States, unless otherwise noted. Dosing, administration and other details listed in licensed product information may differ for other forms and by country. Consult official product information for detail.</div><div class=\"graphic_footnotes\">LAI: intramuscular long-acting injectable (also known as \"depot\" injection).<br />* Not available in the United States. Product details shown from Health Canada Product Monograph.<br />¶ Significant dosage reduction required for older or debilitated adults, patients with low cardiac output or hepatic or renal insufficiency. Certain products are not recommended in renal insufficiency. For additional information, refer to Lexicomp individual drug monographs included with UpToDate.<br />Δ Paliperidone palmitate 12-week LAI suspension is to be used only after adequate treatment and dose have been established with paliperidone palmitate 4-week LAI suspension for at least four months; the last two months should be the same dose before starting the 12-week preparation. Recommended conversions: &#xD;&#xA;<UL>&#xD;&#xA;<LI>If the last dose of paliperidone palmitate 4-week LAI was 78 mg, then initiate 12-week paliperidone palmitate LAI at 273 mg once every 3 months.</LI>&#xD;&#xA;<LI>If the last dose of paliperidone palmitate 4-week LAI was 117 mg, then initiate 12-week paliperidone palmitate LAI at 410 mg once every 3 months.</LI>&#xD;&#xA;<LI>If the last dose of paliperidone palmitate 4-week LAI was 156 mg, then initiate 12-week paliperidone palmitate LAI at 546 mg once every 3 months.</LI>&#xD;&#xA;<LI>If the last dose of paliperidone palmitate 4-week LAI was 234 mg, then initiate 12-week paliperidone palmitate LAI at 819 mg once every 3 months.</LI></UL>Conversion from paliperidone palmitate 4-week LAI 39 mg to the 12-week preparation was not studied.<br />◊ Lateral thigh administration is not listed in the Health Canada monograph but is approved in other countries.<SUP>[1]</SUP><br />§ Alternatively, fluphenazine and haloperidol LAI may be given in the deltoid based upon clinical experience. &nbsp;For deltoid administration, use of a 23 gauge, 1 inch needle is appropriate for most adults; volume per injection is typically limited to 1 mL at this site. Deltoid administration is off-label and published clinical data are unavailable. </div><div class=\"graphic_reference\">Reference:<br />1. Gillespie M, Toner A.&nbsp;The safe administration of long-acting depot antipsychotics. Br J Nurs 2013; 22:465.<br />United States Prescribing Information available at US NIH DailyMed website: <A href=\"http://dailymed.nlm.nih.gov/\" target=_blank>http://dailymed.nlm.nih.gov</A> and Canada Product Monograph available at Health Canada website.</div><div id=\"graphicVersion\">Graphic 59201 Version 12.0</div></div></div>"},"59203":{"type":"graphic_picture","displayName":"Peliosis hepatis high power","title":"Peliosis hepatis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peliosis hepatis</div><div class=\"cntnt\"><img style=\"width:390px; height:287px;\" src=\"images/GAST/59203_Peliosis_hepatis_high_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power (40x) view of reticulin stain showing dilated sinusoids with cyst formation and reticulin frame drop-off.</div><div class=\"graphic_reference\">Courtesy of Tracy Challies, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 59203 Version 1.0</div></div></div>"},"59205":{"type":"graphic_table","displayName":"Differential diagnosis of PID","title":"Differential diagnosis of pelvic inflammatory disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of pelvic inflammatory disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\t\n\t<tr><td>Adenomyosis uteri</td></tr>\n\t<tr><td>Adnexal torsion</td></tr>\n\t<tr><td>Appendicitis</td></tr>\n\t<tr><td>Cervicitis (herpetic)</td></tr>\n\t<tr><td>Crohn's disease</td></tr>\n\t<tr><td>Cystitis</td></tr>\n\t<tr><td>Degenerating myoma</td></tr>\n\t<tr><td>Diverticulitis</td></tr>\n    <tr><td>Ectopic pregnancy*</td></tr>\n\t<tr><td>Endometriosis</td></tr>\n\t<tr><td>Extruding myoma</td></tr>\n\t<tr><td>Functional pain</td></tr>\n\t<tr><td>Genital trauma</td></tr>\n\t<tr><td>Infectious proctitis</td></tr>\n\t<tr><td>Irritable bowel syndrome</td></tr>\n\t<tr><td>Lead intoxication</td></tr>\n\t<tr><td>Lupus serositis</td></tr>\n\t<tr><td>Meckel's diverticulum</td></tr>\n\t<tr><td>Mesenteric lymphadenitis</td></tr>\n\t<tr><td>Mesenteric vascular disease</td></tr>\n\t<tr><td>Ovarian tumor</td></tr>\n\t<tr><td>Ovulation </td></tr>\n\t<tr><td>Pelvic adhesive disease</td></tr>\n\t<tr><td>Rupture of teratoma</td></tr>\n\t<tr><td>Sickle crisis</td></tr>\n\t<tr><td>Ulcerative colitis</td></tr>\n\t<tr><td>Urolithiasis</td></tr>\n    \n\n    \n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Ectopic pregnancy must be excluded with a pregnancy test in any woman suspected of having pelvic inflammatory disease.</div><div id=\"graphicVersion\">Graphic 59205 Version 1.0</div></div></div>"},"59211":{"type":"graphic_diagnosticimage","displayName":"Tumor bleeding 15a","title":"Pelvic angiogram","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Pelvic angiogram</div><div class=\"cntnt\"><img style=\"width:525px; height:520px;\" src=\"images/OBGYN/59211_Tumor_bleeding_15a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pelvic angiogram on a 71-year-old woman with chronic vaginal bleeding and anemia secondary to metastatic renal cell carcinoma. Hypervascular neovascularity and tumor staining (arrow) in the vagina can be seen.</div><div id=\"graphicVersion\">Graphic 59211 Version 3.0</div></div></div>"},"59212":{"type":"graphic_figure","displayName":"Six month outcome EPISTENT","title":"Abciximab improves the outcome at six months after stenting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abciximab improves the outcome at six months after stenting</div><div class=\"cntnt\"><img style=\"width:367px; height:205px;\" src=\"images/CARD/59212_Six_month_outcome_EPISTENT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the EPISTENT trial of 2399 patients, Kaplan-Meier estimates of the incidence of the primary endpoint (death or myocardial infarction) was lower in those treated with abciximab after stenting compared to those undergoing angioplasty with abcixmab therapy (p = 0.01) or stenting with placebo (p &lt;0.001) treatment (5.6, 7.8, and 11.4 percent, respectively).</div><div class=\"graphic_reference\">Data from Lincoff AM, Califf RM, Moliterno DJ, et al, for the EPISTENT Investigators, N Engl J Med 1999; 341:319.</div><div id=\"graphicVersion\">Graphic 59212 Version 2.0</div></div></div>"},"59213":{"type":"graphic_figure","displayName":"Elbow injection site","title":"Landmarks for elbow aspiration","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Landmarks for elbow aspiration</div><div class=\"cntnt\"><img style=\"width:454px; height:344px;\" src=\"images/EM/59213_Elbowinjectionsite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The landmarks for aspiration of the elbow joint are the radial head, lateral epicondyle, and tip of the olecranon. A needle inserted into the center of the triangle (asterisk) penetrates only the anconeus muscle and capsule before entering the joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Mezera K, Hotchkiss RN. Fractures and dislocation of the elbow. In: Rockwood and Green's Fractures in Adults, 5th ed, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59213 Version 10.0</div></div></div>"},"59214":{"type":"graphic_table","displayName":"Causes gestational hyperandrogenism","title":"Causes of gestational hyperandrogenism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of gestational hyperandrogenism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Luteoma</td> </tr> <tr> <td>Theca-lutein cysts</td> </tr> <tr> <td>Exogenous&nbsp;androgen administration</td> </tr> <tr> <td>Placental aromatase deficiency</td> </tr> <tr> <td>Sertoli-Leydig cell tumor</td> </tr> <tr> <td>Other ovarian tumors</td> </tr> <tr> <td>Krukenberg tumors (gastrointestinal cancer metastatic to ovaries)</td> </tr> <tr> <td>Adrenal tumors (adenomas and carcinomas)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: McClamrock HD, Adashi EY. Gestational hyperandrogenism. In: Reproductive Endocrinology, Surgery, and Technology, Adashi EY, Rock JA, Rosenwaks Z (Eds), Lippincott-Raven, Philadelphia, 1996, p. 612.</div><div id=\"graphicVersion\">Graphic 59214 Version 3.0</div></div></div>"},"59215":{"type":"graphic_picture","displayName":"Barretts esophagus CPC Light","title":"Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/GAST/59215_Barretts_example_CPC_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a biopsy specimen from the distal esophagus in a different patient showing intestinal metaplasia diagnostic of Barrett's esophagus. The diagnostic feature is the presence of goblet cells (arrow), characterized by apical basophilic cytoplasm, a dilated lateral cell border and a compressed basal nucleous.</div><div class=\"graphic_reference\">Courtesy of Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 59215 Version 2.0</div></div></div>"},"59216":{"type":"graphic_table","displayName":"Multivisceral transplant evaluation","title":"Pre-transplant recipient evaluation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pre-transplant recipient evaluation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Referral to transplant center:</strong></td> <td>Analysis of medical and surgical history, current medications, current enteral and parenteral nutrition requirements</td> </tr> <tr class=\"divider_top\"> <td><strong>History &#38; physical:</strong></td> <td>Comprehensive history and physical including review of systems</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Laboratory studies:</strong></td> <td>Blood group</td> </tr> <tr> <td>Tissue typing (HLA)</td> </tr> <tr> <td>Panel of reactive antibody (PRA)</td> </tr> <tr> <td>Serology (CMV IgG and IgM, EBV IgG and IgM, HIV, HCV, HBeAg, HBsAg, HBsAb)</td> </tr> <tr> <td>CBC, comprehensive metabolic panel, PT/PTT/INR</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>Imaging studies:</strong></td> <td>Chest x-ray</td> </tr> <tr> <td>Doppler US of liver</td> </tr> <tr> <td>Doppler US of upper and lower extremities veins</td> </tr> <tr> <td>CT scan abdomen and pelvis</td> </tr> <tr> <td>Upper GI study, small bowel follow through</td> </tr> <tr> <td>Barium enema</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Endoscopic studies:</strong></td> <td>EGD</td> </tr> <tr> <td>Colonoscopy</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Motility studies:</strong></td> <td>Gastro-esophageal motility studies</td> </tr> <tr> <td>Small intestine motility studies</td> </tr> <tr> <td>Colon transit time studies</td> </tr> <tr class=\"divider_top\"> <td><strong>Liver:</strong></td> <td>Liver biopsy</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Cardiology evaluation:</strong></td> <td>EKG</td> </tr> <tr> <td>Baseline echocardiogram</td> </tr> <tr> <td>Stress test and/or cardiac catheterization if &#62;50 years or with cardiac history, risk factors (HTN, DM)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Nephrology evaluation:</strong></td> <td>US abdomen with size of kidneys</td> </tr> <tr> <td>Triple renal scan</td> </tr> <tr> <td>24 hour creatinine clearance</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Additional consults:</strong></td> <td>Neurology</td> </tr> <tr> <td>Infectious disease</td> </tr> <tr> <td>Critical care</td> </tr> <tr> <td>Anesthesia</td> </tr> <tr> <td>Pulmonary</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"7\"><strong>Additional studies:</strong></td> <td>Dental evaluation</td> </tr> <tr> <td>Mammogram</td> </tr> <tr> <td>PAP smear test</td> </tr> <tr> <td class=\"sublist1_start\">Vaccinations</td> </tr> <tr> <td class=\"sublist1\">Hepatitis A</td> </tr> <tr> <td class=\"sublist1\">Hepatitis B</td> </tr> <tr> <td class=\"sublist1\">Pneumovax</td> </tr> <tr class=\"divider_top\"> <td><strong>Multidisciplinary team evaluation:</strong></td> <td>Final decision by transplant physician, surgeon, gastroenterologist, nurse coordinator, nutritionist and social worker</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; CMV: cytomegalovirus; CT: computed tomography; DM: diabetes mellitus; EBV: Epstein-Barr virus; EGD: esophagogastroduodenoscopy; EKG: electrocardiogram; GI: gastrointestinal; HBeAg: hepatitis B e-antigen; HBsAb: hepatitis B surface antibody; HBsAG: hepatitis B surface antigen; HCV: hepatitis C virus; HIV: human immunodeficiency virus; HLA: human leukocyte antigen; HTN: hypertension; INR: international normalized ratio; PT: prothrombin time; PTT: partial thromboplastin time; US: ultrasound.</div><div class=\"graphic_reference\">Courtesy of Farrukh Khan, MD and Gennaro Selvaggi, MD.</div><div id=\"graphicVersion\">Graphic 59216 Version 3.0</div></div></div>"},"59217":{"type":"graphic_diagnosticimage","displayName":"Toxic megacolon in C diff","title":"Toxic megacolon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toxic megacolon</div><div class=\"cntnt\"><img style=\"width:369px; height:352px;\" src=\"images/GAST/59217_Toxic_megacolon_in_C_diff.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film of the abdomen from a patient with toxic megacolon associated with <EM>Clostridium difficile</EM> infection. The large and small intestines are grossly dilated. Dilatation of the small bowel, which has the thin transverse folds of the valvulae conniventes (short arrow), is seen best in the left lower quadrant. Large bowel dilatation occupies most of the right lower quadrant and has characteristic thick haustral markings that do not extend across the entire lumen (long arrows).</div><div class=\"graphic_reference\">Courtesy of J Thomas LaMont, MD.</div><div id=\"graphicVersion\">Graphic 59217 Version 5.0</div></div></div>"},"59219":{"type":"graphic_picture","displayName":"Chronic herpes simplex in HIV","title":"Chronic herpes simplex in HIV","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic herpes simplex in HIV</div><div class=\"cntnt\"><img style=\"width:231px; height:360px;\" src=\"images/ID/59219_Chronic_herpes_simplex_in_H.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These extensive ulcerations on the shaft of the penis resolved on oral acyclovir.</div><div class=\"graphic_reference\">Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 59219 Version 5.0</div></div></div>"},"59220":{"type":"graphic_diagnosticimage","displayName":"Doppler cord prolapse3","title":"Transabdominal ultrasound using colorflow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Transabdominal ultrasound using colorflow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal</div><div class=\"cntnt\"><img style=\"width:465px; height:350px;\" src=\"images/OBGYN/59220_Doppler_cord_prolapse3.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59220 Version 3.0</div></div></div>"},"59221":{"type":"graphic_algorithm","displayName":"Diagnostic approach to phosphopenic rickets","title":"Diagnostic approach to phosphopenic rickets","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to phosphopenic rickets</div><div class=\"cntnt\"><img style=\"width:478px; height:403px;\" src=\"images/PEDS/59221_Approachhypophosphatemicr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TRP: total reabsorption of phosphorus; TmP/GFR: maximal tubular reabsorption of phosphorus per glomerular filtration rate; 1,25 (OH)<SUB>2</SUB> vitamin D: 1,25 dihydroxyvitamin D (calcitriol).</div><div id=\"graphicVersion\">Graphic 59221 Version 3.0</div></div></div>"},"59223":{"type":"graphic_picture","displayName":"Herpes simplex stromal keratitis","title":"Herpes simplex (HSV) stromal keratitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes simplex (HSV) stromal keratitis</div><div class=\"cntnt\"><img style=\"width:422px; height:276px;\" src=\"images/PC/59223_HSV_stromal_keratitis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59223 Version 2.0</div></div></div>"},"59224":{"type":"graphic_table","displayName":"Laboratory findings - Brucellosis","title":"Laboratory findings - Brucellosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory findings - Brucellosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Literature reference</td> <td class=\"subtitle1\" colspan=\"9\">Percent of patients with the given feature</td> </tr> <tr> <td class=\"subtitle2\">ESR<br /> &#62;20 mm/h</td> <td class=\"subtitle2\">CRP<br /> &#62;5 mg/L</td> <td class=\"subtitle2\">ALT<br /> &#62;40 U/L</td> <td class=\"subtitle2\">Leucopenia</td> <td class=\"subtitle2\">Leucocytosis</td> <td class=\"subtitle2\">Lymphocytes<br /> &#62;45 percent</td> <td class=\"subtitle2\">Thrombocytopenia</td> <td class=\"subtitle2\">Anemia</td> <td class=\"subtitle2\">Pancytopenia</td> </tr> <tr> <td>Pappas, et al. 2005</td> <td>ND</td> <td>ND</td> <td>24</td> <td>2</td> <td>ND</td> <td>40</td> <td>5</td> <td>ND</td> <td>2</td> </tr> <tr> <td>Dokuzoguz, et al. 2005</td> <td>ND</td> <td>ND</td> <td>31</td> <td>27</td> <td>ND</td> <td>ND</td> <td>15</td> <td>31</td> <td>2</td> </tr> <tr> <td>Aygen, et al. 2002</td> <td>59</td> <td>ND</td> <td>ND</td> <td>8</td> <td>6</td> <td>68</td> <td>ND</td> <td>55</td> <td>ND</td> </tr> <tr> <td>Yinnon, et al. 1993</td> <td>ND</td> <td>ND</td> <td>40</td> <td>31</td> <td>3</td> <td>55</td> <td>3</td> <td>51</td> <td>ND</td> </tr> <tr> <td>Pourbagher, et al. 2006</td> <td>49</td> <td>23</td> <td>10</td> <td>ND</td> <td>ND</td> <td>ND</td> <td>ND</td> <td>30</td> <td>ND</td> </tr> <tr> <td>Gur, et al. 2003</td> <td>ND</td> <td>74</td> <td>39</td> <td>14</td> <td>8</td> <td>32</td> <td>ND</td> <td>70</td> <td>ND</td> </tr> <tr> <td>Hizel, et al. 2007</td> <td>42</td> <td>48</td> <td>18</td> <td>6</td> <td>4</td> <td>ND</td> <td>ND</td> <td>ND</td> <td>ND</td> </tr> <tr> <td>Colmenero, et al. 1990</td> <td>77</td> <td>ND</td> <td>40</td> <td>19</td> <td>9</td> <td>41</td> <td>8</td> <td>7</td> <td>3.5</td> </tr> <tr> <td>Bosilkovski, et al. 2010</td> <td>63</td> <td>79</td> <td>33</td> <td>9</td> <td>8</td> <td>24</td> <td>12</td> <td>27</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Frequency of hematological and biochemical features in patients with brucellosis, as reported in the literature and in the CMJ study.</div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ALT: alanine aminotransferase; ND: not determined.</div><div class=\"graphic_reference\">Reproduced with permission from: Bosilkovski M, Krteva L, Dimova M, et al. Human Brucellosis in Macedonia &ndash; 10 years of Clinical Experience in Endemic Region. Croat Med J 2010; 51:327. Copyright &copy; 2010 Croatian Medical Journal.</div><div id=\"graphicVersion\">Graphic 59224 Version 2.0</div></div></div>"},"59225":{"type":"graphic_figure","displayName":"Typical DXA system","title":"Typical dual-energy x-ray absorptiometry (DXA) system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical dual-energy x-ray absorptiometry (DXA) system</div><div class=\"cntnt\"><img style=\"width:410px; height:206px;\" src=\"images/ENDO/59225_Typical_DXA_system.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59225 Version 2.0</div></div></div>"},"59229":{"type":"graphic_table","displayName":"Doses asthma reliever meds kids","title":"Usual doses for quick-relief asthma medications in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Usual doses for quick-relief asthma medications in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Dose form</td> <td class=\"subtitle1\">0 to &#60;4 years</td> <td class=\"subtitle1\">4 to 11 years</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Inhaled short-acting beta<sub>2</sub>-agonists (SABAs)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Metered dose inhaler (MDI)</td> </tr> <tr> <td class=\"indent2\">Albuterol (salbutamol) HFA MDI with spacer (valved holding chamber)</td> <td>90 mcg/puff</td> <td>Two puffs every four to six hours as needed</td> <td>Two puffs every four to six hours as needed</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Differences in potencies exist, but products shown are essentially comparable on a per puff basis.</p> <p>An increasing use or lack of expected effect indicates diminished control of asthma.</p> <p>Not recommended for long-term daily treatment. Regular use exceeding two days/week for symptom control (not prevention of EIB) indicates the need for additional long-term control therapy.</p> <p>Periodically clean mouthpiece as drug may plug orifice.</p> <p>Instructions for use,&nbsp;priming, and cleaning MDI vary by brand. For specific information, refer to UpToDate topic on use of inhaler devices in children,&nbsp;Lexicomp, and patient leaflet included with MDI.</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Levalbuterol (levosalbutamol) HFA MDI with spacer (valved holding chamber)</td> <td>45 mcg/puff</td> <td>Safety and efficacy not established in children &#60;4 years</td> <td>Two puffs every four to six hours as needed</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Dry powder inhaler (DPI)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Albuterol (salbutamol)&nbsp;breath-activated DPI</td> <td>90 mcg/inhalation</td> <td>Safety and efficacy not established in children &#60;4 years</td> <td>Two puffs every four to six hours as needed</td> <td> <p>DPI&nbsp;alternative for prophylactic use prior to exercise in older children who are comfortable with&nbsp;breath-activated inhaler technique.</p> <p>Use of DPI is not advised as rescue therapy&nbsp;in an acute&nbsp;setting,&nbsp;as&nbsp;some children&nbsp;may be&nbsp;unable&nbsp;to generate sufficient inspiratory flow rate<span style=\"color: #ff0000;\"> </span>to&nbsp;assure optimal lung deposition of drug.</p> <p>Note: DPIs&nbsp;can contain lactose and trace milk proteins, (ie,&nbsp;potential allergens).</p> Also refer to information above on albuterol MDI.</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Nebulizer solution</td> </tr> <tr> <td class=\"indent2\">Albuterol (salbutamol)</td> <td> <p>0.63 mg/3 mL</p> <p>1.25 mg/3 mL</p> <p>2.5 mg/3 mL</p> 5 mg/mL (0.5%)</td> <td>0.63 to 2.5 mg every four to six hours, as needed</td> <td>1.25 to 5 mg every four to eight hours, as needed</td> <td>May mix with budesonide inhalant suspension, ipratropium solution, or cromolyn sodium solution for nebulization.</td> </tr> <tr> <td class=\"indent2\">Levalbuterol (levosalbutamol)</td> <td> <p>0.31 mg/3 mL</p> <p>0.63 mg/3 mL</p> <p>1.25 mg/0.5 mL</p> 1.25 mg/3 mL</td> <td>0.31 to 1.25 mg every four to six hours, as needed</td> <td>0.31 to 0.63 mg every eight hours, as needed</td> <td>May mix with budesonide suspension for nebulization.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Use and dose adjustment of inhaled short-acting beta<SUB>2</SUB>-agonists for acute asthma exacerbations&nbsp;are reviewed separately. Short-acting beta agonists can also be administered 10 to 20 minutes prior to exercise and more frequently than every four hours when patients are in a medically supervised, urgent-care setting. Refer to separate topic reviews and table on recommended doses of medications to treat children with an acute asthma exacerbation.</LI>&#xD;&#xA;<LI>Nonselective agents (ie, epinephrine, isoproterenol, metaproterenol) and orally administered beta<SUB>2</SUB>-agonists are not recommended, due to their potential for excessive cardiac stimulation, especially in high doses.</LI></UL></div><div class=\"graphic_footnotes\">DPI: dry powder inhaler; EIB: exercise-induced bronchospasm; HFA: hydrofluoroalkane; MDI: metered-dose inhaler.<br />* Doses are provided for those products that have been approved by the US Food and Drug Administration or have sufficient clinical trial safety and efficacy data in the appropriate age ranges to support their use. Doses shown and strengths (ie, mcg per puff or inhalation) are based upon product descriptions approved in the United States, which may differ from how strengths are described for products available in other countries. Consult local product information before use.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</LI>&#xD;&#xA;<LI>Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2012. Available at <A href=\"http://www.ginasthma.org/\" target=_blank>www.ginasthma.org</A>.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 59229 Version 13.0</div></div></div>"},"59231":{"type":"graphic_picture","displayName":"Bowel associated dermatosis","title":"Disseminated papulopustular hemorrhagic dermatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated papulopustular hemorrhagic dermatosis</div><div class=\"cntnt\"><img style=\"width:297px; height:320px;\" src=\"images/DERM/59231_Bowel_associated_dermatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scattered papulopustular lesions due to neutrophilic infiltration of the skin is seen in the bowel-associated dermatosis arthritis syndrome in patients with inflammatory bowel disease.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 59231 Version 3.0</div></div></div>"},"59233":{"type":"graphic_table","displayName":"Tachy mediated CM treatment","title":"Tachycardia-mediated cardiomyopathy: Improvement with treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tachycardia-mediated cardiomyopathy: Improvement with treatment</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Associated arrhythmia</td>\n\n      <td class=\"subtitle1\">Number of patients</td>\n\n      <td class=\"subtitle1\">Treatment</td>\n\n      <td class=\"subtitle1\">Evidence for improvement</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Atrial fibrillation</td>\n\n      <td>14</td>\n\n      <td>AV node ablation and pacer</td>\n\n      <td>Increased EF</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Atrial fibrillation</td>\n\n      <td>12</td>\n\n      <td>Cardioversion</td>\n\n      <td>Increased EF</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Atrial fibrillation</td>\n\n      <td>10</td>\n\n      <td>Rate control or conversion</td>\n\n      <td>Increased EF</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ectopic atrial tachycardia</td>\n\n      <td>10</td>\n\n      <td>Surgical ablation</td>\n\n      <td>Increased EF</td>\n\n    </tr>\n\n    <tr>\n\n      <td>AVRT</td>\n\n      <td>4</td>\n\n      <td>Medications</td>\n\n      <td>Increased EF</td>\n\n    </tr>\n\n    <tr>\n\n      <td>RVOT VT</td>\n\n      <td>1</td>\n\n      <td>Ablation</td>\n\n      <td>Increased EF</td>\n\n    </tr>\n\n    <tr>\n\n      <td>LV VT</td>\n\n      <td>1</td>\n\n      <td>Ablation</td>\n\n      <td>Increased EF</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">AVRT: atrioventricular reentrant tachycardia mediated by an accessory pathway; EF: ejection fraction; RVOT VT: right ventricular outflow tract ventricular tachycardia; LV VT: idiopathic left ventricular tachycardia.</div><div id=\"graphicVersion\">Graphic 59233 Version 1.0</div></div></div>"},"59239":{"type":"graphic_figure","displayName":"Asthma annual mortality","title":"Number and rate* of asthma deaths, by year and International Classification of Diseases<SUP>¶</SUP> (ICD) - United States, 1980 to 2004<SUP>Δ</SUP><SUP>◊</SUP><SUP>§¥</SUP>","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Number and rate* of asthma deaths, by year and International Classification of Diseases<SUP>¶</SUP> (ICD) - United States, 1980 to 2004<SUP>Δ</SUP><SUP>◊</SUP><SUP>§¥</SUP></div><div class=\"cntnt\"><img style=\"width:600px; height:343px;\" src=\"images/PULM/59239_Asthmaannualmortality.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Per million population. Age-adjusted to 2000 US population.<br />¶ During 1979 to 1998, ICD-9 was used to classify deaths. In 1999, ICD-10 was implemented.<br />Δ Data from 2008: 3397 deaths, 11 deaths per million population<SUP>[1]</SUP>.<br /><FONT class=lozenge>◊</FONT> Data from 2009: 3388 deaths, 11 deaths per million population<SUP>[2]</SUP>.<br />§ Data from 2010: 3404 deaths, 11 deaths per million population<SUP>[3]</SUP>.<br />¥ Data from 2017: 3615 deaths, 10 deaths per million population<SUP innerHtml>[4]</SUP>.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: Final data for 2008. National Center for Health Statistics. Vital Health Stat Series No. 10 (59) 2011. http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_10.pdf (Accessed on July 7, 2012).</LI>&#xD;&#xA;<LI>Kochanek KD, Xu J, Murphy SL, et al. Deaths: Final data for 2009. National Center for Health Statistics. Vital Health Stat Series No. 3 (60) 2011. http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_03.pdf (Accessed on July 7, 2012).</LI>&#xD;&#xA;<LI>Murphy SL, Xu J, Kochanek KD. Deaths: Final data for 2010. National Center for Health Statistics. National vital statistics reports No. 4, 2013. http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_04.pdf (Accessed on September 4, 2014). </LI>&#xD;&#xA;<LI>CDC Data Statistics and&nbsp;Surveillance: Asthma. https://www.cdc.gov/asthma/most_recent_data.htm (Accessed on September 22, 2017).</LI></OL>&#xD;&#xA;<P>Moorman JE, Rudd RA, Johnson CA, et al. National surveillance for asthma-United States, 1980-2004. MMWR Surveill Summ 2007; 56:1.</P>&#xD;&#xA;<P>&nbsp;</div><div id=\"graphicVersion\">Graphic 59239 Version 5.0</div></div></div>"},"59240":{"type":"graphic_figure","displayName":"Stapled circular colorectal anastomosis - End-to-end","title":"Stapled circular colorectal anastomosis - End-to-end","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Stapled circular colorectal anastomosis - End-to-end</div><div class=\"cntnt\"><img style=\"width:509px; height:432px;\" src=\"images/SURG/59240_Stapled-colorectal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure A depicts the pursestring in place in the proximal colon in preparation for insertion&#160;of the anvil.<br> Figure B depicts the anvil secured in the proximal colon with the pursestring suture.<br> Figure C depicts the attachment of the stapler, which was inserted transanally, to the anvil in preparation for a circular end-to-end anastomosis.</div><div id=\"graphicVersion\">Graphic 59240 Version 1.0</div></div></div>"},"59241":{"type":"graphic_diagnosticimage","displayName":"Normal HIDA scan","title":"Normal HIDA scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Normal HIDA scan</div><div class=\"cntnt\"><img style=\"width:590px; height:396px;\" src=\"images/RADIOL/59241_Normal_HIDA_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an example of a normal 99mTc-hepatic iminodiacetic acid (HIDA) scan and shows early filling of the gallbladder at 15 minutes (arrow) and complete filling by 25 minutes (arrowhead), indicating a patent cystic duct.</div><div id=\"graphicVersion\">Graphic 59241 Version 4.0</div></div></div>"},"59242":{"type":"graphic_figure","displayName":"Bookwalter retractor A","title":"Bookwalter retractor","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Bookwalter retractor</div><div class=\"cntnt\"><img style=\"width:479px; height:262px;\" src=\"images/SURG/59242_Bookwalter_retractor_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bookwalter retractor and accessory retractors in place.</div><div id=\"graphicVersion\">Graphic 59242 Version 2.0</div></div></div>"},"59243":{"type":"graphic_diagnosticimage","displayName":"Drug packet radiograph","title":"Plain abdominal radiography demonstrating drug packets","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Plain abdominal radiography demonstrating drug packets</div><div class=\"cntnt\"><img style=\"width:526px; height:281px;\" src=\"images/PULM/59243_Drug_packet_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In both radiographs, drug packets are clearly visible in the descending colon; on the left, they are also visible in the rectum.</div><div class=\"graphic_reference\">Courtesy of Stephen Traub, MD.</div><div id=\"graphicVersion\">Graphic 59243 Version 2.0</div></div></div>"},"59244":{"type":"graphic_diagnosticimage","displayName":"M mode color Doppler LV","title":"Color Doppler m-mode echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color Doppler m-mode echocardiogram</div><div class=\"cntnt\"><img style=\"width:323px; height:360px;\" src=\"images/CARD/59244_M_mode_color_Doppler_LV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color Doppler M-mode from the four-chamber view, recorded at a speed of 100 mm/sec, demonstrates the rate at which flow propagates into the left ventricle, represented by the slope of the filling signal. In the normal ventricle, the flow propagation is rapid and the slope is steep (panel A). The rate at which flow propagates into the left ventricle of a patient with cardiomyopathy and diastolic dysfunction is considerably slower (panel B). This observation is particularly useful when trying to differentiate normal from &quot;pseudonormal&quot; filling patterns in diastolic dysfunction.</div><div id=\"graphicVersion\">Graphic 59244 Version 4.0</div></div></div>"},"59245":{"type":"graphic_diagnosticimage","displayName":"Primary TB in an infant PA","title":"Primary tuberculosis in infant","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary tuberculosis in infant</div><div class=\"cntnt\"><img style=\"width:320px; height:327px;\" src=\"images/PULM/59245_Primary_TB_in_an_infant_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large left sided pleural effusion produces complete opacification of the left hemithorax with cardiomediastinal shift to the right.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59245 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"59246":{"type":"graphic_diagnosticimage","displayName":"Pulmonary hypertension MCTD","title":"Pulmonary hypertension in mixed connective tissue disease (MCTD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary hypertension in mixed connective tissue disease (MCTD)</div><div class=\"cntnt\"><img style=\"width:432px; height:486px;\" src=\"images/RHEUM/59246_Pulmonary_hypertension_MCTD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a MCTD patient with severe pulmonary hypertension associated with MCTD, showing enlargement of both pulmonary arteries.</div><div class=\"graphic_reference\">Reproduced with permission from: Bull TM, Fagain KA, Badesch DB. Pulmonary Vascular Manifestations of Mixed Connective Tissue Disease. Rheum Dis Clin N Am 2005; 31:451. Copyright © 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 59246 Version 2.0</div></div></div>"},"59248":{"type":"graphic_figure","displayName":"Polarized light physics","title":"Polarized light physics","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Polarized light physics</div><div class=\"cntnt\"><img style=\"width:602px; height:188px;\" src=\"images/DERM/59248_Polarized_light_physics_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonpolarized light vibrates in different orientations. When nonpolarized light is transmitted through a polarizing filter (filter A), the emerging light becomes polarized (vibrations in one plane). Polarized light that maintains its polarization after interacting with the skin is unable to pass through the cross-polarizing filter (filter B), and hence no light will emerge through the cross-polarized filter and the observer will see no structures. Polarized light that interacts with deeper parts of the skin undergoes multiple scattering events resulting in randomization of polarization. The scattered light emerging from the skin that is in the same plane as the cross-polarized filter (filter B) will pass through the filter allowing the observer to recognize structures.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 59248 Version 2.0</div></div></div>"},"59249":{"type":"graphic_picture","displayName":"Cat scratch disease","title":"Cat scratch disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cat scratch disease</div><div class=\"cntnt\"><img style=\"width:379px; height:252px;\" src=\"images/ID/59249_Cat_scratch_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with cat scratch disease has a primary inoculation lesion and prominent cervical lymphadenopathy (arrow).</div><div class=\"graphic_reference\">Courtesy of Joy D Jester. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 59249 Version 3.0</div></div></div>"},"59252":{"type":"graphic_figure","displayName":"Primary megaureter","title":"Primary megaureter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary megaureter</div><div class=\"cntnt\"><img style=\"width:271px; height:608px;\" src=\"images/PEDS/59252_Primarymegaureter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram of primary megaureter that demonstrates the location of a functional or anatomical abnormality at the ureterovesical junction.</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin LS, Kogan BA. Handbook of Pediatric Urology, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59252 Version 10.0</div></div></div>"},"59253":{"type":"graphic_diagnosticimage","displayName":"Mounier Kuhn CXR","title":"Tracheobronchomegaly Mounier-Kuhn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheobronchomegaly Mounier-Kuhn</div><div class=\"cntnt\"><img style=\"width:306px; height:408px;\" src=\"images/PULM/59253_Mounier_Kuhn_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast tracheobronchogram shows tracheobronchomegaly with massive dilation of trachea and mainstem bronchi.</div><div id=\"graphicVersion\">Graphic 59253 Version 2.0</div></div></div>"},"59255":{"type":"graphic_picture","displayName":"Gaucher cells in marrow","title":"Gaucher cells on bone marrow aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gaucher cells on bone marrow aspirate</div><div class=\"cntnt\"><img style=\"width:437px; height:288px;\" src=\"images/HEME/59255_Gaucher_cells_in_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate showing a number of large macrophages laden with cerebrosides (Gaucher cells, arrows) in a patient with Gaucher disease and concomitant multiple myeloma. The cytoplasm has a pattern which has been likened to wrinkled silk or crumpled newspaper.</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD and William C Moloney, MD.</div><div id=\"graphicVersion\">Graphic 59255 Version 2.0</div></div></div>"},"59256":{"type":"graphic_figure","displayName":"Ungrounded electrocautery risks","title":"Hazards of electrocautery with an ungrounded endoscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hazards of electrocautery with an ungrounded endoscope</div><div class=\"cntnt\"><img style=\"width:360px; height:201px;\" src=\"images/PULM/59256_Ungrounded_electrocautery_r.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Current leaking onto the endoscope from a unipolar instrument can flow through the endoscopist, producing burns to the eyes (A) and hands (B). A burn to the patient (C) can result if tissue contacts exposed metal on the endoscope. The use of a grounded safety cord provides a direct, low resistance pathway for current to return to the generator, thus avoiding the undesired pathways indicated by the broken lines.</div><div class=\"graphic_reference\">Redrawn from Barlow, DE, Gastrointest Endosc 1982; 28:73.</div><div id=\"graphicVersion\">Graphic 59256 Version 1.0</div></div></div>"},"59257":{"type":"graphic_figure","displayName":"Prepatellar bursa PI","title":"Knee bursa (prepatellar bursa)","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Knee bursa (prepatellar bursa)</div><div class=\"cntnt\"><img style=\"width:467px; height:353px;\" src=\"images/PI/59257_Prepatellar_bursa_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59257 Version 3.0</div></div></div>"},"59258":{"type":"graphic_picture","displayName":"Lichenoid drug eruption hyperpigmentation","title":"Lichenoid drug eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichenoid drug eruption</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/59258_Lichen_drug_erupt_hyperpig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lichenoid drug eruption manifesting as violaceous and hyperpigmented papules is present in this patient with dark skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59258 Version 3.0</div></div></div>"},"59259":{"type":"graphic_algorithm","displayName":"NBO versus HBO algorithm","title":"Algorithm for using normobaric and hyperbaric oxygen following carbon monoxide exposure","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Algorithm for using normobaric and hyperbaric oxygen following carbon monoxide exposure</div><div class=\"cntnt\"><img style=\"width:529px; height:321px;\" src=\"images/EM/59259_NBO_versus_HBO_algo_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CO: carbon monoxide; ECG: electrocardiogram; CO-Hgb: carboxyhemoglobin; NBO: normobaric oxygen; HBO: hyperbaric oxygen; N/V: nausea and vomiting.</div><div class=\"graphic_reference\">Adapted from: O'Brien C, Manaker S. Carbon monoxide and smoke inhalation. The Intensive Care Manual. Hanson, Lanken, Manaker (Eds), WB Saunders, Philadelphia, 2001.</div><div id=\"graphicVersion\">Graphic 59259 Version 4.0</div></div></div>"},"59261":{"type":"graphic_figure","displayName":"Suture placement Coopers ligmnt","title":"Suture placement through Cooper's ligament for Burch procedure (retropubic colposuspension)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Suture placement through Cooper's ligament for Burch procedure (retropubic colposuspension)</div><div class=\"cntnt\"><img style=\"width:370px; height:374px;\" src=\"images/OBGYN/59261_Suture_placement_Coopers_li.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Robinson, D, Norton, PA. Diagnosis and Management of Urinary Incontinence. In: Gynecologic Surgery. Mann, WJ, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.714.</div><div id=\"graphicVersion\">Graphic 59261 Version 2.0</div></div></div>"},"59263":{"type":"graphic_picture","displayName":"Pelosi technique 3","title":"Delivery and hysterotomy in the Pelosi cesarean technique","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Delivery and hysterotomy in the Pelosi cesarean technique</div><div class=\"cntnt\"><img style=\"width:546px; height:488px;\" src=\"images/OBGYN/59263_Delivery_and_hysterotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A digital vertical extension of the hysterotomy incision is made. The vertical extension may be more efficient than traditional transverse extension.<br />(B) The fetal head is delivered with the support of the surgeon's hand.<br />(C) When head extraction cannot be accomplished using one hand assisted by concomitant fundal pressure, the soft vacuum cup can be employed.<br />(D) Breech delivery is accomplished using standard extraction maneuvers.<br />(E) Following spontaneous separation the placenta is removed by fundal pressure and light cord traction.<br />(F) The hysterotomy is repaired either in situ using a single layer closure or by exteriorizing the uterus and using a double layer closure. When needed, hemostatic individual figure-of-eight sutures are also placed.</div><div class=\"graphic_reference\">Courtesy of Marco Pelosi, MD and Marco Pelosi III, MD.</div><div id=\"graphicVersion\">Graphic 59263 Version 3.0</div></div></div>"},"59264":{"type":"graphic_table","displayName":"Examples of medical child abuse ","title":"Medical child abuse: examples of presenting signs and symptoms in 117 patients*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical child abuse: examples of presenting signs and symptoms in 117 patients*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Symptoms and signs by system involved</td> </tr> <tr> <td class=\"indent1\">Allergic: food allergy, rash</td> </tr> <tr> <td class=\"indent1\">Dermatologic: erythema, vesiculations from burns, lacerations, scratches, puncture wounds, eczema</td> </tr> <tr> <td class=\"indent1\">Developmental: learning disabilities, attention-deficit/ hyperactivity disorders, neuromotor dysfunctions, pervasive developmental delay, psychosis</td> </tr> <tr> <td class=\"indent1\">Endocrine: polydipsia, polyuria, hypoglycemia, diabetes, glycosuria</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal: abdominal pain, anorexia, diarrhea, dehydration, esophageal burns, vomiting, weight loss, bowel obstruction, gut dyskinesias, bleeding including hematemesis and hematochezia or melena, bleeding from nasogastric tube, bleeding from ileostomy, disorders leading to a need for parenteral nutrition</td> </tr> <tr> <td class=\"indent1\">Hematologic: bleeding, easy bruising, anemia</td> </tr> <tr> <td class=\"indent1\">Infection: fever, leukopenia, sepsis, septic arthritis, osteomyelitis; failure to resolve infections with antibiotics to which bacteria are susceptible; onset of new infection while the child is receiving antibiotics to which the bacteria are susceptible; unusual bacteria from the site of infection or infection with multiple simultaneous organisms of low pathogenicity</td> </tr> <tr> <td class=\"indent1\">Metabolic: mitochondrial disorders, without positive testing</td> </tr> <tr> <td class=\"indent1\">Neurologic: seizures, headaches, weakness, disorder of consciousness</td> </tr> <tr> <td class=\"indent1\">Oncologic: leukemia, other cancers</td> </tr> <tr> <td class=\"indent1\">Ophthalmic: recurrent hemorrhagic conjunctivitis, keratitis, eyelid swelling, unequal pupils, nystagmus, periorbital cellulitis</td> </tr> <tr> <td class=\"indent1\">Orthopedic: limping</td> </tr> <tr> <td class=\"indent1\">Otic: otorrhea, recurrent infections</td> </tr> <tr> <td class=\"indent1\">Renal: hematuria, proteinuria, renal calculi, bacteriuria, renal insufficiency, hypertension, nocturia, hypernatremia, hyponatremia, hypokalemia, pyuria, renal failure</td> </tr> <tr> <td class=\"indent1\">Respiratory: presentation with an acute life-threatening event, apnea including sleep apnea, cystic fibrosis, bleeding from the upper respiratory tract, intractable asthma, hemoptysis, cyanosis, hypoxia </td> </tr> <tr> <td class=\"indent1\">Rheumatologic: arthritis, arthralgia, morning stiffness</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Other terms for medical child abuse include Munchausen by proxy, factitious&nbsp;fabricated or induced illness in a child by a carer, and pediatric condition falsification with factitious disorder by proxy.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 132, Pages 590-7, Copyright &copy; 2013 by the AAP.</div><div id=\"graphicVersion\">Graphic 59264 Version 10.0</div></div></div>"},"59265":{"type":"graphic_figure","displayName":"NE and survival ValHeFT","title":"Plasma NE concentration predicts survival in patients with HF","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Plasma NE concentration predicts survival in patients with HF</div><div class=\"cntnt\"><img style=\"width:510px; height:405px;\" src=\"images/CARD/59265_NE_and_survival_ValHeFT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In an analysis from the Val-HeFT trial, patients with NYHA class II to III heart failure (HF) were stratified according to quartiles of plasma concentration of norepinephrine (NE). The mortality rates at two years after randomization were significantly higher in higher quartiles of plasma NE.</div><div class=\"graphic_reference\">Data from: Anand IS, Fisher LD, Chiang YT, et al. Circulation 2003; 107:1278.</div><div id=\"graphicVersion\">Graphic 59265 Version 2.0</div></div></div>"},"59266":{"type":"graphic_diagnosticimage","displayName":"Mini radial probe image","title":"Endobronchial ultrasound (EBUS) mini radial probe image","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Endobronchial ultrasound (EBUS) mini radial probe image</div><div class=\"cntnt\"><img style=\"width:478px; height:250px;\" src=\"images/PULM/59266_mini_radial_probe_image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) The radial probe endobronchial ultrasound image demonstrates six distinct layers of the bronchial wall. Layers 1 and 2 are the mucosa, submucosa, and muscle. Layers 3 and 4 are the cartilage. Layers 5 and 6 are the adventitia. Layers 1, 3, and 5 appear hyperechoic because they are interfaces. B) Cross section of a normal bronchus.</div><div id=\"graphicVersion\">Graphic 59266 Version 4.0</div></div></div>"},"59268":{"type":"graphic_table","displayName":"Causes of peripheral sexual precocity","title":"Peripheral precocity (gonadotropin-independent precocious puberty)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Peripheral precocity (gonadotropin-independent precocious puberty)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"35%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Bone age</td> <td class=\"subtitle1\">Additional evaluation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Girls only</td> </tr> <tr> <td class=\"indent1\">Ovarian cysts</td> <td>Breast development and/or vaginal bleeding. Occasionally presents with ovarian torsion and abdominal pain.</td> <td class=\"centered\">&#8593; to &#8593;&#8593;</td> <td>Pelvic ultrasound may visualize the cyst, although in some cases the cyst may have involuted by the time&nbsp;of the study. Vaginal bleeding is indicative of estrogen withdrawal. Recurrent ovarian cysts&nbsp;suggest McCune Albright Syndrome.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ovarian tumor</td> <td>Development of either isosexual or contrasexual sexual precocity, depending of tumor type.</td> <td class=\"centered\">&#8593;&#8593;</td> <td>Pelvic ultrasound</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Boys only</td> </tr> <tr> <td class=\"indent1\">Leydig cell tumor</td> <td>Asymmetrical enlargement of the testes.</td> <td class=\"centered\">&#8593;&#8593;</td> <td>Pubertal testosterone concentrations. Testicular ultrasound aids in diagnosis.</td> </tr> <tr> <td class=\"indent1\">hCG-secreting germ cell tumors </td> <td> <p>Symmetric testicular enlargement to an early pubertal size, but testes remain smaller than expected for degree of pubertal development.</p> Peripheral precocity is&nbsp;seen only in boys, because hCG only activates LH receptors (estrogen biosynthesis in the ovaries requires both FSH and LH receptor activation).</td> <td class=\"centered\">&#8593;&#8593;</td> <td> <p>These tumors may occur in gonads, brain, liver, retroperitoneum, or mediastinum.</p> When a tumor is identified in the anterior mediastinum, a karyotype must be performed because of an association of this finding with Klinefelter syndrome.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Familial male-limited precocious puberty</td> <td> <p>Symmetric testicular enlargement to an early pubertal size, but testes remain smaller than expected for degree of pubertal development; spermatogenesis may occur.</p> <p>Familial: Male-limited autosomal dominant trait.</p> Peripheral precocity&nbsp;is seen only in boys, because&nbsp;there is only activation of the LH receptors (ovarian estrogen biosynthesis requires both FSH and LH receptor activation).</td> <td class=\"centered\">&#8593;&#8593;</td> <td>Genetic testing for mutations of the LH receptor gene (LHCGR).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Girls and boys</td> </tr> <tr> <td class=\"indent1\">Exogenous sex steroids (estradiol and testosterone creams)</td> <td>Estrogen preparations cause feminization, while topical androgens cause virilization in both sexes.</td> <td class=\"centered\">&#8593; to &#8593;&#8593;</td> <td>Clinical history explores use of exogenous sex steroids and folk remedies by caretakers. </td> </tr> <tr> <td class=\"indent1\"> <p>McCune-Albright syndrome</p> (girls&#62;boys)</td> <td> <p>In girls, may present with recurrent episodes of breast development, regression and vaginal bleeding. In boys, sexual precocity less common.</p> <p>Skin: Multiple irregular-edged caf&#233;-au-lait spots.</p> Bone: Polyostotic fibrous dysplasia.</td> <td class=\"centered\">&#8593; to &#8593;&#8593;</td> <td> <p>Ultrasound: Ovaries enlarged, with follicular cysts. In boys, testicular ultrasound can demonstrate hyper-and hypoechoic lesions (most likely representing areas of leydig cell hyperplasia), microlithiasis and focal calcifications.</p> May have other hyperactive endocrine disorders: ie, thyrotoxicosis, glucocorticoid excess and/or gigantism.</td> </tr> <tr> <td class=\"indent1\">Primary hypothyroidism</td> <td> <p>Girls: vaginal bleeding, breast development and galactorrhea.</p> <p>Boys: testicular enlargement.</p> Other clinical features of hypothyroidism such as short stature.</td> <td class=\"centered\">&#8595;</td> <td>Elevated TSH</td> </tr> <tr> <td class=\"indent1\"> <p>Congenital adrenal hyperplasia</p> (untreated)</td> <td>Boys have prepubertal testes with enlarged phallus and pubic hair development. Girls with \"nonclassic\" CAH may present with early pubic and/or axillary hair, and other signs of androgen excess.</td> <td class=\"centered\">&#8593;&#8593;</td> <td>Sex hormone levels vary depending on the adrenal enzyme block. An early morning 17-OHP &#62;200 ng/dL (6 nmol/L) has a high sensitivity and specificity for congenital adrenal hyperplasia secondary to 21 hydroxylase deficiency. ACTH stimulation test is recommended to confirm the diagnosis of CAH if the 17-OHP level is intermediate (eg, between 200 and 1500 ng/dL). After therapy with glucocorticoids, CPP may develop.</td> </tr> <tr> <td class=\"indent1\">Virilizing adrenal tumor</td> <td> <p>Boys: pubic and/or axillary hair and penile growth with pre-pubertal testes.</p> <p>Girls: pubic and/or axillary hair, other significant signs of androgen excess (acne and clitoromegaly).</p> <p>May present with signs of glucocorticoid excess.</p> May be associated with hereditary cancer syndromes.</td> <td class=\"centered\">&#8593;&#8593;</td> <td> <p>High DHEA or DHEAS, androstenedione and testosterone.</p> CT and/or ultrasound of adrenal glands to locate tumor.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Peripheral precocity is characterized by low or suppressed gonadotropin concentrations with elevated sex hormone levels. Pubertal status should be monitored for six months after treatment,&nbsp;because treatment of peripheral precocity can trigger central precocious puberty (CPP). </div><div class=\"graphic_footnotes\">↑: advanced for chronological age; ↓: delayed for chronological age; hCG: human chorionic gonadotropin; LH: luteinizing hormone; FSH: follicle-stimulating hormone; LHCGR: luteinizing hormone/choriogonadotropin receptor; CPP: central precocious puberty; TSH: thyroid-stimulating hormone; CAH: congenital adrenal hyperplasia; 17-OHP: 17-hydroxyprogesterone; ACTH: adrenocorticotropic hormone; DHEA: dehydroepiandrosterone; DHEAS: dehydroepiandrosterone sulfate; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Drs. Jennifer Harrington and Mark Palmert.</div><div id=\"graphicVersion\">Graphic 59268 Version 12.0</div></div></div>"},"59269":{"type":"graphic_movie","displayName":"Balance walk video","title":"Balance exercise video: Balance walk","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Balance exercise video: Balance walk</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PC/59269_Balancewalkvideo.mp4\" style=\"width:480px;height:336px\"></div><img style=\"width:374px; height:306px;\" src=\"images/PC/59269_BalancewalkimgPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Good balance helps you walk safely and avoid tripping and falling over objects in your way.<br> <ol> <li>Raise arms to sides, shoulder height. </li> <li>Choose a spot ahead of you and focus on it to keep you steady as you walk. </li> <li>Walk in a straight line with one foot in front of the other. </li> <li>As you walk, lift your back leg. Pause for one second before stepping forward. </li> <li>Repeat for 20 steps, alternating legs. </li> </ol> As you progress, try looking from side to side as you walk, but skip this step if you have inner ear problems.</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 59269 Version 2.0</div></div></div>"},"59270":{"type":"graphic_picture","displayName":"Miller blade in proper position","title":"Miller blade in proper position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Miller blade in proper position</div><div class=\"cntnt\"><img style=\"width:432px; height:394px;\" src=\"images/EM/59270_MillerLscopeposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this cadaver, the Miller blade is shown lifting the epiglottis to expose the glottis.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59270 Version 10.0</div></div></div>"},"59272":{"type":"graphic_table","displayName":"HCT-CI and CCI","title":"Comparison of Charlson Comorbidity Index (CCI) and Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) scoring systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of Charlson Comorbidity Index (CCI) and Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) scoring systems</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Comorbidity</td>\r\n                    <td class=\"subtitle1\">CCI definition</td>\r\n                    <td class=\"subtitle1\">CCI score</td>\r\n                    <td class=\"subtitle1\">HCT-CI definition</td>\r\n                    <td class=\"subtitle1\">HCT-CI score</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"5\">Pulmonary disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Mild</td>\r\n                    <td>Dyspnea on moderate activity (or with asthma attacks)</td>\r\n                    <td>1</td>\r\n                    <td>Dyspnea on moderate activity or DLco and/or FEV<sub>1</sub> 81 to 90 percent</td>\r\n                    <td>0</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Moderate</td>\r\n                    <td>Dyspnea on slight activity</td>\r\n                    <td>1</td>\r\n                    <td>Dyspnea on slight activity or DLco and/or FEV<sub>1</sub> 66 to 80 percent</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Severe</td>\r\n                    <td>Dyspnea at rest or requires oxygen</td>\r\n                    <td>1</td>\r\n                    <td>Dyspnea at rest or requires oxygen or DLco and/or FEV<sub>1</sub> &#8804;65 percent</td>\r\n                    <td>3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"5\">Cardiac disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">General</td>\r\n                    <td>Congestive heart failure (symptomatic and requiring treatment) and myocardial infarction were included as independent comorbidities, each acquiring a score of 1</td>\r\n                    <td>1 or 2</td>\r\n                    <td>Coronary artery disease*, congestive heart failure, myocardial infarction, or EF &#8804;50 percent</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Arrhythmia</td>\r\n                    <td>N/A</td>\r\n                    <td>0</td>\r\n                    <td>Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Heart valve disease</td>\r\n                    <td>Except mitral valve prolapse</td>\r\n                    <td>0</td>\r\n                    <td>Except mitral valve prolapse</td>\r\n                    <td>3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"5\">Hepatic disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Mild</td>\r\n                    <td>Chronic hepatitis or cirrhosis</td>\r\n                    <td>1</td>\r\n                    <td>Chronic hepatitis, bilirubin &#62;ULN to 1.5 X ULN, or AST/ALT &#62;ULN to 2.5 X ULN</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Moderate to severe</td>\r\n                    <td>Cirrhosis with portal hypertension &#177; bleeding varices</td>\r\n                    <td>3</td>\r\n                    <td>Cirrhosis or fibrosis or bilirubin &#62;1.5 X ULN or AST/ALT &#62;2.5 X ULN</td>\r\n                    <td>3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"5\">Renal disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Mild</td>\r\n                    <td>Serum creatinine 2 to 3 mg/dL</td>\r\n                    <td>0</td>\r\n                    <td>Creatinine 1.2 to 2 mg/dL</td>\r\n                    <td>0</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Moderate to severe</td>\r\n                    <td>Creatinine &#62;3 mg/dL, renal dialysis, or renal transplant</td>\r\n                    <td>2</td>\r\n                    <td>Creatinine &#62;2 mg/dL, renal dialysis, or renal transplant</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"5\">Other malignancies</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Prior solid tumor</td>\r\n                    <td>Initially treated in the last five years</td>\r\n                    <td>2</td>\r\n                    <td>Treated at any time point in the patient's past history, excluding nonmelanoma skin cancer</td>\r\n                    <td>3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Metastatic cancer</td>\r\n                    <td>Present</td>\r\n                    <td>6</td>\r\n                    <td>Not included</td>\r\n                    <td>N/A</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"5\">Other comorbidities</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Diabetes</td>\r\n                    <td>Requiring treatment with insulin or oral hypoglycemics but not diet alone</td>\r\n                    <td>1</td>\r\n                    <td>Requiring treatment with insulin or oral hypoglycemics but not diet alone</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Cerebrovascular disease</td>\r\n                    <td>Transient ischemic attack or cerebrovascular accident</td>\r\n                    <td>1</td>\r\n                    <td>Transient ischemic attack or cerebrovascular accident</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Rheumatologic</td>\r\n                    <td>SLE, RA, polymyositis, mixed CTD, or polymyalgia rheumatica</td>\r\n                    <td>1</td>\r\n                    <td>SLE, RA, polymyositis, mixed CTD, or polymyalgia rheumatica</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Peptic ulcer</td>\r\n                    <td>Requiring treatment</td>\r\n                    <td>1</td>\r\n                    <td>Requiring treatment</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Psychiatric disturbance</td>\r\n                    <td>Not included</td>\r\n                    <td>N/A</td>\r\n                    <td>Depression or anxiety requiring psychiatric consult or treatment</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Infection</td>\r\n                    <td>Not included</td>\r\n                    <td>N/A</td>\r\n                    <td>Requiring continuation of antimicrobial treatment after day 0</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Inflammatory bowel disease</td>\r\n                    <td>Not included</td>\r\n                    <td>N/A</td>\r\n                    <td>Crohn disease or ulcerative colitis</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Obesity</td>\r\n                    <td>Not included</td>\r\n                    <td>N/A</td>\r\n                    <td>Patients with a body mass index &#62;35 kg/m<sup>2</sup></td>\r\n                    <td>1</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">10/1/2009--Requested permission (JD). 10/6/2009--Contract agreement received, agreed to terms but awaiting formal invoice; figure to Terrence (JD). 10/7/2009--Invoice received, to Catherine for payment (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=25501&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_lgnd\">To convert creatinine from milligrams per deciliter to micromoles per liter, multiply milligrams per deciliter by 88.4.</div><div class=\"graphic_footnotes\">DLco: diffusion capacity of carbon monoxide; FEV<sub>1</sub>: forced expiratory volume in one second; EF: ejection fraction; ULN: upper limit of normal; AST: aspartate aminotransferase; ALT: alanine aminotransferase; SLE: systemic lupus erythematosis; RA: rheumatoid arthritis; CTD: connective tissue disease.<br />* One or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft.</div><div class=\"graphic_reference\">Data from: Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912.</div><div id=\"graphicVersion\">Graphic 59272 Version 10.0</div></div></div>"},"59273":{"type":"graphic_diagnosticimage","displayName":"Apical 4-chamber amylodosis","title":"Amyloid cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amyloid cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:323px; height:217px;\" src=\"images/CARD/59273_Apical4chamberamylodosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four-chamber view from a two-dimensional echocardiogram in a patient with amyloidosis shows greatly thickened walls of the left ventricle (LV) with an intensely reflective myocardium, a small LV cavity, and relatively poor contractility.</div><div id=\"graphicVersion\">Graphic 59273 Version 3.0</div></div></div>"},"59275":{"type":"graphic_picture","displayName":"Lymphadenopathy in syphilis","title":"Cervical lymph node in secondary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical lymph node in secondary syphilis</div><div class=\"cntnt\"><img style=\"width:396px; height:258px;\" src=\"images/ID/59275_Lymphadenopathy_in_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Such nodes (arrow) may be found in various locations and are usually firm, non-tender, and &quot;rubbery&quot; in consistency.</div><div class=\"graphic_reference\">Courtesy of Charles Hicks, MD.</div><div id=\"graphicVersion\">Graphic 59275 Version 1.0</div></div></div>"},"59276":{"type":"graphic_picture","displayName":"Small mycetoma lesion B","title":"Small mycetoma lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small mycetoma lesion</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/ID/59276_Small_eumycetoma_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Beatriz Bustamante, MD.</div><div id=\"graphicVersion\">Graphic 59276 Version 1.0</div></div></div>"},"59277":{"type":"graphic_figure","displayName":"Low-protein diet in CKD","title":"Graph showing effect of dietary protein restriction on progression of nondiabetic chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graph showing effect of dietary protein restriction on progression of nondiabetic chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:440px; height:234px;\" src=\"images/NEPH/59277_LowproteindietinCRF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative fall in GFR over three years in patients with nondiabetic chronic renal failure (mean baseline GFR 39 mL/min) receiving a normal (solid line) and low protein (dashed line) diet. Protein restriction had little or no overall beneficial effect. There was a trend toward more rapid loss of GFR in the first four months followed by a modest slowing of progression during the last 32 months.</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate.</div><div class=\"graphic_reference\">Data from Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.&nbsp;N Engl J Med 1994; 330:877.</div><div id=\"graphicVersion\">Graphic 59277 Version 4.0</div></div></div>"},"59278":{"type":"graphic_table","displayName":"Classification of dystonia","title":"Classification of dystonia by clinical characteristics and etiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of dystonia by clinical characteristics and etiology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Clinical characteristics</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Age of onset</strong></td> <td>Infancy: birth to 2 years</td> </tr> <tr> <td>Childhood: 3 to 12 years</td> </tr> <tr> <td>Adolescence: 13 to 20 years</td> </tr> <tr> <td>Early adulthood: 21 to 40 years</td> </tr> <tr> <td class=\"divider_bottom\">Late adulthood: &#62;40 years</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Body distribution</strong></td> <td>Focal: involving a single body region</td> </tr> <tr> <td>Segmental: involving two or more contiguous body regions</td> </tr> <tr> <td>Multifocal: involving two noncontiguous or more (noncontiguous or not) body regions</td> </tr> <tr> <td>Generalized: involving the trunk and at least two other sites</td> </tr> <tr> <td class=\"divider_bottom\">Hemidystonia: involving more regions restricted to one body side</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"><strong>Temporal pattern</strong></td> <td class=\"sublist1_start\">Disease course:</td> </tr> <tr> <td class=\"sublist1\">Static</td> </tr> <tr> <td class=\"sublist1\">Progressive</td> </tr> <tr> <td class=\"sublist1_start\">Variability:</td> </tr> <tr> <td class=\"sublist1\">Persistent: dystonia that persists to approximately the same extent throughout the day</td> </tr> <tr> <td class=\"sublist1\">Action-specific: dystonia that occurs only during a particular activity or task</td> </tr> <tr> <td class=\"sublist1\">Diurnal: dystonia fluctuates during the day, with recognizable circadian variations in occurrence, severity and phenomenology</td> </tr> <tr> <td class=\"divider_bottom sublist1\">Paroxysmal: sudden self-limited episodes of dystonia usually induced by a trigger with return to preexisting neurologic state</td> </tr> <tr> <td rowspan=\"4\"><strong>Associated features</strong></td> <td class=\"sublist1_start\">Isolated or combined with another movement disorder:</td> </tr> <tr> <td class=\"sublist1\">Isolated: dystonia is the only motor feature, with the exception of tremor</td> </tr> <tr> <td class=\"sublist1\">Combined: dystonia is combined with other movement disorders (such as myoclonus, parkinsonism, etc)</td> </tr> <tr> <td>Occurrence of other neurologic or systemic manifestations</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Etiology</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Nervous system pathology</strong></td> <td>Evidence of degeneration (progressive structural abnormality, such as neuronal loss)</td> </tr> <tr> <td>Evidence of structural (often static) lesions</td> </tr> <tr> <td class=\"divider_bottom\">No evidence of degeneration or structural lesion</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"14\"><strong>Inherited or acquired</strong></td> <td class=\"sublist1_start\">Inherited (dystonia forms of proven genetic origin):</td> </tr> <tr> <td class=\"sublist1\">Autosomal dominant</td> </tr> <tr> <td class=\"sublist1\">Autosomal recessive</td> </tr> <tr> <td class=\"sublist1\">X-linked recessive</td> </tr> <tr> <td class=\"sublist1\">Mitochondrial</td> </tr> <tr> <td class=\"sublist1_start\">Acquired (dystonia due to a known specific cause):</td> </tr> <tr> <td class=\"sublist1\">Cerebrovascular (infarction or hemorrhage)</td> </tr> <tr> <td class=\"sublist1\">Perinatal brain injury</td> </tr> <tr> <td class=\"sublist1\">Traumatic brain injury</td> </tr> <tr> <td class=\"sublist1\">Infection</td> </tr> <tr> <td class=\"sublist1\">Drug</td> </tr> <tr> <td class=\"sublist1\">Toxic</td> </tr> <tr> <td class=\"sublist1\">Neoplastic</td> </tr> <tr> <td class=\"divider_bottom sublist1\">Psychogenic</td> </tr> <tr> <td rowspan=\"2\"><strong>Idiopathic (unknown cause)</strong></td> <td>Sporadic</td> </tr> <tr> <td>Familial</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28:863.</div><div id=\"graphicVersion\">Graphic 59278 Version 3.0</div></div></div>"},"59279":{"type":"graphic_table","displayName":"Screening ECG features SCD A","title":"ECG features of the cardiac diseases detectable at pre-participation screening in young competitive athletes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ECG features of the cardiac diseases detectable at pre-participation screening in young competitive athletes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">QTc interval</td> <td class=\"subtitle1\">P wave</td> <td class=\"subtitle1\">PR interval</td> <td class=\"subtitle1\">QRS complex</td> <td class=\"subtitle1\">ST interval</td> <td class=\"subtitle1\">T wave</td> <td class=\"subtitle1\">Arrhythmias</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">HCM</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>(Left atrial enlargement)</td> <td>Normal</td> <td>Increased voltages in mid-left precordial leads; abnormal Q waves in inferior and/or lateral leads;&nbsp;(LAD, LBBB); (delta wave)</td> <td>Down-sloping (up-sloping)</td> <td>Inverted in mid-left precordial leads; (giant&nbsp;and negative in the apical variant)</td> <td>(Atrial fibrillation); (PVB); (VT)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Arrhythmogenic right ventricular cardiomyopathy/dysplasia</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>Normal</td> <td>Normal</td> <td>Prolonged &#62;110 ms in right precordial leads; epsilon wave in right precordial leads; reduced voltages &#8804;0.5 mV in frontal leads; (RBBB)</td> <td>(Up-sloping in right precordial leads)</td> <td>Inverted right in&nbsp;precordial&nbsp;leads</td> <td>PVB with an LBBB pattern; (VT with an&nbsp;LBBB pattern)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Dilated cardiomyopathy</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>(Left atrial enlargement)</td> <td>(Prolonged &#8805;0.21 s)</td> <td>LBBB</td> <td>Down-sloping (up-sloping)</td> <td>Inverted in inferior and/or lateral leads</td> <td>PVB; (VT)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Long QT syndrome</td> </tr> <tr> <td class=\"indent1\">Prolonged</td> <td rowspan=\"3\">Normal</td> <td rowspan=\"3\">Normal</td> <td rowspan=\"3\">Normal</td> <td rowspan=\"3\">Normal</td> <td rowspan=\"3\">Bifid or biphasic in all leads</td> <td rowspan=\"3\">(PVB); (torsade de pointes)</td> </tr> <tr> <td class=\"indent1\">&#62;440 ms in males</td> </tr> <tr> <td class=\"indent1\">&#62;460 ms in females</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Corrado D, Pelliccia A, Bjornstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:516. Copyright © 2005 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 59279 Version 3.0</div></div></div>"},"59280":{"type":"graphic_movie","displayName":"Intraabdominal free fluid Morisons pouch","title":"Intraabdominal free fluid at Morisons pouch","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Intraabdominal free fluid at Morisons pouch</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/59280_IntraabdMorispouchmovie.mp4\" style=\"width:496px;height:320px\"></div><img style=\"width:504px; height:392px;\" src=\"images/EM/59280_IntraabdMorispouchimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip taken from a FAST examination shows free fluid in Morisons pouch (between the liver and right kidney).</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 59280 Version 1.0</div></div></div>"},"59281":{"type":"graphic_picture","displayName":"Hemophagocytosis","title":"Hemophagocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemophagocytosis</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/HEME/59281_Hemophagocytosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Florid hemophagocytosis by benign histiocytes in conjunction with extensive subtle bone marrow infiltration by aggressive natural killer cell-leukemia/lymphoma in bone marrow core biopsy specimen.</div><div class=\"graphic_reference\">Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59281 Version 7.0</div></div></div>"},"59283":{"type":"graphic_table","displayName":"ECG exercise and ST depression","title":"Relationship in exercise ECG testing between sensitivity, specificity, and the amount of ST segment depression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relationship in exercise ECG testing between sensitivity, specificity, and the amount of ST segment depression</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Amount of ST depression</td>\n<td class=\"subtitle1\">Sensitivity, percent</td>\n<td class=\"subtitle1\">Specificity, percent</td>\n</tr>\n<tr>\n<td>0.5 mm</td>\n<td>80</td>\n<td>60</td>\n</tr>\n<tr>\n<td>1.0 mm</td>\n<td>60</td>\n<td>90</td>\n</tr>\n<tr>\n<td>2.0 mm</td>\n<td>20</td>\n<td>98</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 59283 Version 1.0</div></div></div>"},"59285":{"type":"graphic_table","displayName":"Evidence health benefits","title":"Evidence for health benefits associated with regular physical activity (2008 Physical Activity Guideline)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evidence for health benefits associated with regular physical activity (2008 Physical Activity Guideline)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1_single\">Adults and older adults</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_single\">Strong evidence</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of early death</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of coronary heart disease</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of stroke</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of high blood pressure</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of adverse blood lipid profile</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of type 2 diabetes</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of metabolic syndrome</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of colon cancer</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of breast cancer</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Prevention of weight gain</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Weight loss, particularly when combined with reduced calorie intake</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Improved cardiorespiratory and muscular fitness</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Prevention of falls</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Reduced depression</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Better cognitive function (for older adults)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_single\">Moderate to strong evidence</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Better functional health (for older adults)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Reduced abdominal obesity</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_single\">Moderate evidence</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of hip fracture</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of lung cancer</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Lower risk of endometrial cancer</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Weight maintenance after weight loss</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Increased bone density</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Improved sleep quality</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">US Department of Health &amp; Human Services. 2008 Physical Activity Guidelines for Americans.</div><div id=\"graphicVersion\">Graphic 59285 Version 1.0</div></div></div>"},"59286":{"type":"graphic_figure","displayName":"Plasma concentrations A","title":"Plasma glucose concentrations during the 180 min period after meal ingestion","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Plasma glucose concentrations during the 180 min period after meal ingestion</div><div class=\"cntnt\"><img style=\"width:476px; height:360px;\" src=\"images/PC/59286_Plasma_concentrations_A.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data are means ±SE.</div><div class=\"graphic_footnotes\">SE: standard error.</div><div class=\"graphic_reference\">Modified with permission from: Vilsboll T, Krarup T, Deacon C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609. Copyright © 2001 The American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 59286 Version 2.0</div></div></div>"},"59287":{"type":"graphic_diagnosticimage","displayName":"Mesothelioma MRI III","title":"Mesothelioma with hemorrhagic pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mesothelioma with hemorrhagic pleural effusion</div><div class=\"cntnt\"><img style=\"width:360px; height:316px;\" src=\"images/PULM/59287_Mesothelioma_MRI_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A liquid-liquid level is demonstrated on a sagittal T1- weighted image (arrows), most likely representing a hematocrit effect.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59287 Version 2.0</div></div></div>"},"59288":{"type":"graphic_diagnosticimage","displayName":"RB ILD PA","title":"Respiratory bronchiolitis-associated interstitial lung disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respiratory bronchiolitis-associated interstitial lung disease</div><div class=\"cntnt\"><img style=\"width:350px; height:313px;\" src=\"images/PULM/59288_RB_ILD_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior roentgenogram of the chest showing diffuse reticulonodular opacities most prominent in the lower lung zones in a heavy smoker with chronic cough and exertional dyspnea of six months' duration.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr MD.</div><div id=\"graphicVersion\">Graphic 59288 Version 2.0</div></div></div>"},"59290":{"type":"graphic_table","displayName":"Malaria cases/deaths and percent decreases","title":"World Health Organization (WHO) estimated malaria cases and deaths in 2015 and percent decreases since 2000, by region","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) estimated malaria cases and deaths in 2015 and percent decreases since 2000, by region</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"6\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">WHO region<br /> (percent)</td> <td class=\"subtitle1\">Population*<br /> (1000s)</td> <td class=\"subtitle1\">Cases<br /> (1000s)</td> <td class=\"subtitle1\">Decrease since 2000<br /> (percent)</td> <td class=\"subtitle1\">Proportion due to <em>P.vivax</em><br /> (percent)</td> <td class=\"subtitle1\">Deaths</td> <td class=\"subtitle1\">Decrease since 2000 (percent)</td> </tr> <tr> <td>Africa</td> <td class=\"centered\">989,173</td> <td class=\"centered\">188,000</td> <td class=\"centered\">-12</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">395,000</td> <td class=\"centered\">-48</td> </tr> <tr> <td>Southeast Asia</td> <td class=\"centered\">1,928,174</td> <td class=\"centered\">20,000</td> <td class=\"centered\">-39</td> <td class=\"centered\">50</td> <td class=\"centered\">32,000</td> <td class=\"centered\">-37</td> </tr> <tr> <td>Eastern Mediterranean</td> <td class=\"centered\">643,784</td> <td class=\"centered\">3900</td> <td class=\"centered\">-57</td> <td class=\"centered\">40</td> <td class=\"centered\">7000</td> <td class=\"centered\">-57</td> </tr> <tr> <td>Western Pacific</td> <td class=\"centered\">1,847,250</td> <td class=\"centered\">1500</td> <td class=\"centered\">-59</td> <td class=\"centered\">16</td> <td class=\"centered\">3200</td> <td class=\"centered\">-60</td> </tr> <tr> <td>Americas</td> <td class=\"centered\">986,705</td> <td class=\"centered\">660</td> <td class=\"centered\">-74</td> <td class=\"centered\">71</td> <td class=\"centered\">500</td> <td class=\"centered\">-69</td> </tr> <tr> <td>Europe</td> <td class=\"centered\">910,053</td> <td class=\"centered\">0</td> <td class=\"centered\">-100<sup>&#182;</sup></td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">-&#182;</td> </tr> <tr> <td>World total</td> <td class=\"centered\">7,305,139</td> <td class=\"centered\">214,000</td> <td class=\"centered\">-18</td> <td class=\"centered\">6<sup>&#916;</sup></td> <td class=\"centered\">438,000</td> <td class=\"centered\">-48</td> </tr> <tr> <td>Lower bound</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">149,000</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">236,000</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Upper bound</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">303,000</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">635,000</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* WHO Regional Statistical Reports, 2015.<br />&para; There were 36,000 cases and 0 deaths due to malaria in 2000.<br />&Delta; 51 percent outside sub-Saharan Africa.</div><div class=\"graphic_reference\">Modified from: World Health Organization. World Malaria Report 2015. WHO, Geneva 2015. Available at: <a href=\"http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/\" target=\"_blank\">http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/</a> (Accessed on August 01, 2016).</div><div id=\"graphicVersion\">Graphic 59290 Version 7.0</div></div></div>"},"59293":{"type":"graphic_movie","displayName":"tonsill","title":"Coblation tonsillectomy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coblation tonsillectomy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/59293_tonsillconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:396px; height:358px;\" src=\"images/CARD/59293_tonsill.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The coblation wand is used to dissect and remove the tonsil from its bed.</div><div class=\"graphic_reference\">Courtesy of Jose W Ruiz, MD.</div><div id=\"graphicVersion\">Graphic 59293 Version 2.0</div></div></div>"},"59295":{"type":"graphic_picture","displayName":"Pincer nails 1","title":"Pincer nails deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pincer nails deformity</div><div class=\"cntnt\"><img style=\"width:396px; height:278px;\" src=\"images/DERM/59295_Pincernails1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse overcurvature of the nail is seen in pincer nail deformity. The disorder may be hereditary or acquired. In cases of acquired pincer nails, poorly fitting shoes are often responsible. The condition can be painful.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59295 Version 2.0</div></div></div>"},"59296":{"type":"graphic_table","displayName":"STDs associated with HPV","title":"Sexually transmitted infections seen in conjunction with human papillomavirus infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sexually transmitted infections seen in conjunction with human papillomavirus infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Herpes simplex (HSV I and II)</td> </tr> <tr> <td>Chlamydia trachomatis</td> </tr> <tr> <td>Neisseria gonorrhoeae</td> </tr> <tr> <td>Syphilis (Treponema pallidum)</td> </tr> <tr> <td>Human immunodeficiency virus</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td>Molluscum contagiosum</td> </tr> <tr> <td class=\"sublist1_start\">Genital ulcer disease</td> </tr> <tr> <td class=\"sublist1\">Chancroid (Haemophilus ducreyi)</td> </tr> <tr> <td class=\"sublist1\">Granuloma inguinale (Calymmatobacterium granulomatis)</td> </tr> <tr> <td class=\"sublist1\">Lymphogranuloma venereum (Chlamydia trachomatis)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Jha PK, Beral V, Peto J, et al. Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet 1993; 341:1116.</div><div id=\"graphicVersion\">Graphic 59296 Version 3.0</div></div></div>"},"59297":{"type":"graphic_picture","displayName":"Atypical carcinoid necrosis","title":"Atypical pulmonary carcinoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical pulmonary carcinoid</div><div class=\"cntnt\"><img style=\"width:389px; height:261px;\" src=\"images/PULM/59297_Atyp_carcin_necros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power photomicrograph of an atypical pulmonary carcinoid tumor shows focal necrosis (arrows) within a nest of tumor cells.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 59297 Version 3.0</div></div></div>"},"59298":{"type":"graphic_algorithm","displayName":"Mediator release in sepsis","title":"Potential outcomes of mediator release in sepsis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Potential outcomes of mediator release in sepsis</div><div class=\"cntnt\"><img style=\"width:438px; height:332px;\" src=\"images/PULM/59298_Mediator_release_in_sepsis.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59298 Version 2.0</div></div></div>"},"59299":{"type":"graphic_figure","displayName":"2D TTE Short axis pleural effusion","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis position showing a pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis position showing a pleural effusion</div><div class=\"cntnt\"><img style=\"width:447px; height:206px;\" src=\"images/CARD/59299_Short_axis_pleural_effusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short axis view shows that there is large posteromedial space (arrow) behind the heart. Although superficially resembling a pericardial effusion, its sheer size, unaccompanied by any anterior collection, typifies large pleural effusion. Careful inspection reveals a small posterior pericardial effusion (x).</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle; A: anterior; P: posterior; R: right; L: left.</div><div id=\"graphicVersion\">Graphic 59299 Version 4.0</div></div></div>"},"59300":{"type":"graphic_picture","displayName":"Lichen sclerosus on the wrists in dark skin","title":"Extragenital lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Extragenital lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/59300_Lich_scler_wrists_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented and hypopigmented papules are present on the ventral wrists.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59300 Version 3.0</div></div></div>"},"59301":{"type":"graphic_diagnosticimage","displayName":"FAST thoracic evaluation","title":"FAST: Evaluation for pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">FAST: Evaluation for pneumothorax</div><div class=\"cntnt\"><img style=\"width:432px; height:460px;\" src=\"images/EM/59301_FAST_thoracic_evaluat_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image of the chest, obtained during a FAST examination, reveals comet tail artifacts (indicated by arrows) extending down from the visceral pleura (P). The presence of these artifacts is one sign indicating the absence of a pneumothorax.</div><div class=\"graphic_footnotes\">FAST: Focused Assessment with Sonography for Trauma.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 59301 Version 4.0</div></div></div>"},"59302":{"type":"graphic_picture","displayName":"LCDD in liver IF","title":"Light chain deposition disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light chain deposition disease</div><div class=\"cntnt\"><img style=\"width:388px; height:248px;\" src=\"images/NEPH/59302_LCDD_in_liver_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy using anti-kappa light chain antiserum on a liver biopsy from a patient with light chain deposition disease. There is diffuse deposition of kappa light chains. A stain for lambda light chains was negative.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 59302 Version 1.0</div></div></div>"},"59304":{"type":"graphic_figure","displayName":"Median weight for length","title":"Determination of median weight for length for a boy who weighs 9 kg and is 78 cm long","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Determination of median weight for length for a boy who weighs 9 kg and is 78 cm long</div><div class=\"cntnt\"><img style=\"width:444px; height:547px;\" src=\"images/PEDS/59304_Median_weight_for_length.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To determine the median weight for length, plot the child on the weight-for-length curve (Point A). Draw a vertical line to the 50th percentile curve (Point B). Draw a horizontal line to the weight scale (Point C). In the above example, the child weighs 9 kg and has a length of 78 cm. The median weight for a length of 78 cm is 10.4 kg.</div><div class=\"graphic_reference\">Data from: The National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000). Available at www.cdc.gov/growthcharts.</div><div id=\"graphicVersion\">Graphic 59304 Version 1.0</div></div></div>"},"59305":{"type":"graphic_picture","displayName":"Ptosis","title":"Ptosis","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Ptosis</div><div class=\"cntnt\"><img style=\"width:496px; height:341px;\" src=\"images/PEDS/59305_Ptosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Significant congenital ptosis of the right upper lid encroaching into the visual axis. Such significant ptosis can lead to amblyopia and should be repaired.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59305 Version 3.0</div></div></div>"},"59306":{"type":"graphic_diagnosticimage","displayName":"Glenohumeral osteoarthritis","title":"Glenohumeral osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glenohumeral osteoarthritis</div><div class=\"cntnt\"><img style=\"width:365px; height:348px;\" src=\"images/PC/59306_Glenohumeral_osteoarthritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain&nbsp;radiograph is from a 67-year-old woman with anterolateral shoulder pain and stiffness for several years. She denies any history of fracture, dislocation, or severe injury. However, she states: \"People say I've always done man's work. It doesn't surprise me that it is arthritic since arthritis runs in my family.\"&nbsp;On plain&nbsp;radiograph,&nbsp;glenohumeral osteoarthritis is characterized by loss of articular cartilage between the humeral head and the glenoid, osteophyte formation extending from the inferior portion of the humeral head, and humeral head sclerosis. The combination of the loss of cartilage and the osteophyte creates the club-like deformity.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 59306 Version 3.0</div></div></div>"},"59307":{"type":"graphic_table","displayName":"PHQ-9 questionnaire","title":"PHQ-9 depression questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PHQ-9 depression questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Name:</td> <td class=\"subtitle1_single\" colspan=\"4\">Date:</td> </tr> <tr> <td class=\"subtitle2_left\">Over the last two weeks, how often have you been bothered by any of the following problems?</td> <td class=\"subtitle2_left\">Not at all</td> <td class=\"subtitle2_left\">Several days</td> <td class=\"subtitle2_left\">More than half the days</td> <td class=\"subtitle2_left\">Nearly every day</td> </tr> <tr> <td class=\"indent1\">Little interest or pleasure in doing things</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Feeling down, depressed, or hopeless</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Trouble falling or staying asleep, or sleeping too much</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Feeling tired or having little energy</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Poor appetite or overeating</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Feeling bad about yourself, or that you are a failure, or that you have let yourself or your family down</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Trouble concentrating on things, such as reading the newspaper or watching television</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Moving or speaking so slowly that other people could have noticed? Or the opposite, being so fidgety or restless that you have been moving around a lot more than usual.</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Thoughts that you would be better off dead, or of hurting yourself in some way</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"indent1\"><strong>Total ___ =</strong></td> <td><strong>___</strong></td> <td><strong>+ ___</strong></td> <td><strong>+ ___</strong></td> <td><strong>+ ___</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">PHQ-9 score &#8805;10: Likely major depression</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Depression score ranges:</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">5 to 9: mild</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">10 to 14: moderate</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">15 to 19: moderately severe</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8805;20: severe</td> </tr> <tr> <td><strong>If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?</strong></td> <td> <p>Not difficult at all</p> <p>___</p> </td> <td> <p>Somewhat difficult</p> <p>___</p> </td> <td> <p>Very difficult</p> <p>___</p> </td> <td> <p>Extremely difficult</p> <p>___</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PHQ: Patient Health Questionnaire. </div><div class=\"graphic_reference\">Developed by Drs. Robert L Spitzer, Janet BW Williams, Kurt Kroenke, and colleagues, with an educational grant from Pfizer, Inc. No permission required to reproduce, translate, display or distribute.</div><div id=\"graphicVersion\">Graphic 59307 Version 9.0</div></div></div>"},"59310":{"type":"graphic_figure","displayName":"Atrial activation in AF","title":"Atrial activation in atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial activation in atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:301px; height:370px;\" src=\"images/CARD/59310_Atrial_activation_in_AF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spread of activation through right (upper half) and left (lower half) atria during stable atrial fibrillation. These activation maps show propagation of impulse through the atria, as visualized by color isochrones of 10 milliseconds (ms). White arrows indicate general direction of wavelets. Asterisks represent sites of impulse fragmentation and development of new wavelets.</div><div class=\"graphic_reference\">Redrawn from Allissie MA, Lammers WJEP, Bonke FIM, et al. In: Cardiac Arrhythmias, Grane &amp;Stratton, Orlando, 1985, p. 265.</div><div id=\"graphicVersion\">Graphic 59310 Version 2.0</div></div></div>"},"59313":{"type":"graphic_movie","displayName":"TEE multiple atrial septal defects","title":"Multiple atrial septal defects","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple atrial septal defects</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/59313_teec2asdconv.mp4\" style=\"width:383px;height:276px\"></div><img style=\"width:281px; height:259px;\" src=\"images/CARD/59313_teec2asd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram with color flow Doppler shows two distinct jets of blood flow (arrows) from the left atrium (LA) to right atrium (RA), a result of two separate atrial septal defects.</div><div class=\"graphic_footnotes\">Ao: aorta.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 59313 Version 2.0</div></div></div>"},"59316":{"type":"graphic_figure","displayName":"MVG restrictive cardiomyopathy","title":"Tissue doppler echocardiogram can distinguish restrictive cardiomyopathy and constrictive pericarditis","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Tissue doppler echocardiogram can distinguish restrictive cardiomyopathy and constrictive pericarditis</div><div class=\"cntnt\"><img style=\"width:454px; height:445px;\" src=\"images/CARD/59316_MVGrestrictivecardiomyopa.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The schematic diagram shows the early diastolic pattern of the myocardial velocity gradient (MVG), measured by tissue Doppler echocardiography, in normals and in patients with a restrictive cardiomyopathy (RCM) and constrictive pericarditis (CP). The sign of the MVG depends on the relative fastness of subendocardial or subepicardial velocities; it is positive if subendocardial velocities move faster and negative if subepicardial velocities are faster. The MVGs during both isovolumetric relaxation (IR) and rapid ventricular filling (RVF) phases are reduced in RCM compared&nbsp;with CP or normals.</div><div class=\"graphic_reference\">Data from Palka P, Lange A, Donnelly JE, Nihoyannopoulos P. Circulation 2000; 102:655.</div><div id=\"graphicVersion\">Graphic 59316 Version 3.0</div></div></div>"},"59318":{"type":"graphic_diagnosticimage","displayName":"Intercostal neurofibroma CT","title":"Intercostal nerve neurofibroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intercostal nerve neurofibroma</div><div class=\"cntnt\"><img style=\"width:380px; height:274px;\" src=\"images/PULM/59318_Intercostal_neurofibroma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pleural/extrapleural mass in the right hemithorax (arrow). CT shows homogeneous soft tissue attenuation of this mass which originates from the intercostal space structures.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59318 Version 3.0</div></div></div>"},"59319":{"type":"graphic_picture","displayName":"Cracked red lips seen in Kawasaki disease","title":"Cracked, red lips seen in Kawasaki disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cracked, red lips seen in Kawasaki disease</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ALLRG/59319_Cracked_red_lips_Kawasaki.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59319 Version 3.0</div></div></div>"},"59320":{"type":"graphic_figure","displayName":"Omalizumab mechanism of action","title":"Omalizumab mechanism of action","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Omalizumab mechanism of action</div><div class=\"cntnt\"><img style=\"width:536px; height:657px;\" src=\"images/ALLRG/59320_Omalizumab_mechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Omalizumab binds free IgE in the serum, forming trimers and hexamers. The drug binds to IgE at the same site that the high-affinity IgE receptor (Fc-epsilon-RI) binds, so IgE bound to drug cannot bind its receptor on mast cells and basophils. Omalizumab does not bind IgE that is already bound to Fc-epsilon-RI and so should not result in cross-linking of receptors. As a result of the binding of free IgE, the number of IgE receptors on the surface of mast cells and basophils declines over time, which is believed to be a critical component of the clinical effect of the drug. Omalizumab also blocks binding of IgE to the low-affinity IgE receptor (Fc-epsilon-RII or CD23, not shown), although the therapeutic relevance of this is not known.</div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 59320 Version 6.0</div></div></div>"},"59321":{"type":"graphic_waveform","displayName":"Doppler transmitral inflow pattern","title":"Normal Doppler echocardiographic transmitral diastolic inflow pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal Doppler echocardiographic transmitral diastolic inflow pattern</div><div class=\"cntnt\"><img style=\"width:385px; height:329px;\" src=\"images/CARD/59321_Doppler_transmitral_inflow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The recording of the transmitral diastolic inflow (panel B) is obtained by placing the Doppler sample volume between the tips of the open mitral valve leaflets, as shown in panel A. The most commonly measured values are given in tabular format (panel C) and the site of the pulsed wave Doppler sample volume is shown in the upper left panel.</div><div class=\"graphic_footnotes\">m/s: meters per second; VTI: velocity time integral; ms: milliseconds.</div><div id=\"graphicVersion\">Graphic 59321 Version 6.0</div></div></div>"},"59323":{"type":"graphic_table","displayName":"Causes weight loss and FTT","title":"Medical causes of weight loss and failure to thrive in the elderly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical causes of weight loss and failure to thrive in the elderly</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"8\">\r\n  \r\n   Malignancy\r\n  \r\n   </td>\r\n  \r\n   <td>Lung</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Breast</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hematologic</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Gastrointestinal</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Genitourinary</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ovarian</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Prostate</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hepatobiliary</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"8\">\r\n  \r\n   Gastrointestinal\r\n  \r\n   </td>\r\n  \r\n   <td>Peptic ulcer disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Dysmotility syndromes</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cirrhosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bacterial overgrowth</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chronic pancreatitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mesenteric ischemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Inflammatory bowel disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Celiac disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"2\">\r\n  \r\n   Cardiac\r\n  \r\n   </td>\r\n  \r\n   <td>Heart failure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Coronary artery disease, unstable angina</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"3\">\r\n  \r\n   Pulmonary\r\n  \r\n   </td>\r\n  \r\n   <td>Chronic obstructive pulmonary disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Interstitial lung disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bronchiectasis-chronic infection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"4\">\r\n  \r\n   Infectious\r\n  \r\n   </td>\r\n  \r\n   <td>Tuberculosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Subacute bacterial endocarditis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Recurrent bladder infections</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Recurrent aspiration pneumonia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"4\">\r\n  \r\n   Neurologic\r\n  \r\n   </td>\r\n  \r\n   <td>Dementia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Stroke</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Parkinson disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Motor neuron disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"5\">\r\n  \r\n   Endocrine\r\n  \r\n   </td>\r\n  \r\n   <td>Diabetes mellitus</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Adrenal insufficiency</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hyperparathyroidism</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hyperthyroidism</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hypothyroidism</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"4\">\r\n  \r\n   Deficiency states\r\n  \r\n   </td>\r\n  \r\n   <td>Thiamine deficiency</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Vitamin B12 deficiency</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Vitamin C deficiency</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Zinc deficiency</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"2\">\r\n  \r\n   Renal\r\n  \r\n   </td>\r\n  \r\n   <td>Uremia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nephrotic syndrome</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"4\">\r\n  \r\n   Psychiatric\r\n  \r\n   </td>\r\n  \r\n   <td>Depression</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bereavement</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Alcoholism</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mania/psychosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Rheumatic\r\n  \r\n   </td>\r\n  \r\n   <td>Polymyalgia rheumatica/giant cell arteritis</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">5/18/2007 - perm requested via info@americangeriatrics.org.mt 6/21/2007 - bugged.mt 6/28/2007 - publisher responded to say that the fee would be $300. Checking to see if this is a one time fee, or a yearly fee; this is a one time fee. Checking in with EA to see if DE still wants.mt 7/24/2007 -Au is going to try and modify such that permisson will not be needed.mt 8/6/2007 - decided to go with permission since au could not modify it enough. to tammy. CL will give to TH when she and au decide which version to use.mt</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57841&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Causes_weight_loss_and_FTT.htm</title></head></div><div class=\"graphic_reference\">Adapted with permission from: Rehman, H. Involuntary Weight Loss in the Elderly. Clinical Geriatrics 2005; 13:37. Copyright © 2005 American Geriatrics Society.</div><div id=\"graphicVersion\">Graphic 59323 Version 3.0</div></div></div>"},"59325":{"type":"graphic_figure","displayName":"Seating pressure on coccyx","title":"Seating position and coccydynia (pain in the coccyx)","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Seating position and coccydynia (pain in the coccyx)</div><div class=\"cntnt\"><img style=\"width:542px; height:374px;\" src=\"images/PC/59325_Pressure_on_coccyx.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59325 Version 3.0</div></div></div>"},"59326":{"type":"graphic_figure","displayName":"Spectrum of frailty","title":"Potential interventions along the spectrum of frailty in older adults","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Potential interventions along the spectrum of frailty in older adults</div><div class=\"cntnt\"><img style=\"width:540px; height:382px;\" src=\"images/PC/59326_Spectrum_of_frailty.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACE unit: Acute Care for Elders unit; GEM: Geriatric Evaluation and Management; PACE: Program for All-Inclusive Care of the Elderly.</div><div class=\"graphic_reference\">Modified with permission from: Walston JD, Fried LP. Frailty and its Implications for Care. Chapter 9. In: Geriatric Palliative Care, Morrison RS, Meire DE. Oxford University Press, New York 2003. p.93. Copyright &copy;2003 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 59326 Version 3.0</div></div></div>"},"59327":{"type":"graphic_algorithm","displayName":"Rx acute variceal bleed","title":"Management of acute variceal hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of acute variceal hemorrhage</div><div class=\"cntnt\"><img style=\"width:284px; height:303px;\" src=\"images/GAST/59327_Rx_acute_variceal_bleed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are only general guidelines and appropriate therapy should be based on the patient's individual circumstances and the expertise available.</div><div class=\"graphic_footnotes\">EST: endoscopic sclerotherapy; EVL: endoscopic variceal band ligation.</div><div class=\"graphic_reference\">Adapted from Sanyal A, et al, Semin Liver Dis 1993; 13:4.</div><div id=\"graphicVersion\">Graphic 59327 Version 3.0</div></div></div>"},"59328":{"type":"graphic_waveform","displayName":"Ashman phenomenon in AF","title":"Functional right bundle branch block (RBBB) in atrial fibrillation occurring in the short cycle following a preceding long cycle that lengthened the refractory period in the right bundle branch (the ashman phenomenon)","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Functional right bundle branch block (RBBB) in atrial fibrillation occurring in the short cycle following a preceding long cycle that lengthened the refractory period in the right bundle branch (the ashman phenomenon)</div><div class=\"cntnt\"><img style=\"width:540px; height:80px;\" src=\"images/CARD/59328_Ashman_phenomenon_in_AF.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59328 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"59329":{"type":"graphic_figure","displayName":"Clinical findings Mycoplasma pneumoniae","title":"Chronology of untreated <EM>Mycoplasma pneumoniae</EM> pneumonia","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Chronology of untreated <EM>Mycoplasma pneumoniae</EM> pneumonia</div><div class=\"cntnt\"><img style=\"width:498px; height:387px;\" src=\"images/ID/59329_Clinical_findings_M_pneumon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The horizontal dimension depicts the estimated duration of symptoms, signs, positive cultures of respiratory tract samples, and radiographic abnormalities. The temporal correlations of these features are shown vertically.</div><div class=\"graphic_reference\">Redrawn from: Denny FW, Clyde WA Jr, Glezen WP. Mycoplasma pneumoniae disease: Clinical spectrum, pathophysiology, epidemiology, and control. J Infect Dis 1971; 123:74, by permission of Oxford University Press. Copyright © 1971.</div><div id=\"graphicVersion\">Graphic 59329 Version 9.0</div></div></div>"},"59330":{"type":"graphic_picture","displayName":"Haemophilus chocolate agar","title":"<em>Haemophilus influenzae</em> on chocolate agar plate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Haemophilus influenzae</em> on chocolate agar plate</div><div class=\"cntnt\"><img style=\"width:369px; height:238px;\" src=\"images/ID/59330_Haemophilus_chocolate_agar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Haemophilus influenzae</EM> does not grow on a sheep blood agar plate but does produce small, translucent colonies on chocolate agar.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 59330 Version 3.0</div></div></div>"},"59332":{"type":"graphic_table","displayName":"Rx EC amp resistance","title":"Parenteral treatment for infection due to enterococci with high-level ampicillin resistance in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral treatment for infection due to enterococci with high-level ampicillin resistance in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Dose and route</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Preferred options for monotherapy*:</td> </tr> <tr> <td class=\"indent1\">Vancomycin<sup>&#182;</sup></td> <td>Initially 15 mg/kg/dose IV every 12 hours, not to exceed 2 g per dose; subsequent dosing guided by serum trough concentration monitoring</td> </tr> <tr> <td class=\"indent1\">Ampicillin-sulbactam<sup>&#916;</sup></td> <td>3 g IV every 6 hours </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">High-dose ampicillin<sup>&#9674;</sup></td> <td>3 to 4 g IV every 4 hours </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\"> <p>Options for combination therapy:</p> One of above agents PLUS one of the following agents (for bactericidal activity):</td> </tr> <tr> <td class=\"indent1\">Gentamicin<sup>&#167;</sup></td> <td>1&nbsp;mg/kg IV every 8 hours </td> </tr> <tr> <td class=\"indent1\">Streptomycin<sup>&#165;</sup></td> <td>7.5 mg/kg IV or IM every 12 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Adjustment of dose may be required depending upon site and severity of infection and patient kidney function; for additional information, refer to appropriate UpToDate clinical treatment reviews and Lexicomp drug monographs.</div><div class=\"graphic_footnotes\">IV: intravenously; IM: intramuscularly.<br />* Daptomycin and tigecycline are also approved for use in complicated skin and skin structure infections due to vancomycin-susceptible <EM>E. faecalis</EM>; in addition, tigecycline has approval for complicated intraabdominal infections associated with <EM>E. faecalis</EM>. (Refer to the&nbsp;UpToDate table on&nbsp;parenteral therapy for infections due to vancomycin-resistant enterococci.)<br />¶ Teicoplanin (where available) may be used in place of vancomycin for treatment of infection due to isolates with minimum inhibitory concentration (MIC) ≤2 mg/L; for vancomycin-resistant strains (very common with <EM>E. faecium</EM>), teicoplanin should not be used (even if susceptible in vitro) because of concern about emergence of resistance. Teicoplanin loading and maintenance doses vary depending on the site and severity of infection. Loading doses range from 400 mg (approximately 6 mg/kg per dose) intravenously every 12 hours for 3 doses to 800 mg (approximately 12 mg/kg per dose) every 12 hours for 3 to 5 doses; maintenance doses range from 6 to 12 mg/kg/day. Therapeutic drug monitoring may be warranted; refer to local product information. <br />Δ If penicillin and ampicillin resistance&nbsp;are due to beta-lactamase production, ampicillin-sulbactam may be used as the cell wall active agent.<br /><FONT class=lozenge>◊</FONT> High-dose ampicillin may be considered if MIC 16 to 64 mcg/mL and penicillin resistance is not due to penicillinase. (Refer to the&nbsp;UpToDate table on&nbsp;therapy of vancomycin-resistant and highly ampicillin-resistant <EM>E. faecium</EM>.)<br />§ In patients with normal renal function, gentamicin dosing should be adjusted to achieve a one-hour post-dose&nbsp;serum concentration of 3 mcg/mL and a trough concentration of &lt;1 mcg/mL.<br />¥ In patients with normal renal function, streptomycin dosing should be adjusted to achieve a one-hour post-dose serum concentration of 20 to 35 mcg/mL and a trough concentration of &lt;10 mcg/mL.</div><div id=\"graphicVersion\">Graphic 59332 Version 12.0</div></div></div>"},"59333":{"type":"graphic_table","displayName":"Approach to mediastinal nodes","title":"Anatomic considerations in TBNA of mediastinal lymph nodes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anatomic considerations in TBNA of mediastinal lymph nodes</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Station\n   </td>\n   <td  class=\"subtitle1\">\n   Level\n   </td>\n   <td  class=\"subtitle1\">\n   Best approach\n   </td>\n   <td  class=\"subtitle1\">\n   Pitfalls\n   </td>\n   </tr>\n   <tr>\n   <td>7</td>\n   <td>Subcarinal nodes</td>\n   <td>From a point 3-5 mm below on either side of the primary carina, with the needle pointed in an inferomedial direction.</td>\n   <td>Direct puncture of a normal looking carina should usually be avoided.</td>\n   </tr>\n   <tr>\n   <td>4R</td>\n   <td>Right paratracheal lymph nodes</td>\n   <td>From the second or third intercartilaginous space (or 2 cm) proximal to the carina at the 1-2 o'clock position.</td>\n   <td>The mediastinal reflection of the pleura and the azygos vein lie at the 3 o'clock position and should be avoided.</td>\n   </tr>\n   <tr>\n   <td>4L</td>\n   <td>Left paratracheal nodes</td>\n   <td>From the lateral wall of the left main bronchus at the level of the carina at the 9 o'clock position.</td>\n   <td>&nbsp;</td>\n   </tr>\n   <tr>\n   <td>10R</td>\n   <td>Right hilar nodes</td>\n   <td>Through the bronchus intermedius at 3 o'clock position, just below the level of the right upper lobe bronchus or proximal to the origin of the superior segment of the right lower lobe bronchus.</td>\n   <td>&nbsp;</td>\n   </tr>\n   <tr>\n   <td>10L</td>\n   <td>Left hilar nodes</td>\n   <td>At the origin of the left lower lobe bronchus at the nine o'clock position.</td>\n   <td>&nbsp;</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research - Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 59333 Version 1.0</div></div></div>"},"59336":{"type":"graphic_algorithm","displayName":"Algorithm VT versus SVT with possible ventricular preexcitation","title":"Algorithm for the diagnosis of wide QRS tachycardia in the setting of ventricular preexcitation","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of wide QRS tachycardia in the setting of ventricular preexcitation</div><div class=\"cntnt\"><img style=\"width:474px; height:531px;\" src=\"images/CARD/59336_AlgorithmIIVTversusSVT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for distinguishing ventricular tachycardia (VT) from supraventricular tachycardia (SVT) in the setting of preexcitation syndrome.</div><div class=\"graphic_footnotes\">sens: sensitivity; spec: specificity; ECG: electrocardiography; AV: atrioventricular.</div><div id=\"graphicVersion\">Graphic 59336 Version 5.0</div></div></div>"},"59337":{"type":"graphic_algorithm","displayName":"Assessment and Rx of delirium","title":"Assessment and management of patient with delirium","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Assessment and management of patient with delirium</div><div class=\"cntnt\"><img style=\"width:608px; height:618px;\" src=\"images/PC/59337_Assessment_and_Rx_of_deliri.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBC: complete blood count; BUN: blood urea nitrogen; EKG: electrocardiogram; CT: computed tomography; EEG: electroencephalogram; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 59337 Version 3.0</div></div></div>"},"59338":{"type":"graphic_table","displayName":"Causes of dizziness","title":"Causes of dizziness in different clinical settings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of dizziness in different clinical settings</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Variable</td>\n\n      <td class=\"subtitle1\">Kroenke, et al 1992</td>\n\n      <td class=\"subtitle1\">Drachman and Hart 1972</td>\n\n      <td class=\"subtitle1\">Nedzelski, et al 1986</td>\n\n      <td class=\"subtitle1\">Herr, et al 1989</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">Primary care</td>\n\n      <td class=\"subtitle2\">Dizziness clinic</td>\n\n      <td class=\"subtitle2\">Dizziness clinic</td>\n\n      <td class=\"subtitle2\">Emergency room</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Patients</td>\n\n      <td>100</td>\n\n      <td>102</td>\n\n      <td>2222</td>\n\n      <td>125</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"subtitle2_left\">Average age</td>\n      <td>46</td>\n      <td>-</td>\n      <td>48</td>\n      <td>47</td>\n    </tr>\n    <tr>\n      <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">Cause, percent</td>\n      \n      \n      \n      \n    </tr>\n    <tr>\n\n      <td class=\"sublist2_start\">Vertigo</td>\n\n      <td class=\"sublist_other_start\">54</td>\n\n      <td class=\"sublist_other_start\">46</td>\n\n      <td class=\"sublist_other_start\">45</td>\n\n      <td class=\"sublist_other_start\">50</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist2\">Benign positional vertigo</td>\n\n      <td class=\"sublist_other\">16</td>\n\n      <td class=\"sublist_other\">12</td>\n\n      <td class=\"sublist_other\">17</td>\n\n      <td class=\"sublist_other\">-</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Vestibular neuronitis</td>\n\n      <td class=\"sublist_other\">4</td>\n\n      <td class=\"sublist_other\">4</td>\n\n      <td class=\"sublist_other\">10</td>\n\n      <td class=\"sublist_other\">1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Other vestibular</td>\n\n      <td class=\"sublist_other\">10</td>\n\n      <td class=\"sublist_other\">9</td>\n\n      <td class=\"sublist_other\">6</td>\n\n      <td class=\"sublist_other\">-</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Central</td>\n      <td class=\"sublist_other\">10</td>\n      <td class=\"sublist_other\"> 7</td>\n      <td class=\"sublist_other\">4 </td>\n      <td class=\"sublist_other\">7</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\">Migraine</td>\n      <td class=\"sublist_other\">1</td>\n      <td class=\"sublist_other\">-</td>\n      <td class=\"sublist_other\">-</td>\n      <td class=\"sublist_other\">-</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\">Nonspecific</td>\n      <td class=\"sublist_other\"> 10</td>\n      <td class=\"sublist_other\">10</td>\n      <td class=\"sublist_other\">-</td>\n      <td class=\"sublist_other\">-</td>\n    </tr>\n    <tr>\n\n      <td class=\"indent1\">Psychiatric disorder</td>\n\n      <td>16</td>\n\n      <td>9</td>\n\n      <td>21</td>\n\n      <td>11</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Presyncope</td>\n\n      <td>6</td>\n\n      <td>4</td>\n\n      <td>-</td>\n\n      <td>14</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Disequilibrium</td>\n\n      <td>2 </td>\n\n      <td>16</td>\n\n      <td>-</td>\n\n      <td>1</td>\n\n    </tr>\n    <tr>\n      <td class=\"indent1\">Hyperventilation</td>\n      <td>1 </td>\n      <td>23</td>\n      <td>-</td>\n      <td> 5</td>\n    </tr>\n    <tr>\n      <td class=\"indent1\">Multicausal</td>\n      <td>13</td>\n      <td>12</td>\n      <td>-</td>\n      <td>-</td>\n    </tr>\n    <tr>\n      <td class=\"indent1\">Unknown</td>\n      <td> 8</td>\n      <td>9</td>\n      <td>19</td>\n      <td>10</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Kroenke, K, Lucas, CA, Rosenberg, ML, et al, Ann Intern Med 1992; 117:898.</div><div id=\"graphicVersion\">Graphic 59338 Version 1.0</div></div></div>"},"59339":{"type":"graphic_picture","displayName":"Favre Racouchot","title":"Favre-Racouchot Syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Favre-Racouchot Syndrome</div><div class=\"cntnt\"><img style=\"width:396px; height:295px;\" src=\"images/DERM/59339_Favre_Racouchot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 87-year-old man, with a history of chronic sun exposure, developed prominent asymptomatic open comedones on the upper cheeks and sides of his nose.</div><div class=\"graphic_reference\">Copyright © Shahbaz A Janjua, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 59339 Version 7.0</div></div></div>"},"59340":{"type":"graphic_table","displayName":"Herbs affecting glucose","title":"Hypoglycemic and hyperglycemic herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypoglycemic and hyperglycemic herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Drug</td>\n\n      <td class=\"subtitle1\">Effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Hypoglycemic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Alfalfa</td>\n\n      <td>Hypoglycemic, manganese, human</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Aloes/Aloe vera</td>\n\n      <td>Hypoglycemic, in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Burdock</td>\n\n      <td>Hypoglycemic, in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Celery</td>\n\n      <td>Hypoglycemic, in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Cornsilk</td>\n\n      <td>Hypoglycemic, in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Damiana</td>\n\n      <td>Hypoglycemic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Elecampane</td>\n\n      <td>Hypoglycemic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Eucalyptus</td>\n\n      <td>Hypoglycemic, in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Fenugreek</td>\n\n      <td>Hypoglycemic, human</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Garlic</td>\n\n      <td>Hypoglycemic, in vivo, human</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Ginger</td>\n\n      <td>Hypoglycemic, in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Ginseng, Panax</td>\n\n      <td>Hypoglycemic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Juniper</td>\n\n      <td>Hypoglycemic, in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Marshmallow</td>\n\n      <td>Hypoglycemic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Myrrh</td>\n\n      <td>Hypoglycemic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Nettle</td>\n\n      <td>Hypoglycemic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Sage</td>\n\n      <td>Hypoglycemic, in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Tansy</td>\n\n      <td>Hypoglycemic, in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Hyperglycemic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Devil's claw</td>\n\n      <td>Stated to be contraindicated in diabetics</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Elecampane</td>\n\n      <td>Hyperglycemic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Figwort</td>\n\n      <td>Similar constituents as Devil's claw</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Ginseng, Panax</td>\n\n      <td>Hyperglycemic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hydrocotyle</td>\n\n      <td>Hyperglycemic, human</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Liquorice</td>\n\n      <td>Hypokalemia aggravates glucose tolerance</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.283.</div><div id=\"graphicVersion\">Graphic 59340 Version 2.0</div></div></div>"},"59341":{"type":"graphic_table","displayName":"Postictal symptoms","title":"Common postictal symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common postictal symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Confusion</td>\n</tr>\n<tr>\n<td>Depression</td>\n</tr>\n<tr>\n<td>Difficulty talking</td>\n</tr>\n<tr>\n<td>Embarrassment</td>\n</tr>\n<tr>\n<td>Exhaustion, sleep</td>\n</tr>\n<tr>\n<td>Fear</td>\n</tr>\n<tr>\n<td>Frustration</td>\n</tr>\n<tr>\n<td>Headache</td>\n</tr>\n<tr>\n<td>Loneliness</td>\n</tr>\n<tr>\n<td>Memory loss</td>\n</tr>\n<tr>\n<td>Nausea</td>\n</tr>\n<tr>\n<td>Pain</td>\n</tr>\n<tr>\n<td>Perceptual alterations</td>\n</tr>\n<tr>\n<td>Psychosis</td>\n</tr>\n<tr>\n<td>Thirst</td>\n</tr>\n<tr>\n<td>Weakness</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 59341 Version 1.0</div></div></div>"},"59342":{"type":"graphic_picture","displayName":"Results after incision and drainage of breast abscess","title":"Results after incision and drainage of breast abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Results after incision and drainage of breast abscess</div><div class=\"cntnt\"><img style=\"width:361px; height:396px;\" src=\"images/PC/59342_Skin_compromise_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results one week post incision and drainage.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 59342 Version 3.0</div></div></div>"},"59344":{"type":"graphic_movie","displayName":"Echocardiogram PLAX view of calcific AS","title":"Echocardiogram parasternal long-axis view of calcific aortic stenosis ","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram parasternal long-axis view of calcific aortic stenosis </div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/59344_aoslngecconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:319px; height:480px;\" src=\"images/CARD/59344_aoslngec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-axis view of 2-D echocardiogram showing echo dense calcified aortic valve and left ventricular hypertrophy as evidenced by increased thickness of the posterior wall and septum.</div><div id=\"graphicVersion\">Graphic 59344 Version 3.0</div></div></div>"},"59345":{"type":"graphic_movie","displayName":"Pericardial effusion with tamponade short axis","title":"Pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/59345_shaxpericonv.mp4\" style=\"width:249px;height:202px\"></div><img style=\"width:287px; height:215px;\" src=\"images/CARD/59345_shaxperi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal short axis view from a two-dimensional echocardiogram shows a very large pericardial effusion (PE) surrounding the left ventricle (LV) and right ventricle (RV) which is collapsed. The patient had severe hemodynamic compromise and tamponade physiology.</div><div class=\"graphic_reference\">Courtesy of Ralph Shabetai, MD.</div><div id=\"graphicVersion\">Graphic 59345 Version 2.0</div></div></div>"},"59348":{"type":"graphic_table","displayName":"Sports rehab progression","title":"Progression of rehabilitation for nonoperative musculoskeletal injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Progression of rehabilitation for nonoperative musculoskeletal injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical and functional objective</td> <td class=\"subtitle1\">Types of exercise</td> <td class=\"subtitle1\">Examples of progression</td> </tr> <tr> <td rowspan=\"6\">Flexibility</td> <td rowspan=\"6\"> <p>Static stretching (low-load long-duration stretching)</p> <p>Dynamic drills</p> </td> <td class=\"sublist1_start\">Progressive velocity flexibility program:</td> </tr> <tr> <td class=\"sublist1\">- Static stretching</td> </tr> <tr> <td class=\"sublist1\">- Slow short-end range stretching</td> </tr> <tr> <td class=\"sublist1\">- Slow full-range stretching</td> </tr> <tr> <td class=\"sublist1\">- Fast short-end range stretching</td> </tr> <tr> <td class=\"sublist1\">- Fast full-range stretching</td> </tr> <tr class=\"divider_top\"> <td>Proprioception</td> <td>Balance exercises</td> <td> <p>Two limbs on firm surface</p> <p>One limb on firm surface</p> <p>Two limbs on compliant surface</p> <p>One limb on compliant surface</p> <p>Increase speed</p> <p>Perform task without looking</p> </td> </tr> <tr class=\"divider_top\"> <td>Increased load tolerance/strength</td> <td> <p>Isometric*</p> <p>Isotonic*</p> <p>Concentric*</p> <p>Eccentric*</p> <p>Stretch-shortening cycle activities*</p> </td> <td> <p>From general strength to specific strength</p> <p>Increase the percentage of body weight</p> <p>Increase resistance</p> <p>Increase speed</p> </td> </tr> <tr class=\"divider_top\"> <td>Endurance</td> <td>High-repetition, low-load</td> <td>Increase the load or speed when 30 repetitions can be tolerated without pain</td> </tr> <tr class=\"divider_top\"> <td>Power</td> <td>Plyometric exercises at 30 to 50 percent of maximum voluntary contraction or resistance training at 50 to 90 percent of maximum voluntary contraction*</td> <td>3 sets of 1 to 8 repetitions per exercise</td> </tr> <tr class=\"divider_top\"> <td>Agility</td> <td> <p>Figure-eight running</p> <p>Zigzag running</p> <p>Carioca</p> <p>Running backwards</p> <p>Cross-over cutting</p> </td> <td> <p>Increase speed from half-speed to full-speed</p> <p>Increase cutting angle from 45 to 90 degrees</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* See&nbsp;text for descriptions.</div><div id=\"graphicVersion\">Graphic 59348 Version 5.0</div></div></div>"},"59349":{"type":"graphic_picture","displayName":"Out of scope lithotriptor","title":"Out of scope lithotriptor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Out of scope lithotriptor</div><div class=\"cntnt\"><img style=\"width:389px; height:259px;\" src=\"images/GAST/59349_Out_of_scope_lithotriptor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The out of scope lithotriptor is attached to a retrieval basket after the endoscope has been removed from the patient. Cranking of the handle tightens the basket's wires, causing disruption of the stone.</div><div class=\"graphic_reference\">Courtesy of Isaac Raijman, MD.</div><div id=\"graphicVersion\">Graphic 59349 Version 1.0</div></div></div>"},"59352":{"type":"graphic_table","displayName":"Effective strong ion difference","title":"Effective strong ion difference formula","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effective strong ion difference formula</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Effective SID (SIDeff)</td> </tr> <tr> <td><span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">SIDeff = (12.2 &times; Pco<sub>2</sub>/10<sup>-pH</sup>) + 10 &times; [Albumin &times; (0.123 &times; pH &ndash; 0.631)] + [PO<sub>4</sub>&nbsp;&times; (0.309 &times; pH &ndash; 0.469)]</span></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59352 Version 2.0</div></div></div>"},"59354":{"type":"graphic_table","displayName":"Nonrandomized trials novel targeted therapies GEP-NET","title":"Nonrandomized trials of novel targeted therapies in gastroenteropancreatic neuroendocrine tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonrandomized trials of novel targeted therapies in gastroenteropancreatic neuroendocrine tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Molecular target(s)</td> <td class=\"subtitle1\">Patients*</td> <td class=\"subtitle1\">Tumor type</td> <td class=\"subtitle1\">Objective tumor response rate, percent</td> <td class=\"subtitle1\">Median TTP or PFS</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">VEGF pathway inhibitors</td> </tr> <tr> <td class=\"indent1\">Bevacizumab</td> <td>VEGF</td> <td>22</td> <td>Carcinoid</td> <td>18<sup>&#182;</sup></td> <td>66 weeks</td> <td>Yao J; 2008</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Sunitinib</td> <td rowspan=\"2\">VEGFR-1, -2, -3; PDGFR-alpha, -beta; KIT; RET; CSF-1R; FLT3</td> <td>41</td> <td>Carcinoid</td> <td>2</td> <td>10.2 months (TTP)</td> <td rowspan=\"2\">Kulke M; 2008</td> </tr> <tr> <td>66</td> <td>Pancreatic NET</td> <td>17</td> <td>7.7 months (TTP)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Sorafenib</td> <td rowspan=\"2\">VEGFR-2, PDGFR, FGFR-1, BRAF</td> <td>50</td> <td>Carcinoid</td> <td>7<sup>&#916;</sup></td> <td>7.8 months</td> <td rowspan=\"2\">Hobday T; 2007</td> </tr> <tr> <td>43</td> <td>Pancreatic NET</td> <td>11<sup>&#916;</sup></td> <td>11.9 months</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Pazopanib</td> <td class=\"divider_bottom\" rowspan=\"2\">VEGFR-1, -2, -3; PDGFR-alpha, -beta; KIT</td> <td>22</td> <td>Carcinoid</td> <td>0</td> <td>12.7 months</td> <td class=\"divider_bottom\" rowspan=\"2\">Phan AT; 2010</td> </tr> <tr> <td class=\"divider_bottom\">29</td> <td class=\"divider_bottom\">Pancreatic NET</td> <td class=\"divider_bottom\">17</td> <td class=\"divider_bottom\">11.7 months</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">mTOR inhibitors</td> </tr> <tr> <td class=\"indent1\">Everolimus</td> <td>mTOR</td> <td>115</td> <td>Pancreatic NET</td> <td>8</td> <td>9.3 months</td> <td>Yao J; 2009</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Everolimus</td> <td rowspan=\"2\">mTOR</td> <td>30</td> <td>Carcinoid</td> <td>17</td> <td>63 weeks</td> <td rowspan=\"2\">Yao J; 2010</td> </tr> <tr> <td>30</td> <td>Pancreatic NET</td> <td>27</td> <td>50 weeks</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Everolimus</td> <td rowspan=\"2\">mTOR</td> <td>115<sup>&#9674;</sup></td> <td>Pancreatic NET</td> <td>9</td> <td>9.7 months</td> <td rowspan=\"2\">Yao J; 2010</td> </tr> <tr> <td>45<sup>&#167;</sup></td> <td>Pancreatic NET</td> <td>4</td> <td>16.7 months</td> </tr> <tr> <td class=\"indent1\">Everolimus</td> <td>mTOR</td> <td>27</td> <td>Nonfunctioning pancreatic NET</td> <td>12</td> <td>17.1 months</td> <td>Oh DY; 2012</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Temsirolimus</td> <td rowspan=\"2\">mTOR</td> <td>21</td> <td>Carcinoid</td> <td>5</td> <td>6 months</td> <td rowspan=\"2\">Duran I; 2006</td> </tr> <tr> <td>15</td> <td>Pancreatic NET</td> <td>7</td> <td>10.6 months</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF-1R: colony-stimulating factor receptor; EGFR: epidermal growth factor receptor; KIT: stem cell factor receptor; mTOR: mammalian target of rapamycin; PDGFR: platelet-derived growth factor receptor; RET: rearranged during transfection or glial cell-line derived neurotrophic factor; VEGF: vascular endothelial growth factor; VEGFR: VEGF receptor; NET: neuroendocrine tumor; PFS: progression-free survival; TTP: time to tumor progression; NR: not reported.<br />* Number of patients evaluable for efficacy endpoints.<br />¶ Patients also received treatment with octreotide.<br />Δ Confirmed.<br /><FONT class=lozenge>◊</FONT> After failure of octreotide.<br />§ Concurrent with octreotide.</div><div id=\"graphicVersion\">Graphic 59354 Version 16.0</div></div></div>"},"59355":{"type":"graphic_figure","displayName":"Barrx360 ablation catheter","title":"Barrx360 ablation catheter","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Barrx360 ablation catheter</div><div class=\"cntnt\"><img style=\"width:540px; height:345px;\" src=\"images/GAST/59355_HALO360_ablation_catheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barrx360 ablation catheter.</div><div class=\"graphic_reference\">Reproduced with permission from: BÂRRX Medical Inc. Copyright © 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 59355 Version 3.0</div></div></div>"},"59356":{"type":"graphic_picture","displayName":"Graves' eye infiltrate","title":"Graves' eye infiltrate: Findings on extraocular muscle biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graves' eye infiltrate: Findings on extraocular muscle biopsy</div><div class=\"cntnt\"><img style=\"width:432px; height:307px;\" src=\"images/ENDO/59356_Graveseyeinfiltrate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Disrupted muscle fibers and an area of inflammatory cell accumulation in the superior rectus muscle of a patient with ophthalmic Graves' disease. The sample was obtained at the time of decompression surgery. The extraocular muscles are swollen, and some muscle fibers show loss of striation, fragmentation, and infiltration with lymphocytes, most of which are T lymphocytes.</div><div class=\"graphic_reference\">Courtesy of Terry F Davies, MD, FRCP, FACE.</div><div id=\"graphicVersion\">Graphic 59356 Version 3.0</div></div></div>"},"59357":{"type":"graphic_figure","displayName":"Sulfonamide structures","title":"Structures of sulfonamide medications","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Structures of sulfonamide medications</div><div class=\"cntnt\"><img style=\"width:592px; height:516px;\" src=\"images/ALLRG/59357_Sulfonamide_structures.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified with permission from: Tilles SA, Slatore CG. Hypersensitivity reactions to non-beta-lactam antibiotics. Clin Rev Allergy Immunol 2003; 24:221. Copyright ©2003 Humana Press.</div><div id=\"graphicVersion\">Graphic 59357 Version 3.0</div></div></div>"},"59359":{"type":"graphic_figure","displayName":"Headache diary PI","title":"Headache diary","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Headache diary</div><div class=\"cntnt\"><img style=\"width:558px; height:625px;\" src=\"images/PI/59359_Headache_diary_PI.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bristol-Myers Squibb Company. Copyright 2001 Bristol-Myers Squibb Company.</div><div id=\"graphicVersion\">Graphic 59359 Version 1.0</div></div></div>"},"59360":{"type":"graphic_figure","displayName":"Expansion rates of thoracic aortic aneurysm","title":"Expansion rates of thoracic aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Expansion rates of thoracic aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:396px; height:301px;\" src=\"images/CARD/59360_Expansion_vs_initial_diamet.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segments with initial diameter ≥60 mm manifested a median expansion rate of 4 mm/year, while smaller aneurysms (&lt;50 mm diameter) had a median expansion rate of 1.33 mm/year (p&lt;0.01).</div><div class=\"graphic_reference\">Data from Bonser, RS, Pagano, D, Lewis, ME, et al, Heart 2000; 84:277.</div><div id=\"graphicVersion\">Graphic 59360 Version 2.0</div></div></div>"},"59361":{"type":"graphic_picture","displayName":"Candidal diaper dermatitis A","title":"Candidal diaper dermatitis ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Candidal diaper dermatitis </div><div class=\"cntnt\"><img style=\"width:360px; height:427px;\" src=\"images/PEDS/59361_Candidaldiaperdermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques and satellite pustules in an infant.</div><div class=\"graphic_reference\">Courtesy of Anthony Mancini, MD, Children's Memorial Hospital, Chicago, IL.</div><div id=\"graphicVersion\">Graphic 59361 Version 9.0</div></div></div>"},"59362":{"type":"graphic_picture","displayName":"Grade III asbestosis","title":"Grade III asbestosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grade III asbestosis</div><div class=\"cntnt\"><img style=\"width:380px; height:299px;\" src=\"images/PULM/59362_Grade_III_asbestosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph showing predominantly Grade III asbestosis, partially defined by diffuse interstitial fibrosis extending from acinus to acinus The respiratory bronchiole at bottom left (*) could be classified as a Grade I lesion.</div><div class=\"graphic_reference\">Am J Respir Crit Care Med 2004; 170:692; www.atsjournals.org.</div><div id=\"graphicVersion\">Graphic 59362 Version 1.0</div></div></div>"},"59363":{"type":"graphic_picture","displayName":"Well-differentiated thymic carcinoid (high power)","title":"Well-differentiated thymic carcinoid: histologic appearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Well-differentiated thymic carcinoid: histologic appearance</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/PULM/59363_Thymic_carcinoid_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Organoid nests composed of uniform polygonal cells with centrally located nuclei and finely granular nuclear chromatin, forming rosettes, are characteristic features of carcinoid tumors. Necrosis is frequently seen in thymic carcinoid. (Hematoxylin and eosin, magnification 100x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 59363 Version 3.0</div></div></div>"},"59364":{"type":"graphic_picture","displayName":"Epidermolysis bullosa simplex - hands","title":"Epidermolysis bullosa simplex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa simplex</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/59364_Epid_bullosa_simplex_hands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullae are present on the hands of this infant with epidermolysis bullosa simplex.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59364 Version 3.0</div></div></div>"},"59367":{"type":"graphic_figure","displayName":"Placental vasculature","title":"Placental vasculature","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Placental vasculature</div><div class=\"cntnt\"><img style=\"width:526px; height:571px;\" src=\"images/OBGYN/59367_Placental_vasculature_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Vander AJ, Sherman JH, Luciano DS. Human Physiology, 6th ed, McGraw-Hill, Inc 2001. p.679. Original Figure 19-24. Copyright &#169; 2001 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 59367 Version 3.0</div></div></div>"},"59369":{"type":"graphic_picture","displayName":"Focal atrophy","title":"Focal atrophy of tympanic membrane at tympanostomy tube site","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal atrophy of tympanic membrane at tympanostomy tube site</div><div class=\"cntnt\"><img style=\"width:253px; height:503px;\" src=\"images/PEDS/59369_Focal_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In Panel A, the former tympanostomy tube site is weaker than the remainder of the eardrum and susceptible to retraction or perforation. In Panel B, an area of focal atrophy bulges more than the remainder of the tympanic membrane during an episode of acute otitis media.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 59369 Version 1.0</div></div></div>"},"59370":{"type":"graphic_table","displayName":"Type 1 vs type 2 DM","title":"Characteristics of type 1 and type 2 diabetes mellitus in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of type 1 and type 2 diabetes mellitus in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Type 1 diabetes</td> <td class=\"subtitle1\">Type 2 diabetes</td> </tr> <tr> <td><strong>Prevalence</strong></td> <td>Common, increasing</td> <td>Increasing</td> </tr> <tr> <td><strong>Age at presentation</strong></td> <td>Throughout childhood</td> <td>Puberty</td> </tr> <tr> <td><strong>Onset</strong></td> <td>Typically&nbsp;acute severe</td> <td>Insidious to severe</td> </tr> <tr> <td><strong>Ketosis at onset</strong></td> <td>Common</td> <td>5 to 10 percent*</td> </tr> <tr> <td><strong>Affected relative</strong></td> <td>5 to 10 percent</td> <td>75 to 90 percent</td> </tr> <tr> <td><strong>Female:male</strong></td> <td>1:1</td> <td>~2:1</td> </tr> <tr> <td><strong>Inheritance</strong></td> <td>Polygenic</td> <td>Polygenic</td> </tr> <tr> <td><strong>HLA-DR3/4</strong></td> <td>Strong association</td> <td>No association</td> </tr> <tr> <td><strong>Ethnicity</strong></td> <td>Most common in non-Hispanic white</td> <td>All<sup>&#182;</sup></td> </tr> <tr> <td><strong>Insulin secretion</strong></td> <td>Decreased/absent</td> <td>Variable</td> </tr> <tr> <td><strong>Insulin sensitivity</strong></td> <td>Normal when controlled</td> <td>Decreased</td> </tr> <tr> <td><strong>Insulin dependence</strong></td> <td>Permanent</td> <td>Variable</td> </tr> <tr> <td><strong>Obese or overweight</strong></td> <td>20 to 25 percent overweight<sup>&#916;</sup></td> <td>&#62;80 percent obese</td> </tr> <tr> <td><strong>Acanthosis nigricans</strong></td> <td>12 percent<sup>&#9674;</sup></td> <td>50 to 90 percent<sup>&#9674;</sup></td> </tr> <tr> <td><strong>Pancreatic antibodies</strong></td> <td>Yes<sup>&#167;</sup></td> <td>No<sup>&#165;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Reported frequency of ketonuria or ketoacidosis at time of diagnosis of T2DM varies widely.<br />¶ In North America, type 2 diabetes mellitus (T2DM) predominates in Native American, African-American, Hispanic, Canadian First Nation, Pacific Islander, and Asian-American youth.<SUP>[1]</SUP><br />Δ With increased prevalence of childhood overweight, 20 to 25 percent of newly diagnosed children with type 1 diabetes mellitus (T1DM) are overweight, which is higher than the prevalence of <EM>overweight</EM> in a similar population without T1DM. However, the prevalence of <EM>obesity</EM> is not increased among children and adolescents with T1DM.<SUP innerHtml>[2,3] </SUP>Recent weight loss is common at presentation of children with T1DM, including among those who are overweight or obese. <br /><FONT class=lozenge>◊</FONT> These frequencies of acanthosis nigricans are based on a registry study in the United States. Populations with lower rates of obesity or different ethnic mixes may have different results.<SUP>[4]</SUP><br />§ Autoantibodies to insulin (IAA), islet cell cytoplasm (ICA), glutamic acid decarboxylase (GAD), tyrosine phosphatase (insulinoma associated) antibody (IA-2 and IA-2β), or zinc channel antibody (ZnT8) are present at diagnosis in 85 to 98 percent of patients with T1DM.<SUP>[4,5]</SUP><br />¥ One study reported that 9.8 percent of youth with phenotypic type 2 diabetes mellitus have pancreatic antibodies to IA-2 and/or GAD.<SUP>[6]</SUP></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Mayer-Davis EJ, Bell RA, Dabelea D, et al. The many faces of diabetes in American youth: type 1 and type 2 diabetes in five race and ethnic populations: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S99.</li>&#xD;&#xA;    <li>Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 2010; 11:4.</li>&#xD;&#xA;    <li>Kaminski BM, Klingensmith GJ, Beck RW, et al. Body mass index at the time of diagnosis of autoimmune type 1 diabetes in children. J Pediatr 2013; 162:736.</li>&#xD;&#xA;    <li>Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care 2011; 34:1628.</li>&#xD;&#xA;    <li>Steck AK, Johnson K, Barriga KJ. Age of Islet Autoantibody Appearance and Mean Levels of Insulin, but Not GAD or IA-2 Autoantibodies, Predict Age of Diagnosis of Type 1 Diabetes. Diabetes Care 2011; 34:1397.</li>&#xD;&#xA;    <li>Klingensmith GJ, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care 2010; 33:1970.</li>&#xD;&#xA;</ol>&#xD;&#xA;Modified from: Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes care 1999; 22:345-354.</div><div id=\"graphicVersion\">Graphic 59370 Version 17.0</div></div></div>"},"59373":{"type":"graphic_table","displayName":"Effect of maternal age and embryos transferred on outcome","title":"Effect of maternal age and number of embryos transfered on birth outcome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effect of maternal age and number of embryos transfered on birth outcome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Maternal age, years</td> <td class=\"subtitle1\" colspan=\"2\">Three embryos transfered</td> <td class=\"subtitle1\" colspan=\"2\">Two embryos transfered</td> </tr> <tr> <td class=\"subtitle2\">Live birth*</td> <td class=\"subtitle2\">Triplet or higher<sup>&#182;</sup></td> <td class=\"subtitle2\">Live birth</td> <td class=\"subtitle2\">Triplet or higher</td> </tr> <tr> <td>&#60;35</td> <td>41.6</td> <td>5.6</td> <td>48.6</td> <td>0.4</td> </tr> <tr> <td>35 to 37</td> <td>39.4</td> <td>3.7</td> <td>39.7</td> <td>0.4</td> </tr> <tr> <td>38 to 40</td> <td>29</td> <td>1.4</td> <td>27.3</td> <td>0.3</td> </tr> <tr> <td>41 to 42</td> <td>15.7</td> <td>0.4</td> <td>12</td> <td>not available</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Percent of live births per IVF transfer procedure.<br />&para; Multiple births per live birth.</div><div class=\"graphic_reference\">Adapted from Sunderam S, Chang J, Flowers L et al. MMWR Surveill Summ 2009; 58:1.</div><div id=\"graphicVersion\">Graphic 59373 Version 3.0</div></div></div>"},"59374":{"type":"graphic_picture","displayName":"Cystic fibrosis lung","title":"Gross pathology of the lung in cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross pathology of the lung in cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:357px; height:233px;\" src=\"images/PULM/59374_Cystic_fibrosis_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lung specimen from a patient with cystic fibrosis demonstrating grossly purulent secretions in dilated airways.</div><div class=\"graphic_reference\">Courtesy of Claire Langston, MD.</div><div id=\"graphicVersion\">Graphic 59374 Version 2.0</div></div></div>"},"59376":{"type":"graphic_table","displayName":"CRP reactive adults","title":"C-reactive protein levels in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">C-reactive protein levels in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp; </td> <td class=\"subtitle1\">0 to 2 mg/L (0 to 0.2 mg/dL) </td> <td class=\"subtitle1\">2 to 3 mg/L (0.2 to 0.3 mg/dL) </td> <td class=\"subtitle1\">3 to 10 mg/L (0.3 to 1.0 mg/dL) </td> <td class=\"subtitle1\">&#62;10 mg/L (&#62;1.0 mg/dL) </td> </tr> <tr> <td>All adults</td> <td>48%</td> <td>14%</td> <td>29%</td> <td>10%</td> </tr> <tr> <td>Men</td> <td>56%</td> <td>14 %</td> <td>24%</td> <td>6%</td> </tr> <tr> <td>Women</td> <td>40%</td> <td>13%</td> <td>33%</td> <td>13%</td> </tr> <tr> <td>White</td> <td>48%</td> <td>14%</td> <td>29%</td> <td>9%</td> </tr> <tr> <td>Black</td> <td>44%</td> <td>12%</td> <td>29%</td> <td>15%</td> </tr> <tr> <td>Age 20 to 29</td> <td>59%</td> <td>12%</td> <td>22%</td> <td>7%</td> </tr> <tr> <td>Age &#62;70</td> <td>36%</td> <td>17%</td> <td>34%</td> <td>13%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: National Health and Nutrition Evaluation Survey, 2005.</div><div id=\"graphicVersion\">Graphic 59376 Version 3.0</div></div></div>"},"59377":{"type":"graphic_picture","displayName":"JXG single face nodule 2","title":"Juvenile xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:352px; height:219px;\" src=\"images/DERM/59377_JXG_single_face_nod_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single nodule of juvenile xanthogranuloma on the chin of a child.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Kate P&#252;ttgen.</div><div id=\"graphicVersion\">Graphic 59377 Version 1.0</div></div></div>"},"59378":{"type":"graphic_figure","displayName":"Gnathostomiasis life cycle","title":"<em>Gnathostomiasis</em> life cycle","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\"><em>Gnathostomiasis</em> life cycle</div><div class=\"cntnt\"><img style=\"width:522px; height:485px;\" src=\"images/ID/59378_Gnathostomiasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the natural definitive host (pigs, cats, dogs, wild animals) the adult worms reside in a tumor which they induce in the gastric wall. They deposit eggs that are unembryonated when passed in the feces <strong>(1)</strong>. Eggs become embryonated in water, and eggs release first-stage larvae <strong>(2)</strong>. If ingested by a small crustacean (<em>Cyclops</em>, first intermediate host), the first-stage larvae develop into second-stage larvae <strong>(3)</strong>. Following ingestion of the <em>Cyclops</em> by a fish, frog, or snake (second intermediate host), the second-stage larvae migrate into the flesh and develop into third-stage larvae <strong>(4)</strong>. When the second intermediate host is ingested by a definitive host, the third-stage larvae develop into adult parasites in the stomach wall <strong>(5)</strong>. Alternatively, the second intermediate host may be ingested by the paratenic host (animals such as birds, snakes, and frogs) in which the third-stage larvae do not develop further but remain infective to the next predator <strong>(6)</strong>. Humans become infected by eating undercooked fish or poultry containing third-stage larvae, or reportedly by drinking water containing infective second-stage larvae in <em>Cyclops</em> <strong>(7)</strong>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Gnathostomiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/gnathostomiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/gnathostomiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 59378 Version 4.0</div></div></div>"},"59379":{"type":"graphic_picture","displayName":"HSTCL CD3 staining","title":"Hepatosplenic T-cell lymphoma CD3 expression","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hepatosplenic T-cell lymphoma CD3 expression</div><div class=\"cntnt\"><img style=\"width:540px; height:359px;\" src=\"images/HEME/59379_HSTCLliverbiopCD3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy reveals positive staining of the tumor cells with CD3 antibody. Immunoperoxidase, 40x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry and Immunochemistry for Hematologic Neoplasms, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59379 Version 7.0</div></div></div>"},"59381":{"type":"graphic_diagnosticimage","displayName":"30 year old man with moyamoya","title":"30 year old man with presumed moyamoya disease","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">30 year old man with presumed moyamoya disease</div><div class=\"cntnt\"><img style=\"width:477px; height:520px;\" src=\"images/NEURO/59381_30_yr_old_man_MMD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) FLAIR images show increased linear signal in the sulci (white arrow) due to retrograde slow flow in engorged pial arteries via leptomeningeal anastomoses*. B) Right internal carotid artery injection from a conventional angiogram, lateral projection, confirms no flow in the proximal right middle and anterior cerebral arteries with &quot;puff of smoke&quot; appearance of collateral vessels (black arrow). C) CTA shows almost no flow in the supraclinoid internal carotid arteries and the proximal middle and anterior cerebral arteries. White arrows indicate multiple surrounding collaterals around the proximal middle cerebral arteries.</div><div class=\"graphic_footnotes\">* Maeda M, Yagishita A, Yamamoto T et al. Abnormal hyperintensity within the subarachnoid space evaluated by fluid-attenuated inversion-recovery MR imaging: a spectrum of central nervous system diseases, Eur Radiol (2003) 13:L192-L201.</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 59381 Version 3.0</div></div></div>"},"59384":{"type":"graphic_table","displayName":"DDx growing pains","title":"Differential diagnosis of growing pains in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of growing pains in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">Viral myositis</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Trichinosis</td> </tr> <tr> <td class=\"indent1\">Poststreptococcal polymyalgia</td> </tr> <tr> <td class=\"indent1\">Osteomyelitis</td> </tr> <tr> <td class=\"indent1\">Septic arthritis</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td class=\"indent1\">Osteomalacia (Rickets)</td> </tr> <tr> <td class=\"indent1\">Hypervitaminosis A</td> </tr> <tr> <td class=\"indent1\">Scurvy</td> </tr> <tr> <td class=\"indent1\">Gaucher disease</td> </tr> <tr> <td class=\"indent1\">Renal tubular acidosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Tumors</td> </tr> <tr> <td class=\"indent1\">Leukemia</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> </tr> <tr> <td class=\"indent1\">Spinal cord tumors</td> </tr> <tr> <td class=\"sublist2_start\">Bone tumors</td> </tr> <tr> <td class=\"sublist2\">Ewing sarcoma</td> </tr> <tr> <td class=\"sublist2\">Osteogenic sarcoma</td> </tr> <tr> <td class=\"sublist2\">Osteoid osteoma</td> </tr> <tr> <td class=\"indent1\">Metastatic tumors (eg, neuroblastoma)</td> </tr> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td class=\"indent1\">Fractures</td> </tr> <tr> <td class=\"indent1\">Stress fractures</td> </tr> <tr> <td class=\"indent1\">Overuse syndromes</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Hypermobility syndrome</td> </tr> <tr> <td class=\"indent1\">Collagen vascular disease</td> </tr> <tr> <td class=\"indent1\">Somatization</td> </tr> <tr> <td class=\"indent1\">Fibromyalgia</td> </tr> <tr> <td class=\"indent1\">Intermittent nocturnal leg cramps</td> </tr> <tr> <td class=\"indent1\">Reflex sympathetic dystrophy</td> </tr> <tr> <td class=\"indent1\">Restless legs</td> </tr> <tr> <td class=\"indent1\">Sickle cell anemia</td> </tr> <tr> <td class=\"indent1\">Ostenecrosis (avascular necrosis)</td> </tr> <tr> <td class=\"indent1\">Slipped capital femoral epiphysis</td> </tr> <tr> <td class=\"indent1\">School phobia</td> </tr> <tr> <td class=\"indent1\">Patellofemoral pain syndrome</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Leg Pain. In: Tunnessen WW, Roberts KB. Signs and Symptoms in Pediatrics, 3rd edition, Lippincott, Williams, and Wilkins, Philadelphia, 1999. p.633 and Atar D, Lehman WB, Grant AD. Growing pains. Orthop Rev 1991; 20:133.</div><div id=\"graphicVersion\">Graphic 59384 Version 4.0</div></div></div>"},"59385":{"type":"graphic_picture","displayName":"Foreign body fragmentation","title":"Potential complication of foreign body extraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Potential complication of foreign body extraction</div><div class=\"cntnt\"><img style=\"width:270px; height:206px;\" src=\"images/PULM/59385_Foreign_body_fragmentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Half peanut grasped and fragmented by an optical forceps.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 59385 Version 2.0</div></div></div>"},"59386":{"type":"graphic_diagnosticimage","displayName":"Tracheobronchial lymph nodes CT","title":"N2 lymph nodes in lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">N2 lymph nodes in lung cancer</div><div class=\"cntnt\"><img style=\"width:292px; height:238px;\" src=\"images/PULM/59386_Tracheobronchial_lymph_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows slightly enlarged lymph nodes located anterior to the tracheal bifurcation (arrow).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59386 Version 3.0</div></div></div>"},"59388":{"type":"graphic_figure","displayName":"Incisions for mastectomy","title":"Incisions for mastectomy","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Incisions for mastectomy</div><div class=\"cntnt\"><img style=\"width:589px; height:405px;\" src=\"images/SURG/59388_Incisionsmastectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A practical incision based on that of Stewart is planned by choosing two points, in line with the nipple, to either side of the breast, with the lateral site along the posterior axillary fold, under the hairline.<br> (B) The breast skin is pulled down orthogonal to that imaginary line and a straight line drawn between the points.<br> (C) The breast is pushed up orthogonal to the imaginary line between the two points and a lower straight line drawn between the points below the nipple.<br> (D) With the breast relaxed, an ellipse has formed, which will close relatively ﬂat against the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaughnessy EA. Simple mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59388 Version 7.0</div></div></div>"},"59389":{"type":"graphic_picture","displayName":"Gastric B cell lymphoma CPC Light","title":"Gastric B cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric B cell lymphoma</div><div class=\"cntnt\"><img style=\"width:359px; height:507px;\" src=\"images/GAST/59389_B_cell_lymphoma_CPC_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy specimens of a gastric mass showing diffuse large B cell lymphoma. This lesion may arise as transformation from MALT lymphoma or de novo. The majority are single lesions, most involve the muscularis propria, and there is a male predominance.</div><div class=\"graphic_reference\">Courtesy of Don Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 59389 Version 2.0</div></div></div>"},"59390":{"type":"graphic_table","displayName":"Immune globulin products for SC and IM use","title":"Immune globulin products for subcutaneous and intramuscular use","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immune globulin products for subcutaneous and intramuscular use</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Trade name</td> <td class=\"subtitle1\">Licensed route(s) of administration</td> <td class=\"subtitle1\">Manufacturer<br /> (processed by)</td> <td class=\"subtitle1\">Available in&nbsp;</td> <td class=\"subtitle1\">Available vial sizes<br /> (mL)</td> <td class=\"subtitle1\">Dose adjustment factor*</td> <td class=\"subtitle1\">Concentration (%)</td> <td class=\"subtitle1\">Stabilizer concentration</td> <td class=\"subtitle1\">IgA content<br /> (average)</td> </tr> <tr> <td>Cuvitru</td> <td>Subcutaneous</td> <td>Baxalta</td> <td> <p>Europe (some countries)</p> <p>United States</p> </td> <td>5, 10, 20, 40</td> <td>1.30</td> <td>20</td> <td>Glycine 0.25 M</td> <td>80 mcg/mL</td> </tr> <tr> <td>Gammagard Liquid</td> <td>Subcutaneous<sup>&#182;</sup> and intravenous</td> <td> <p>Baxalta </p> </td> <td> <p>Canada</p> <p>United States</p> </td> <td>10, 25, 50, 100, 200, 300</td> <td>1.37</td> <td>10</td> <td>Glycine 0.25 M</td> <td>37 mcg/mL(&#8804;140 mcg/mL Canada)</td> </tr> <tr> <td>Gamunex-C</td> <td>Subcutaneous<sup>&#182;</sup> and intravenous</td> <td>Grifols</td> <td> <p>Canada</p> <p>United Kingdom</p> <p>United States</p> </td> <td>10, 25, 50, 100, 200, 400</td> <td>1.37</td> <td>10 </td> <td>Glycine 0.16 to 0.24 M</td> <td>46 mcg/mL (&#8804;84 mcg/mL Canada)</td> </tr> <tr> <td>GamaSTAN S/D</td> <td>Intramuscular</td> <td>Grifols</td> <td> <p>Canada</p> <p>United States</p> </td> <td>2, 10</td> <td>Not applicable </td> <td>15 to 18 </td> <td>Glycine 0.21 to 0.32 M</td> <td>IgA present but concentration in final product not determined by processor</td> </tr> <tr> <td>Gammaked</td> <td>Subcutaneous and intravenous</td> <td>Kedrion</td> <td>United States</td> <td>10, 25, 50, 100, 200</td> <td>1.37</td> <td>10 </td> <td>Glycine 0.16 to 0.24 M</td> <td>46 mcg/mL</td> </tr> <tr> <td>Hizentra<sup>&#916;</sup></td> <td>Subcutaneous</td> <td>CSL Behring</td> <td> <p>Canada</p> <p>United Kingdom&nbsp;</p> <p>United States</p> <p>&nbsp;</p> </td> <td>5, 10, 20, 50</td> <td>1.37</td> <td>20</td> <td>L-proline 0.25 M</td> <td>&#8804;50 mcg/mL</td> </tr> <tr> <td>HyQvia<sup>&#9674;</sup></td> <td>Subcutaneous</td> <td> <p>Baxalta </p> </td> <td> <p>United Kingdom&nbsp;</p> <p>United States</p> </td> <td> <p>25, 50, 100, 200, 300</p> <p>(each supplied with a separate vial of recombinant human hyaluronidase<sup>&#9674;</sup>)</p> </td> <td>Requires seven-week dose escalation when initiated; for patients previously receiving IVIG, use the same dose and frequency after initial dose escalation</td> <td>10 </td> <td>Glycine 0.25 M</td> <td> <p>37 mcg/mL</p> <p>(&#8804;140 mcg/mL United Kingdom)</p> </td> </tr> <tr> <td>Subgam</td> <td>Subcutaneous, intramuscular</td> <td>Bio Products Laboratory (BPL)</td> <td>United Kingdom</td> <td>5, 10</td> <td>Not applicable in Europe</td> <td>16</td> <td>Glycine,&nbsp;polysorbate 80&nbsp;</td> <td>&nbsp;&#60;64 mcg/mL</td> </tr> <tr> <td>Subcuvia</td> <td>Subcutaneous, intramuscular</td> <td>Baxalta</td> <td>United Kingdom</td> <td>5, 10</td> <td>Not applicable in Europe&nbsp;</td> <td>16</td> <td>Glycine</td> <td>&#8804;4800 mcg/mL </td> </tr> <tr> <td>Gammanorm</td> <td>Subcutaneous, intramuscular</td> <td>Octapharma</td> <td>United Kingdom</td> <td>6, 10, 12, 20, 24, 48</td> <td>Not applicable in Europe</td> <td>16.5 </td> <td>Glycine,&nbsp;polysorbate 80&nbsp;</td> <td>&#8804;82.5 mcg/mL&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">An empiric starting dose (after loading) for subcutaneous immune globulin (SCIG) is 100 mg/kg per week, for both adults and children. Doses should be rounded to the nearest full vial of drug to avoid wastage. For patients converting from IVIG to SCIG, the same total monthly dose that has been given&nbsp;intravenously is usually divided by four, and that amount is given weekly.<br />Please refer to the table on immune globulin products&nbsp;for intravenous administration (IVIG or IGIV) for more information on products available for intravenous use.</div><div class=\"graphic_footnotes\">IgA: immunoglobulin A; IVIG: intravenous immune globulin; SCIG: subcutaneous immune globulin; <FONT color=black>rHH: recombinant human hyaluronidase.</FONT><br />* To calculate the initial weekly dose for subcutaneous administration, multiply the previous IVIG<FONT color=black> </FONT>dose in grams by the dose adjustment factor shown. Then, divide this by the number of weeks between doses (eg, three or four).<br />¶ Subcutaneous route is licensed in the United States.<br />Δ Contains <FONT color=black>polysorbate 80</FONT> (concentration 8 to 30 mg/L), which is a potential allergen.<br /><FONT class=lozenge>◊</FONT> Recombinant human hyaluronidase (rHH)&nbsp;is infused subcutaneously prior to immune globulin to increase dispersion and absorption of immune globulin. Description: &#xD;&#xA;<UL>&#xD;&#xA;<LI>25 mL immune globulin 10% supplied with a separate 1.25 mL (200 units) vial of rHH</LI>&#xD;&#xA;<LI>50 mL immune globulin 10% and separate 2.5 mL (400 units) rHH</LI>&#xD;&#xA;<LI>100 mL immune globulin 10% and separate 5 mL (800 units) rHH</LI>&#xD;&#xA;<LI>200 mL immune globulin 10% and separate 10 mL (1600 units) rHH</LI>&#xD;&#xA;<LI>300 mL immune globulin 10% and separate 15 mL (2400 units) rHH</LI></UL></div><div class=\"graphic_reference\">Data from: <br />US licensed product information (available online at <A href=\"http://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=_blank>http://dailymed.nlm.nih.gov/dailymed/about.cfm</A>)<br />Health Canada licensed product monograph (available online at <A href=\"http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp\" target=_blank>http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp</A>)<br />United Kingdom Summary of Product Characteristics (available online at <A href=\"http://www.medicines.org.uk/emc/\">http://www.medicines.org.uk/emc/</A>) <br />All preparations are in liquid form.</div><div id=\"graphicVersion\">Graphic 59390 Version 27.0</div></div></div>"},"59392":{"type":"graphic_diagnosticimage","displayName":"MRI of ICA dissection","title":"MRI of ICA dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of ICA dissection</div><div class=\"cntnt\"><img style=\"width:367px; height:432px;\" src=\"images/NEURO/59392_MRI_of_ICA_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial T1-weighted MRI showing a right internal carotid artery dissection as a crescent-shaped hypersignal within the internal carotid artery wall.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; ICA: internal carotid artery.</div><div id=\"graphicVersion\">Graphic 59392 Version 3.0</div></div></div>"},"59393":{"type":"graphic_algorithm","displayName":"Pathogenesis preterm birth","title":"Pathogenesis of preterm birth","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of preterm birth</div><div class=\"cntnt\"><img style=\"width:519px; height:362px;\" src=\"images/OBGYN/59393_Pathogenesis_preterm_birth.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HPA: hypothalamus-pituitary-adrenal; ACTH: Adrenocorticotropic hormone 16-OH; DHEA: 16-hydroxydehydroepiandrosterone; E1 - E3: estrogen, estradiol, estrone; CRH: Corticotropin releasing hormone; Cox-2: Cyclooxygenase 2; PG: Prostaglandin; MLCK: Myosin light chain kinase; PROM: Premature rupture of membranes; PGDH: Hydroxyprostaglandin dehydrogenase</div><div id=\"graphicVersion\">Graphic 59393 Version 2.0</div></div></div>"},"59394":{"type":"graphic_diagnosticimage","displayName":"Bone sarcoma imaging studies","title":"Proximal tibia giant cell tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal tibia giant cell tumor</div><div class=\"cntnt\"><img style=\"width:437px; height:246px;\" src=\"images/ONC/59394_Bone_sarcoma_imaging_studie.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AP plain radiograph and magnetic resonance image (MRI) of a a giant cell tumor involving the proximal tibia in a 33-year-old man. The joint is not invaded by the tumor and soft tissue extension of the mass is clearly demonstrated. There is no skip lesion within the tibia.</div><div class=\"graphic_reference\">Courtesy of Francis J Hornicek, MD, PhD.</div><div id=\"graphicVersion\">Graphic 59394 Version 3.0</div></div></div>"},"59395":{"type":"graphic_table","displayName":"Features neonatal seizures","title":"Clinical characteristics, classification, and presumed pathophysiology of neonatal seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical characteristics, classification, and presumed pathophysiology of neonatal seizures</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Focal clonic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Repetitive, rhythmic contracts of muscle groups of the limbs, face or trunk</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>May be unifocal or multifocal</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May occur synchronously or asynchronously in muscle groups on one side of the body</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May occur simultaneously, but asynchronously on both sides</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Cannot be suppressed by restraint</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Pathophysiology: epileptic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Focal tonic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Sustained posturing of single limbs</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Sustained asymmetrical posturing of the trunk</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Sustained eye deviation</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Cannot be provoked by stimulation or suppressed by restraint</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Pathophysiology: epileptic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Generalized tonic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Sustained symmetrical posturing of limbs, trunk and neck</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May be flexor, extensor or mixed extensor/flexor</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May be provoked or intensified by stimulation</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May be suppressed by restraint or repositioning</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Presumed pathophysiology:nonepileptic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Myoclonic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Random, single, rapid contractions of muscle groups of the limbs, face or trunk</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Typically not repetitive or may recur at a slow rate</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May be generalized, focal or fragmentary</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>May be provoked by stimulation</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Presumed pathophysiology:may be epileptic or nonepileptic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Spasms</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">May be flexor, extensor, or mixed extensor/flexor</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>May occur in clusters</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Cannot be provoked by stimulation or suppressed by restraint</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Pathophysiology: Epileptic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Motor Automatisms</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Described in table \"Motor automatisms\"</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from: Mizrahi, EM, Kellaway, P. Diagnosis and Management of Neonatal Seizures. Lippincott-Raven, Philadelphia 1998. p.181. Copyright &#169; 1998 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59395 Version 1.0</div></div></div>"},"59396":{"type":"graphic_algorithm","displayName":"Male infants UTI","title":"Diagnostic algorithm for febrile male infants aged 3 to 24 months suspected of having a UTI","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for febrile male infants aged 3 to 24 months suspected of having a UTI</div><div class=\"cntnt\"><img style=\"width:539px; height:642px;\" src=\"images/PEDS/59396_Male_infants_UTI.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">UTI: urinary tract infection; LR: likelihood ratio.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaikh N, Morone NE, Lopez L, et al. Does this child have a urinary tract infection? JAMA 2008; 298:2895. Copyright &#169; 2008 American Medical Association.</div><div id=\"graphicVersion\">Graphic 59396 Version 3.0</div></div></div>"},"59397":{"type":"graphic_picture","displayName":"Transient pustular melanosis","title":"Transient neonatal pustular melanosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transient neonatal pustular melanosis</div><div class=\"cntnt\"><img style=\"width:432px; height:328px;\" src=\"images/PEDS/59397_Transpustularmelanosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transient neonatal pustular melanosis results in pigmented macules that gradually fade over several weeks.</div><div class=\"graphic_reference\">Reproduced with permission from: Kenneth Greer, MD.</div><div id=\"graphicVersion\">Graphic 59397 Version 2.0</div></div></div>"},"59399":{"type":"graphic_picture","displayName":"Disseminated gonorrhea skin lesions","title":"Skin lesions in disseminated gonococcal infection","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Skin lesions in disseminated gonococcal infection</div><div class=\"cntnt\"><img style=\"width:459px; height:309px;\" src=\"images/DERM/59399_Dissem_gonorrh_skin_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This woman developed a fever, several painful joints, and exquisitely tender necrotic acral pustules. A culture from her cervix grew Neisseria gonorrhoeae.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 59399 Version 5.0</div></div></div>"},"59400":{"type":"graphic_picture","displayName":"Histology of a variola maculopapular lesion","title":"Histology of a variola maculopapular lesion (500x magnification)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histology of a variola maculopapular lesion (500x magnification)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/59400_Hist_variola_maculopapular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The predominate layer in this particular image is the stratum spinosum and cells demonstrating &quot;ballooning degeneration&quot;, which is the intracellular swelling that eventually will lead to cellular lysis. The coalescence of these ruptured cells leads to the formation of microvesicles. The outward growth of the maculopapular lesion is due to the formation of these microvesicles, which are filled with an infiltration of proteinaceous material, inflammatory cells, and cellular debris. Arrow points to a Guarnieri body.</div><div class=\"graphic_reference\">Reproduced from: The Public Health Image Library, Centers for Disease Control and Prevention. Photo by Dr. RB Haraszti.</div><div id=\"graphicVersion\">Graphic 59400 Version 2.0</div></div></div>"},"59402":{"type":"graphic_picture","displayName":"Child ecchymoses","title":"Ecchymoses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ecchymoses</div><div class=\"cntnt\"><img style=\"width:396px; height:357px;\" src=\"images/EM/59402_Child_ecchymoses.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Leslie Raffini, MD.</div><div id=\"graphicVersion\">Graphic 59402 Version 1.0</div></div></div>"},"59403":{"type":"graphic_table","displayName":"ADA classification DM","title":"Etiologic classification of diabetes mellitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologic classification of diabetes mellitus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Type 1 diabetes (beta cell destruction, usually leading to absolute insulin deficiency)</td> </tr> <tr> <td>A. Immune-mediated</td> </tr> <tr> <td>B. Idiopathic</td> </tr> <tr> <td class=\"subtitle1_single\">Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deficiency to a predominantly secretory defect with insulin resistance)</td> </tr> <tr> <td class=\"subtitle1_single\">Other specific types</td> </tr> <tr> <td class=\"sublist1_start\">A. Genetic defects of beta cell function</td> </tr> <tr> <td class=\"sublist1\">1. Chromosome 12, HNF-1-alpha (MODY3) </td> </tr> <tr> <td class=\"sublist1\">2. Chromosome 7, glucokinase (MODY2)</td> </tr> <tr> <td class=\"sublist1\">3. Chromosome 20, HNF-4-alpha (MODY1)</td> </tr> <tr> <td class=\"sublist1\">4. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4)</td> </tr> <tr> <td class=\"sublist1\">5. Chromosome 17, HNF-1-beta (MODY5)</td> </tr> <tr> <td class=\"sublist1\">6. Chromosome 2, NeuroD1 (MODY6)</td> </tr> <tr> <td class=\"sublist1\">7. Mitochondrial DNA </td> </tr> <tr> <td class=\"sublist1\">8. Others</td> </tr> <tr> <td class=\"sublist1_start\">B. Genetic defects in insulin action</td> </tr> <tr> <td class=\"sublist1\">1. Type A insulin resistance</td> </tr> <tr> <td class=\"sublist1\">2. Leprechaunism</td> </tr> <tr> <td class=\"sublist1\">3. Rabson-Mendenhall syndrome</td> </tr> <tr> <td class=\"sublist1\">4. Lipoatrophic diabetes</td> </tr> <tr> <td class=\"sublist1\">5. Others</td> </tr> <tr> <td class=\"sublist1_start\">C. Diseases of the exocrine pancreas</td> </tr> <tr> <td class=\"sublist1\">1. Pancreatitis</td> </tr> <tr> <td class=\"sublist1\">2. Trauma/pancreatectomy</td> </tr> <tr> <td class=\"sublist1\">3. Neoplasia</td> </tr> <tr> <td class=\"sublist1\">4. Cystic fibrosis </td> </tr> <tr> <td class=\"sublist1\">5. Hemochromatosis</td> </tr> <tr> <td class=\"sublist1\">6. Fibrocalculous pancreatopathy</td> </tr> <tr> <td class=\"sublist1\">7. Others</td> </tr> <tr> <td class=\"sublist1_start\">D. Endocrinopathies</td> </tr> <tr> <td class=\"sublist1\">1. Acromegaly</td> </tr> <tr> <td class=\"sublist1\">2. Cushing's syndrome</td> </tr> <tr> <td class=\"sublist1\">3. Glucagonoma</td> </tr> <tr> <td class=\"sublist1\">4. Pheochromocytoma</td> </tr> <tr> <td class=\"sublist1\">5. Hyperthyroidism</td> </tr> <tr> <td class=\"sublist1\">6. Somatostatinoma</td> </tr> <tr> <td class=\"sublist1\">7. Aldosteronoma</td> </tr> <tr> <td class=\"sublist1\">8. Others</td> </tr> <tr> <td class=\"sublist1_start\">E. Drug or chemical induced</td> </tr> <tr> <td class=\"sublist1\">1. Vacor</td> </tr> <tr> <td class=\"sublist1\">2. Pentamidine</td> </tr> <tr> <td class=\"sublist1\">3. Nicotinic acid</td> </tr> <tr> <td class=\"sublist1\">4. Glucocorticoids </td> </tr> <tr> <td class=\"sublist1\">5. Thyroid hormone</td> </tr> <tr> <td class=\"sublist1\">6. Diazoxide</td> </tr> <tr> <td class=\"sublist1\">7. Beta-adrenergic agonists</td> </tr> <tr> <td class=\"sublist1\">8. Thiazides </td> </tr> <tr> <td class=\"sublist1\">9. Dilantin</td> </tr> <tr> <td class=\"sublist1\">10. Alpha interferon</td> </tr> <tr> <td class=\"sublist1\">11. Others</td> </tr> <tr> <td class=\"sublist1_start\">F. Infections</td> </tr> <tr> <td class=\"sublist1\">1. Congenital rubella</td> </tr> <tr> <td class=\"sublist1\">2. Cytomegalovirus</td> </tr> <tr> <td class=\"sublist1\">3. Others</td> </tr> <tr> <td class=\"sublist1_start\">G. Uncommon forms of immune-mediated diabetes</td> </tr> <tr> <td class=\"sublist1\">1. \"Stiff man\" syndrome</td> </tr> <tr> <td class=\"sublist1\">2. Anti-insulin receptor antibodies </td> </tr> <tr> <td class=\"sublist1\">3. Others</td> </tr> <tr> <td class=\"sublist1_start\">H. Other genetic syndromes sometimes associated with diabetes</td> </tr> <tr> <td class=\"sublist1\">1. Down syndrome </td> </tr> <tr> <td class=\"sublist1\">2. Klinefelter syndrome</td> </tr> <tr> <td class=\"sublist1\">3. Turner syndrome</td> </tr> <tr> <td class=\"sublist1\">4. Wolfram syndrome</td> </tr> <tr> <td class=\"sublist1\">5. Friederich's ataxia</td> </tr> <tr> <td class=\"sublist1\">6. Huntington's chorea </td> </tr> <tr> <td class=\"sublist1\">7. Laurence-Moon-Biedl syndrome </td> </tr> <tr> <td class=\"sublist1\">8. Myotonic dystrophy</td> </tr> <tr> <td class=\"sublist1\">9. Porphyria</td> </tr> <tr> <td class=\"sublist1\">10. Prader-Willi syndrome</td> </tr> <tr> <td class=\"sublist1\">11. Others</td> </tr> <tr> <td class=\"subtitle1_single\">Gestational diabetes mellitus</td> </tr> <tr> <td>Patients with any form of diabetes may require insulin treatment at some stage of their disease. Such use of insulin does not, of itself, classify the patient.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Copyright © 2007 American Diabetes Association From Diabetes Care Vol 30, Supplement 1, 2007. Reprinted with permission from The American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 59403 Version 4.0</div></div></div>"},"59404":{"type":"graphic_figure","displayName":"Grasping cone specimen","title":"Removing the cervical (uterine cervix) cone specimen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Removing the cervical (uterine cervix) cone specimen</div><div class=\"cntnt\"><img style=\"width:416px; height:327px;\" src=\"images/OBGYN/59404_Grasping_cone_specimen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Partially released cone specimen is gently grasped with an Allis clamp, avoiding the mucosal surfaces.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 59404 Version 2.0</div></div></div>"},"59407":{"type":"graphic_picture","displayName":"Ulcerated basal cell carcinoma","title":"Basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:186px; height:281px;\" src=\"images/ONC/59407_Rodent_ulcer_of_basal_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large basal cell tumors may develop vascular compromise, leading to central ulceration. This appearance has been historically referred to as a &quot;rodent ulcer.&quot;</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 59407 Version 2.0</div></div></div>"},"59408":{"type":"graphic_table","displayName":"CYSHCN transition resources","title":"Resources for addressing the transition to adulthood for children and youth with special health care needs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for addressing the transition to adulthood for children and youth with special health care needs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>American College of Physicians</strong><br /> <strong>Pediatric to Adult Care Transitions Initiative</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <p><a href=\"http://www.acponline.org/clinical-information/high-value-care/resources-for-clinicians/pediatric-to-adult-care-transitions-initiative\" target=\"_blank\">www.acponline.org/clinical-information/high-value-care/resources-for-clinicians/pediatric-to-adult-care-transitions-initiative</a></p> </td> </tr> <tr> <td><strong>National Alliance to Advance Adolescent Health</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <p><a href=\"http://www.gottransition.org/resources/\" spellcheck=\"true\" target=\"_blank\">www.gottransition.org/families-resources</a></p> </td> </tr> <tr> <td><strong>National Center on Secondary Education and Transition</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <p><a href=\"http://www.ncset.org/\" target=\"_blank\">www.ncset.org</a></p> </td> </tr> <tr> <td><strong>National Collaborative on Workforce and Disability</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <p><a href=\"http://www.ncwd-youth.info/\" spellcheck=\"true\" target=\"_blank\">www.ncwd-youth.info</a></p> </td> </tr> <tr> <td><strong>TelAbility: Enhancing the lives of children with disabilities</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <p><a href=\"http://www.telability.org/\" target=\"_blank\">www.telability.org</a></p> </td> </tr> <tr> <td><strong>The Youthhood</strong></td> </tr> <tr> <td> <p><a href=\"http://www.youthhood.org/index.asp\" target=\"_blank\">www.youthhood.org/index.asp</a></p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Levey EB, Murphy NA. Addressing transition to adulthood with special needs patients. AAP News September 2005; 26:19.</div><div id=\"graphicVersion\">Graphic 59408 Version 9.0</div></div></div>"},"59409":{"type":"graphic_figure","displayName":"Gutter splints","title":"Gutter splints","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gutter splints</div><div class=\"cntnt\"><img style=\"width:239px; height:423px;\" src=\"images/PEDS/59409_Gutter_splints.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gutter splints are used for phalangeal and metacarpal fractures. The ulnar gutter splint is depicted above. For radial gutter splint, apply to opposite (radial) side with hole cut for thumb to pass through.</div><div id=\"graphicVersion\">Graphic 59409 Version 1.0</div></div></div>"},"59411":{"type":"graphic_table","displayName":"Biological effects of VIP","title":"Biological effects of vasoactive intestinal peptide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biological effects of vasoactive intestinal peptide</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">1. Cardiovascular system</td> </tr> <tr> <td class=\"sublist2_start\">Vasodilation</td> </tr> <tr> <td class=\"sublist2\">Peripheral</td> </tr> <tr> <td class=\"sublist2\">Splanchnic</td> </tr> <tr> <td class=\"sublist2\">Coronary</td> </tr> <tr> <td class=\"sublist2\">Extracranial</td> </tr> <tr> <td class=\"sublist2\">Cerebral</td> </tr> <tr> <td class=\"sublist2\">Pulmonary</td> </tr> <tr> <td class=\"sublist2\">Genital</td> </tr> <tr> <td class=\"indent1\">Chronotropic effect</td> </tr> <tr> <td class=\"indent1\">Inotropic effect</td> </tr> <tr> <td class=\"subtitle1_single\">2. Digestive system</td> </tr> <tr> <td class=\"sublist2_start\">Esophagus</td> </tr> <tr> <td class=\"sublist2\">Relaxation of lower sphincter</td> </tr> <tr> <td class=\"sublist2\">Contraction in the body</td> </tr> <tr> <td class=\"sublist2_start\">Stomach</td> </tr> <tr> <td class=\"sublist2\">Relaxation of antral smooth muscle</td> </tr> <tr> <td class=\"sublist2\">Relaxation of fundic smooth muscle</td> </tr> <tr> <td class=\"sublist2\">Relaxation of oluscularis mucosae</td> </tr> <tr> <td class=\"sublist2_start\">Small intestine</td> </tr> <tr> <td class=\"sublist2\">Relaxation followed by contractions of circular muscle</td> </tr> <tr> <td class=\"sublist2\">Contraction of longitudinal muscle</td> </tr> <tr> <td class=\"sublist2\">Stimulation or water and ion secretion</td> </tr> <tr> <td class=\"sublist2\">Stimulation or Brunner's gland secretion</td> </tr> <tr> <td class=\"sublist2\">Regulation of epithelial tight junction proteins</td> </tr> <tr> <td class=\"sublist2_start\">Large intestine</td> </tr> <tr> <td class=\"sublist2\">Relaxation of smooth muscle</td> </tr> <tr> <td class=\"sublist2\">Water and chloride secretion</td> </tr> <tr> <td class=\"sublist2_start\">Gallbladder</td> </tr> <tr> <td class=\"sublist2\">Relaxation of smooth muscle</td> </tr> <tr> <td class=\"sublist2\">Inhibition of fluid and NaCl absorption</td> </tr> <tr> <td class=\"sublist2_start\">Liver</td> </tr> <tr> <td class=\"sublist2\">Stimulation or biliary secretion</td> </tr> <tr> <td class=\"sublist2_start\">Pancreas</td> </tr> <tr> <td class=\"sublist2\">Stimulation of water and HCO<sub>3</sub>-secretion</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">3. Endocrine function and metabolism</td> </tr> <tr> <td class=\"sublist2_start\">Metabolism</td> </tr> <tr> <td class=\"sublist2\">Lipolysis</td> </tr> <tr> <td class=\"sublist2\">Glycogenolysis</td> </tr> <tr> <td class=\"sublist2_start\">Adrenal gland</td> </tr> <tr> <td class=\"sublist2\">Stimulation of adrenal steroidogenesis</td> </tr> <tr> <td class=\"sublist2_start\">Kidney</td> </tr> <tr> <td class=\"sublist2\">Stimulation of renin secretion</td> </tr> <tr> <td class=\"sublist2_start\">Pancreas</td> </tr> <tr> <td class=\"sublist2\">Release of insulin, glucagon, somatostatin, and pancreatic polypeptide</td> </tr> <tr> <td class=\"sublist2_start\">Pituitary/hypothalamus</td> </tr> <tr> <td class=\"sublist2\">Release of prolactin, oxytocin, and vasopressin</td> </tr> <tr> <td class=\"sublist2_start\">Thyroid</td> </tr> <tr> <td class=\"sublist2\">Stimulation of hormone secretion</td> </tr> <tr> <td class=\"subtitle1_single\">4. Urogenital system</td> </tr> <tr> <td class=\"indent1\">Inhibition or myoelectrical and smooth muscle activity</td> </tr> <tr> <td class=\"indent1\">Potential of electrically induced and pilocarpine-induced prostatic secretion</td> </tr> <tr> <td class=\"subtitle1_single\">5. Respiratory system</td> </tr> <tr> <td class=\"indent1\">Bronchodilation</td> </tr> <tr> <td class=\"indent1\">Stimulation of submucosal gland secretion</td> </tr> <tr> <td class=\"subtitle1_single\">6. Central nervous system</td> </tr> <tr> <td class=\"indent1\">Excitation of cerebral cortical and spinal cord neurons</td> </tr> <tr> <td class=\"indent1\">Hyperthermia</td> </tr> <tr> <td class=\"indent1\">Stimulation or glycogenolysis and of glucose utilization</td> </tr> <tr> <td class=\"indent1\">Hypnogenic and antidipsogenic effects</td> </tr> <tr> <td class=\"subtitle1_single\">7. Immune system</td> </tr> <tr> <td class=\"indent1\">Inhibition of mitogen-induced transformation of T-lymphocytes</td> </tr> <tr> <td class=\"indent1\">Stimulation of Ig synthesis</td> </tr> <tr> <td class=\"indent1\">Inhibition of mast cell histamine release</td> </tr> <tr> <td class=\"indent1\">Inhibition of Th1 immune responses</td> </tr> <tr> <td class=\"indent1\">Promotion of Th2 immune responses</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Fahrenkurg J. Pharmacol Toxicol 1993; 72:354. Copyright &copy; 1993 Pharmacology &amp; Toxicology.</div><div id=\"graphicVersion\">Graphic 59411 Version 7.0</div></div></div>"},"59412":{"type":"graphic_picture","displayName":"DBE NSAID induced stricture","title":"DBE NSAID induced stricture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">DBE NSAID induced stricture</div><div class=\"cntnt\"><img style=\"width:396px; height:334px;\" src=\"images/GAST/59412_DBE_NSAID_induced_stricture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proximal ileal nonsteroidal antiinflammatory drug (NSAID)-induced diaphragm-like stricture diagnosed by double balloon enteroscopy (DBE).</div><div class=\"graphic_reference\">Courtesy of Louis-Michel Wong Kee Song, MD, FRCP(C).</div><div id=\"graphicVersion\">Graphic 59412 Version 2.0</div></div></div>"},"59413":{"type":"graphic_picture","displayName":"Familial polyposis Endosc","title":"Endoscopic appearance of multiple polyps in familial adenomatous polyposis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic appearance of multiple polyps in familial adenomatous polyposis</div><div class=\"cntnt\"><img style=\"width:368px; height:367px;\" src=\"images/GAST/59413_Familial_polyposis_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic findings at multiple levels in a 50-year-old man with familial adenomatous polyposis. Multiple polyps of various sizes are seen. At colectomy, some of these polyps had areas of high-grade dysplasia and early malignant transformation.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 59413 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal sigmoid colon</div><div class=\"cntnt\"><img style=\"width:216px; height:216px;\" src=\"images/GAST/55563_Normal_sigmoid_colon_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 55563 Version 1.0</div></div></div>"},"59414":{"type":"graphic_table","displayName":"IDUS vs ERCP EUS ERP panc ca","title":"Sensitivity and specificity of intraductal ultrasound (IDUS), endoscopic ultrasound (EUS), computed tomographic (CT) scanning, and endoscopic retrograde pancreatography (ERP) in the diagnosis of pancreatic cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specificity of intraductal ultrasound (IDUS), endoscopic ultrasound (EUS), computed tomographic (CT) scanning, and endoscopic retrograde pancreatography (ERP) in the diagnosis of pancreatic cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">IDUS (percent)</td> <td class=\"subtitle1\">EUS (percent)</td> <td class=\"subtitle1\">CT (percent)</td> <td class=\"subtitle1\">ERP (percent)</td> </tr> <tr> <td><strong>Sensitivity</strong></td> <td>100</td> <td>90</td> <td>67</td> <td>90</td> </tr> <tr> <td><strong>Specificity</strong></td> <td>92</td> <td>60</td> <td>64</td> <td>64</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Furukawa T, Oohashi K, Yamao K, et al. Endoscopy 1997; 29:561.</div><div id=\"graphicVersion\">Graphic 59414 Version 3.0</div></div></div>"},"59415":{"type":"graphic_figure","displayName":"Intercostal space","title":"Contents of typical intercostal space","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contents of typical intercostal space</div><div class=\"cntnt\"><img style=\"width:369px; height:418px;\" src=\"images/OBGYN/59415_Intercostal_space.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note order of structures in the costal groove from superior to inferior: VAN (vein, artery, and nerve).</div><div class=\"graphic_reference\">Reproduced with permission from: Moore, KL and Agur, A. Essential Clinical Anatomy, 2nd Ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &#169;2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59415 Version 1.0</div></div></div>"},"59417":{"type":"graphic_figure","displayName":"Planimetric z-plasty","title":"Planimetric Z-plasty","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Planimetric Z-plasty</div><div class=\"cntnt\"><img style=\"width:543px; height:704px;\" src=\"images/SURG/59417_Planimetric_z-plasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The planimetric Z-plasty uses a 75&#176; angle and limb incisions that are twice as long as the central incision. The central incision is then elongated in both directions to twice the length of the limb incisions. The two triangular areas that are created are excised prior to flap transposition.</div><div id=\"graphicVersion\">Graphic 59417 Version 1.0</div></div></div>"},"59418":{"type":"graphic_picture","displayName":"Toxic epidermal necrolysis - abdomen","title":"Toxic epidermal necrolysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toxic epidermal necrolysis</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/59418_Toxicepidnecrolysisabd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple bullae and areas of denuded epidermis are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" style=\"font-style: italic;\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59418 Version 8.0</div></div></div>"},"59419":{"type":"graphic_picture","displayName":"Applanation tonometry","title":"Applanation tonometry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Applanation tonometry</div><div class=\"cntnt\"><img style=\"width:410px; height:432px;\" src=\"images/PC/59419_Applanation_tonometry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Applanation tonometry calculates intraocular pressure indirectly by measuring the force required to flatten (applanate) a constant area of the cornea.</div><div id=\"graphicVersion\">Graphic 59419 Version 1.0</div></div></div>"},"59420":{"type":"graphic_diagnosticimage","displayName":"Gastric prolapse after gastric banding","title":"Gastric prolapse after gastric banding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric prolapse after gastric banding</div><div class=\"cntnt\"><img style=\"width:331px; height:648px;\" src=\"images/SURG/59420_Gastric_prolapse_gastr_band.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An esophagram showing the appearance of gastric prolapse after gastric banding. This radiograph illustrates the classic appearance of gastric prolapse with stomach overhanging the band.<br />(B) Computed tomography (CT) images showing change in the band axis and a large amount of stomach above the band, indicative of gastric prolapse.<br />(C) This esophagram demonstrates a gastric prolapse. Note that the axis of the band is located in the 10:00 to 4:00 position. The axis of a normally positioned band extends from 2:00 to 8:00.</div><div id=\"graphicVersion\">Graphic 59420 Version 8.0</div></div></div>"},"59421":{"type":"graphic_picture","displayName":"Ultrasound transducers","title":"Variety of transducer options","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variety of transducer options</div><div class=\"cntnt\"><img style=\"width:430px; height:308px;\" src=\"images/EM/59421_US_probes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The center probe, a linear 12-5 mHz transducer, is most often used for peripheral vascular imaging. The left-hand probe, called a \"hockey stick,\" can be useful in tight locations. The right-hand probe is a curved, lower-frequency transducer that allows for greater tissue penetration in obese patients.</div><div class=\"graphic_reference\">Courtesy of Lauren W Averill, MD.</div><div id=\"graphicVersion\">Graphic 59421 Version 4.0</div></div></div>"},"59423":{"type":"graphic_picture","displayName":"Optic disc Frisen grade 2","title":"Optic disc Frisén Grade II","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic disc Fris&#233;n Grade II</div><div class=\"cntnt\"><img style=\"width:450px; height:354px;\" src=\"images/NEURO/59423_Optic_disc_Frisen_grade_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fris&#233;n Grade II showing the halo of disc edema is circumferential.</div><div class=\"graphic_reference\">Courtesy of Michael Wall, MD.</div><div id=\"graphicVersion\">Graphic 59423 Version 1.0</div></div></div>"},"59424":{"type":"graphic_table","displayName":"Cairo-Bishop define TLS","title":"Cairo-Bishop definition of laboratory tumor lysis syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cairo-Bishop definition of laboratory tumor lysis syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Element </td> <td class=\"subtitle1\">Value </td> <td class=\"subtitle1\">Change from baseline </td> </tr> <tr> <td>Uric acid</td> <td>&#8805;476 micromol/L (8 mg/dL)</td> <td>25% increase</td> </tr> <tr> <td>Potassium</td> <td>&#8805;6.0 mmol/L (or 6 mEq/L)</td> <td>25% increase</td> </tr> <tr> <td>Phosphorus</td> <td> <p>&#8805;2.1 mmol/L (6.5 mg/dL) for children or</p> <p>&#8805;1.45 mmol/L (4.5 mg/dL) for adults</p> </td> <td>25% increase</td> </tr> <tr> <td>Calcium</td> <td>&#8804;1.75 mmol/L (7 mg/dL)</td> <td>25% decrease</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Two or more laboratory changes within&nbsp;three days before or&nbsp;seven days after cytotoxic therapy.</div><div class=\"graphic_reference\">Reproduced with permission from: Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767. Copyright ©2008 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 59424 Version 3.0</div></div></div>"},"59425":{"type":"graphic_picture","displayName":"Bell's palsy photos PI","title":"Bell's palsy","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Bell's palsy</div><div class=\"cntnt\"><img style=\"width:512px; height:522px;\" src=\"images/PI/59425_Bells_palsy_photos_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These pictures show a man with Bell's palsy, which causes one side of the face to become weak or droop. People with Bell's palsy can&nbsp;have trouble raising the eyebrow, lifting the corner of the mouth,&nbsp;or&nbsp;closing the eye on that side.</div><div class=\"graphic_reference\">Reproduced with permission from: Charles Goldberg, MD and The University of California, San Diego. Copyright © 2005 The Regents of the University of California. <A style=\"FONT-STYLE: italic\" href=\"http://meded.ucsd.edu/clinicalmed/neuro2.htm\" target=_blank>http://meded.ucsd.edu/clinicalmed/neuro2.htm</A>.</div><div id=\"graphicVersion\">Graphic 59425 Version 8.0</div></div></div>"},"59426":{"type":"graphic_table","displayName":"HSANs in newborns","title":"Hereditary sensory and autonomic neuropathies that affect newborns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hereditary sensory and autonomic neuropathies that affect newborns</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>HSAN1 (autosomal dominant hereditary sensory radicular neuropathy)</td> </tr> <tr> <td>HSAN2 (autosomal recessive congenital sensory neuropathy)</td> </tr> <tr> <td>HSAN3 (Riley-Day syndrome or familial dysautonomia)</td> </tr> <tr> <td>HSAN4 (congenital insensitivity to pain with anhidrosis)</td> </tr> <tr> <td>Congenital autonomic dysfunction with universal pain loss</td> </tr> <tr> <td>Familial amyloid neuropathy (autosomal dominant)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59426 Version 6.0</div></div></div>"},"59427":{"type":"graphic_table","displayName":"NHANES Normal pediatric lipid values","title":"Lipid and lipoprotein distributions in subjects aged 5 to 19 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lipid and lipoprotein distributions in subjects aged 5 to 19 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Males</td> <td class=\"subtitle1\" colspan=\"3\">Females</td> </tr> <tr> <td class=\"subtitle2\">5 to 9 years</td> <td class=\"subtitle2\">10 to 14 years</td> <td class=\"subtitle2\">15 to 19 years</td> <td class=\"subtitle2\">5 to 9 years</td> <td class=\"subtitle2\">10 to 14 years</td> <td class=\"subtitle2\">15 to 19 years</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Total cholesterol, mg/dL</td> </tr> <tr> <td class=\"indent1\">50th percentile</td> <td>153</td> <td>161</td> <td>152</td> <td>164</td> <td>159</td> <td>157</td> </tr> <tr> <td class=\"indent1\">75th percentile</td> <td>168</td> <td>173</td> <td>168</td> <td>177</td> <td>171</td> <td>176</td> </tr> <tr> <td class=\"indent1\">90th percentile</td> <td>183</td> <td>191</td> <td>183</td> <td>189</td> <td>191</td> <td>198</td> </tr> <tr> <td class=\"indent1\">95th percentile</td> <td>186</td> <td>201</td> <td>191</td> <td>197</td> <td>205</td> <td>208</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Triglyceride, mg/dL</td> </tr> <tr> <td class=\"indent1\">50th percentile</td> <td>48</td> <td>58</td> <td>68</td> <td>57</td> <td>68</td> <td>64</td> </tr> <tr> <td class=\"indent1\">75th percentile</td> <td>58</td> <td>74</td> <td>88</td> <td>74</td> <td>85</td> <td>85</td> </tr> <tr> <td class=\"indent1\">90th percentile</td> <td>70</td> <td>94</td> <td>125</td> <td>103</td> <td>104</td> <td>112</td> </tr> <tr> <td class=\"indent1\">95th percentile</td> <td>85</td> <td>111</td> <td>143</td> <td>120</td> <td>120</td> <td>126</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">LDL, mg/dL</td> </tr> <tr> <td class=\"indent1\">50th percentile</td> <td>90</td> <td>94</td> <td>93</td> <td>98</td> <td>94</td> <td>93</td> </tr> <tr> <td class=\"indent1\">75th percentile</td> <td>103</td> <td>109</td> <td>109</td> <td>115</td> <td>110</td> <td>110</td> </tr> <tr> <td class=\"indent1\">90th percentile</td> <td>117</td> <td>123</td> <td>123</td> <td>125</td> <td>126</td> <td>129</td> </tr> <tr> <td class=\"indent1\">95th percentile</td> <td>129</td> <td>133</td> <td>130</td> <td>140</td> <td>136</td> <td>137</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">HDL, mg/dL</td> </tr> <tr> <td class=\"indent1\">5th percentile</td> <td>38</td> <td>37</td> <td>30</td> <td>36</td> <td>37</td> <td>35</td> </tr> <tr> <td class=\"indent1\">10th percentile</td> <td>43</td> <td>40</td> <td>34</td> <td>38</td> <td>40</td> <td>38</td> </tr> <tr> <td class=\"indent1\">25th percentile</td> <td>49</td> <td>46</td> <td>39</td> <td>48</td> <td>45</td> <td>43</td> </tr> <tr> <td class=\"indent1\">50th percentile</td> <td>55</td> <td>55</td> <td>46</td> <td>52</td> <td>52</td> <td>51</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Normal fasting lipoprotein profiles from the United States National Health and Nutrition Examination Surveys (NHANES).</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 122, Pages 198-208, Copyright © 2008 by the AAP.</div><div id=\"graphicVersion\">Graphic 59427 Version 16.0</div></div></div>"},"59428":{"type":"graphic_table","displayName":"Acute NSAID toxicity - Rapid overview","title":"Acute NSAID toxicity: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute NSAID toxicity: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td>Ask specifically about acetaminophen and aspirin ingestion</td> </tr> <tr> <td>Ascertain type of NSAID, amount ingested, when ingested</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical and laboratory features</td> </tr> <tr> <td>NSAIDS are usually well tolerated in overdose, with minimal toxicity</td> </tr> <tr> <td>Severe acute overdose may result in alterations in mental status, seizure, metabolic acidosis, or renal insufficiency</td> </tr> <tr> <td>Anaphylaxis may occur</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>Basic electrolytes to assess concentrations and acid-base status; baseline renal function (indicated only in moderate to severe overdose)</td> </tr> <tr> <td>Acetaminophen and salicylate concentrations to rule out concurrent pain medication ingestion</td> </tr> <tr> <td>Fingerstick glucose to rule out hypoglycemia as an etiology of any alteration in mental status</td> </tr> <tr> <td>Electrocardiogram to assess for toxin-induced prolongation of the QRS or QTc intervals</td> </tr> <tr> <td>Arterial or venous blood gas in severe overdose or altered mental status</td> </tr> <tr> <td>Pregnancy test for women of child-bearing age</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Secure airway, breathing, and circulation (rarely an issue in pure NSAID poisoning)</td> </tr> <tr> <td>Give gastrointestinal decontamination if patient presents within two hours of acute ingestion: Activated charcoal, 1 g/kg (maximum dose 50 g)</td> </tr> <tr> <td>There is no antidote for NSAID poisoning; supportive care will usually suffice</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59428 Version 10.0</div></div></div>"},"59429":{"type":"graphic_figure","displayName":"Landmarks diagnosis of Barretts esophagus and hiatus hernia","title":"Landmarks for the diagnosis of Barrett’s esophagus and hiatus hernia","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Landmarks for the diagnosis of Barrett&#8217;s esophagus and hiatus hernia</div><div class=\"cntnt\"><img style=\"width:538px; height:328px;\" src=\"images/GAST/59429_GE_junc_Barretts_esoph_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the relationship between the gastroesophageal junction, Z-line and hiatus hernia in patients with Barrett's esophagus. The Barrett's mucosa can appear as a confluent area (left picture), as tongues arising from the distal esophagus (middle picture), or as patches containing islands of squamous mucosa or squamous mucosa containing islands of Barrett's mucosa (right picture).</div><div class=\"graphic_reference\">Adapted from: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 59429 Version 5.0</div></div></div>"},"59431":{"type":"graphic_picture","displayName":"Acute myeloid leukemia","title":"Acute myeloid leukemia ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute myeloid leukemia </div><div class=\"cntnt\"><img style=\"width:364px; height:252px;\" src=\"images/HEME/59431_ANLLFABM1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate smear from a patient with AML. The blasts are large, with a moderate amount of grayish blue cytoplasm, distinct nucleoli, and no cytoplasmic granules. (Wright-Giemsa).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 59431 Version 2.0</div></div></div>"},"59432":{"type":"graphic_figure","displayName":"Glucocorticoid effects on gene expression","title":"Glucocorticoid effects on gene expression","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Glucocorticoid effects on gene expression</div><div class=\"cntnt\"><img style=\"width:499px; height:373px;\" src=\"images/PULM/59432_Steroid_effects_gene_expres.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glucocorticoids may regulate gene expression in several ways. Glucocorticoids enter the cell to bind to glucocorticoid receptors in the cytoplasm. The resultant GR&nbsp;homodimers translocate to the nucleus. GR homodimers then bind to glucocorticoid-response elements (GRE) in the promoter region of steroid-sensitive genes, which may encode anti-inflammatory proteins. Less commonly, GR homodimers interact with negative GREs to suppress genes, particularly those linked to side effects of glucocorticoids. Nuclear GR also interact with coactivator molecules, such as CREB-binding protein (CBP), which is activated by proinflammatory transcription factors, such as nuclear factor-kB (NF-kB), thus switching off the inflammatory genes that are activated by these transcription factors.</div><div class=\"graphic_footnotes\">SLPI: secretory leukoprotease inhibitor; MKP-1: mitogen-activated kinase phosphatase-1; IkB-α: inhibitor of NF-kB; GILZ: glucocorticoid-induced leucine zipper protein; POMC: pro-opiomelanocortin; CRF: corticotrophin-releasing factor; GR: glucocorticoid receptor.</div><div id=\"graphicVersion\">Graphic 59432 Version 2.0</div></div></div>"},"59433":{"type":"graphic_figure","displayName":"Anatomy of the thoracic outlet","title":"Anatomy of the thoracic outlet","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Anatomy of the thoracic outlet</div><div class=\"cntnt\"><img style=\"width:490px; height:398px;\" src=\"images/SURG/59433_Thoracicoutletanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thoracic outlet refers to the confined space between the clavicle and first rib. Structures that pass through this region include the nerves of the brachial plexus, the subclavian artery, and the subclavian vein.</div><div id=\"graphicVersion\">Graphic 59433 Version 6.0</div></div></div>"},"59434":{"type":"graphic_figure","displayName":"Schematic PSAX  VSDs","title":"Schematic illustration of a parasternal short-axis echocardiographic view showing ventricular septal defects","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic illustration of a parasternal short-axis echocardiographic view showing ventricular septal defects</div><div class=\"cntnt\"><img style=\"width:450px; height:415px;\" src=\"images/CARD/59434_Parasternal_VSD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic of the parasternal short-axis echocardiographic view shows the location of the membranous septum (MS; blue) with membranous defect (M), the infundibular septum (IS; yellow) with infundibular defect (I), and atrioventricular septum (AVS; pink).</div><div class=\"graphic_footnotes\">R: right coronary cusp of the aortic valve; N: noncoronary cusp; L: left coronary cusp; LA: left atrium; RA: right atrium; TV: tricuspid valve; RV: right ventricle; MPA: main pulmonary artery.</div><div class=\"graphic_reference\">Reprinted with permission: Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes CA (Ed). © 2009 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 59434 Version 11.0</div></div></div>"},"59435":{"type":"graphic_table","displayName":"CASH algorithm","title":"CASH algorithm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CASH algorithm</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Score range</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Score*</td> </tr> <tr> <td rowspan=\"6\"><strong>Color</strong></td> <td rowspan=\"6\">1-6</td> <td>Light brown</td> <td>1</td> </tr> <tr> <td>Dark brown</td> <td>1</td> </tr> <tr> <td>Brown</td> <td>1</td> </tr> <tr> <td>Red</td> <td>1</td> </tr> <tr> <td>White</td> <td>1</td> </tr> <tr> <td>Blue</td> <td>1</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Architectural disorder</strong></td> <td rowspan=\"3\">0-2</td> <td> <p><strong>None/mild</strong></p> <p>Colors and dermoscopic structures are distributed in an organized or slightly disordered manner.</p> </td> <td>0</td> </tr> <tr> <td> <p><strong>Moderate</strong></p> <p>The dermoscopic structures lose their uniformity and are distributed in an irregular manner.</p> </td> <td>1</td> </tr> <tr> <td> <p><strong>Marked</strong></p> <p>The arrangement of colors and dermoscopic structures is completely disorganized (chaotic).</p> </td> <td>2</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"> <p><strong>Symmetry</strong></p> <p>(taking into account shape and dermoscopic structures)</p> </td> <td rowspan=\"3\">0-2</td> <td>Bi-axial symmetry</td> <td>0</td> </tr> <tr> <td>Mono-axial symmetry</td> <td>1</td> </tr> <tr> <td>Bi-axial asymmetry</td> <td>2</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"7\"><strong>Homogeneity/heterogeneity of dermoscopic structures</strong></td> <td rowspan=\"7\">1-7</td> <td>Network</td> <td>1</td> </tr> <tr> <td>Dots/globules</td> <td>1</td> </tr> <tr> <td>Streaks/pseudopods</td> <td>1</td> </tr> <tr> <td>Blue-white veil</td> <td>1</td> </tr> <tr> <td>Regression structures</td> <td>1</td> </tr> <tr> <td>Blotches</td> <td>1</td> </tr> <tr> <td>Polymorphous vessels</td> <td>1</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">21</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=92304&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">CASH: color, architectural disorder, symmetry, homogeneity/heterogeneity of dermoscopic structures.</div><div class=\"graphic_footnotes\">* Interpretation: The total score can range between 2 and 17 points. A total score of 8 or more is considered to be suggestive of melanoma.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Henning JS, Dusza SW, Wang SQ, et al. The CASH (color, architecture, symmetry, and homogeneity) algorithm for dermoscopy. J Am Acad Dermatol 2007; 56:45.</LI></OL>Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 59435 Version 5.0</div></div></div>"},"59437":{"type":"graphic_figure","displayName":"Cross section of the leg and forearm compartments","title":"Cross section of the leg and forearm compartments","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Cross section of the leg and forearm compartments</div><div class=\"cntnt\"><img style=\"width:534px; height:587px;\" src=\"images/EM/59437_Compartments_leg_forearm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These diagrams show the compartments of the leg (A) and forearm (B), including all major nerves and vascular structures. Note how inaccessible the leg's deep posterior compartment is to direct palpation.</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss A, MD, FACEP, Wolfson AB, MD, FACEP, FACP, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59437 Version 2.0</div></div></div>"},"59438":{"type":"graphic_table","displayName":"Obstetric complications by BMI","title":"Obstetric complications by maternal body mass index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Obstetric complications by maternal body mass index</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Outcome</td> <td class=\"subtitle1\">Control (n = 13,752), percent</td> <td class=\"subtitle1\">Obese (n = 1473), percent</td> <td class=\"subtitle1\">Morbidly obese (n = 877), percent</td> </tr> <tr> <td>Gestational hypertension</td> <td class=\"centered\">4.8</td> <td class=\"centered\">10.2</td> <td class=\"centered\">12.3</td> </tr> <tr> <td>Preeclampsia</td> <td class=\"centered\">2.1</td> <td class=\"centered\">3.0</td> <td class=\"centered\">6.3</td> </tr> <tr> <td>Gestational diabetes</td> <td class=\"centered\">2.3</td> <td class=\"centered\">6.3</td> <td class=\"centered\">9.5</td> </tr> <tr> <td>Preterm premature rupture of membranes</td> <td class=\"centered\">1.7</td> <td class=\"centered\">2.1</td> <td class=\"centered\">2.2</td> </tr> <tr> <td>Preterm delivery</td> <td class=\"centered\">3.3</td> <td class=\"centered\">4.0</td> <td class=\"centered\">5.5</td> </tr> <tr> <td>Fetal growth restriction</td> <td class=\"centered\">1.1</td> <td class=\"centered\">1.0</td> <td class=\"centered\">0.8</td> </tr> <tr> <td>Birth weight &#62;4000 g</td> <td class=\"centered\">8.3</td> <td class=\"centered\">13.3</td> <td class=\"centered\">14.6</td> </tr> <tr> <td>Birth weight &#62;4500 g</td> <td class=\"centered\">1.0</td> <td class=\"centered\">2.1</td> <td class=\"centered\">2.6</td> </tr> <tr> <td>Placenta previa</td> <td class=\"centered\">0.6</td> <td class=\"centered\">0.8</td> <td class=\"centered\">0.5</td> </tr> <tr> <td>Placental abruption</td> <td class=\"centered\">0.8</td> <td class=\"centered\">0.8</td> <td class=\"centered\">0.8</td> </tr> <tr> <td>Operative vaginal delivery</td> <td class=\"centered\">10.5</td> <td class=\"centered\">8.5</td> <td class=\"centered\">11.1</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Weiss JL, Malone FD, Emig D, et al. Obesity, obstetric complications, and cesarean delivery rate: A population-based screening study. Am J Obstet Gynecol 2004; 190:1091.</div><div id=\"graphicVersion\">Graphic 59438 Version 6.0</div></div></div>"},"59439":{"type":"graphic_table","displayName":"5 year DFS node neg colon CA","title":"Predicted five year DFS estimates for patients with node-negative colon cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predicted five year DFS estimates for patients with node-negative colon cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Disease stage</td> <td class=\"subtitle1\" colspan=\"2\">Low grade</td> <td class=\"subtitle1\" colspan=\"2\">High grade</td> </tr> <tr> <td class=\"subtitle2\">Surgery alone, percent</td> <td class=\"subtitle2\">Surgery and chemo, percent</td> <td class=\"subtitle2\">Surgery alone, percent</td> <td class=\"subtitle2\">Surgery and chemo, percent</td> </tr> <tr> <td>T3N0</td> <td class=\"centered\"> <p>73</p> (69 to 76)</td> <td class=\"centered\"> <p>77</p> (74 to 80)</td> <td class=\"centered\"> <p>65</p> (60 to 70)</td> <td class=\"centered\"> <p>70</p> (65 to 74)</td> </tr> <tr> <td>T4N0</td> <td class=\"centered\"> <p>60</p> (54 to 68)</td> <td class=\"centered\"> <p>66</p> (59 to 73)</td> <td class=\"centered\"> <p>51</p> (43 to 60)</td> <td class=\"centered\"> <p>57</p> (49 to 66)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Range of numbers in parentheses represent 95 percent confidence intervals.</div><div class=\"graphic_footnotes\">DFS: disease-free survival; chemo: chemotherapy.</div><div class=\"graphic_reference\">Based upon a model derived from 1440 patients with node-negative colon cancer enrolled on seven randomized trials comparing adjuvant 5-fluorouracil-based treatment with surgery alone (Gill S, et al. J Clin Oncol 2004; 22:1797).</div><div id=\"graphicVersion\">Graphic 59439 Version 3.0</div></div></div>"},"59441":{"type":"graphic_table","displayName":"NCDB no surg surv panc","title":"Five-year overall survival for pancreatic adenocarcinoma from the National Cancer Data Base: nonresected<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five-year overall survival for pancreatic adenocarcinoma from the National Cancer Data Base: nonresected<sup>[1]</sup></div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\" colspan=\"3\">\n   Nonsurgical patients\n   </td>\n   <td  class=\"subtitle1\" colspan=\"5\">\n   Observed survival\n   </td>\n   <td  class=\"subtitle1\" rowspan=\"2\">\n   Median survival, months\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2\">\n   Stage\n   </td>\n   <td  class=\"subtitle2\">\n   Number of patients\n   </td>\n   <td  class=\"subtitle2\">\n   Percent\n   </td>\n   <td  class=\"subtitle2\">\n   1-year, percent\n   </td>\n   <td  class=\"subtitle2\">\n   2-year, percent\n   </td>\n   <td  class=\"subtitle2\">\n   3-year, percent\n   </td>\n   <td  class=\"subtitle2\">\n   4-year, percent\n   </td>\n   <td  class=\"subtitle2\">\n   5-year, percent\n   </td>\n   </tr>\n   <tr>\n   <td>IA</td>\n   <td>3412</td>\n   <td>4.4</td>\n   <td>29.2</td>\n   <td>10.5</td>\n   <td>6.2</td>\n   <td>4.6</td>\n   <td>3.8</td>\n   <td>6.8</td>\n   </tr>\n   <tr>\n   <td>IB</td>\n   <td>4298</td>\n   <td>5.4</td>\n   <td>26.0</td>\n   <td>9.4</td>\n   <td>5.7</td>\n   <td>4.0</td>\n   <td>3.4</td>\n   <td>6.1</td>\n   </tr>\n   <tr>\n   <td>IIA</td>\n   <td>8486</td>\n   <td>10.1</td>\n   <td>25.0</td>\n   <td>7.7</td>\n   <td>4.1</td>\n   <td>2.8</td>\n   <td>2.4</td>\n   <td>6.2</td>\n   </tr>\n   <tr>\n   <td>IIB</td>\n   <td>6570</td>\n   <td>11.8</td>\n   <td>26.9</td>\n   <td>7.7</td>\n   <td>3.8</td>\n   <td>2.6</td>\n   <td>2.0</td>\n   <td>6.7</td>\n   </tr>\n   <tr>\n   <td>III</td>\n   <td>12,981</td>\n   <td>13.0</td>\n   <td>27.0</td>\n   <td>7.3</td>\n   <td>3.4</td>\n   <td>2.4</td>\n   <td>1.8</td>\n   <td>7.2</td>\n   </tr>\n   <tr>\n   <td>IV</td>\n   <td>64,454</td>\n   <td>55.2</td>\n   <td>8.3</td>\n   <td>2.3</td>\n   <td>1.2</td>\n   <td>0.8</td>\n   <td>0.6</td>\n   <td>2.5</td>\n   </tr>\n   <tr>\n   <td><strong>Total</strong></td>\n   <td><strong>100,201</strong></td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   <td><strong>3.5</strong></td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">4/1/2010--These are in the AJCC folder and should be renewed annually for the life of the 7th Edition; this has been paid for 2010 (JD). The total fee of $&amp;quot;160.00&amp;quot;was originally charged to TNM_staging_adrenal_CA TNM_staging_ampullary_CA anal_cancer_TNM_stage anal_cancer_stage_group Anal_outcome_hist_AJCC TNM_stage_append_CA TNM_stage_append_carcinoid Surv_rates_appendix_CA TNM_staging_bone_tumors TNM_stage_breast_cancer Breast_reg_lymph_nodes 2002_TNM_breast_cancer Staging_cervical_cancer TNM_staging_colorec_CA CRC_tumor_regression_grade SEER_surv_adeno_colon SEER_surv_adeno_rectum Reg_nodes_colorec_CA CRC_resection_margin Staging_uterine_carcinoma Staging_uterine_sarcoma TNM_distal_cholangio TNM_staging_esoph_SCC TNM_staging_esoph_EGJ_adenoCA Esoph_CA_site T_stage_esophageal_cancer Staging_fallopian_cancer TNM_staging_gallbladder_CA OS_gallbladder_CA TNM_staging_GIST Dis_prog_gastric_GIST Dis_prog_small_int_GIST Staging_gest_trop_neoplas TNM_stage_hypopharynx TNM_small_bowel_cancer TNM_intrahep_cholangio SEER_surv_intrahep_cholang TNM_staging_RCC TNM_stage_larynx TNM_stage_oral_cavity TNM_staging_HCC 7th_TNM_lung_stage system Lung_CA staging_6th_TNM 7th_TNM_lung_CA_changes TNM_path_staging_mel_conj TNM_clin_staging_mel_conj Melanoma_7thTNM_stage_group Melanoma_7th_TNM_staging TNM_staging_muc_melanoma_HN Muc_melanoma_HN_stage_group Ciliary_choroid_thickness TNM_stage_uveal_melanoma TNM_stage_Merkel_cell_CA TNM_stage_sinonasal_sites TNM_stage_nasopharynx TNM_stage_gastric_carcinoid TNM_gastrointest_carcinoid TNM_amp_sm_bowel_carcinoid TNM_staging_CRC_carcinoid Surv_rates_GI_neuroendo Staging_ovar_prim_perit_ca TNM_panc_endo_exo_CA NCDB_no_surg_surv_panc NCDB_surg_surv_panc Prog_panc_neuroendo_tum TNM_staging_penile_cancer TNM_perihilar_cholangio TNM_stage_oropharynx TNM_stage_mesothelioma TNM_staging_prostate_CA TNM_group_prostate_CA TNM_staging_renal_pelvis TNM_stage_salivary_glands TNM_stage_sarcoma_orbit TNM_staging_soft_tis_sarc 2010_TNM_staging_STS TNM_stage_cutan_SCC 2010_TNM_staging_stomach_CA SEER_survival_gast_CA TMN_staging_testicular_CA Stage_group_testicular_CA TNM_staging_thyroid_cancer Urethral_CA_TNM_women TNM_stage_group_urethra Urethral_CA_TNM_men TNM_staging_bladder_CA Staging_vaginal_cancer Staging_vulvar_cancer</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=47182&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>NCDB_no_surg_surv_panc.htm</title></head></div><div class=\"graphic_reference\">Reference:<br> <ol> <li>Bilimoria KY, Bentrem DJ, Ko Cy, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007; 110(4):738-44, with permission of Wiley. </li> </ol> Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 59441 Version 11.0</div></div></div>"},"59444":{"type":"graphic_table","displayName":"Differential diagnosis of globus sensation","title":"Differential diagnosis of globus sensation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of&nbsp;globus sensation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Achalasia</td> </tr> <tr> <td>Hypertensive upper esophageal sphincter</td> </tr> <tr> <td>After uvulopalatoplasty</td> </tr> <tr> <td>Carcinoma of the base of the tongue</td> </tr> <tr> <td>Enlarged cervical lymph nodes</td> </tr> <tr> <td>Esophageal inlet patch</td> </tr> <tr> <td>Goiter</td> </tr> <tr> <td>Hiatal hernia</td> </tr> <tr> <td>Gastroesophageal reflux disease</td> </tr> <tr> <td>Hyperplastic tonsils</td> </tr> <tr> <td>Paraesophageal masses</td> </tr> <tr> <td>Postcricoid webs</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59444 Version 2.0</div></div></div>"},"59445":{"type":"graphic_diagnosticimage","displayName":"EUS fiducial placement","title":"EUS-guided fiducial placement for pancreatic tumor localization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">EUS-guided fiducial placement for pancreatic tumor localization</div><div class=\"cntnt\"><img style=\"width:432px; height:317px;\" src=\"images/GAST/59445_EUS_fiducial_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EUS&nbsp;image showing needle insertion into pancreatic tumor in preparation for fiducial placement.</div><div class=\"graphic_footnotes\">EUS: endoscopic ultrasound.</div><div class=\"graphic_reference\">Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.</div><div id=\"graphicVersion\">Graphic 59445 Version 4.0</div></div></div>"},"59446":{"type":"graphic_picture","displayName":"Hyperplast colonic polyp Light","title":"Hyperplastic colonic polyp","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperplastic colonic polyp</div><div class=\"cntnt\"><img style=\"width:441px; height:288px;\" src=\"images/GAST/59446_Hyperplast_colonic_polyp_Li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a hyperplastic colonic polyp shows a serrated surface contour and marked luminal infolding of the crypt epithelium.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 59446 Version 1.0</div></div><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Normal colon</div><div class=\"cntnt\"><img style=\"width:518px; height:172px;\" src=\"images/GAST/81083_Normal_colon_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 81083 Version 1.0</div></div></div>"},"59447":{"type":"graphic_table","displayName":"Types of bariatric procedures","title":"Types of bariatric procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of bariatric procedures</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Restrictive\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Vertical banded gastroplasty</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Laparoscopic adjustable gastric band</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sleeve gastrectomy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Malabsorptive\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Jejunoileal bypass</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Biliopancreatic diversion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Biliopancreatic diversion with duodenal switch</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Combination of restrictive and malabsorptive\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Roux-en-Y gastric bypass</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 59447 Version 1.0</div></div></div>"},"59449":{"type":"graphic_diagnosticimage","displayName":"Spiculated pulmonary nodule","title":"Spiculated pulmonary nodule in the right apex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spiculated pulmonary nodule in the right apex</div><div class=\"cntnt\"><img style=\"width:432px; height:263px;\" src=\"images/PULM/59449_Spiculated_pulm_nod_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right apical bronchogenic carcinoma presenting as a spiculated nodule surrounded by paracicatricial emphysema characteristic for a corona radiata.</div><div id=\"graphicVersion\">Graphic 59449 Version 2.0</div></div></div>"},"59451":{"type":"graphic_diagnosticimage","displayName":"Transverse distal phalanx fracture","title":"Transverse distal phalanx fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse distal phalanx fracture</div><div class=\"cntnt\"><img style=\"width:396px; height:169px;\" src=\"images/EM/59451_Trans_dist_phalanx_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse fractures are at greater risk of displacement. Widening of the fracture line (as seen here) may indicate entrapment of the nail bed.</div><div class=\"graphic_reference\">Reproduced with permission from: Henry M. Fractures and Dislocations of the Hand. In: Rockwood and Green's Fractures in Adults, 5th edition, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59451 Version 11.0</div></div></div>"},"59452":{"type":"graphic_figure","displayName":"Hypoglycemia and A1C","title":"Increased risk of hypoglycemia with strict glycemic control","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increased risk of hypoglycemia with strict glycemic control</div><div class=\"cntnt\"><img style=\"width:367px; height:237px;\" src=\"images/ENDO/59452_HypoglycemiaandHbA1c.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Diabetes Control and Complications Trial (DCCT), there was a progressive increase in the incidence of severe hypoglycemic episodes (per 100 patient-years) at lower attained A1C values during intensive insulin therapy in patients with type 1 diabetes.</div><div class=\"graphic_footnotes\">A1C: glycated hemoglobin.</div><div class=\"graphic_reference\">Data from: Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977.</div><div id=\"graphicVersion\">Graphic 59452 Version 4.0</div></div></div>"},"59453":{"type":"graphic_figure","displayName":"Time course of insulin action","title":"Effect of twice-daily insulin regimen","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Effect of twice-daily insulin regimen</div><div class=\"cntnt\"><img style=\"width:474px; height:248px;\" src=\"images/ENDO/59453_Time_course_of_insulin_acti.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twice-daily administration of regular (solid lines) and intermediate-acting lente or NPH (dashed lines) insulins before breakfast and the evening meal provides peaks of insulin after the injections as well as a relatively constant baseline level of insulin throughout the day after injections of the intermediate-acting insulins.</div><div class=\"graphic_footnotes\">NPH: neutral protamine hagedorn.</div><div id=\"graphicVersion\">Graphic 59453 Version 2.0</div></div></div>"},"59454":{"type":"graphic_figure","displayName":"Angle-closure glaucoma","title":"Acute angle-closure glaucoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute angle-closure glaucoma</div><div class=\"cntnt\"><img style=\"width:394px; height:294px;\" src=\"images/PEDS/59454_Angle-closure_glaucoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pupillary margin blocks the passage of aqueous from the posterior chamber to the anterior chamber (pupillary block), ballooning the iris forward (iris bombe), causing the iris root to occlude the trabecular meshwork and completely obstruct drainage of aqueous fluid from the anterior chamber (angle closure). The resulting rapid elevation of intraocular pressure requires urgent intervention to prevent permanent visual loss.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD. The Physician's Guide to Eye Care. Foundation of the American Academy of Ophthalmology, San Francisco, 2001. p.158. Copyright &copy; American Academy of Ophthalmology.</div><div id=\"graphicVersion\">Graphic 59454 Version 3.0</div></div></div>"},"59455":{"type":"graphic_table","displayName":"Causes DIC children","title":"Causes of disseminated intravascular coagulation in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of disseminated intravascular coagulation in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td>Bacteria - Meningococcus, Gram positive and negative bacterial sepsis</td> </tr> <tr> <td>Virus - Human immunodeficiency virus, Varicella-zoster, cytomegalovirus (CMV), Dengue fever, Ebola virus</td> </tr> <tr> <td>Fungal - Candida, Aspergillus</td> </tr> <tr> <td>Rickettsia - Rocky Mountain Spotted fever</td> </tr> <tr> <td>Malaria</td> </tr> <tr> <td class=\"subtitle1_single\">Injury</td> </tr> <tr> <td>Brain injury</td> </tr> <tr> <td>Crush injury</td> </tr> <tr> <td>Massive burns</td> </tr> <tr> <td>Extensive surgery</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr> <td>Acute promyelocytic leukemia</td> </tr> <tr> <td>Acute lymphoblastic leukemia</td> </tr> <tr> <td class=\"subtitle1_single\">Microangiopathic disorders</td> </tr> <tr> <td>Giant hemangioma - Kasabach-Merritt syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal disease</td> </tr> <tr> <td>Acute and chronic liver disease</td> </tr> <tr> <td>Reye syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Neonatal causes</td> </tr> <tr> <td>Birth asphyxia</td> </tr> <tr> <td>Respiratory distress syndrome</td> </tr> <tr> <td>Meconium aspiration</td> </tr> <tr> <td>Amniotic fluid aspiration</td> </tr> <tr> <td>Necrotizing enterocolitis</td> </tr> <tr> <td>Congenital infections - Neonatal CMV, Herpes simplex virus, bacterial or fungal infections</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital thrombotic disorders</td> </tr> <tr> <td>Homozygous deficiencies of proteins C and S</td> </tr> <tr> <td>Antithrombin III deficiency</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Wendy Wong, MD and Bertil Glader MD, PhD.</div><div id=\"graphicVersion\">Graphic 59455 Version 2.0</div></div></div>"},"59459":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum - early lesion","title":"Early lesion of pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early lesion of pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/59459_Pyod_gangr_early_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pustule on an erythematous base represents an early lesion of pyoderma gangrenosum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59459 Version 3.0</div></div></div>"},"59460":{"type":"graphic_table","displayName":"Birth attendant home birth","title":"Birth attendant and race/ethnicity, US Planned Home Births, 47 states, 2014","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Birth attendant and race/ethnicity, US Planned Home Births, 47 states, 2014</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Medical doctor or doctor of osteopathy<br /> (percent)</td> <td class=\"subtitle1\">Certified nurse midwife<br /> (percent)</td> <td class=\"subtitle1\">Other midwife<br /> (percent)</td> <td class=\"subtitle1\">Other<br /> (percent)</td> <td class=\"subtitle1\">Total<br /> (percent)</td> <td class=\"subtitle1\">Number*</td> </tr> <tr> <td>All</td> <td>0.9</td> <td>28.0</td> <td>49.6</td> <td>21.5</td> <td>100</td> <td><strong>28,367</strong></td> </tr> <tr> <td>White, non-Hispanic</td> <td>0.8</td> <td>27.7</td> <td>49.8</td> <td>21.7</td> <td>100</td> <td><strong>25,752</strong></td> </tr> <tr> <td>Black, non-Hispanic</td> <td>1.9</td> <td>31.0</td> <td>41.1</td> <td>26.0</td> <td>100</td> <td><strong>589</strong></td> </tr> <tr> <td>Hispanic</td> <td>2.0</td> <td>29.7</td> <td>56.3</td> <td>11.0</td> <td>100</td> <td><strong>1430</strong></td> </tr> <tr class=\"divider_bottom\"> <td>All other</td> <td>1.7</td> <td>30.4</td> <td>49.8</td> <td>18.1</td> <td>100</td> <td><strong>596</strong></td> </tr> <tr> <td><strong>Number*</strong></td> <td><strong>250</strong></td> <td><strong>7929</strong></td> <td><strong>14,184</strong></td> <td><strong>6004</strong></td> <td><strong>&ndash;</strong></td> <td><strong>28,637</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Excludes cases where either attendant or race/ethnicity is unspecified.</div><div class=\"graphic_reference\">Source: National Center for Health Statistics. VitalStats website. Birth data 2014 state and county files. <A href=\"http://www.cdc.gov/nchs/VitalStats.htm\">http://www.cdc.gov/nchs/VitalStats.htm</A> (Accessed January 5, 2016).</div><div id=\"graphicVersion\">Graphic 59460 Version 19.0</div></div></div>"},"59461":{"type":"graphic_picture","displayName":"Vulvar lichen sclerosus with purpura 2","title":"Vulvar lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:210px; height:432px;\" src=\"images/OBGYN/59461_LS_purp_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severely itchy lichen sclerosus in a figure of 8 pattern around vulva and perianal area with loss of clitoris and labia minora. Swollen, irritated hemorrhoidal tags are seen. Typical white shiny lichen sclerosus changes are visible with purpura and erosions from scratching.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD,&nbsp;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 59461 Version 6.0</div></div></div>"},"59464":{"type":"graphic_diagnosticimage","displayName":"Post fossa ependymoma MRI Gad","title":"Posterior fossa ependymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior fossa ependymoma</div><div class=\"cntnt\"><img style=\"width:310px; height:323px;\" src=\"images/ONC/59464_Post_fossa_ependymoma_MRI_G.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1 weighted axial MR image demonstrating a posterior fossa lesion that enhances with gadolinium.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Mark Kieran, MD.</div><div id=\"graphicVersion\">Graphic 59464 Version 5.0</div></div></div>"},"59465":{"type":"graphic_figure","displayName":"Bicycle helmet fit PI","title":"Bicycle helmet fit","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bicycle helmet fit</div><div class=\"cntnt\"><img style=\"width:197px; height:270px;\" src=\"images/PI/59465_Bicycle_helmet_fit_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A properly fitting bicycle helmet should rest just above the eyebrows and not slide around on the head. The straps of the helmet should be adjusted to form a &quot;Y&quot; just under the ear of the child. The chin strap should be snug enough to pull down on the helmet when the child opens the mouth wide.</div><div id=\"graphicVersion\">Graphic 59465 Version 1.0</div></div></div>"},"59467":{"type":"graphic_figure","displayName":"Sperm count at conception secondary hypogonadism","title":"Sperm count at conception in men with secondary hypogonadism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sperm count at conception in men with secondary hypogonadism</div><div class=\"cntnt\"><img style=\"width:252px; height:273px;\" src=\"images/ENDO/59467_Sperm_count_at_conception_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean sperm concentration at the time of first pregnancy (left) and subsequent pregnancies (right) in men with IHH (secondary hypogonadism). The horizontal bars represent the mean for each group and the shaded area represents the conventional range of normal. Pregnancy was often achieved at sperm counts well below normal.</div><div class=\"graphic_footnotes\">IHH: isolated hypogonadotropin hypogonadism.</div><div class=\"graphic_reference\">Data from: Burris AS, Clark RV, Vantman DJ, Sherins RJ. A low sperm concentration does not preclude fertility in men with isolated hypogonadotropic hypogonadism after gonadotropin therapy.&nbsp;Fertil Steril 1988; 50:343.</div><div id=\"graphicVersion\">Graphic 59467 Version 3.0</div></div></div>"},"59470":{"type":"graphic_table","displayName":"ESA Adult dosing guidelines","title":"Dosing guidelines for epoetin and darbepoetin in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing guidelines for epoetin and darbepoetin in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Three times weekly dosing</td> <td class=\"subtitle1\">Weekly dosing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Epoetin Alfa</td> </tr> <tr> <td class=\"indent1\">Starting dose (adults):</td> <td>150 units/kg subcutaneously (SC) three times weekly</td> <td>40,000 units SC</td> </tr> <tr> <td class=\"indent1\">Reduce dose by 25 percent if:</td> <td colspan=\"2\">Hemoglobin reaches a level needed to avoid transfusion or increases &#62;1 g/dL in any two-week period.</td> </tr> <tr> <td class=\"indent1\">Withhold dose if:</td> <td colspan=\"2\">Hemoglobin exceeds a level needed to avoid red blood cell (RBC) transfusion; restart at 25 percent below the previous dose when the hemoglobin approaches a level where transfusions may be required.</td> </tr> <tr> <td class=\"indent1\">Increase dose:</td> <td>To 300 units/kg SC three times weekly, if response is not satisfactory (rise in hemoglobin &#60;1 g/dL after four weeks of therapy and remains below 10 g/dL) to achieve and maintain the lowest hemoglobin level sufficient to avoid the need for RBC transfusion.</td> <td>To 60,000 units SC weekly, if response is not satisfactory (rise in hemoglobin &#60;1 g/dL after four weeks of therapy and remains below 10 g/dL) to achieve and maintain the lowest hemoglobin level sufficient to avoid the need for RBC transfusion.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Discontinue if:</td> <td colspan=\"2\">After completion of chemotherapy course, or if after eight weeks of therapy there is no response as measured by hemoglobin levels or if transfusions are still required.</td> </tr> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Weekly dosing</td> <td class=\"subtitle1\">Once every three weeks dosing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Darbepoetin Alfa</td> </tr> <tr> <td class=\"indent1\">Starting dose (adults):</td> <td>2.25 microgram/kg SC once weekly</td> <td>500 micrograms SC every three weeks</td> </tr> <tr> <td class=\"indent1\">Reduce dose by 40 percent if:</td> <td colspan=\"2\">Hemoglobin exceeds a level needed to avoid transfusion, or increases &#62;1 g/dL in any two-week period.</td> </tr> <tr> <td class=\"indent1\">Withhold dose if:</td> <td colspan=\"2\">The hemoglobin exceeds a level needed to avoid RBC transfusion; restart at 40 percent below the previous dose when the hemoglobin approaches a level where transfusions may be required.</td> </tr> <tr> <td class=\"indent1\">Increase dose:</td> <td>To 4.5 microgram/kg, if response is not satisfactory (no reduction in transfusion requirements or rise in hemoglobin by &#60;1 g/dL after six weeks of therapy in the absence of a RBC transfusion) to achieve and maintain the lowest hemoglobin level sufficient to avoid the need for RBC transfusion.</td> <td>N/A</td> </tr> <tr> <td class=\"indent1\">Discontinue if:</td> <td colspan=\"2\">After completion of chemotherapy course, or if after eight weeks of therapy there is no response as measured by hemoglobin levels or if transfusions are still required.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: US Food and Drug Administration.</div><div id=\"graphicVersion\">Graphic 59470 Version 6.0</div></div></div>"},"59471":{"type":"graphic_table","displayName":"Annual testing for hematopoietic cell transplantation survivors","title":"Annual testing for hematopoietic cell transplantation survivors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Annual testing for hematopoietic cell transplantation survivors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Blood tests</td> </tr> <tr> <td class=\"subtitle2_single\">Hematology</td> </tr> <tr> <td class=\"indent1\">Complete blood count with differential</td> </tr> <tr> <td class=\"subtitle2_single\">Hepatic</td> </tr> <tr> <td class=\"indent1\">Liver function tests</td> </tr> <tr> <td class=\"indent1\">Serum ferritin (if iron overload suspected; not required if previously normal and no longer receiving blood transfusions)</td> </tr> <tr> <td class=\"indent1\">Hepatitis B surface antigen and hepatitis B/C viral load (in patients with known hepatitis B or C)</td> </tr> <tr> <td class=\"indent1\">Consider liver biopsy in patients with known chronic hepatitis C after 8 to 10 years</td> </tr> <tr> <td class=\"subtitle2_single\">Renal</td> </tr> <tr> <td class=\"indent1\">Urinalysis and urine microalbumin</td> </tr> <tr> <td class=\"indent1\">Kidney function testing (BUN/creatinine)</td> </tr> <tr> <td class=\"subtitle2_single\">Endocrine</td> </tr> <tr> <td class=\"indent1\">Fasting lipid profile*</td> </tr> <tr> <td class=\"indent1\">Vitamin D level</td> </tr> <tr> <td class=\"indent1\">Thyroid stimulating hormone and free T4</td> </tr> <tr> <td class=\"indent1\">Fasting glucose and hemoglobin A1c</td> </tr> <tr> <td class=\"indent1\">Testosterone (male)</td> </tr> <tr> <td class=\"indent1\">Follicle-stimulating hormone&nbsp;and luteinizing hormone (female)</td> </tr> <tr> <td class=\"subtitle2_single\">Immunology/infectious disease</td> </tr> <tr> <td class=\"indent1\">CD4 count (to be done&nbsp;one year post transplant)</td> </tr> <tr> <td class=\"indent1\">Immunoglobulin levels</td> </tr> <tr> <td class=\"subtitle1_single\">Radiology and other tests/interventions</td> </tr> <tr> <td class=\"indent1\">Electrocardiogram (optional)</td> </tr> <tr> <td class=\"indent1\">Echocardiogram or exercise stress testing (optional)</td> </tr> <tr> <td class=\"indent1\">Pulmonary function testing and&nbsp;diffusing capacity for carbon monoxide (if previously abnormal)</td> </tr> <tr> <td class=\"indent1\">Bone densitometry (at one year)</td> </tr> <tr> <td class=\"indent1\">Opthalmologic evaluation: Schirmer test and intraocular pressure measurement (at one year)</td> </tr> <tr> <td class=\"indent1\">Review of immunization status</td> </tr> <tr> <td class=\"indent1\">Dental examination</td> </tr> <tr> <td class=\"indent1\">Review smoking status</td> </tr> <tr> <td class=\"indent1\">Second cancer vigilance counseling and age-appropriate cancer screening</td> </tr> <tr> <td class=\"indent1\">Blood pressure screening</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen.<br />*Patients with ongoing risk factors (including those receiving sirolimus, calcineurin inhibitors, and corticosteroids) should undergo evaluation of lipid profiles every three to six months.</div><div id=\"graphicVersion\">Graphic 59471 Version 9.0</div></div></div>"},"59472":{"type":"graphic_table","displayName":"University of Washington Burn Center Pain Medication Guidelines","title":"University of Washington Burn Center Pain Medication Guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">University of Washington Burn Center Pain Medication Guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Critical care treatment (without oral intake)</td> <td class=\"subtitle1\">Critical care treatment (with oral intake)</td> <td class=\"subtitle1\">Non-critical care treatment (large open areas)</td> <td class=\"subtitle1\">Non-critical care treatment (small open areas/predischarge)</td> </tr> <tr> <td><strong>Background pain</strong></td> <td>Continuous morphine sulfate (IV) drip or scheduled doses or PCA</td> <td>Scheduled methadone or extended-release morphine or PCA</td> <td>Scheduled methadone or extended-release morphine or PCA</td> <td>Scheduled NSAIDs/acetaminophen, oxycodone or none</td> </tr> <tr> <td><strong>Procedural pain</strong></td> <td> <p>General or regional anesthesia or deep sedation for severe pain</p> <p>Morphine sulfate (IV), fentanyl (IV), ketamine and dexmedetomidine (IV)</p> </td> <td>Oxycodone, fentanyl IV, or oral transmucosal fentanyl or ketamine</td> <td>Oxycodone, fentanyl (IV), nitrous oxide (IH), or oral transmucosal fentanyl or ketamine or propofol</td> <td>Oxycodone or ketamine or propofol</td> </tr> <tr> <td><strong>Breakthrough pain</strong></td> <td>Morphine sulfate (IV) or fentanyl (IV)</td> <td>Oxycodone</td> <td>Oxycodone</td> <td>NSAIDs/acetaminophen or oxycodone</td> </tr> <tr> <td><strong>Postoperative pain</strong></td> <td>Continuous morphine sulfate (IV) drip or scheduled doses or PCA</td> <td>Scheduled methadone or extended-release morphine or PCA</td> <td>Scheduled methadone or extended-release morphine or PCA</td> <td>Scheduled NSAIDs/acetaminophen, oxycodone or none</td> </tr> <tr> <td><strong>Chronic pain</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Gabapentin or other nonopiods or antidepressants</td> <td>Gabapentin or anxiolysis or NSAIDS or antidepressants</td> </tr> <tr> <td><strong>Anxiolysis medications for background and/or procedure management</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Background anxiolysis</strong></td> <td>Scheduled lorazepam (IV) or continuous lorazepam (IV) drip</td> <td>Scheduled lorazepam</td> <td>None or scheduled lorazepam</td> <td>None</td> </tr> <tr> <td><strong>Procedural anxiolysis</strong></td> <td>Lorazepam or midazolam (IV)</td> <td>Lorazepam</td> <td>None or lorazepam</td> <td>None</td> </tr> <tr> <td><strong>Post-hospitalization pain control</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Discharge or transfer pain medications</strong></td> <td>N/A</td> <td>For transfer to non-critical care treatment: wean drips; establish PO pain medication early; anticipate dose tapering as needs decrease</td> <td>Oxycodone for procedural pain; methadone taper or extended-release morphine; taper if applicable</td> <td>Oxycodone or NSAIDs for procedural pain</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Representative pain and sedation management guideline for adult (nonpediatric, nongeriatric) burn patients from the University of Washington Burn Center. General medication recommendations are provided for specific pain and anxiolysis needs encountered in various intensive care units and ward-care settings. Medication options are intentionally limited (for simplicity) and do not include specific dose recommendations (to allow for individual patient variability). Complex or refractory cases are managed through special consultation with the burn care team and/or pain specialists.</div><div class=\"graphic_footnotes\">PCA: patient-controlled analgesia; IV: intravenously; NSAIDs: nonsteroidal antiinflammatory drugs; IH: inhalation.</div><div id=\"graphicVersion\">Graphic 59472 Version 6.0</div></div></div>"},"59473":{"type":"graphic_diagnosticimage","displayName":"Healing transverse fracture of little toe","title":"Healing transverse fracture of little toe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Healing transverse fracture of little toe</div><div class=\"cntnt\"><img style=\"width:381px; height:388px;\" src=\"images/EM/59473_Healing_trans_fx_prox_phala.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AP view (panel A) and oblique view (panel B). Note the easily seen calcific density adjacent to both sides of the fracture site (arrow), indicating the presence of callus. A more subtle sign of callus formation is seen in panel B: diffuse increased bony density overlying the fracture site (arrowhead).</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 59473 Version 5.0</div></div></div>"},"59474":{"type":"graphic_diagnosticimage","displayName":"Radiographs of depressed skull fracture","title":"Depressed skull fracture","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Depressed skull fracture</div><div class=\"cntnt\"><img style=\"width:500px; height:499px;\" src=\"images/EM/59474_Skull_fx_depressed_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depressed skull fracture with intracerebral hemorrhage.<br />(A) Lateral radiograph shows a comminuted depressed fracture in the parietal region (arrows).<br />(B) CT image using bone windows shows the depressed fragment (arrow).<br />(C) Same image using brain windows shows multiple areas of intracranial hemorrhage (arrows) adjacent to the fracture.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.</div><div id=\"graphicVersion\">Graphic 59474 Version 3.0</div></div></div>"},"59475":{"type":"graphic_figure","displayName":"Swan Ganz balloon inflation","title":"Balloon inflation of pulmonary artery catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balloon inflation of pulmonary artery catheter</div><div class=\"cntnt\"><img style=\"width:264px; height:384px;\" src=\"images/PULM/59475_Swan_Ganz_balloon_inflation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic diagram shows the appearance of a pulmonary artery (Swan-Ganz) catheter tip with the balloon at full inflation (top) and at less than full inflation (bottom). The tip of the catheter protrudes beyond the balloon when the balloon is less than fully inflated.</div><div id=\"graphicVersion\">Graphic 59475 Version 1.0</div></div></div>"},"59476":{"type":"graphic_table","displayName":"Differential diagnosis of Marfan syndrome","title":"Differential diagnosis of Marfan syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of Marfan syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Differential diagnosis</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Features similar to Marfan syndrome</td> <td class=\"subtitle1\">Discriminating features</td> </tr> <tr> <td>Loeys-Dietz syndrome (LDS)</td> <td>TGFBR1/2</td> <td>Aortic aneurysm/dissection</td> <td>Bifid uvula/cleft palate, arterial tortuosity, hypertelorism, diffuse aortic and arterial aneurysms, craniosynostosis, clubfoot, cervical spine instability, thin and velvety skin, easy bruising</td> </tr> <tr> <td>Shprintzen-Goldberg syndrome (SGS)</td> <td>FBN1 and other</td> <td>Pectus abnormalities, scoliosis, arachnodactyly</td> <td>Craniosynostosis, mental retardation</td> </tr> <tr> <td>MASS phenotype*</td> <td>FBN1* and other</td> <td>Mitral valve prolapse, mild aortic dilatation, striae atrophica, and at least one skeletal feature; systemic score &#8805;5</td> <td>Aortic root size Z&#60;2; no ectopia lentis</td> </tr> <tr> <td>Mitral valve prolapse syndrome</td> <td>Several candidate gene loci</td> <td>Mitral valve prolapse, pectus excavatum, scoliosis, mild arachnodactyly</td> <td>Lack of aortic enlargement, lack of ectopia lentis, systemic score &#60;5</td> </tr> <tr> <td>Congenital contractural arachnodactyly (CCA)</td> <td>FBN2</td> <td>Marfanoid habitus, arachnodactyly, kyphosis/scoliosis, mild enlargement of the sinuses of Valsalva</td> <td>Crumpled ears (folded upper helix), contractures of major joints (knees and ankles) at birth, flexion contractures of the proximal interphalangeal joints (camptodactyly), absence of aortic dissection or rupture</td> </tr> <tr> <td>Weill-Marchesani syndrome (WMS)</td> <td>FBN1 and ADAMTS10</td> <td>Ectopia lentis</td> <td>Microspherophakia, brachydactyly, joint stiffness</td> </tr> <tr> <td>Ectopia lentis syndrome (ELS)</td> <td>FBN1, LTBP2, ADAMTSL4</td> <td>Ectopia lentis, may have mild skeletal findings</td> <td>Lack of aortic root dilatation</td> </tr> <tr> <td>Familial thoracic aortic aneurysm and dissection syndrome (FTAAD/FTAA)</td> <td>TGFBR1/2, ACTA2</td> <td>Aortic dilatation and dissection</td> <td>Livedo reticularis, iris flocculi, lack of Marfanoid skeletal features</td> </tr> <tr> <td>FTAAD with bicuspid aortic valve</td> <td>ACTA2</td> <td>Aortic aneurysm and dissection</td> <td>Livedo reticularis, iris flocculi, cerebral aneurysm, premature ischemic strokes, Moyamoya disease, premature coronary artery disease, bicuspid aortic valve, patent ductus arteriosus</td> </tr> <tr> <td>FTAAD with patent ductus arteriosus</td> <td>MYH11</td> <td>Aortic root aneurysm</td> <td>Patent ductus arteriosus</td> </tr> <tr> <td>Homocystinuria</td> <td>CBS</td> <td>Marfanoid habitus, ectopia lentis</td> <td>Thrombosis, mental retardation</td> </tr> <tr> <td>Arterial tortuosity syndrome (ATS)</td> <td>SLC2A10</td> <td>Aortic aneurysm</td> <td>Generalized arterial tortuosity, arterial stenosis, facial dysmorphism</td> </tr> <tr> <td>Ehlers-Danlos syndrome (vascular type)</td> <td>COL3A1</td> <td>Aortic aneurysm/dissection occurs in some</td> <td>Middle sized artery aneurysm, translucent skin, dystrophic scars, intestinal or uterine rupture</td> </tr> <tr> <td>Ehlers-Danlos syndrome (cardiac valvular subtype)</td> <td>COL1A2</td> <td>Mitral valve prolapse, joint hypermobility</td> <td>Severe aortic and/or mitral valvular regurgitation, atrophic scars, skin hyperelasticity</td> </tr> <tr> <td>Ehlers-Danlos syndrome (kyphoscoliotic type)</td> <td>PLOD1</td> <td>Aortic dilatation/dissection, kyphoscoliosis, joint laxity</td> <td>Middle sized artery aneurysm/rupture</td> </tr> <tr> <td>Stickler syndrome (hereditary arthroophthalmopathy)</td> <td>COL2A1, COL11A1</td> <td>Marfinoid habitus, mitral valve prolapse, retrognathia</td> <td>Vitreal degeneration, retinal detachment, myopia, open angle glaucoma, early cataracts, cleft palate, hearing loss, epiphysial changes</td> </tr> <tr> <td>Klinefelter's syndrome </td> <td>47,XXY (and other X&#62;1 genotypes in men)</td> <td>Marfanoid habitus</td> <td>Small testes and genitalia, cognitive impairment</td> </tr> <tr> <td>Congenital bicuspid aortic valve disease with associated aortopathy</td> <td>NOTCH1, KCNJ2, and putative loci on chromosomes 18q, 5q and 13q</td> <td>Ascending aortic aneurysm, some have pectus deformity, scoliosis</td> <td>Bicuspid aortic valve (may occur together with or separately from aortic aneurysm in various family members); lack of ocular and other systemic findings of Marfan syndrome; aortic dilatation is commonly maximal or exclusively above the sinotubular junction</td> </tr> <tr> <td>Aortic coarctation with associated ascending aortic enlargement</td> <td>NOTCH1, ERBB4, largely unknown</td> <td>Aortic dilatation</td> <td>Coarctation of the aorta</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TGFBR: TGF-beta receptor.<BR>* An individual with MASS phenotype with an FBN1 mutation may subsequently transition to Marfan syndrome, but the probability of such transition is not known.</div><div class=\"graphic_reference\">Adapted in part from: Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010; 47:476.</div><div id=\"graphicVersion\">Graphic 59476 Version 4.0</div></div></div>"},"59477":{"type":"graphic_picture","displayName":"Rose Bengal stain in Sjogrens","title":"Rose bengal stain of the cornea and conjunctiva in Sjögren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rose bengal stain of the cornea and conjunctiva in Sj&#246;gren's syndrome</div><div class=\"cntnt\"><img style=\"width:327px; height:218px;\" src=\"images/RHEUM/59477_Rose_Bengal_stain_in_Sjogre.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Rose Bengal stain stains areas of devitalized tissue (seen as a purple color) and can, therefore, detect end-organ damage to conjunctival and corneal epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Oliver Schein, MD.</div><div id=\"graphicVersion\">Graphic 59477 Version 2.0</div></div></div>"},"59478":{"type":"graphic_picture","displayName":"Histologic changes in thromboangiitis obliterans ","title":"Histologic changes in thromboangiitis obliterans ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic changes in thromboangiitis obliterans </div><div class=\"cntnt\"><img style=\"width:350px; height:470px;\" src=\"images/SURG/59478_Buergers_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three phases of thromboangiitis obliterans have been described pathologically. In the acute phase (shown above), occlusive inflammatory thrombus develop within the vessel. Polymorphonuclear leukocytes, micro-abscesses, and multinucleated giant cells may also be present. The intermediate phase is characterized by progressive organization of the thrombus. In the chronic phase, only organized thrombus and fibrosis remain; the inflammation is no longer present.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin, E, Farber, JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59478 Version 3.0</div></div></div>"},"59479":{"type":"graphic_figure","displayName":"Trend of induction therapy in pediatric renal transplantation","title":"Choice of antibody induction therapy in pediatric renal transplantation over time","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Choice of antibody induction therapy in pediatric renal transplantation over time</div><div class=\"cntnt\"><img style=\"width:596px; height:406px;\" src=\"images/PEDS/59479_Induction_therapy_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the North American Pediatric Renal Transplant Collaborative Trials and Studies on the use of various antibody induction therapy in pediatric renal transplantation from 1996 through 2013.</div><div class=\"graphic_footnotes\">ATG: antithymocyte globulin; ALG: antilymphocyte globulin.</div><div class=\"graphic_reference\">Reproduced with permission from: North American Pediatric Renal Transplant Collaborative Trials and Studies. 2014 Annual Report. Copyright &copy; 2014 NAPRTCS.</div><div id=\"graphicVersion\">Graphic 59479 Version 4.0</div></div></div>"},"59480":{"type":"graphic_table","displayName":"Normal high blood pressure definitions PI","title":"Definition of normal and high blood pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of normal and high blood pressure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Level</td> <td class=\"subtitle1\"><span style=\"color: black;\">Top number</span></td> <td class=\"subtitle1\"><span style=\"color: black;\">Bottom number</span></td> </tr> <tr> <td><span style=\"color: black;\">High</span></td> <td><span style=\"color: black;\">130 or above</span></td> <td><span style=\"color: black;\">80 or above</span></td> </tr> <tr> <td><span style=\"color: black;\">Elevated</span></td> <td><span style=\"color: black;\">120 to 129</span></td> <td><span style=\"color: black;\">79 or below</span></td> </tr> <tr> <td><span style=\"color: black;\">Normal</span></td> <td><span style=\"color: black;\">119 or below</span></td> <td><span style=\"color: black;\">79 or below</span></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">\"Elevated blood pressure\" is a term doctor or nurses use as a warning.&nbsp;It means you&nbsp;do not yet have high blood pressure, but&nbsp;your blood pressure is not as low as it should be for good health</SPAN>.</div><div id=\"graphicVersion\">Graphic 59480 Version 4.0</div></div></div>"},"59484":{"type":"graphic_diagnosticimage","displayName":"SLS MRS","title":"Brain MRI and MR spectroscopy (MRS) of a 5-year-old with Sjogren-Larsson syndrome","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Brain MRI and MR spectroscopy (MRS) of a 5-year-old with Sjogren-Larsson syndrome</div><div class=\"cntnt\"><img style=\"width:501px; height:239px;\" src=\"images/NEURO/59484_SLS_MRS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Image shows voxel locations in the occipital trigone (Box A) and in the central occipital gray matter (Box B). <br />(B) Proton MR spectra (TE = 20 msec) obtained from cerebral white matter (Spectrum C) and gray matter (Spectrum D). Note the presence of the high, sharp lipid peak at 1.3 ppm and a small peak at 0.8 to 0.9 ppm in the spectrum obtained from the white matter.</div><div class=\"graphic_footnotes\">MR: magnetic resonance; TE: echo time.</div><div class=\"graphic_reference\">Reproduced with permission from: Willemsen MA, Van Der Graaf M, Van Der Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004; 25:649. Copyright &copy;2004 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 59484 Version 3.0</div></div></div>"},"59486":{"type":"graphic_picture","displayName":"Morquio syndrome","title":"Mucopolysaccharidosis type IV A (MPS IV A, Morquio syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucopolysaccharidosis type IV A (MPS IV A, Morquio syndrome)</div><div class=\"cntnt\"><img style=\"width:410px; height:256px;\" src=\"images/PEDS/59486_Morquio_syndrome_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Children with Morquio syndrome, showing typical bony features including a protuberant chest (pectus carinatum), deformed and misshapen long bones, extreme short stature, and knock-knee deformity (genu valgum).</div><div class=\"graphic_reference\">Reproduced with permission from: Neufeld, E, Muenzer, J. The Mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver, CR, Beaudet, AL, Valle, D, et al (Eds), McGraw-Hill, New York 2001. Copyright &#169; 2001 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 59486 Version 4.0</div></div></div>"},"59487":{"type":"graphic_diagnosticimage","displayName":"MRI pancreatic neuroendocrine tumor","title":"T1-weighted MRI image of a neuroendocrine tumor of the pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T1-weighted MRI image of a neuroendocrine tumor of the pancreas</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ONC/59487_MRI_islet_cell_tumor_pancr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Malignant neuroendocrine tumor of the pancreas. T1-weighted gradient echo image of abdomen demonstrates mass (arrow) near junction of pancreatic body and tail. Note that mass (arrow) is lower in signal intensity than adjacent normal pancreatic parenchyma (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Leyendecker JR, Brown JJ. Practical Guide to Abdominal and Pelvic MRI. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59487 Version 5.0</div></div></div>"},"59489":{"type":"graphic_picture","displayName":"Skin bx pyoderma gangrenosum","title":"Pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:324px; height:221px;\" src=\"images/GAST/59489_Skin_bx_pyoderma_gangrenosu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy in pyoderma gangrenosum showing a diffuse neutrophilic infiltrate with dermolysis.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 59489 Version 1.0</div></div></div>"},"59492":{"type":"graphic_table","displayName":"Classification of teratomas","title":"Classification of extragonadal teratomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of extragonadal teratomas</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">I. Benign teratomas</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Mature\nteratoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Grade 0 - All component tissues appear well\ndifferentiated</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Grade 1 - Occasional microscopic foci contain\nincompletely differentiated tissues, not exceeding 10 percent of the\nsampled surface</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Immature\nteratoma, benign</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Grade 2 - Immature tissues make up between 10 and 50\npercent of the sampled tumor surface</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Grade 3 - Over half of the surface examined is composed\nof undifferentiated tissues of uncertain metastatic potential; a benign\ncourse is still possible</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">II. Malignant\nteratomas</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">With\nareas of germ cell tumor</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Germinoma (seminoma, dysgerminoma)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Embryonal carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Choriocarcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Yolk sac tumor</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Mixed (any combination of the above)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">With\nnongerminal malignant tumor pattern</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Sarcoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Malignant embryonal tumor</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Mixed</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Immature\nteratoma, malignant</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">A teratoma that would otherwise be classified as benign\nimmature teratoma, but which subsequently became metastatic</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Gonzalez-Crussi, F. Atlas of Tumor Pathology: Extragonadal Teratomas, 2nd ed, Armed Forces Institute of Pathology, Washington, DC, 1982.</div><div id=\"graphicVersion\">Graphic 59492 Version 1.0</div></div></div>"},"59493":{"type":"graphic_diagnosticimage","displayName":"Lat tibial avulsion fract","title":"Avulsion fracture of the lateral tibial condyle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Avulsion fracture of the lateral tibial condyle</div><div class=\"cntnt\"><img style=\"width:335px; height:385px;\" src=\"images/RHEUM/59493_Lat_tibial_avulsion_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior view of the knee demonstrates a small avulsion fracture of the lateral tibial condyle (arrow), consistent with a Segond fracture.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 59493 Version 2.0</div></div></div>"},"59494":{"type":"graphic_figure","displayName":"Pravastatin for primary prevention of coronary heart disease","title":"Pravastatin for primary prevention of coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pravastatin for primary prevention of coronary heart disease</div><div class=\"cntnt\"><img style=\"width:364px; height:477px;\" src=\"images/CARD/59494_Pravastatin_prevents_CHD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis of the efficacy of pravastatin versus placebo in 6595 middle-aged men with hypercholesterolemia (mean serum cholesterol concentration 272 mg/dL [7.0 mmol/L]). At the end of the study, the men treated with pravastatin (red line) had a 32% reduction in definite nonfatal MI or death from CHD (top panel) and a 22% reduction in death from any cause (lower panel).</div><div class=\"graphic_footnotes\">MI: myocardial infarction; CHD: coronary heart disease.</div><div class=\"graphic_reference\">Data from: Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301.</div><div id=\"graphicVersion\">Graphic 59494 Version 7.0</div></div></div>"},"59495":{"type":"graphic_diagnosticimage","displayName":"Grisel syndrome","title":"Grisel syndrome with atlantoaxial subluxation and torticollis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grisel syndrome with atlantoaxial subluxation and torticollis</div><div class=\"cntnt\"><img style=\"width:360px; height:332px;\" src=\"images/EM/59495_Gisel_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography of the cervical spine showing atlantoaxial cervical spine subluxation in a child caused by inflammation after adenoidectomy.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 59495 Version 5.0</div></div></div>"},"59499":{"type":"graphic_table","displayName":"Rx of orthostatic hypotension","title":"Management of chronic orthostatic hypotension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of chronic orthostatic hypotension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Correct precipitating factors (eg, hypovolemia) and withdraw offending drugs (diuretics, vasodilators, tranquilizers and sedatives)</td> </tr> <tr> <td class=\"subtitle1_single\">Physical measures</td> </tr> <tr> <td class=\"indent1\">Raise the head of the bed by 10 to 20&#176;</td> </tr> <tr> <td class=\"indent1\">Arise slowly, in stages, from supine to seated to standing</td> </tr> <tr> <td class=\"indent1\">Dorsiflexion of the feet, handgrip isometric, leg crossing/squatting before standing</td> </tr> <tr> <td class=\"indent1\">Liberalize salt and fluid intake</td> </tr> <tr> <td class=\"indent1\">Small meals and coffee only in the early morning</td> </tr> <tr> <td class=\"indent1\">Fitted compression&nbsp;stockings and pressure suits (often not acceptable)</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Fludrocortisone </td> </tr> <tr> <td class=\"indent1\">Sympathomimetic drugs - midodrine</td> </tr> <tr> <td class=\"sublist2_start\">Supplementary agents</td> </tr> <tr> <td class=\"sublist2\">Erythropoietin (if anemic)</td> </tr> <tr> <td class=\"sublist2\">Caffeine</td> </tr> <tr> <td class=\"sublist2\">Pyridostigmine</td> </tr> <tr> <td class=\"sublist2\">Nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td class=\"sublist2_start\">Third-line and experimental drugs</td> </tr> <tr> <td class=\"sublist2\">Vasopressin receptor agonists - dDAVP, lysine vasopressin</td> </tr> <tr> <td class=\"sublist2\">Yohimbine</td> </tr> <tr> <td class=\"sublist2\">Somatostatin analogues - octreotide, especially for postprandial hypotension</td> </tr> <tr> <td class=\"sublist2\">Dihydroergotamine</td> </tr> <tr> <td class=\"sublist2\">Fluoxetine</td> </tr> <tr> <td class=\"sublist2\">Dihydroxyphenylserine</td> </tr> <tr> <td class=\"sublist2\">Dopamine antagonists - metoclopramide, domperidone</td> </tr> <tr> <td class=\"sublist2\">Monoamine oxidase inhibitor with tyramine - can produce severe hypertension</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59499 Version 4.0</div></div></div>"},"59500":{"type":"graphic_picture","displayName":"Congenital epulis","title":"Congenital epulis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital epulis</div><div class=\"cntnt\"><img style=\"width:396px; height:393px;\" src=\"images/PEDS/59500_Congenital_epulis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epulis is a congenital granular cell tumor that arises from the mucosa of the gingiva, usually from the anterior part of the maxillary alveolar ridge. Large lesions may interfere with breathing or feeding and require excision.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 59500 Version 1.0</div></div></div>"},"59502":{"type":"graphic_diagnosticimage","displayName":"Lateral view displaced transverse patella fracture","title":"Lateral view of displaced transverse patella fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral view of displaced transverse patella fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:333px;\" src=\"images/EM/59502_Displaced_transverse_patell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the significant articular step-off (arrow) and fracture diastasis (arrowhead). This injury must be referred for orthopedic care.</div><div class=\"graphic_reference\">Courtesy of Jim Blount, MD.</div><div id=\"graphicVersion\">Graphic 59502 Version 3.0</div></div></div>"},"59503":{"type":"graphic_picture","displayName":"Reflux esophagitis","title":"Esophagitis and patulous gastroesophageal junction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophagitis and patulous gastroesophageal junction</div><div class=\"cntnt\"><img style=\"width:400px; height:410px;\" src=\"images/EM/59503_Reflux_esophagitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 7-year-old with intermittent burning in her abdomen that was not responsive to routine pharmacologic therapy. Endoscopy demonstrates mild esophagitis with slight erythema at patulous gastroesophageal junction.</div><div class=\"graphic_reference\">Courtesy of Karen Murray, MD.</div><div id=\"graphicVersion\">Graphic 59503 Version 1.0</div></div></div>"},"59504":{"type":"graphic_figure","displayName":"Prednisone metabolism toxicity","title":"Prednisolone metabolism may influence side effects","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prednisolone metabolism may influence side effects</div><div class=\"cntnt\"><img style=\"width:427px; height:319px;\" src=\"images/ENDO/59504_Prednisone_metabolism_toxic.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Disappearance curves of tritiated prednisolone in five patients who did not develop side effects while taking prednisone and in eight who did. The patients who developed side effects cleared prednisolone from the circulation more slowly.</div><div class=\"graphic_reference\">Data from: Kozower M, Veatch L, Kaplan MM. Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects.&nbsp;J Clin Endocrinol Metab 1974; 38:407.</div><div id=\"graphicVersion\">Graphic 59504 Version 2.0</div></div></div>"},"59505":{"type":"graphic_table","displayName":"Contact lens solutions","title":"Contact lens solutions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contact lens solutions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Multi-purpose solutions for rinsing, storage, and disinfection</td> </tr> <tr> <td class=\"indent1\">&#8226; Opti-Free Express (Alcon)</td> </tr> <tr> <td class=\"indent1\">&#8226; Opti-Free Replenish (Alcon)</td> </tr> <tr> <td class=\"indent1\">&#8226; Complete (AMO)</td> </tr> <tr> <td class=\"indent1\">&#8226; Aquify (Ciba Vision)</td> </tr> <tr> <td class=\"indent1\">&#8226; Renu (Bausch &#38; Lomb)</td> </tr> <tr> <td class=\"indent1\">&#8226; Sauflon (Sauflon)</td> </tr> <tr> <td class=\"indent1\">&#8226; RevitaLens (Abott Medical Optics)</td> </tr> <tr> <td class=\"indent1\">&#8226; Opti-Free PureMoist (Alcon)</td> </tr> <tr> <td class=\"indent1\">&#8226; Biotrue (Bausch &#38; Lomb)</td> </tr> <tr> <td class=\"subtitle1_single\">Peroxide systems</td> </tr> <tr> <td class=\"indent1\"><strong>AOSept</strong> (CIBA Vision)&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span> Three bottle system: Miraflow (concentrated cleaner), SoftWear saline (to rinse off the Miraflow), and AOSept (neutralized by a catalytic disc in the storage case).</td> </tr> <tr> <td class=\"indent1\"><strong>Clear Care</strong> (CIBA Vision)&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span> Similar to AOSept, but a one-step system with cleaner incorporated into the Clear Care solution and neutralized with a catalytic disc in the storage case. 6 hour minimum.</td> </tr> <tr> <td class=\"indent1\"><strong>UltraCare</strong> (Advanced Medical Optics)&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span> Four parts: cleaner, saline rinse, peroxide solution, and a neutralizing tablet (solution changes color to indicate neutralization).</td> </tr> <tr> <td class=\"indent1\"><strong>Sauflon One Step</strong> (Sauflon USA)&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span> One-step system with added wetting agent. Neutralization is with a catalytic disc. Available only through eye care professionals.</td> </tr> <tr> <td class=\"indent1\"><strong>PeroxiClear</strong>&nbsp;(Bausch &#38; Lomb) <span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash; One-step system with a catalytic disc in the storage case. 4 hour minimum.</span></td> </tr> <tr> <td class=\"subtitle1_single\">Solutions/systems for RGP Lenses</td> </tr> <tr> <td class=\"indent1\"><strong>Boston Solutions</strong> (Bausch &#38; Lomb)&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span> available retail in three forms: Original, Advance, and Simplus</td> </tr> <tr> <td class=\"indent1\"><strong>Unique pH</strong> (Menicon)&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span> available online only</td> </tr> <tr> <td class=\"indent1\"><strong>Optimum</strong> (Lobob) <span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash; </span>available retail, online, and through RGP distributors</td> </tr> <tr> <td class=\"indent1\"><strong>MeniCare</strong> (Menicon)&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span> available online and through RGP distributors</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RGP: rigid gas-permeable.</div><div id=\"graphicVersion\">Graphic 59505 Version 6.0</div></div></div>"},"59507":{"type":"graphic_diagnosticimage","displayName":"Chronic thromboemboli Angio","title":"Chronic thromboemboli","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic thromboemboli</div><div class=\"cntnt\"><img style=\"width:267px; height:370px;\" src=\"images/PULM/59507_Chronic_thromboemboli_Angio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right-sided pulmonary angiogram demonstrating multiple findings consistent with chronic thromboembolic disease including &quot;pouch defect,&quot; webs, post-stenotic dilation, and abrupt cut-offs.</div><div class=\"graphic_reference\">Courtesy of Peter F Fedullo, MD.</div><div id=\"graphicVersion\">Graphic 59507 Version 2.0</div></div></div>"},"59509":{"type":"graphic_table","displayName":"PAINAD","title":"PAINAD - Pain Assessment in Advanced Dementia scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PAINAD - Pain Assessment in Advanced Dementia scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"22%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Items*</td> <td class=\"subtitle1\">0</td> <td class=\"subtitle1\">1</td> <td class=\"subtitle1\">2</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td>Breathing independent of vocalization</td> <td>Normal</td> <td>Occasional labored breathing. Short period of hyperventilation.</td> <td>Noisy labored breathing. Long period of hyperventilation. Cheyne-Stokes respirations.</td> <td>&nbsp;</td> </tr> <tr> <td>Negative vocalization</td> <td>None</td> <td>Occasional moan or groan. Low-level speech with a negative or disapproving quality.</td> <td>Repeated troubled calling out. Loud moaning or groaning. Crying.</td> <td>&nbsp;</td> </tr> <tr> <td>Facial expression</td> <td>Smiling or inexpressive</td> <td>Sad. Frightened. Frown.</td> <td>Facial grimacing.</td> <td>&nbsp;</td> </tr> <tr> <td>Body language</td> <td>Relaxed</td> <td>Tense. Distressed pacing. Fidgeting.</td> <td>Rigid. Fists clenched. Knees pulled up. Pulling or pushing away. Striking out.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Consolability</td> <td>No need to console</td> <td>Distracted or reassured by voice or touch.</td> <td>Unable to console, distract or reassure.</td> <td>&nbsp;</td> </tr> <tr> <td style=\"text-align: right;\" colspan=\"4\"><strong>Total</strong><sup>&#182;</sup>:</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This pain assessment score can be used to assess pain in demented patients. Patients should be observed for five minutes prior to performing the assessment. Total scores range from 0 to 10, with 10 representing severe pain.</div><div class=\"graphic_footnotes\">* Five-item observational tool.<br />¶ Total scores range from 0 to 10 (based on a scale of 0 to 2 for five items), with a higher score indicating more severe pain (0 = \"no pain\" to 10 = \"severe pain\").</div><div class=\"graphic_reference\">Original figure modified for this publication. Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the pain assessment in advanced dementia (PAINAD) scale. J Am Med Dir Assoc 2003; 4:9. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 59509 Version 3.0</div></div></div>"},"59510":{"type":"graphic_picture","displayName":"Taeniasis eggs","title":"Taeniasis eggs","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Taeniasis eggs</div><div class=\"cntnt\"><img style=\"width:582px; height:583px;\" src=\"images/ID/59510_Taeniasis_eggs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) <em>Taenia</em> spp eggs in unstained wet mounts. Four hooks can clearly be seen in figure A.<br> (C) Cross-section of a proglottid of <em>Taenia</em> spp, stained with hematoxylin and eosin (H&amp;E). Note the thick outer tegument and the loose parenchyma filling the body. Calcareous corpuscles (red arrows), characteristic of the cestodes, can be seen in the parenchyma. Eggs (blue arrows) can also be seen.<br> (D) Higher magnification of figure C showing a close-up of the eggs. Note the characteristic striations, typical for the taeniids. Not visible in these images are the hooks commonly seen in cestode eggs. Hooks do not stain with H&amp;E but are refractile and visible with fine focusing of the microscope.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Taeniasis. Available at: <A href=\"http://www.cdc.gov/dpdx/taeniasis/index.html\">http://www.cdc.gov/dpdx/taeniasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 59510 Version 5.0</div></div></div>"},"59511":{"type":"graphic_figure","displayName":"UDCA response in PBC","title":"Response to ursodeoxycholic acid in primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Response to ursodeoxycholic acid in primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:424px; height:240px;\" src=\"images/GAST/59511_UDCA_response_in_PBC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probability of response (defined as the absence of treatment failure) to ursodeoxycholic acid (UDCA) in primary biliary cholangitis. Patients were randomized to UDCA (solid line) or placebo (dashed line) for the first 24 months and then all patients were treated with UDCA for the next 24 months. The probability of a beneficial response at four years was significantly higher in the patients treated with UDCA throughout the study.</div><div class=\"graphic_reference\">Data from: Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group, N Engl J Med 1994; 330:1342.</div><div id=\"graphicVersion\">Graphic 59511 Version 4.0</div></div></div>"},"59512":{"type":"graphic_figure","displayName":"Vitreous aspirate vitrectomy","title":"Vitreous aspirate and vitrectomy","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Vitreous aspirate and vitrectomy</div><div class=\"cntnt\"><img style=\"width:484px; height:602px;\" src=\"images/ID/59512_Vitreous_aspirate_vitrectom.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59512 Version 6.0</div></div></div>"},"59515":{"type":"graphic_table","displayName":"Drugs causing coma","title":"Select toxic agents causing coma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Select toxic agents causing coma</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n\t\t<tr>\r\n\t\t\t\t\t\t<td class=\"subtitle1\">Toxic agent</td>\r\n\t\t\t\t\t\t<td class=\"subtitle1\">Features which may distinguish from opioids</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Antihistamines</td>\r\n\t\t\t\t\t\t<td>Anticholinergic toxidrome</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Antipsychotics</td>\r\n\t\t\t\t\t\t<td>Pupils, bowel sounds normal</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Barbiturates</td>\r\n\t\t\t\t\t\t<td>Mild to severe hypotension, serum concentration</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>&#946;-adrenergic antagonists</td>\r\n\t\t\t\t\t\t<td>Cardiovascular findings (hypotension, bradycardia) more prominent than mental status findings</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Calcium channel blockers</td>\r\n\t\t\t\t\t\t<td>Cardiovascular findings (hypotension, bradycardia, or tachycardia) more prominent than mental status findings</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Carbamazepine</td>\r\n\t\t\t\t\t\t<td>Serum concentration</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Carbon monoxide</td>\r\n\t\t\t\t\t\t<td>Carboxyhemoglobin level</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Clonidine</td>\r\n\t\t\t\t\t\t<td>Bradycardia, hypotension</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Cyclic antidepressants</td>\r\n\t\t\t\t\t\t<td>QRS prolongation, hypotension, tachycardia</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Ethanol</td>\r\n\t\t\t\t\t\t<td>Pupils, bowel sounds normal, serum concentration</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Ethylene glycol</td>\r\n\t\t\t\t\t\t<td>Pupils, bowel sounds normal</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Hypoglycemic agents</td>\r\n\t\t\t\t\t\t<td>Serum glucose concentration</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Isoniazid</td>\r\n\t\t\t\t\t\t<td>History of seizures, normal pupils, bowel sounds</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Isopropanol</td>\r\n\t\t\t\t\t\t<td>Pupils, bowel sounds normal</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Lithium</td>\r\n\t\t\t\t\t\t<td>Tremor, hyperreflexia, serum concentration</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Methanol</td>\r\n\t\t\t\t\t\t<td>Pupils, bowel sounds normal</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Organic-phosphorous compounds</td>\r\n\t\t\t\t\t\t<td>Cholinergic toxidrome</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Phencyclidine</td>\r\n\t\t\t\t\t\t<td>Nystagmus (horizontal, vertical, or rotary)</td></tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Sedative-hypnotic agents</td>\r\n\t\t\t\t\t\t<td>Pupil size normal to decreased, bowel sounds normal, less respiratory depression</td></tr>\r\n\r\n\t\t</table></div><div id=\"graphicVersion\">Graphic 59515 Version 1.0</div></div></div>"},"59518":{"type":"graphic_figure","displayName":"Serum creatinine and GFR","title":"Serum creatinine and GFR","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum creatinine and GFR</div><div class=\"cntnt\"><img style=\"width:338px; height:227px;\" src=\"images/NEPH/59518_Serum_creatinine_and_GFR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Idealized steady-state relationship between the serum creatinine concentration (SCr) and the GFR. A fall in GFR decreases creatinine filtration and produces a proportionate rise in the serum creatinine concentration.</div><div id=\"graphicVersion\">Graphic 59518 Version 1.0</div></div></div>"},"59519":{"type":"graphic_picture","displayName":"KS involvement of colon","title":"Kaposi's sarcoma of the colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaposi's sarcoma of the colon</div><div class=\"cntnt\"><img style=\"width:423px; height:238px;\" src=\"images/ONC/59519_KS_involvement_of_colon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaposi's sarcoma of the gastrointestinal tract in a patient with AIDS presenting as large annular masses with circumferential infiltration and luminal obstruction in the colon and rectum.</div><div class=\"graphic_reference\">By permission from: van den Brink MR, Dezube BJ, J Clin Oncol 1997; 15:1283.</div><div id=\"graphicVersion\">Graphic 59519 Version 3.0</div></div></div>"},"59522":{"type":"graphic_table","displayName":"Accuracy US acute appendicitis","title":"Sensitivity and specificity of ultrasonography in the detection of acute appendicitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specificity of ultrasonography in the detection of acute appendicitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><div class=\"figure\">&nbsp;</div> <div>&nbsp;</div> <tbody> </tbody></table><table style=\"height: 1382px; width: 94.92%;\" cellspacing=\"0\"> <colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Sensitivity</td> <td class=\"subtitle1\">Specificity</td> <td class=\"subtitle1\">PPV</td> <td class=\"subtitle1\">NPV</td> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\" colspan=\"2\"><span class=\"subtitle1\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></td> </tr> <tr> <td class=\"centered\">&nbsp;70</td> <td class=\"centered\">94</td> <td class=\"centered\">89</td> <td class=\"centered\">89</td> <td class=\"centered\">94</td> <td class=\"centered\">[1]</td> <td class=\"centered\">Vignault F, et al</td> <td class=\"centered\">1990</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">857</td> <td class=\"centered\">90</td> <td class=\"centered\">98</td> <td class=\"centered\">94</td> <td class=\"centered\">97</td> <td class=\"centered\">[2]</td> <td class=\"centered\">Schwerk WB, et al</td> <td class=\"centered\">1990</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">462</td> <td class=\"centered\">77</td> <td class=\"centered\">NE</td> <td class=\"centered\">&#62;92</td> <td class=\"centered\">NE</td> <td class=\"centered\">[3]</td> <td class=\"centered\">Bendeck SE, et al</td> <td class=\"centered\">2002</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">283</td> <td class=\"centered\">86</td> <td class=\"centered\">95</td> <td class=\"centered\">91</td> <td class=\"centered\">92</td> <td class=\"centered\">[4]</td> <td class=\"centered\">Kaiser S, et al</td> <td class=\"centered\">2002</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">49</td> <td class=\"centered\">84</td> <td class=\"centered\">96</td> <td class=\"centered\">90</td> <td class=\"centered\">NE</td> <td class=\"centered\">[5]</td> <td class=\"centered\">Sun SS, et al</td> <td class=\"centered\">2002</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Age &#62;50 years old </li> </ul> </td> </tr> <tr> <td class=\"centered\">40</td> <td class=\"centered\">87</td> <td class=\"centered\">90</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[6]</td> <td class=\"centered\">Chang CC, et al</td> <td class=\"centered\">2003</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">199</td> <td class=\"centered\">79</td> <td class=\"centered\">78</td> <td class=\"centered\">87</td> <td class=\"centered\">65</td> <td class=\"centered\">[7]</td> <td class=\"centered\">Poortman P, et al</td> <td class=\"centered\">2003</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">174</td> <td class=\"centered\">100</td> <td class=\"centered\">37</td> <td class=\"centered\">50</td> <td class=\"centered\">100</td> <td class=\"centered\">[8]</td> <td class=\"centered\">Rettenbacher T, et al</td> <td class=\"centered\">2003</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">125</td> <td class=\"centered\">83</td> <td class=\"centered\">95</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[9]</td> <td class=\"centered\">Kessler N, et al</td> <td class=\"centered\">2004</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">174</td> <td class=\"centered\">83</td> <td class=\"centered\">95</td> <td class=\"centered\">86</td> <td class=\"centered\">94</td> <td class=\"centered\">[10]</td> <td class=\"centered\">Chan I, et al</td> <td class=\"centered\">2005</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">MA</td> <td class=\"centered\">88</td> <td class=\"centered\">94</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[11] </td> <td class=\"centered\">Doria AS, et al</td> <td class=\"centered\">2006</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Meta-analysis in children, 26 studies, 9356 patients </li> </ul> </td> </tr> <tr> <td class=\"centered\">MA</td> <td class=\"centered\">83</td> <td class=\"centered\">93</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[11] </td> <td class=\"centered\">Doria AS, et al</td> <td class=\"centered\">2006</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Meta-analysis in adults, 31 studies, 4341 patients </li> </ul> </td> </tr> <tr> <td class=\"centered\">MA</td> <td class=\"centered\">87</td> <td class=\"centered\">89</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[12]</td> <td class=\"centered\">Klein MD</td> <td class=\"centered\">2007</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Meta-analysis, nine studies </li> </ul> </td> </tr> <tr> <td class=\"centered\">420</td> <td class=\"centered\">74</td> <td class=\"centered\">97</td> <td class=\"centered\">88</td> <td class=\"centered\">93</td> <td class=\"centered\">[13]</td> <td class=\"centered\">Gaitini D, et al</td> <td class=\"centered\">2008</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">132</td> <td class=\"centered\">65</td> <td class=\"centered\">90</td> <td class=\"centered\">84</td> <td class=\"centered\">76</td> <td class=\"centered\">[14]</td> <td class=\"centered\">Fox JC, et al</td> <td class=\"centered\">2008</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">33</td> <td class=\"centered\">50</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">66</td> <td class=\"centered\">[15]</td> <td class=\"centered\">Israel GM, et al</td> <td class=\"centered\">2008</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Pregnant women </li> </ul> &nbsp;</td> </tr> <tr> <td class=\"centered\">121</td> <td class=\"centered\">90</td> <td class=\"centered\">93</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[16]</td> <td class=\"centered\">Je BK, et al</td> <td class=\"centered\">2009</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Criterion is the maximal-outer-diameter&nbsp; &#62;0.57 mm </li> </ul> </td> </tr> <tr> <td class=\"centered\">121</td> <td class=\"centered\">85</td> <td class=\"centered\">96</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[16]</td> <td class=\"centered\">Je BK, et al</td> <td class=\"centered\">2009</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Criterion is the maximal-mural-thickness&nbsp; &#62;0.22 mm </li> </ul> </td> </tr> <tr> <td class=\"centered\">162</td> <td class=\"centered\">87&nbsp;</td> <td class=\"centered\">46&nbsp;</td> <td class=\"centered\">49&nbsp;</td> <td class=\"centered\">85&nbsp;</td> <td class=\"centered\">[17]&nbsp;</td> <td class=\"centered\">Schuh S, et al&nbsp;</td> <td class=\"centered\">2010</td> <td colspan=\"2\"> <ul id=\"_telerik_insertedList_id\"> <li>Pediatric patients</li> </ul> </td> </tr> <tr> <td class=\"centered\">193</td> <td class=\"centered\">81</td> <td class=\"centered\">88</td> <td class=\"centered\">61</td> <td class=\"centered\">95</td> <td class=\"centered\">[18]</td> <td class=\"centered\">Pacharn P, et al</td> <td class=\"centered\">2010</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">204</td> <td class=\"centered\">99</td> <td class=\"centered\">95&nbsp;</td> <td class=\"centered\">NE&nbsp;</td> <td class=\"centered\">NE&nbsp;</td> <td class=\"centered\">[19]&nbsp;</td> <td class=\"centered\">Goldin AB, et al&nbsp;</td> <td class=\"centered\">2011&nbsp;</td> <td colspan=\"2\"> <ul id=\"_telerik_insertedList_id\"> <li>Pediatric patients</li> </ul> </td> </tr> <tr> <td class=\"centered\">147</td> <td class=\"centered\">38</td> <td class=\"centered\">97&nbsp;</td> <td class=\"centered\">NE&nbsp;</td> <td class=\"centered\">NE</td> <td class=\"centered\">[20]</td> <td class=\"centered\">Abo A, et al</td> <td class=\"centered\">2011&nbsp;</td> <td colspan=\"2\"> <ul id=\"_telerik_insertedList_id\"> <li>Pediatric patients</li> </ul> </td> </tr> <tr> <td class=\"centered\">230</td> <td class=\"centered\">77&nbsp;</td> <td class=\"centered\">94&nbsp;</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[21]</td> <td class=\"centered\">Leeuwenburgh MM, et al&nbsp;</td> <td class=\"centered\">&nbsp;2013</td> <td class=\"centered\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"centered\">&nbsp;965*/469<sup>&#182;</sup></td> <td class=\"centered\">73*/98<sup>&#182;</sup></td> <td class=\"centered\">97*/92<sup>&#182;</sup></td> <td class=\"centered\">NE</td> <td class=\"centered\">NE&nbsp;</td> <td class=\"centered\">[22]</td> <td class=\"centered\">Mittal MK, et al</td> <td class=\"centered\">2013</td> <td colspan=\"2\"> <ul> <li>Pediatric patients </li> </ul> </td> </tr> <tr> <td class=\"centered\">150<span style=\"font-size: 13px;\"><sup>&#916;</sup></span>/50<span style=\"font-size: 13px;\"><sup>&#9674;</sup></span></td> <td class=\"centered\">60<sup><span style=\"font-size: 13px;\">&#167;</span></sup>/63<sup><span style=\"font-size: 13px;\">&#165;</span></sup>&nbsp;</td> <td class=\"centered\">94<sup><span style=\"font-size: 13px;\">&#167;</span></sup>/99<sup><span style=\"font-size: 13px;\">&#165;</span></sup>&nbsp;</td> <td class=\"centered\">NE&nbsp;</td> <td class=\"centered\">NE</td> <td class=\"centered\">[22]&nbsp;</td> <td class=\"centered\">Mittal MK, et al&nbsp;</td> <td class=\"centered\">2013</td> <td colspan=\"2\"> <ul> <li>Pediatric patients </li> </ul> </td> </tr> <tr> <td class=\"centered\">230&nbsp;&nbsp;</td> <td class=\"centered\">48&nbsp;</td> <td class=\"centered\">&nbsp;93&nbsp;</td> <td class=\"centered\">&nbsp;68&nbsp;</td> <td class=\"centered\">84&nbsp;</td> <td class=\"centered\">[23]</td> <td class=\"centered\">Leeuwenburgh MM, et al&nbsp;</td> <td class=\"centered\">2014&nbsp;</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Results of ultrasound imaging with conditional CT&nbsp; </li> <li>Data indicating the role of US use to discriminate simple from perforated appendicitis </li> </ul> </td> </tr> <tr> <td class=\"centered\">97</td> <td class=\"centered\">44&nbsp;</td> <td class=\"centered\">85</td> <td class=\"centered\">70</td> <td class=\"centered\">66&nbsp;</td> <td class=\"centered\">[24]</td> <td class=\"centered\">Fathi M, et al</td> <td class=\"centered\">2014</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Emergency clinicians </li> </ul> </td> </tr> <tr> <td class=\"centered\">85&nbsp;</td> <td class=\"centered\">85</td> <td class=\"centered\">93</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE&nbsp;</td> <td class=\"centered\">[25]&nbsp;</td> <td class=\"centered\">Sivitz AB, et al</td> <td class=\"centered\">2014&nbsp;</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Pediatric emergency clinicians </li> <li>Pediatric population </li> </ul> </td> </tr> <tr> <td class=\"centered\">81&nbsp;</td> <td class=\"centered\">90<sup>&#135;</sup>/87<sup>&#134;</sup>&nbsp;</td> <td class=\"centered\">86<sup>&#135;</sup>/100<sup>&#134;</sup>&nbsp;</td> <td class=\"centered\">79<sup>&#135;</sup>/100<sup>&#134;</sup>&nbsp;</td> <td class=\"centered\">94<sup>&#135;</sup>/93<sup>&#134;</sup>&nbsp;</td> <td class=\"centered\">[26]&nbsp;</td> <td class=\"centered\">Orth RC, et al&nbsp;</td> <td class=\"centered\">&nbsp;2014</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Pediatric patients </li> </ul> </td> </tr> <tr> <td class=\"centered\">97</td> <td class=\"centered\">68</td> <td class=\"centered\">98&nbsp;</td> <td class=\"centered\">NE&nbsp;</td> <td class=\"centered\">NE&nbsp;</td> <td class=\"centered\">[27]</td> <td class=\"centered\">Mallin M, et al&nbsp;</td> <td class=\"centered\">&nbsp;2015</td> <td class=\"sublist_other_start\" colspan=\"2\"> <ul> <li>Bedside US performed in the emergency department by trained residents with attending supervision and reviewed by a blinded US fellowship-trained clinician </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPV: positive predictive value; NPV: negative predictive value; NE: not evaluable; MA: meta-analysis; CT: computed tomography; US: ultrasound.<br />* Overall results in 10 centers.<br />¶ Cases in which the appendix has been clearly visualized on ultrasound.<br />Δ Enrolled patients (with suspected appendicitis).<br /><FONT class=lozenge>◊</FONT> Point of care ultrasound.<br />§ Radiology ultrasound.<br />¥ Pediatric patients.<br />‡ When equivocal interpretations were designated positive.<br />† When equivocal interpretations were designated negative.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Vignault F, Filiatrault D, Brandt ML, Garel L, Grignon A, Ouimet A. Acute appendicitis in children: evaluation with US. Radiology 1990; 176:501.</LI>&#xD;&#xA;<LI>Schwerk WB, Wichtrup B, Ruschoff J, Rothmund M. Acute and perforated appendicitis: current experience with ultrasound-aided diagnosis. World J Surg 1990; 14:271.</LI>&#xD;&#xA;<LI>Bendeck SE, Nino-Murcia M, Berry GJ, Jeffrey RB, Jr. Imaging for suspected appendicitis: negative appendectomy and perforation rates. Radiology 2002; 225:131.</LI>&#xD;&#xA;<LI>Kaiser S, Frenckner B, Jorulf HK. Suspected appendicitis in children: US and CT--a prospective randomized study. Radiology 2002; 223:633.</LI>&#xD;&#xA;<LI>Sun SS, Wu HS, Wang JJ, Ho ST, Kao A. Comparison between technetium 99m hexamethylpropyleneamine oxide labeled white blood cell abdominal scan and abdominal sonography to detect appendicitis in adult patients with atypical clinical presentation. Abdom Imaging 2002; 27:734.</LI>&#xD;&#xA;<LI>Chang CC, Tsai CY, Lin CC, Jeng LB, Lee CC, Kao CH. Comparison between technetium-99m hexamethylpropyleneamineoxide labeled white blood cell abdomen scan and abdominal sonography to detect appendicitis in children with an atypical clinical presentation. Hepatogastroenterology 2003; 50:426.</LI>&#xD;&#xA;<LI>Poortman P, Lohle PN, Schoemaker CM, Oostvogel HJ, Teepen HJ, Zwinderman KA et al. Comparison of CT and sonography in the diagnosis of acute appendicitis: a blinded prospective study. AJR Am J Roentgenol 2003; 181:1355.</LI>&#xD;&#xA;<LI>Rettenbacher T, Hollerweger A, Macheiner P, Gritzmann N, Daniaux M, Schwamberger K et al. Ovoid shape of the vermiform appendix: a criterion to exclude acute appendicitis--evaluation with US. Radiology 2003; 226:95.</LI>&#xD;&#xA;<LI>Kessler N, Cyteval C, Gallix B, Lesnik A, Blayac PM, Pujol J et al. Appendicitis: evaluation of sensitivity, specificity, and predictive values of US, Doppler US, and laboratory findings. Radiology 2004; 230:472.</LI>&#xD;&#xA;<LI>Chan I, Bicknell SG, Graham M. Utility and diagnostic accuracy of sonography in detecting appendicitis in a community hospital. AJR Am J Roentgenol 2005; 184:1809.</LI>&#xD;&#xA;<LI>Doria AS, Moineddin R, Kellenberger CJ, Epelman M, Beyene J, Schuh S et al. US or CT for Diagnosis of Appendicitis in Children and Adults? A Meta-Analysis. Radiology 2006; 241:83.</LI>&#xD;&#xA;<LI>Klein MD. Clinical approach to a child with abdominal pain who might have appendicitis. Pediatr Radiol 2007; 37:11.</LI>&#xD;&#xA;<LI>Gaitini D, Beck-Razi N, Mor-Yosef D, Fischer D, Ben Itzhak O, Krausz MM, Engel A. Diagnosing acute appendicitis in adults: accuracy of color Doppler sonography and MDCT compared with surgery and clinical follow-up. AJR Am J Roentgenol. 2008; 190:1300.</LI>&#xD;&#xA;<LI>Fox JC, Solley M, Anderson CL, Zlidenny A, Lahham S, Maasumi K. Prospective evaluation of emergency physician performed bedside ultrasound to detect acute appendicitis. Eur J Emerg Med. 2008; 15:80.</LI>&#xD;&#xA;<LI>Israel GM, Malguria N, McCarthy S, Copel J, Weinreb J. MRI vs. ultrasound for suspected appendicitis during pregnancy. J Magn Reson Imaging. 2008; 28:428.</LI>&#xD;&#xA;<LI>Je BK, Kim SB, Lee SH, Lee KY, Cha SH. Diagnostic value of maximal-outer-diameter and maximal-mural-thickness in use of ultrasound for acute appendicitis in children. World J Gastroenterol. 2009; 15:2900.</LI>&#xD;&#xA;<LI>Schuh S, Man C, Cheng A, Murphy A, Mohanta A, Moineddin R, Tomlinson G, Langer JC, Doria AS. Predictors of non-diagnostic ultrasound scanning in children with suspected appendicitis. J Pediatr. 2011; 158:112.</LI>&#xD;&#xA;<LI>Pacharn P, Ying J, Linam LE, Brody AS, Babcock DS. Sonography in the evaluation of acute appendicitis: are negative sonographic findings good enough? J Ultrasound Med. 2010; 29:1749.</LI>&#xD;&#xA;<LI>Goldin AB, Khanna P, Thapa M, McBroom JA, Garrison MM, Parisi MT. Revised ultrasound criteria for appendicitis in children improve diagnostic accuracy. Pediatr Radiol. 2011; 41:993.</LI>&#xD;&#xA;<LI>Abo A, Shannon M, Taylor G, Bachur R. The influence of body mass index on the accuracy of ultrasound and computed tomography in diagnosing appendicitis in children. Pediatr Emerg Care. 2011; 27:731.</LI>&#xD;&#xA;<LI>Leeuwenburgh MM, Wiarda BM, Wiezer MJ, et al. Comparison of imaging strategies with conditional contrast-enhanced CT and unenhanced MR imaging in patients suspected of having appendicitis: a multicenter diagnostic performance study. Radiology 2013; 268:135.</LI>&#xD;&#xA;<LI>Mittal MK, Dayan PS, Macias CG, et al. Performance of ultrasound in the diagnosis of appendicitis in children in a multicenter cohort. Acad Emerg Med 2013; 20:697.</LI>&#xD;&#xA;<LI>Leeuwenburgh MM, Wiezer MJ, Wiarda BM, et al. Accuracy of MRI compared with ultrasound imaging and selective use of CT to discriminate simple from perforated appendicitis. Br J Surg 2014; 101:e147.</LI>&#xD;&#xA;<LI>Fathi M, Hasani SA, Zare MA, et al. Diagnostic accuracy of emergency physician performed graded compression ultrasound study in acute appendicitis: a prospective study. J Ultrasound 2014; 18:57.</LI>&#xD;&#xA;<LI>Sivitz AB, Cohen SG, Tejani C. Evaluation of acute appendicitis by pediatric emergency physician sonography. Ann Emerg Med 2014; 64:358.</LI>&#xD;&#xA;<LI>Orth RC, Guillerman RP, Zhang W, et al. Prospective comparison of MR imaging and US for the diagnosis of pediatric appendicitis. Radiology 2014; 272:233.</LI>&#xD;&#xA;<LI>Mallin M, Craven P, Ockerse P, et al. Diagnosis of appendicitis by bedside ultrasound in the ED. Am J Emerg Med 2015; 33:430.</LI></OL></div><div id=\"graphicVersion\">Graphic 59522 Version 5.0</div></div></div>"},"59524":{"type":"graphic_figure","displayName":"BP and efficacy of thrombolysis","title":"Importance of blood pressure on clot dissolution","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Importance of blood pressure on clot dissolution</div><div class=\"cntnt\"><img style=\"width:375px; height:242px;\" src=\"images/CARD/59524_BP_efficacy_of_thrombol_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dogs with a left anterior descending coronary artery occlusion by thrombus were made hypotensive by phlebotomy. Rates of thrombolysis (percent per 30 min) were depressed by low BP and restored with norepinephrine (NE) titrated to a systolic BP of 130 mmHg or with intraaortic balloon counterpulsation (IABC).</div><div class=\"graphic_reference\">Data from: Prewitt RM, Gu S, Garger PJ, Ducas J. J Am Coll Cardiol 1992; 20:1626, and Prewitt RM, Gu S, Schick U, Ducas J. J Am Coll Cardiol 1994; 23:794.</div><div id=\"graphicVersion\">Graphic 59524 Version 4.0</div></div></div>"},"59526":{"type":"graphic_diagnosticimage","displayName":"Color coded tissue Doppler ","title":"Color-coded tissue Doppler echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color-coded tissue Doppler echocardiogram</div><div class=\"cntnt\"><img style=\"width:417px; height:258px;\" src=\"images/CARD/59526_ColorcodedtissueDoppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The color-coded tissue Doppler echocardiography&nbsp;image of the normal left ventricle is obtained from the apical four-chamber view (panel C); the corresponding color tissue Doppler M-mode through medial mitral annulus is seen in panel B, and the mitral annular time-velocity plot is shown in panel A.</div><div id=\"graphicVersion\">Graphic 59526 Version 5.0</div></div></div>"},"59528":{"type":"graphic_algorithm","displayName":"Pathogenesis of LPG","title":"Summary and proposed mechanisms of LPG","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Summary and proposed mechanisms of LPG</div><div class=\"cntnt\"><img style=\"width:482px; height:488px;\" src=\"images/NEPH/59528_Pathogenesis_of_LPG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LPG: lipoprotein glomerulopathy; ApoE: apolipoprotein E; VLDL: very low-density lipoprotein; IDL: intermediate density lipoprotein.</div><div class=\"graphic_reference\">Reproduced with permission from: Saito, T, et al. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199. Copyright ©2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 59528 Version 3.0</div></div></div>"},"59529":{"type":"graphic_picture","displayName":"Erythrasma in axilla 2","title":"Erythrasma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythrasma</div><div class=\"cntnt\"><img style=\"width:366px; height:396px;\" src=\"images/DERM/59529_Erythrasma_axilla2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 40-year-old diabetic male presented with red-brown patches in the axillae that resolved with erythromycin therapy.</div><div class=\"graphic_reference\">Copyright © Jayakar Thomas, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 59529 Version 7.0</div></div></div>"},"59533":{"type":"graphic_picture","displayName":"Tinea versicolor arm","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:380px; height:267px;\" src=\"images/PC/59533_Tinea_versicolor_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small salmon-colored macules are evident on the arm that coalesce in some areas.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 59533 Version 1.0</div></div></div>"},"59535":{"type":"graphic_diagnosticimage","displayName":"Paracardiac mass on MRI","title":"Choriocarcinoma with mediastinal invasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choriocarcinoma with mediastinal invasion</div><div class=\"cntnt\"><img style=\"width:354px; height:230px;\" src=\"images/PULM/59535_Paracardiac_mass_on_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial section on MRI demonstrates a paracardiac mass due to metastatic choriocarcinoma with severe narrowing of the main pulmonary artery (arrow). A right pleural metastasis is also present (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59535 Version 3.0</div></div></div>"},"59536":{"type":"graphic_picture","displayName":"Skin biopsy lupus profundus II","title":"Lupus profundus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus profundus</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/RHEUM/59536_Skin_biopsy_lupus_profund1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histiocytes within the fat lobule contain engulfed nuclear debris producing cells with a morphology reminiscent of a lupus erythematosus&nbsp;(LE) cell.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 59536 Version 2.0</div></div></div>"},"59537":{"type":"graphic_table","displayName":"PSI and mortality","title":"PSI class and mortality in the Pneumonia PORT validation cohort","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PSI class and mortality in the Pneumonia PORT validation cohort</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\">Mortality<br /> (percent)</td> </tr> <tr class=\"centered\"> <td>I</td> <td>No predictors</td> <td>0.1</td> </tr> <tr class=\"centered\"> <td>II</td> <td>&#8804;70</td> <td>0.6</td> </tr> <tr class=\"centered\"> <td>III</td> <td>71 to 90</td> <td>0.9</td> </tr> <tr class=\"centered\"> <td>IV</td> <td>91 to 130</td> <td>9.3</td> </tr> <tr class=\"centered\"> <td>V</td> <td>&#62;130</td> <td>27.0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PSI: Pneumonia Severity Index; PORT: Patient Outcomes Research Team.</div><div class=\"graphic_reference\">Data from: Fine MJ, Auble TE, Yealy DM. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243.</div><div id=\"graphicVersion\">Graphic 59537 Version 9.0</div></div></div>"},"59538":{"type":"graphic_movie","displayName":"Echocardiogram apical long axis view of calcific aortic stenosis ","title":"Echocardiogram apical long axis view of calcific aortic stenosis ","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram apical long axis view of calcific aortic stenosis </div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/59538_aorstaplconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:250px; height:392px;\" src=\"images/CARD/59538_aorstapl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical long axis view from a 2-D echocardiogram shows significant calcification of the aortic valve and aortic root with limited leaflet mobility. There is also significant concentric hypertrophy of the left ventricular myocardium.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 59538 Version 3.0</div></div></div>"},"59539":{"type":"graphic_figure","displayName":"CK levels post PTCA outcome","title":"Elevated serum CK-MB is associated with cardiac events after angioplasty","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Elevated serum CK-MB is associated with cardiac events after angioplasty</div><div class=\"cntnt\"><img style=\"width:545px; height:293px;\" src=\"images/CARD/59539_CK_levels_post_PTCA_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After percutaneous transluminal coronary angioplasty (PTCA), the six-month incidence of cardiac events including death, myocardial infarction (MI), or revascularization with bypass surgery (CABG) or repeat PTCA was directly associated with the serum CK-MB. Shown are point estimates and 95 percent confidence intervals by postintervention CK-MB stratum.</div><div class=\"graphic_reference\">Data from Tardiff BE, Califf RM, Tcheng JE, et al. J Am Coll Cardiol 1999; 33:88.</div><div id=\"graphicVersion\">Graphic 59539 Version 3.0</div></div></div>"},"59544":{"type":"graphic_table","displayName":"Pericardial involvement in connective tissue and other diseases","title":"Estimated frequency and type of pericardial involvement in connective tissue diseases, granulomatous diseases, and autoinflammatory diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated frequency and type of pericardial involvement in connective tissue diseases, granulomatous diseases, and autoinflammatory diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Systemic disease</td> <td class=\"subtitle1\">Estimated frequency of pericardial involvement (percent)</td> <td class=\"subtitle1\">Type of pericardial involvement</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Connective tissue diseases</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> <td>&#62;50</td> <td>Pericardial effusion, pericarditis</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> <td>10-30</td> <td>Pericardial effusion (30 percent), pericarditis (10 percent)</td> </tr> <tr> <td class=\"indent1\">Systemic sclerosis</td> <td>Symptomatic (&#60;20), overall (&#62;60)</td> <td>Pericardial effusion, pericarditis</td> </tr> <tr> <td class=\"indent1\">Polymyositis and dermatomyositis</td> <td>&#60;10</td> <td>Pericarditis, pericardial effusion, cardiac tamponade (case reports)</td> </tr> <tr> <td class=\"indent1\">Mixed connective tissue disease</td> <td>10-30</td> <td>Pericarditis, pericardial effusion</td> </tr> <tr> <td class=\"indent1\">Sjogren syndrome</td> <td>&#60;30</td> <td>Pericarditis</td> </tr> <tr> <td class=\"indent1\">Behcet disease</td> <td>Rare</td> <td>Pericarditis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Granulomatous diseases</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> <td>Rare</td> <td>Pericardial effusion, pericarditis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Autoinflammatory diseases</td> </tr> <tr> <td class=\"indent1\">Familial Mediterranean Fever (FMF)</td> <td>1</td> <td>Pericarditis</td> </tr> <tr> <td class=\"indent1\">TNF receptor-1 associated periodic syndrome (TRAPS)</td> <td>Rare</td> <td>Pericarditis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59544 Version 2.0</div></div></div>"},"59545":{"type":"graphic_picture","displayName":"Dermatomyositis dilated capillary loops","title":"Dilated capillary loops at the proximal nail fold in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dilated capillary loops at the proximal nail fold in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:415px; height:313px;\" src=\"images/DERM/59545_Dermatomyositis_capillary.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59545 Version 2.0</div></div></div>"},"59546":{"type":"graphic_picture","displayName":"Fiberglass fx tape","title":"Fiberglass casting tape","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Fiberglass casting tape</div><div class=\"cntnt\"><img style=\"width:468px; height:360px;\" src=\"images/EM/59546_Fiberglass_fx_tape.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fiberglass casting tape is lighter, stronger, more breathable, and sets more quickly than plaster. It should be applied with a stretch-relax technique.</div><div class=\"graphic_reference\">Courtesy of Stephen Titus, MD.</div><div id=\"graphicVersion\">Graphic 59546 Version 1.0</div></div></div>"},"59548":{"type":"graphic_table","displayName":"Adolescent suicide Oregon","title":"Number and rate* of fatal and nonfatal suicide attempts among persons aged 10-17 years, by age group and sex - Oregon, 1988-1993","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Number and rate* of fatal and nonfatal suicide attempts among persons aged 10-17 years, by age group and sex - Oregon, 1988-1993</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Attempt/age group</td> <td class=\"subtitle1\" colspan=\"2\">Male</td> <td class=\"subtitle1\" colspan=\"2\">Female</td> <td class=\"subtitle1\" colspan=\"2\">Total</td> </tr> <tr> <td class=\"subtitle2\">Number</td> <td class=\"subtitle2\">Rate</td> <td class=\"subtitle2\">Number</td> <td class=\"subtitle2\">Rate</td> <td class=\"subtitle2\">Number</td> <td class=\"subtitle2\">Rate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Nonfatal<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">10-14 years</td> <td>167</td> <td>26.6</td> <td>1037</td> <td>174</td> <td>1204</td> <td>98.4</td> </tr> <tr> <td class=\"indent1\">15-17 years</td> <td>556</td> <td>156.1</td> <td>2013</td> <td>594.4</td> <td>2569</td> <td>369.7</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Total</td> <td>723</td> <td>73.4</td> <td>3050</td> <td>326.4</td> <td>3773</td> <td>196.6</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Fatal<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">10-14 years</td> <td>22</td> <td>3.5</td> <td>10</td> <td>1.7</td> <td>32</td> <td>2.6</td> </tr> <tr> <td class=\"indent1\">15-17 years</td> <td>72</td> <td>20.2</td> <td>19</td> <td>5.6</td> <td>91</td> <td>13.1</td> </tr> <tr> <td class=\"indent1\">Total</td> <td>94</td> <td>9.5</td> <td>29</td> <td>3.1</td> <td>123</td> <td>6.4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Per 100,000 population in specified group.<br />¶ Source: Oregon Adolescent Suicide Attempt Data System.<br />Δ Source: Oregon death certificate data.</div><div class=\"graphic_reference\">Adapted from MMWR Morb Mortal Wkly Rep 1995; 44:312.</div><div id=\"graphicVersion\">Graphic 59548 Version 2.0</div></div></div>"},"59550":{"type":"graphic_picture","displayName":"Keratoacanthoma eyelid","title":"Keratoacanthoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratoacanthoma</div><div class=\"cntnt\"><img style=\"width:396px; height:257px;\" src=\"images/PC/59550_Keratoacanthoma_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A central keratin plug is present in this rapidly growing lower lid nodule.</div><div class=\"graphic_reference\">With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 59550 Version 1.0</div></div></div>"},"59551":{"type":"graphic_figure","displayName":"Multihormonal regulation of glucose","title":"Multihormonal regulation of glucose","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Multihormonal regulation of glucose</div><div class=\"cntnt\"><img style=\"width:515px; height:339px;\" src=\"images/PC/59551_Multihormonal_regulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In healthy individuals, (1) ingestion of food results in (2) release of gastrointestinal peptides (GLP-1 and GIP) as well as (3) pancreatic beta cell hormones (insulin and amylin). GLP-1 and amylin, in particular, have inhibitory effects on (4) gastric emptying, (5) glucagon release, and (6) appetite. (7) Following the absorption of food, GLP-1 and GIP promote insulin secretion, otherwise known as the incretin effect. In diabetes, these steps are disrupted.</div><div class=\"graphic_footnotes\">GLP-1: glucagon-like peptide 1; GIP: glucose-dependent insulinotropic polypeptide, gastric inhibitory peptide.</div><div id=\"graphicVersion\">Graphic 59551 Version 4.0</div></div></div>"},"59552":{"type":"graphic_picture","displayName":"Flexible bronchoscopes","title":"Flexible bronchoscopes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexible bronchoscopes</div><div class=\"cntnt\"><img style=\"width:405px; height:243px;\" src=\"images/PULM/59552_Flexible_bronchoscopes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Varius sized flexible bronchoscopes and retrieval instruments for foreign body removal. From top to bottom: 6 mm outer diameter (OD) bronchoscope with a 2.8 mm diameter working channel (WC); 4.9 mm OD bronchoscope with a 2.2 mm diameter WC; 3.5 mm OD bronchoscope with a 1.2 mm diameter WC; and 2.7 mm OD bronchoscope with a 1.2 mm diameter WC. A large variety of ancillary equipment, including forceps, grasping claws, and baskets, can be passed through these bronchoscopes to grip various foreign bodies.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 59552 Version 3.0</div></div></div>"},"59553":{"type":"graphic_figure","displayName":"Local and systemic distribution of ICS","title":"Pharmacokinetics of inhaled corticosteroids","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Pharmacokinetics of inhaled corticosteroids</div><div class=\"cntnt\"><img style=\"width:498px; height:320px;\" src=\"images/PULM/59553_ICS_side_effects_local_syst.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sixty to 90 percent&nbsp;of the corticosteroid dose from a metered dose or dry powder inhaler lands in the mouth or pharynx and is swallowed and absorbed from the gastrointestinal tract. This fraction is then largely metabolized by the liver (\"first pass metabolism\") so that only a small amount is absorbed into the systemic circulation. Approximately 10 to 40 percent&nbsp;of a dose of inhaled corticosteroid is delivered to the respiratory tract. This portion is absorbed from the lung periphery directly into the systemic circulation. Thus, although less of the dose is delivered to the respiratory tract, that is the amount that contributes proportionately more to systemic side effects.</div><div class=\"graphic_footnotes\">ICS: inhaled corticosteroid or glucocorticoid; GI: gastrointestinal.</div><div id=\"graphicVersion\">Graphic 59553 Version 3.0</div></div></div>"},"59554":{"type":"graphic_algorithm","displayName":"Dx and Rx of suspected SBP","title":"Approach to the management of suspected spontaneous bacterial peritonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to the management of suspected spontaneous bacterial peritonitis</div><div class=\"cntnt\"><img style=\"width:430px; height:326px;\" src=\"images/GAST/59554_Dx_and_Rx_of_suspected_SBP.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PMN: polymorphonuclear leukocyte; IV: intravenous.<br />* Albumin infusion should be given if the creatinine is &gt;1 mg/dL (88 micromol/L), the blood urea nitrogen is &gt;30 mg/dL (10.7 mmol/L), or the total bilirubin is &gt;4 mg/dL (68 micromol/L).</div><div id=\"graphicVersion\">Graphic 59554 Version 2.0</div></div></div>"},"59556":{"type":"graphic_picture","displayName":"Endoscopy nasal cavity","title":"Endoscopic view of the nose","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of the nose</div><div class=\"cntnt\"><img style=\"width:326px; height:314px;\" src=\"images/ID/59556_Endoscopy_nasal_cavity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the right nasal cavity showing purulent discharge flowing from the maxillary and ethmoid sinuses onto the middle&nbsp;meatus. The middle turbinate&nbsp;(MT), lateral nasal wall (L), and nasal septum (S) are visible.</div><div id=\"graphicVersion\">Graphic 59556 Version 3.0</div></div></div>"},"59561":{"type":"graphic_figure","displayName":"Female pelvis - Sagittal view","title":"Female pelvis - Sagittal view","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Female pelvis - Sagittal view</div><div class=\"cntnt\"><img style=\"width:538px; height:345px;\" src=\"images/SURG/59561_Female-pelvis-sagittal-section.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the sagittal view of the female pelvis. Note the rectovaginal septum and the proximity of the uterus and bladder to the rectum.</div><div id=\"graphicVersion\">Graphic 59561 Version 1.0</div></div></div>"},"59564":{"type":"graphic_figure","displayName":"Dose response PEG rHuMGDF A","title":"Response to thrombopoietin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Response to thrombopoietin</div><div class=\"cntnt\"><img style=\"width:447px; height:324px;\" src=\"images/HEME/59564_DoseresponsePEGrHuMGDFA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dose-response of daily subcutaneous injections of PEG-rHuMGDF for 28 days on the peripheral platelet count in baboons. The daily doses were 0.05 (squares), 0.10 (triangles), 0.50 (closed circle), and 2.50 (open circle) mcg/kg. The peripheral platelet count increased incrementally in a log-linear dose-response manner.</div><div class=\"graphic_footnotes\">PEG-rHuMGDF: PEG-recombinant human megakaryocyte growth and development factor.</div><div class=\"graphic_reference\">Data from Harker, LA, Marzec, UM, Hunt, P, et al, Blood 1996; 88:511.</div><div id=\"graphicVersion\">Graphic 59564 Version 2.0</div></div></div>"},"59566":{"type":"graphic_figure","displayName":"ELF elastase with aerosol AAT","title":"Efficacy of aerosolized alpha-1 antitrypsin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efficacy of aerosolized alpha-1 antitrypsin</div><div class=\"cntnt\"><img style=\"width:442px; height:239px;\" src=\"images/PULM/59566_ELF_elastase_with_aerosol_A.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of aerosolized alpha-1 antitrypsin (100 mg every 12 hours) on epithelial lining fluid (ELF) antineutrophil elastase capacity. Replacement therapy raised ELF antielastase capacity into the normal range. The linear relationship between days 1 and 7 is illustrative and not necessarily representative of the real changes that occurred.</div><div class=\"graphic_reference\">Redrawn from Hubbard, RC, Brantly, ML, Sellers, SE, et al, Ann Intern Med 1989; 111:206.</div><div id=\"graphicVersion\">Graphic 59566 Version 1.0</div></div></div>"},"59567":{"type":"graphic_picture","displayName":"Noninvasive thymoma Gross","title":"Noninvasive thymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Noninvasive thymoma</div><div class=\"cntnt\"><img style=\"width:360px; height:242px;\" src=\"images/PULM/59567_Noninvasive_thymoma_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen shows a well- circumscribed, solid mass with a tan-ivory and lobulated cut surface.</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 59567 Version 1.0</div></div></div>"},"59570":{"type":"graphic_picture","displayName":"Facial nerve danger zones","title":"Danger zones for temporal, marginal mandibular, buccal, and zygomatic branches of the facial nerve. Danger zones for the great auricular and the spinal accessory nerves, and the parotid gland.","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Danger zones for temporal, marginal mandibular, buccal, and zygomatic branches of the facial nerve. Danger zones for the great auricular and the spinal accessory nerves, and the parotid gland.</div><div class=\"cntnt\"><img style=\"width:320px; height:504px;\" src=\"images/DERM/59570_Facial_nerve_danger_zones-edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Facial nerve danger zones. The frontal branch (F) of the facial nerve where it crosses the zygoma (area 4). The marginal mandibular (M) nerve where the superficial musculoaponeurotic system is thinned in the lower face (area 5). The parotid duct (PD) and the buccal (B) and zygomatic (Z) branches at the anterior border of the masseter muscle (area 6). The great auricular nerve (GAN) and the spinal accessory nerve (SAN) at Erb's point on the posterior margin of the sternocleidomastoid muscle (area 7). The parenchyma of the parotid gland (P) (area 8).</div><div id=\"graphicVersion\">Graphic 59570 Version 2.0</div></div></div>"},"59572":{"type":"graphic_table","displayName":"Definitions angina CASS","title":"Coronary artery surgery study definitions of angina","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Coronary artery surgery study definitions of angina</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Definite angina</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Substernal discomfort precipitated by exertion, with a\ntypical radiation to the shoulder, jaw or inner aspect of the\narm relieved by rest or nitroglycerin in less than 10 minutes</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Probable angina</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Has most of the features of definite angina but may not\nbe entirely typical in some aspects</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">\"Probably not\" angina</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Defined as an atypical overall pattern of chest pain\nthat does not fit the description of definite angina</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">\"Definitely not\"\nangina</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chest pain is unrelated to activity, appears to be\nclearly of non-cardiac origin and is not relieved by nitroglycerin</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from CASS Investigators. National Heart Lung and Blood Institute Coronary Artery Study, Circulation 1981; 63(Suppl I):I-81.</div><div id=\"graphicVersion\">Graphic 59572 Version 1.0</div></div></div>"},"59573":{"type":"graphic_table","displayName":"Syndrome associated strabismus","title":"Syndromes associated with strabismus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Syndromes associated with strabismus</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n   <tr>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td>Angelman</td>\n   </tr>\n   <tr>\n   <td>Apert</td>\n   </tr>\n   <tr>\n   <td>Cri du chat (Deletion 5p)</td>\n   </tr>\n   <tr>\n   <td>Crouzon</td>\n   </tr>\n   <tr>\n   <td>Down</td>\n   </tr>\n   <tr>\n   <td>Fanconi</td>\n   </tr>\n   <tr>\n   <td>Fetal alcohol</td>\n   </tr>\n   <tr>\n   <td>Fetal hydantoin</td>\n   </tr>\n   <tr>\n   <td>Fetal rubella</td>\n   </tr>\n   <tr>\n   <td>Incontinentia pigmenti</td>\n   </tr>\n   </table></td>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td>Laurence-Moon-Biedl</td>\n   </tr>\n   <tr>\n   <td>Marfan</td>\n   </tr>\n   <tr>\n   <td>Noonan</td>\n   </tr>\n   <tr>\n   <td>Ocular-auricular-vertebral (Goldenhar, hemifacial microsomia)</td>\n   </tr>\n   <tr>\n   <td>Pierre Robin</td>\n   </tr>\n   <tr>\n   <td>Prader-Willi</td>\n   </tr>\n   <tr>\n   <td>Smith-Lemli-Opitz</td>\n   </tr>\n   <tr>\n   <td>Sotos</td>\n   </tr>\n   <tr>\n   <td>Turner</td>\n   </tr>\n   <tr>\n   <td>Trisomy 18</td>\n   </tr>\n   <tr>\n   <td>Williams</td>\n   </tr>\n   </table></td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted from: Pattern of malformaton differential diagnosis by anomalies. In: Smith's Recognizable Patterns of Human Malformation, 5th ed, Jones, KL (Ed), WB Saunders, Philadelphia 1997. p. 785.</div><div id=\"graphicVersion\">Graphic 59573 Version 1.0</div></div></div>"},"59575":{"type":"graphic_table","displayName":"Drugs chemicals impair taste","title":"Drugs and chemicals associated with decreased taste sensation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs and chemicals associated with decreased taste sensation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Taste defect</td> <td class=\"subtitle1\">Mechanism</td> </tr> <tr> <td>Acetazolamide</td> <td>Bitter dysgeusia</td> <td>Ion channel disturbance</td> </tr> <tr> <td>Alcohol</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Allopurinol</td> <td>Metallic dysgeusia</td> <td>Second messengers disturbed</td> </tr> <tr> <td>Amiloride</td> <td>Hypogeusia to salt</td> <td>Ion channel disturbance</td> </tr> <tr> <td>Amphetamines</td> <td>Bitter dysgeusia</td> <td>Decreased bitter threshold</td> </tr> <tr> <td>Amphotericin B</td> <td>Hypogeusia</td> <td>Ion channel disturbance</td> </tr> <tr> <td>Amrinone</td> <td>Hypogeusia</td> <td>Second messengers disturbed</td> </tr> <tr> <td>Auranofin</td> <td>Metallic dysgeusia</td> <td>Displaces zinc?</td> </tr> <tr> <td>B-Lactam antibiotics</td> <td>Metallic dysgeusia</td> <td>Chelate zinc?</td> </tr> <tr> <td>Bleomycin</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Bretylium</td> <td>Hypogeusia to salt</td> <td>&nbsp;</td> </tr> <tr> <td>Captopril</td> <td>Dysgeusia</td> <td>Zinc deficiency or excess bradykin accumulation</td> </tr> <tr> <td>Carbamazepine</td> <td>Hypogeusia</td> <td>Decreased calcium-mediated neurotransmission?</td> </tr> <tr> <td>Carboplatin</td> <td>Hypogeusia</td> <td>Mucosal death with decreased regeneration</td> </tr> <tr> <td>Cisplatin</td> <td>Hypogeusia to ageusia</td> <td>Mucosal death with decreased regeneration</td> </tr> <tr> <td>Chlorhexidine mouth wash</td> <td>Salt hypogeusia</td> <td>Binds to sodium channels</td> </tr> <tr> <td>Choline magnesium trisalicylate</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Dicyclomine</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Diltiazem</td> <td>Hypogeusia, dysgeusia, ageusia</td> <td>Decreased calcium-mediated neurotransmission?</td> </tr> <tr> <td>Dipyridamole</td> <td>Dysgeusia or parageusia</td> <td>Second messenger system</td> </tr> <tr> <td>EDTA</td> <td>Dysgeusia</td> <td>Chelates zinc</td> </tr> <tr> <td>Enalapril</td> <td>Dysgeusia and ageusia</td> <td>Zinc deficiency or excell bradykin accumulation</td> </tr> <tr> <td>Ethambutol</td> <td>Metallic dysgeusia</td> <td>Unknown</td> </tr> <tr> <td>Ethionamide</td> <td>Metallic dysgeusia</td> <td>&nbsp;</td> </tr> <tr> <td>Etidronate</td> <td>Ageusia</td> <td>Chelates zinc</td> </tr> <tr> <td>Flurazepam</td> <td>Metallic dysgeusia</td> <td>&nbsp;</td> </tr> <tr> <td>Flunisolide (metered dose inhaler)</td> <td>Dysgeusia</td> <td>&nbsp;</td> </tr> <tr> <td>5-fluorouracil</td> <td>Sweet dysgeusia</td> <td>Mucosal toxicity</td> </tr> <tr> <td>Glycoprrolate</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Hydrochlorothiazide</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Hydrocortisone</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hyoscyamine</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Interferon-gamma</td> <td>Metallic dysgeusia</td> <td>&nbsp;</td> </tr> <tr> <td>Iodine</td> <td>Metallic dysgeusia</td> <td>&nbsp;</td> </tr> <tr> <td>Isotretinoin</td> <td>Loss of sour taste</td> <td>Disturbs ion channels</td> </tr> <tr> <td>Levamisole</td> <td>Metallic dysgeusia</td> <td>&nbsp;</td> </tr> <tr> <td>Levodopa</td> <td>Hypogeusia</td> <td>Dopaminergic nerve depression of taste transmission</td> </tr> <tr> <td>Lisinopril</td> <td>Dysgeusia</td> <td>Zinc deficiency or excess bradykin accumulation</td> </tr> <tr> <td>Lithium</td> <td>Metallic dysgeusia</td> <td>Ion channels or second messenger systems</td> </tr> <tr> <td>Lomefloxacin</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Losartan</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Lovastatin</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Methyl methacrylate</td> <td>Ageusia?</td> <td>Bone cement solvent exposure</td> </tr> <tr> <td>Methimazole</td> <td>Ageusia</td> <td>Zinc depletion</td> </tr> <tr> <td>Methotrexate</td> <td>&nbsp;</td> <td>Mucosal death with regeneration</td> </tr> <tr> <td>Metronidazole</td> <td>Metallic dysgeusia to hyposmia</td> <td>Unknown</td> </tr> <tr> <td>Nifedipine</td> <td>Hypogeusia, dysgeusia, ageusia</td> <td>Decreased calcium-mediated neurotransmission?</td> </tr> <tr> <td>Nitroglycerin</td> <td>Dysgeusia</td> <td>Poisoned cyclic adenosine 3', 5' monophosphate synthesis</td> </tr> <tr> <td>Ofloxacin</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Selegiline</td> <td>Dysgeusia*</td> <td>&nbsp;</td> </tr> <tr> <td>Spironolactone</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Sulfasalazine</td> <td>Hypogeusia</td> <td>Unknown</td> </tr> <tr> <td>Terbinafine</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Tetracycline</td> <td>Metallic dysgeusia</td> <td>Disturbed ion channels?</td> </tr> <tr> <td>Tocainide</td> <td>Metallic dysgeusia</td> <td>&nbsp;</td> </tr> <tr> <td>Triazolam</td> <td>Ageusia</td> <td>&nbsp;</td> </tr> <tr> <td>Vandetanib</td> <td>Dysgeusia</td> <td>&nbsp;</td> </tr> <tr> <td>Vismodegib</td> <td>Dysgeusia</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EDTA: ethylenediaminetetraacetic acid.<br />* Incidence greater than 3 percent.</div><div class=\"graphic_reference\">Adapted with permission from: Ackerman BH, Kasbekar N, Pharmacotherapy 1997; 17:1.</div><div id=\"graphicVersion\">Graphic 59575 Version 6.0</div></div></div>"},"59576":{"type":"graphic_figure","displayName":"Overdiagnosis in cancer scrn","title":"Mechanism of overdiagnosis in cancer screening","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Mechanism of overdiagnosis in cancer screening</div><div class=\"cntnt\"><img style=\"width:453px; height:252px;\" src=\"images/PC/59576_Overdiagnosisincancerscr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that nonprogressive, as well as some very slow growing, cancers will never cause clinical harm. When these cancers are found on screening, overdiagnosis has occurred. Overdiagnosis is an extreme form of length-time bias.</div><div class=\"graphic_reference\">Originally reprinted from Welsh HG. Should I be tested for cancer? Maybe not and here's why. Berkeley and Los Angeles, California: University of California Press, 2004. Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59576 Version 11.0</div></div></div>"},"59577":{"type":"graphic_picture","displayName":"Aspiration of chancroid bubo","title":"Aspiration of a chancroid bubo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspiration of a chancroid bubo</div><div class=\"cntnt\"><img style=\"width:380px; height:240px;\" src=\"images/ID/59577_Aspiration_of_chancroid_bub.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aspiration of purulent fluid (seen in the syringe) from a fluctuant bubo in a patient with chancroid. Repeated needle aspirations may be necessary, even after effective antimicrobial therapy.</div><div id=\"graphicVersion\">Graphic 59577 Version 1.0</div></div></div>"},"59579":{"type":"graphic_table","displayName":"Molecular test transverse myelitis","title":"Molecular tests for infectious causes of transverse myelitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular tests for infectious causes of transverse myelitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Availability*</td> <td class=\"subtitle1\">When inclusion of NAT is indicated</td> <td class=\"subtitle1\">Preferred testing method(s)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Mycoplasma</em> spp</td> <td>Yes</td> <td>When clinically suspected</td> <td>NAT, serology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Mycobacterium tuberculosis</em><sup>&#916;</sup></td> <td>Yes</td> <td>Potentially</td> <td>AFB stain, culture, histologic exam +/&ndash; NAT</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Viruses</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> <td>Yes</td> <td>When clinically suspected</td> <td>NAT, preferably quantitative</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> <td>Yes</td> <td>When clinically suspected</td> <td>NAT, preferably quantitative</td> </tr> <tr> <td class=\"indent1\">Enteroviruses</td> <td>Widespread</td> <td>When clinically suspected</td> <td>NAT</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> <td>Widespread</td> <td>When clinically suspected</td> <td>NAT</td> </tr> <tr> <td class=\"indent1\">Mumps</td> <td>Limited</td> <td>Rarely</td> <td>History, viral culture, serology, and NAT</td> </tr> <tr> <td class=\"indent1\">Varicella-zoster virus</td> <td>Yes</td> <td>When clinically suspected</td> <td>NAT</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">West Nile virus<sup>&#9674;</sup></td> <td>Yes</td> <td>Rarely (unless immunocompromised)</td> <td>Serology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Spirochetes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Treponema pallidum</em> (syphilis)</td> <td>Limited</td> <td>No</td> <td>Serology, CSF VDRL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Parasites</td> </tr> <tr> <td class=\"indent1\"><em>Schistosoma</em> spp</td> <td>Limited</td> <td>Rarely</td> <td>Serology, histologic exam</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPV: positive predictive value; CDC: Centers for Disease Control and Prevention; NAT: nucleic acid amplification testing; CSF: cerebrospinal fluid; AFB: acid-fast bacilli; VDRL: Venereal Disease Research Laboratories.<br />* Widespread: readily available; Yes: consistently available, but not yet common; Limited: one or two specialized laboratories (eg, CDC or research groups).<br />¶ Test on CSF except where noted.<br />Δ Limited experience, presumably poor sensitivity, high PPV.<br /><FONT class=lozenge>◊</FONT> Virus is usually cleared from blood and CSF prior to symptom onset.</div><div id=\"graphicVersion\">Graphic 59579 Version 6.0</div></div></div>"},"59583":{"type":"graphic_picture","displayName":"Nodular sclerosis Hodgkin lymphoma","title":"Nodular sclerosis Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Nodular sclerosis Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:501px; height:756px;\" src=\"images/HEME/59583_NodsclerosisHodglymph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Broad bands of fibrosis separate several nodules in nodular sclerosis Hodgkin lymphoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al. Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59583 Version 8.0</div></div></div>"},"59584":{"type":"graphic_table","displayName":"Sources of latex","title":"Potential sources of latex","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential sources of latex</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Home environment </td> </tr> <tr> <td>Latex dishwashing gloves</td> </tr> <tr> <td>Balloons</td> </tr> <tr> <td>Condoms, diaphragms</td> </tr> <tr> <td>Bandages (adhesives)</td> </tr> <tr> <td>Pacifiers/baby bottle nipples/teething rings</td> </tr> <tr> <td>Spandex*</td> </tr> <tr> <td>Erasers</td> </tr> <tr> <td>Golf and tennis racquet grips*</td> </tr> <tr> <td>Rubber bands (minor source)</td> </tr> <tr> <td>Rubber cement</td> </tr> <tr> <td>Foam pillows and mattresses</td> </tr> <tr> <td class=\"subtitle1_single\">Medical settings </td> </tr> <tr> <td>Gloves</td> </tr> <tr> <td>Blood pressure cuffs</td> </tr> <tr> <td>Tourniquets</td> </tr> <tr> <td>Catheters</td> </tr> <tr> <td>Equipment previously handled with latex gloves</td> </tr> <tr> <td>Ostomy bags</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Emergency care settings </td> </tr> <tr> <td>Oral and nasal airways</td> </tr> <tr> <td>Oxygen masks and nasal cannulae</td> </tr> <tr> <td>Self-inflating bag</td> </tr> <tr> <td>Blood pressure monitor</td> </tr> <tr> <td>Emergency medications (latex seals?)</td> </tr> <tr> <td class=\"subtitle1_single\">Dental office </td> </tr> <tr> <td>Gutta Balota (used to seal root canals)</td> </tr> <tr> <td>Dental dams</td> </tr> <tr> <td>Some wedges</td> </tr> <tr> <td>Local anaesthetic cartridges</td> </tr> <tr> <td>Prophylaxis polishing cups</td> </tr> <tr> <td>Orthodontic rubber bands</td> </tr> <tr> <td>General anesthesia/sedation equipment including tubing, face masks, props</td> </tr> <tr> <td>Endodontic stops</td> </tr> <tr> <td>Amalgam carrier tips</td> </tr> <tr> <td>Adhesives and dressings and their packaging</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Sometimes contaminated with natural rubber latex. Check with manufacturer.</div><div id=\"graphicVersion\">Graphic 59584 Version 2.0</div></div></div>"},"59585":{"type":"graphic_table","displayName":"Risk factors ovarian cancer","title":"Risk factors for ovarian cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for ovarian cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Relative risk</td> <td class=\"subtitle1\">Lifetime probability, percent<sup>[1]</sup></td> </tr> <tr> <td>General population</td> <td>1.0</td> <td>1.4<sup>[1]</sup></td> </tr> <tr> <td><em>BRCA1</em> gene mutation</td> <td>&nbsp;</td> <td>35 to 46<sup>[2]</sup></td> </tr> <tr> <td><em>BRCA2</em> gene mutation</td> <td>&nbsp;</td> <td>13 to 23<sup>[2]</sup></td> </tr> <tr> <td>Lynch syndrome (hereditary nonpolyposis colon cancer)</td> <td>&nbsp;</td> <td>3 to 14<sup>[3,4]</sup></td> </tr> <tr> <td>Family history of ovarian cancer (with negative testing for a familial ovarian cancer syndrome)</td> <td>Uncertain<sup>[5,6]</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Infertility</td> <td>2.67<sup>[7]</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Polycystic ovarian syndrome</td> <td>2.52<sup>[8]</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Endometriosis (increase in risk of clear cell, endometrioid, or low grade serous carcinomas)</td> <td>2.04 to 3.05<sup>[9]</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Cigarette smoking (increase in risk of mucinous carcinoma)</td> <td>2.1<sup>[10]</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Intrauterine device</td> <td>1.76<sup>[11]</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Past use of oral contraceptives</td> <td>0.73<sup>[12]</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Past breast feeding (for &#62;12 months)</td> <td>0.72<sup>[13]</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Tubal ligation</td> <td>0.69<sup>[14]</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Previous pregnancy</td> <td>0.6</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>http://seer.cancer.gov/statfacts/html/ovary.html.</LI>&#xD;&#xA;<LI>Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25:1329.</LI>&#xD;&#xA;<LI>Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009; 10:400.</LI>&#xD;&#xA;<LI>Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome:&nbsp;A report of 121 families with proven mutations. Clin Genet 2009; 75:141.</LI>&#xD;&#xA;<LI>Kauff ND, Mitra N, Robson ME, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.&nbsp;J Natl Cancer Inst 2005; 97:1382.</LI>&#xD;&#xA;<LI>Lee JS, John EM, McGuire V, et al. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev 2006; 15:359.</LI>&#xD;&#xA;<LI>Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217.</LI>&#xD;&#xA;<LI>Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: A systematic review. Reprod Biomed Online 2009; 19:398.</LI>&#xD;&#xA;<LI>Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. Lancet Oncol 2012; 13:385.</LI>&#xD;&#xA;<LI>Jordan SJ, Whiteman DC, Purdie DM, et al. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006; 103:1122.</LI>&#xD;&#xA;<LI>Tworoger SS, Fairfield KM, Colditz GA, et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007; 166:894.</LI>&#xD;&#xA;<LI>Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371:303.</LI>&#xD;&#xA;<LI>Ip S, Chung M, Raman G, et al. A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries. Breastfeed Med 2009; 4 Suppl 1:S17.</LI>&#xD;&#xA;<LI>Cibula D, Widschwendter M, Májek O, Dusek L. Tubal ligation and the risk of ovarian cancer: Review and meta-analysis. Hum Reprod Update 2011; 17:55.</LI></OL></div><div id=\"graphicVersion\">Graphic 59585 Version 5.0</div></div></div>"},"59586":{"type":"graphic_table","displayName":"Effector cell properties","title":"Properties of effector cell populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Properties of effector cell populations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Property</td>\n<td class=\"subtitle1\">Natural killer cells</td>\n<td class=\"subtitle1\">Cytotoxic T lymphocytes</td>\n<td class=\"subtitle1\">NK-like T cells</td>\n</tr>\n<tr>\n<td>Phenotype</td>\n<td>CD3-CD56+CD16+</td>\n<td>CD3+CD56-CD8+</td>\n<td>CD3+CD56+CD16-</td>\n</tr>\n<tr>\n<td>Precursor cell</td>\n<td>NK</td>\n<td>T</td>\n<td>T</td>\n</tr>\n<tr>\n<td>Antigen specific</td>\n<td>No</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n<tr>\n<td>Expandable</td>\n<td>Limited</td>\n<td>Yes</td>\n<td>Yes</td>\n</tr>\n<tr>\n<td>Require IL-2 in vivo</td>\n<td>Yes</td>\n<td>No</td>\n<td>No</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Lu, LPH, Negrin, RS, Biol Blood Marrow Transplant 1997; 3:113.</div><div id=\"graphicVersion\">Graphic 59586 Version 1.0</div></div></div>"},"59587":{"type":"graphic_figure","displayName":"Remission from splenectomy in ITP","title":"Frequency of complete remission in immune thrombocytopenia (ITP) following splenectomy","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Frequency of complete remission in immune thrombocytopenia (ITP) following splenectomy</div><div class=\"cntnt\"><img style=\"width:550px; height:346px;\" src=\"images/HEME/59587_Splenectomy_results_ITP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data for all 47 case series of 15 or more adults who had splenectomy for ITP, 1966-2004, with follow-up of 1 to 153 months (median, 29 months). The data demonstrate that the rate of complete remissions (defined as a normal platelet count on no further treatment for the duration of observation) did not change with longer follow-up.</div><div class=\"graphic_reference\">This research was originally published in Blood. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104:2623. Copyright © 2004 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 59587 Version 4.0</div></div></div>"},"59588":{"type":"graphic_diagnosticimage","displayName":"Positive remodeling IVUS","title":"Example of positive remodeling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of positive remodeling</div><div class=\"cntnt\"><img style=\"width:431px; height:262px;\" src=\"images/CARD/59588_Positive_remodeling_IVUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intravascular ultrasound images of the proximal reference and lesion site are shown. The remodeling ratio (EEM area lesion/EEM area proximal reference) is 1.32.</div><div class=\"graphic_footnotes\">EEM: external elastic membrane.</div><div class=\"graphic_reference\">Reprinted with permission from: Schoenhagen P, Ziada KM, Vince DC, et al. J Am Coll Cardiol 2001; 38:297. Copyright © 2001 American College of Cardiology.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 59588 Version 5.0</div></div></div>"},"59590":{"type":"graphic_picture","displayName":"Bullous pemphigoid trunk","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/59590_Bullous_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory plaques, bullae, erosions, crusts, and postinflammatory hyperpigmentation on&nbsp;trunk skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59590 Version 4.0</div></div></div>"},"59591":{"type":"graphic_picture","displayName":"Lentigo maligna nose","title":"Lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna</div><div class=\"cntnt\"><img style=\"width:377px; height:504px;\" src=\"images/DERM/59591_Lentigo_maligna_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59591 Version 2.0</div></div></div>"},"59592":{"type":"graphic_figure","displayName":"TMLR freedom rehospitalization","title":"Transmyocardial laser revascularization reduces cardiac-related rehospitalizations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transmyocardial laser revascularization reduces cardiac-related rehospitalizations</div><div class=\"cntnt\"><img style=\"width:379px; height:266px;\" src=\"images/CARD/59592_TMLR_freedom_rehospitalizat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 275 patients with refractory angina, Kaplan-Meier estimates show that freedom from cardiac-related rehospitalization at one year was higher with transmyocardial laser revascularization (TMLR) compared to medical therapy (61 versus 33 percent, p &lt;0.001).</div><div class=\"graphic_reference\">Data from Allen KB, Dowling RD, Fudge TL, et al. N Engl J Med 1999; 341:1029.</div><div id=\"graphicVersion\">Graphic 59592 Version 2.0</div></div></div>"},"59593":{"type":"graphic_picture","displayName":"Keratoacanthoma on hand","title":"Keratoacanthoma","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Keratoacanthoma</div><div class=\"cntnt\"><img style=\"width:476px; height:318px;\" src=\"images/DERM/59593_Keratoacanthoma_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A keratoacanthoma with a characteristic central accumulation of keratin on the dorsal hand.</div><div id=\"graphicVersion\">Graphic 59593 Version 2.0</div></div></div>"},"59594":{"type":"graphic_picture","displayName":"Paraneoplastic pemphigus oral findings","title":"Paraneoplastic pemphigus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic pemphigus</div><div class=\"cntnt\"><img style=\"width:333px; height:360px;\" src=\"images/DERM/59594_Paraneoplasticpemphigus2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erosive mucositis in a&nbsp;patient with paraneoplastic pemphigus associated with Castleman's tumor; mucous membrane and cutaneous lesions cleared with tumor removal.</div><div class=\"graphic_reference\">Copyright © Chris Ha, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 59594 Version 9.0</div></div></div>"},"59595":{"type":"graphic_diagnosticimage","displayName":"Transverse temporal fracture","title":"Transverse temporal bone fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse temporal bone fracture</div><div class=\"cntnt\"><img style=\"width:322px; height:318px;\" src=\"images/PC/59595_Transverse_temporal_fractur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blunt trauma to the occipital or frontal region, resulting in a line of fracture through the cochlea&nbsp;(arrow).</div><div class=\"graphic_reference\">Courtesy of Peter C Weber, MD.</div><div id=\"graphicVersion\">Graphic 59595 Version 3.0</div></div></div>"},"59598":{"type":"graphic_table","displayName":"Bronchoscopic yield in HIV","title":"Bronchoscopic yield for various infectious and noninfectious pulmonary diseases associated with HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bronchoscopic yield for various infectious and noninfectious pulmonary diseases associated with HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"> <tbody>\n<tr> <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Disease</td> <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Procedure</td>\n</tr> <tr> <td class=\"subtitle2\">Bronchial\nwash/brush/biopsy</td> <td class=\"subtitle2\">Bronchoalveolar\nlavage</td> <td class=\"subtitle2\">Transbronchial\nbiopsy</td> </tr> <tr> <td>PCP</td> <td>0-1</td>\n<td>3</td> <td>3</td> </tr> <tr>\n<td>Tuberculosis</td> <td>2-3</td> <td>2</td>\n<td>2</td> </tr> <tr> <td>Routine\nbacteria</td> <td>2-3*</td> <td>2-3*</td>\n<td>NA</td> </tr> <tr> <td>Pathologic\nfungi</td> <td>1-2</td> <td>2</td> <td>1</td>\n</tr> <tr> <td>Kaposi's sarcoma</td> <td>0-1</td>\n<td>0</td> <td>0</td> </tr> <tr>\n<td>Lymphocytic or non-specific interstitial pneumonia</td>\n<td>0</td> <td>0</td> <td>1-2</td>\n</tr> </tbody>\n</table></div><div class=\"graphic_footnotes\">Scale: 0 = very poor; 1 = poor; 2 = moderate; 3 = high; NA = not applicable.<br> * Protected brush/BAL with patient off antibiotics.</div><div id=\"graphicVersion\">Graphic 59598 Version 1.0</div></div></div>"},"59599":{"type":"graphic_table","displayName":"Environmental history of asthma","title":"Environmental history for the child with asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Environmental history for the child with asthma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Passive tobacco smoke exposure (house, car, daycare)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Siblings and ages</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wood-burning stoves and ventilation system</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Animals (dogs, cats, birds, furry pets); where animals reside and how often they are in the house or in the patient's bedroom</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Leaky plumbing, recent flooding, obvious mold, mildew in any part of the house</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Method of heating, cooling; is there an evaporative cooler? window air conditioner?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Patient's bedroom: type and age of mattress, bedding, window-coverings, flooring, dust-collecting items, stuffed animals and how often laundered</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 59599 Version 2.0</div></div></div>"},"59601":{"type":"graphic_table","displayName":"Infant mortality based on race and ethnicity of mother","title":"Infant mortality rates per 100 live births by maternal race in the United States, 2005 and 2013","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infant mortality rates per 100 live births by maternal race in the United States, 2005 and 2013</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Race and hispanic origin</td> <td class=\"subtitle1\">2005</td> <td class=\"subtitle1\">2013</td> </tr> <tr> <td>Asian or Pacific Islander*</td> <td class=\"centered\">4.89</td> <td class=\"centered\">4.07</td> </tr> <tr> <td>Non-Hispanic white</td> <td class=\"centered\">5.76</td> <td class=\"centered\">5.06</td> </tr> <tr> <td>All Hispanic groups</td> <td class=\"centered\">5.62</td> <td class=\"centered\">5.00</td> </tr> <tr> <td>American Indian or Alaska native</td> <td class=\"centered\">8.06</td> <td class=\"centered\">7.61</td> </tr> <tr> <td>Non-Hispanic black</td> <td class=\"centered\">13.63</td> <td class=\"centered\">11.11</td> </tr> <tr> <td>Total</td> <td class=\"centered\">6.86</td> <td class=\"centered\">5.96</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Includes persons of Hispanic and non-Hispanic origin.</div><div class=\"graphic_reference\">Data from: National Vital Statistics System. Linked Birth and Infant Death Data. Centers for Disease Control and Prevention. Available at: <A spellcheck=true href=\"http://www.cdc.gov/nchs/linked.htm\" target=_blank>http://www.cdc.gov/nchs/linked.htm</A> (Accessed on June 5, 2017).</div><div id=\"graphicVersion\">Graphic 59601 Version 5.0</div></div></div>"},"59602":{"type":"graphic_diagnosticimage","displayName":"Osteomyelitis MRI","title":"Magnetic resonance image demonstrating osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image demonstrating osteomyelitis</div><div class=\"cntnt\"><img style=\"width:327px; height:540px;\" src=\"images/PEDS/59602_Osteomyelitis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The proximal shaft and metaphysis of the left tibia show an abnormal mottled appearance.<br />(B) The marrow signal from the left tibia is abnormal. In addition, there is soft tissue inflammation surrounding the left tibia.</div><div class=\"graphic_reference\">Courtesy of Sheldon L Kaplan, MD. Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 59602 Version 3.0</div></div></div>"},"59603":{"type":"graphic_figure","displayName":"Phenylalanine and tyrosine metabolism","title":"Phenylalanine and tyrosine metabolism","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Phenylalanine and tyrosine metabolism</div><div class=\"cntnt\"><img style=\"width:470px; height:616px;\" src=\"images/PEDS/59603_Phe_and_tyr_metabolism_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PKU: phenylketonuria; HPA: hyperphenylalaninemia; NTBC: nitisinone.</div><div id=\"graphicVersion\">Graphic 59603 Version 5.0</div></div></div>"},"59606":{"type":"graphic_table","displayName":"Extrahepatic symptoms in AIH","title":"Extrahepatic disorders associated with autoimmune hepatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Extrahepatic disorders associated with autoimmune hepatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Extrahepatic diseases</td> <td class=\"subtitle1\">Frequency among patients with AIH (%)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Pulmonary disorders</td> <td>Fibrosing alveolitis</td> <td>&#60;1</td> </tr> <tr> <td>Pulmonary fibrosis</td> <td>&#60;1</td> </tr> <tr> <td>Sarcoidosis</td> <td>&#60;1</td> </tr> <tr class=\"divider_bottom\"> <td>Asthma</td> <td>1 to 4</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Hematological disorders</td> <td>Immune thrombocytopenia</td> <td>&#60;1</td> </tr> <tr> <td>Autoimmune hemolytic anemia</td> <td>&#60;1</td> </tr> <tr> <td>Pernicious anemia </td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Antiphospholipid syndrome</td> <td>1</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Neurologic disorders</td> <td>Multiple sclerosis</td> <td>&#60;1</td> </tr> <tr class=\"divider_bottom\"> <td>Mononeuritis multiplex</td> <td>&#60;1</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Miscellaneous</td> <td>Primary amenorrhoea</td> <td>4</td> </tr> <tr> <td>Glomerulonephritis</td> <td>1</td> </tr> <tr> <td>Cryoglobulinemia</td> <td>&#60;1</td> </tr> <tr> <td>Uveitis</td> <td>&#60;1</td> </tr> <tr class=\"divider_bottom\"> <td>Polyglandular autoimmune syndrome</td> <td>&#60;1</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Endocrine disorders</td> <td>Autoimmune thyroiditis</td> <td>8 to 23</td> </tr> <tr class=\"divider_bottom\"> <td>Diabetes (type 1)</td> <td>1 to 10</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Gastrointestinal disorders</td> <td>IBD (ulcerative colitis)</td> <td>2 to 8</td> </tr> <tr class=\"divider_bottom\"> <td>Celiac disease +/&ndash; IgA deficiency</td> <td>1 to 6</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\">Connective tissue disorders</td> <td>Rheumatoid arthritis</td> <td>2 to 4</td> </tr> <tr> <td>Sj&#246;gren's syndrome</td> <td>1 to 7</td> </tr> <tr> <td>Mixed connective tissue disease</td> <td>1 to 2.5</td> </tr> <tr> <td>Systemic lupus erythematosus</td> <td>1 to 2.6</td> </tr> <tr> <td>Systemic sclerosis/scleroderma/CREST</td> <td>&#60;1</td> </tr> <tr> <td>Polymyalgia rheumatica</td> <td>&#60;1</td> </tr> <tr> <td>Polymyositis</td> <td>&#60;1</td> </tr> <tr class=\"divider_bottom\"> <td>Dermatomyositis</td> <td>&#60;1</td> </tr> <tr> <td rowspan=\"8\">Skin disorders</td> <td>Psoriasis</td> <td>3</td> </tr> <tr> <td>Vitiligo</td> <td>1 to 2</td> </tr> <tr> <td>Pyoderma gangrenosum</td> <td>&#60;1</td> </tr> <tr> <td>Acne</td> <td>&#60;1</td> </tr> <tr> <td>Urticaria</td> <td>&#60;1</td> </tr> <tr> <td>Lichen planus</td> <td>&#60;1</td> </tr> <tr> <td>Erythema nodosum</td> <td>&#60;1</td> </tr> <tr> <td>Dermatitis herpetiformis</td> <td>&#60;1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIH: autoimmune hepatitis; IBD: inflammatory bowel disease; CREST: calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.</div><div id=\"graphicVersion\">Graphic 59606 Version 2.0</div></div></div>"},"59607":{"type":"graphic_movie","displayName":"Bicuspid aortic valve short axis echocardiogram 1","title":"Short axis view from an echocardiogram of bicupsid aortic valve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Short axis view from an echocardiogram of bicupsid aortic valve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/59607_biav1saxconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:270px; height:442px;\" src=\"images/CARD/59607_biav1sax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis view from a 2-D echocardiogram shows a biscupid aortic valve with two leaflets that move normally. The aortic root appears to be thickened.</div><div class=\"graphic_reference\">Courtesy of David W Brown, MD. </div><div id=\"graphicVersion\">Graphic 59607 Version 4.0</div></div></div>"},"59608":{"type":"graphic_picture","displayName":"Massive perivillous fibrin deposition(maternal floor infarction)","title":"Massive perivillous fibrin deposition (maternal floor infarction)","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Massive perivillous fibrin deposition (maternal floor infarction)</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/59608_Maternalfloorinfarction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Band of fibrinoid materal along maternal floor of placenta causing \"strangulation\" and necrosis of the villi.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 59608 Version 4.0</div></div></div>"},"59609":{"type":"graphic_table","displayName":"Pregnancy lipoprotein levels","title":"Approximate average lipoprotein concentrations in 19 healthy women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approximate average lipoprotein concentrations in 19 healthy women</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Type of lipoprotein\n   </td>\n   <td  class=\"subtitle1\">\n   Nonpregnant*\n   </td>\n   <td  class=\"subtitle1\">\n   Early pregnancy*\n   </td>\n   <td  class=\"subtitle1\">\n   Late pregnancy*\n   </td>\n   </tr>\n   <tr>\n   <td>Total triglycerides</td>\n   <td>60</td>\n   <td>75 to 100</td>\n   <td>210</td>\n   </tr>\n   <tr>\n   <td>Total cholesterol</td>\n   <td>170</td>\n   <td>175 to 200</td>\n   <td>250</td>\n   </tr>\n   <tr>\n   <td>VLDL cholesterol</td>\n   <td>10</td>\n   <td>10</td>\n   <td>25</td>\n   </tr>\n   <tr>\n   <td>LDL cholesterol</td>\n   <td>105</td>\n   <td>100 to 125</td>\n   <td>150</td>\n   </tr>\n   <tr>\n   <td>HDL cholesterol</td>\n   <td>55</td>\n   <td>55 to 75</td>\n   <td>65</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">* Units are mg/dL; divide cholesterol values by 38.5 and triglycerides by 88.6 to convert to mmol/L.</div><div class=\"graphic_reference\">Data from: Fahraeus, L, Larsson-Cohn, U, Wallentin, L. Obstet Gynecol 1985; 66:468.</div><div id=\"graphicVersion\">Graphic 59609 Version 1.0</div></div></div>"},"59611":{"type":"graphic_diagnosticimage","displayName":"X-linked hypophosphatemic rickets radiograph","title":"X-linked hypophosphatemic rickets radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">X-linked hypophosphatemic&nbsp;rickets radiograph</div><div class=\"cntnt\"><img style=\"width:282px; height:360px;\" src=\"images/PEDS/59611_XLHricketsradiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standing anteroposterior films of both lower extremities help distinguish physiologic bowing from pathologic causes. This patient with X-linked hypophosphatemic rickets (XLH) has multiple widened physes. Osteopenia is evident in the adjacent metaphysis, which is also flared. Bowing tends to be more diffuse throughout the bone, rather than focal in the proximal tibia.</div><div class=\"graphic_reference\">Reproduced with permission from: Schoenecker PL, Rich MM. The Lower Extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6<SUP>th</SUP> ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59611 Version 13.0</div></div></div>"},"59612":{"type":"graphic_figure","displayName":"Serum prolactin and suckling","title":"Serum prolactin and suckling","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Serum prolactin and suckling</div><div class=\"cntnt\"><img style=\"width:470px; height:300px;\" src=\"images/ENDO/59612_Serum_prolactin_and_sucklin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum prolactin concentrations basally and in response to suckling as a function of time after delivery. Within the first week after delivery, the basal value is high relative to the nonpregnant state, and there may be a further increase in response to suckling. Several weeks after delivery, the basal value is close to that of the nonpregnant state, but there is still a pronounced increase in response to suckling. Three months after delivery, the basal value is similar to that of the nonpregnant state, and there is a minimal response to suckling, if any.</div><div class=\"graphic_reference\">Data from Tyson JE, Ito P, Guyda H, et al. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972; 113:14.</div><div id=\"graphicVersion\">Graphic 59612 Version 2.0</div></div></div>"},"59614":{"type":"graphic_diagnosticimage","displayName":"LV noncompaction short axis","title":"Left ventricular noncompaction","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Left ventricular noncompaction</div><div class=\"cntnt\"><img style=\"width:504px; height:308px;\" src=\"images/CARD/59614_LV_noncompaction_short_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short-axis view of a two-dimensional echocardiogram at endsystole in a patient with isolated left ventricular noncompaction. The ratio of noncompacted myocardium (white line) to compacted myocardium (red line) is 2.2:1. A ratio ≥2:1 at end-systole with thickening of the myocardial wall is considered to be diagnostic of left ventricular noncompaction. A ratio ≥2:1 is occasionally seen in patients with dilated cardiomyopathy, but there is no thickening of the myocardial wall.</div><div id=\"graphicVersion\">Graphic 59614 Version 2.0</div></div></div>"},"59617":{"type":"graphic_figure","displayName":"Fasciotomy and fasciectomy chronic compartment syndrome","title":"Fasciotomy and fasciectomy for chronic compartment syndrome","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Fasciotomy and fasciectomy for chronic compartment syndrome</div><div class=\"cntnt\"><img style=\"width:487px; height:587px;\" src=\"images/SURG/59617_Fasciotomy-and-fasciectomy-chronic-compartment-syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcutaneous fasciotomy of the anterior and lateral compartments (pictured on the left) is performed using two transverse skin incisions overlying the intermuscular septum between the anterior and lateral compartments. These incisions are oriented at the proximal and distal ends of the planned fasciotomies in these compartments. Using the two skin incisions, the anterior and lateral compartments are identified and blunt-tipped (Cooley or Metzenbaum) scissors are used to extend the fascial incisions between the two incisions. <br> Fasciectomy (depicted in the image on the right) is performed through a lateral longitudinal skin incision overlying the intermuscular septum between the anterior and lateral compartments. Using this incision, standard fasciotomies of the anterior and lateral compartments are performed. In addition, a 2 x 6 cm ellipse of fascia is resected (&quot;fasciectomy&quot;), preserving the fascia overlying the intermuscular septum to ensure more complete fascial release for patients with chronic exertional compartment syndrome.</div><div id=\"graphicVersion\">Graphic 59617 Version 3.0</div></div></div>"},"59618":{"type":"graphic_picture","displayName":"Laser induced purpura","title":"Purpura due to a pulsed dye laser","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Purpura due to a pulsed dye laser</div><div class=\"cntnt\"><img style=\"width:300px; height:300px;\" src=\"images/DERM/59618_Laser_induced_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Temporary purpura can occur during treatment with pulsed dye lasers.</div><div id=\"graphicVersion\">Graphic 59618 Version 1.0</div></div></div>"},"59619":{"type":"graphic_picture","displayName":"BL neoplastic cells","title":"Burkitt lymphoma neoplastic cells","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Burkitt lymphoma neoplastic cells</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/HEME/59619_BLneoplasticcells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At high power magnification, the neoplastic cells are of intermediate size, similar to the size of benign histiocyte nuclei. The neoplastic cells have round nuclear contours, multiple nucleoli, frequent mitoses, and basophilic cytoplasm. Macrophages with engulfed pyknotic nuclei and nuclear debris are also present. Hematoxylin-eosin stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Burkitt lymphoma. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59619 Version 6.0</div></div></div>"},"59626":{"type":"graphic_table","displayName":"Classification diabetic neuropathy","title":"Classification and staging of diabetic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification and staging of diabetic neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      \n<td class=\"subtitle1_single\"> Class I Subclinical Neuropathy*</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"subtitle2_single\">Abnormal electrodiagnostic tests (EDX)</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Decreased nerve conduction velocity</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\" colspan=\"1\">Decreased amplitude of evoked muscle or nerve action potential</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"subtitle2_single\">Abnormal quantitative sensory testing (QST)</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Vibratory/tactile</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Thermal warming/cooling</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Other</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"subtitle2_single\">Abnormal autonomic function tests (AFT)</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Diminished sinus arrhythmia (beat-to-beat heart rate variation)</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Diminished sudomotor function</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Increased pupillary latency</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"subtitle1_single\">Class II Clinical Neuropathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"subtitle2_single\">Diffuse neuropathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2_start\">Distal symmetric sensorimotor polyneuropathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2\">Primarily small fiber neuropathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2\">Primarily large fiber neuropathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2\">Mixed</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2_start\">Autonomic neuropathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2\">Abnormal pupillary function</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2\">Sudomotor dysfunction</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2\">Genitourinary autonomic neuropathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist3\">Bladder dysfunction</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist3\">Sexual dysfunction</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2\">Gastrointestinal autonomic neuropathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist3\">Gastric atony</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist3\">Gall bladder atony</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist3\">Diabetic diarrhea</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist3\" colspan=\"1\">Hypoglycemic unawareness (adrenal medullary neuropathy)</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2\">Cardiovascular autonomic neuropathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"sublist2\">Hypoglycemic unawareness</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"subtitle2_single\">Focal neuropathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Mononeuropathy (upper or lower extremity)</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Mononeuropathy multiplex</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Plexopathy</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Polyradiculopathy (can occur with diffuse neuropathy)</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n<td class=\"indent1\">Cranial mononeuropathy</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Neurological function tests are abnormal, but no neurological symptoms or clinically detectable neurological deficits indicative of a diffuse or focal neuropathy are present. Class I &quot;Subclinical neuropathy&quot; is further subdivided into Class Ia if an AFT or QST abnormality is present, Class Ib if EDX or AFT and QST abnormalities are present, and Class Ic if an EDX and either AFT or QST abnormalities or both are present.</div><div class=\"graphic_reference\">Adapted from Consensus Panel: Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes 1988; 37:1000.</div><div id=\"graphicVersion\">Graphic 59626 Version 2.0</div></div></div>"},"59627":{"type":"graphic_diagnosticimage","displayName":"Ulcerative colitis US","title":"Ulcerative colitis on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulcerative colitis on ultrasound</div><div class=\"cntnt\"><img style=\"width:356px; height:287px;\" src=\"images/GAST/59627_Ulcerative_colitis_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal ultrasound of chronic active ulcerative colitis of the sigmoid colon showing a symmetric mural inflammatory reaction by color Doppler imaging. Bowel wall thickening of the mucosa (M), echorich and hypervascular submucosa (SM) and echopoor muscularis propria (Musc) is indicated. The lumen is not seen due to mucosal swelling. A small (6 mm) periintestinal lymph node (LN) is indicated as well.</div><div class=\"graphic_reference\">Courtesy of Christoph F Dietrich, MD.</div><div id=\"graphicVersion\">Graphic 59627 Version 3.0</div></div></div>"},"59628":{"type":"graphic_diagnosticimage","displayName":"Lymphoma liver CT","title":"Diffuse large B cell lymphoma involving the liver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse large B cell lymphoma involving the liver</div><div class=\"cntnt\"><img style=\"width:387px; height:267px;\" src=\"images/HEME/59628_Lymphoma_liver_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography&nbsp;of the upper abdomen shows an enlarged liver containing many discrete nodular areas (arrows). The biopsy was consistent with diffuse large B-cell non-Hodgkin lymphoma.</div><div class=\"graphic_reference\">Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.</div><div id=\"graphicVersion\">Graphic 59628 Version 3.0</div></div></div>"},"59629":{"type":"graphic_diagnosticimage","displayName":"Congen pulm airways malform CT I","title":"Infant with congenital pulmonary airways malformation (Type I )","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infant with congenital pulmonary airways malformation (Type I )</div><div class=\"cntnt\"><img style=\"width:360px; height:374px;\" src=\"images/PULM/59629_Adenomatoid_malform_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right lung displays several large cysts that cause cardiomediastinal shift to the left. The residual right lower lung is displaced caudad.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59629 Version 3.0</div></div></div>"},"59630":{"type":"graphic_table","displayName":"Temperature and blood gas","title":"The effect of temperature on blood gas measurements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The effect of temperature on blood gas measurements</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Temperature</td> <td class=\"subtitle1\" rowspan=\"2\">pH</td> <td class=\"subtitle1\" rowspan=\"2\">PCO<sub>2</sub></td> <td class=\"subtitle1\" rowspan=\"2\">PO<sub>2</sub></td> </tr> <tr> <td class=\"subtitle2\">&ordm;C</td> <td class=\"subtitle2\">&ordm;F</td> </tr> <tr> <td>20</td> <td>68</td> <td>7.65</td> <td>19</td> <td>27</td> </tr> <tr> <td>30</td> <td>86</td> <td>7.50</td> <td>30</td> <td>51</td> </tr> <tr> <td>35</td> <td>95</td> <td>7.43</td> <td>37</td> <td>70</td> </tr> <tr> <td>36</td> <td>97</td> <td>7.41</td> <td>38</td> <td>75</td> </tr> <tr> <td>37</td> <td>98</td> <td>7.40</td> <td>40</td> <td>80</td> </tr> <tr> <td>38</td> <td>100</td> <td>7.39</td> <td>42</td> <td>85</td> </tr> <tr> <td>40</td> <td>104</td> <td>7.36</td> <td>45</td> <td>97</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Shapiro, Peruzzi, Kozelowski-Templin: Clinical Application of Blood Gases, ed 5. St. Louis, Mosby-Year Book, 1994, p. 128.</div><div id=\"graphicVersion\">Graphic 59630 Version 2.0</div></div></div>"},"59631":{"type":"graphic_figure","displayName":"Fucosylation of macromolecules is defective in LAD II","title":"Fucosylation of macromolecules is defective in leukocyte-adhesion deficiency II","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Fucosylation of macromolecules is defective in leukocyte-adhesion deficiency II</div><div class=\"cntnt\"><img style=\"width:537px; height:341px;\" src=\"images/ALLRG/59631_Fucosylation_macromolecules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biochemical abnormality in leukocyte-adhesion deficiency (LAD) II is a general defect in fucosylation of macromolecules. More specifically, it resides at the stage of transport of fucose to the Golgi apparatus.</div><div class=\"graphic_footnotes\">GDP: guanosine diphosphate; FX-protein: human GDP-I fucose synthase; LAD II: leukocyte-adhesion deficiency type II.</div><div id=\"graphicVersion\">Graphic 59631 Version 5.0</div></div></div>"},"59632":{"type":"graphic_table","displayName":"Dissociative PTSD vs hyperaroused PTSD","title":"Typical differences between dissociative PTSD and hyperaroused PTSD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical differences between dissociative PTSD and hyperaroused PTSD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dissociative subtype of PTSD</td> <td class=\"subtitle1\">Hyperaroused PTSD</td> </tr> <tr> <td>Etiology</td> <td>Likely to be more severe, chronic, repeated, usually childhood and adult trauma</td> <td>Likely to be later-occurring trauma and/or less cumulative trauma</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Likely response when presented with traumatic narrative or triggers</td> <td>Dissociation, numbing</td> <td>Terror</td> </tr> <tr> <td>Decreased, blunted autonomic arousal</td> <td>Increased autonomic arousal</td> </tr> <tr> <td>Decreased heart rate</td> <td>Increased heart rate</td> </tr> <tr> <td>Cortisol release is delayed</td> <td>Rapidly increased cortisol level</td> </tr> <tr> <td>Decreased skin conductance</td> <td>Increased skin conductance</td> </tr> <tr> <td>Brain areas activated that may over-control emotion and alter sense of self (eg, MPFC)</td> <td>Brain areas activated that may under-control emotion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTSD: posttraumatic stress disorder; MPFC: medial prefrontal cortex.</div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Vermetten E, Dorahy MJ, Spiegel D. Traumatic Dissociation Neurobiology and Treatment, American Psychiatric Press, Washington DC, 2007. </li> <li>Brand B, Loewenstein RJ. Dissociative disorders: An overview of assessment, phenomenology and treatment, Psychiatric Times, 2010. </li> </ol></div><div id=\"graphicVersion\">Graphic 59632 Version 3.0</div></div></div>"},"59633":{"type":"graphic_figure","displayName":"Coxa vara","title":"Normal femur versus coxa vara","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Normal femur versus coxa vara</div><div class=\"cntnt\"><img style=\"width:535px; height:525px;\" src=\"images/PEDS/59633_Coxa_vara.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal femur (left) versus coxa vara (right). Coxa vara is defined by an angle of less than 120&#176; between the femoral neck and shaft. Coxa vara deformity elevates the greater trochanter.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright &#169; 2011. Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 59633 Version 2.0</div></div></div>"},"59634":{"type":"graphic_figure","displayName":"Pediatric immobilization on spine board","title":"Pediatric immobilization on spine board","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Pediatric immobilization on spine board</div><div class=\"cntnt\"><img style=\"width:541px; height:230px;\" src=\"images/EM/59634_Pediatric_spine_board.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59634 Version 4.0</div></div></div>"},"59636":{"type":"graphic_picture","displayName":"Lop ear deformity 2","title":"Lop ear deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lop ear deformity</div><div class=\"cntnt\"><img style=\"width:371px; height:445px;\" src=\"images/PEDS/59636_Lop_ear_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lop ear deformity: preoperative (panels on the left) and postoperative (panels on the right) anterior and posterior views.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 59636 Version 1.0</div></div></div>"},"59637":{"type":"graphic_figure","displayName":"Traditional TMJ dislocation reduction technique","title":"Traditional temporomandibular joint dislocation reduction technique","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Traditional&nbsp;temporomandibular joint&nbsp;dislocation reduction technique</div><div class=\"cntnt\"><img style=\"width:515px; height:592px;\" src=\"images/EM/59637_TMJdislocationreductedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Position of the patient, assistant, and physician in preparation for reduction.<br> (B) Application and direction of forces in the reduction of an anteriorly dislocated temporomandibular joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Pratt A, Loiselle JM. Reduction of temporomandibular joint dislocation. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59637 Version 10.0</div></div></div>"},"59638":{"type":"graphic_table","displayName":"Lymph node invasion BE","title":"Lymph node invasion in surgical resection specimens of patients with early cancer in a Barrett's esophagus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lymph node invasion in surgical resection specimens of patients with early cancer in a Barrett's esophagus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author (year)</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Selection criteria</td> <td class=\"subtitle1\">Number of lymph nodes resected</td> <td class=\"subtitle1\">Positive lymph node in T1m</td> <td class=\"subtitle1\">Survival in T1m</td> <td class=\"subtitle1\">Positive lymph node in T1sm</td> <td class=\"subtitle1\">Survival in T1smN1</td> </tr> <tr> <td>Peters (1994)</td> <td>17</td> <td>Preoperative HGD/early cancer*</td> <td>-</td> <td>0/4 HGD 0/9 T1m</td> <td>100 percent 5-yr</td> <td>1/2</td> <td>-</td> </tr> <tr> <td>Ruol (1997)</td> <td>26<sup>&#182;</sup></td> <td>Postoperative diagnosis pT1</td> <td>-</td> <td>0/4</td> <td>94 percent 5-yr<sup>&#916;</sup></td> <td>8/22</td> <td>37 percent 5-yr</td> </tr> <tr> <td>Nigro (1999)</td> <td>37</td> <td>Postoperative diagnosis pT1/2</td> <td>41<sup>&#9674;</sup></td> <td>1/15 T1m</td> <td>-</td> <td>6/12 T1sm</td> <td>-</td> </tr> <tr> <td>Nigro (1999)</td> <td>28</td> <td>Postoperative diagnosis pT1/2</td> <td>14<sup>&#9674;</sup></td> <td>0/13 T1m</td> <td>-</td> <td>1/6 T1sm</td> <td>-</td> </tr> <tr> <td>Van Sandick (2000)</td> <td>32</td> <td>Postoperative diagnosis pT1</td> <td>13<sup>&#167;</sup></td> <td>0/12</td> <td>100 percent 3-yr</td> <td>6/20</td> <td>50 percent 3-yr</td> </tr> <tr> <td>Stein (2000)</td> <td>94</td> <td>Postoperative diagnosis pT1</td> <td>21 and 19<sup>&#9674;</sup> + IHC</td> <td>0/38</td> <td>90 percent 5-yr</td> <td>10/56</td> <td>60 percent 5-yr</td> </tr> <tr> <td>Rice (2001)</td> <td>122</td> <td>Postoperative diagnosis pT1</td> <td>-</td> <td>0/38 HGD 2/53 T1m</td> <td>95 percent 5-yr 80 percent 5-yr</td> <td>6/31</td> <td>25 percent TxN1</td> </tr> <tr> <td>Fernando (2002)</td> <td>28</td> <td>Preoperative HGD<sup>&#165;</sup></td> <td>16<sup>&#167;</sup></td> <td>0/17 HGD 0/6 T1m</td> <td>100 percent 1-yr</td> <td>1/5</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HGD: high-grade dysplasia.<br />* Preoperative work-up: no review histology, Seattle Bx protocol, EUS not mentioned, inclusion: 1985-1993.<br />&para; 11 cardia and 15 Barrett's lesions.<br />&Delta; For T1m/sm No.<br /><span class=\"lozenge\">&loz;</span> Median.<br />&sect; Mean.<br />&yen; Preoperative work-up: review histology, four-quadrant Bx in 64 percent, EUS in 57 percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Siersema PD, Rosenbrand CG, Bergman JJ, et al. (Guideline \"Diagnosis and treatment of oesophageal carcinoma\".) Ned Tijdschr Geneeskd 2006; 150:1877. Copyright &copy; 2006 Nederlands Tijdschrift voor Geneeskunde.</div><div id=\"graphicVersion\">Graphic 59638 Version 3.0</div></div></div>"},"59639":{"type":"graphic_picture","displayName":"Flexible hysteroscope","title":"Flexible hysteroscope","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Flexible hysteroscope</div><div class=\"cntnt\"><img style=\"width:473px; height:338px;\" src=\"images/OBGYN/59639_Flexible_hysteroscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 59639 Version 1.0</div></div></div>"},"59641":{"type":"graphic_figure","displayName":"Complement pathways 2","title":"Complement activation pathways","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Complement activation pathways</div><div class=\"cntnt\"><img style=\"width:490px; height:455px;\" src=\"images/NEPH/59641_Complement_activ_pathways.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complement activation pathways and their regulators (in red) are depicted in this figure.</div><div class=\"graphic_footnotes\">DAF: decay accelerating factor; CR1: complement receptor 1; MCP: membrane cofactor protein; MAC: membrane attack complex; C1-est inhib: C1 esterase inhibitor; MBL: mannose-binding lectin; MASP: mannose-binding lectin-associated proteases; C4bp: C4-binding protein; B: factor B; P: properdin.<br />* Factor H also acts as a cofactor for factor I to regulate the C3 and C5 convertases.</div><div class=\"graphic_reference\">Reproduced with permission from: Noris M, Remuzzi G. Hemolytic Uremic Syndrome. J Am Soc Nephrol 2005; 16:1035. Copyright © 2005 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 59641 Version 5.0</div></div></div>"},"59642":{"type":"graphic_figure","displayName":"Extracranial vertebral arteries","title":"Anatomy of extracranial vertebral arteries","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Anatomy of extracranial vertebral arteries</div><div class=\"cntnt\"><img style=\"width:513px; height:510px;\" src=\"images/NEURO/59642_ECVAs.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59642 Version 3.0</div></div></div>"},"59643":{"type":"graphic_table","displayName":"Periictal imaging abnormalities","title":"Periictal imaging abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Periictal imaging abnormalities</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Local</td> </tr> <tr> <td class=\"indent1\">Mass effect, sulcal effacement</td> </tr> <tr> <td class=\"indent1\">Hippocampal swelling</td> </tr> <tr> <td class=\"indent1\">Focal cortical lesions, increased T2 signal, restricted diffusion</td> </tr> <tr> <td class=\"indent1\">Migratory lesions</td> </tr> <tr> <td class=\"indent1\">Blood brain barrier breakdown, contrast enhancement</td> </tr> <tr> <td class=\"indent1\">Increased vessel caliber/flow</td> </tr> <tr> <td class=\"indent1\">Increased perfusion</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Remote</td> </tr> <tr> <td class=\"indent1\">Cerebellar diaschesis</td> </tr> <tr> <td class=\"indent1\">Unilateral/bilateral diencephalic lesions</td> </tr> <tr> <td class=\"indent1\">Splenium abnormalities</td> </tr> <tr> <td class=\"indent1\">Posterior leukoencephalopathy</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59643 Version 3.0</div></div></div>"},"59645":{"type":"graphic_table","displayName":"Malignancies highrisk TLS","title":"Malignancies commonly diagnosed in patients perceived to be at high risk for developing tumor lysis syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Malignancies commonly diagnosed in patients perceived to be at high risk for developing tumor lysis syndrome</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">\r\n  \r\n   Malignancy\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   \t<p>Pediatric</p>\n\t<p> \t\t\t\t\t\t(n = 682)</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   \t<p>Adult</p>\n\t<p> \t\t\t\t\t\t(n = 387)</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">\r\n  \r\n   \t<p>Total</p>\n\t<p> \t\t\t\t\t\t(n = 1069)</p>\n\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Number\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Number\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Number\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Percent\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute lymphoblastic leukemia</td>\r\n  \r\n   <td>433</td>\r\n  \r\n   <td>63</td>\r\n  \r\n   <td>73</td>\r\n  \r\n   <td>19</td>\r\n  \r\n   <td>506</td>\r\n  \r\n   <td>47</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute myeloid leukemia</td>\r\n  \r\n   <td>74</td>\r\n  \r\n   <td>11</td>\r\n  \r\n   <td>104</td>\r\n  \r\n   <td>27</td>\r\n  \r\n   <td>178</td>\r\n  \r\n   <td>17</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chronic lymphocytic leukemia</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>37</td>\r\n  \r\n   <td>10</td>\r\n  \r\n   <td>37</td>\r\n  \r\n   <td>3.5</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chronic myeloid leukemia</td>\r\n  \r\n   <td>6</td>\r\n  \r\n   <td>0.9</td>\r\n  \r\n   <td>36</td>\r\n  \r\n   <td>9</td>\r\n  \r\n   <td>42</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Non-Hodgkin's lymphoma</td>\r\n  \r\n   <td>122</td>\r\n  \r\n   <td>18</td>\r\n  \r\n   <td>109</td>\r\n  \r\n   <td>28</td>\r\n  \r\n   <td>231</td>\r\n  \r\n   <td>22</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hodgkin's disease</td>\r\n  \r\n   <td>8</td>\r\n  \r\n   <td>1.2</td>\r\n  \r\n   <td>6</td>\r\n  \r\n   <td>1.6</td>\r\n  \r\n   <td>14</td>\r\n  \r\n   <td>1.3</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Multiple myeloma</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>15</td>\r\n  \r\n   <td>3.9</td>\r\n  \r\n   <td>15</td>\r\n  \r\n   <td>1.4</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Other hematologic malignancies</td>\r\n  \r\n   <td>5</td>\r\n  \r\n   <td>0.7</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   <td>0.7</td>\r\n  \r\n   <td>8</td>\r\n  \r\n   <td>0.7</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Solid tumors</td>\r\n  \r\n   <td>34</td>\r\n  \r\n   <td>5</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   <td>38</td>\r\n  \r\n   <td>3.6</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_lgnd\">NOTE: Data represent consecutive patients enrolled onto a compassionate-use trial evaluating the efficacy and safety of rasburicase in patients with cancer who presented with, or were at risk of developing, hyperuricemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767. Copyright &#169;2008 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 59645 Version 2.0</div></div></div>"},"59646":{"type":"graphic_picture","displayName":"AML FAB M1","title":"Acute myeloid leukemia (M1)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute myeloid leukemia (M1)</div><div class=\"cntnt\"><img style=\"width:415px; height:288px;\" src=\"images/HEME/59646_AMLFABM1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with AML (FAB classification M1). (Wright-Giemsa stain). The majority of cells have a rim of pale to slightly basophilic agranular cytoplasm. The nuclei have finely dispersed chromatin and prominent nucleoli.</div><div class=\"graphic_reference\">(From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.)</div><div id=\"graphicVersion\">Graphic 59646 Version 1.0</div></div></div>"},"59647":{"type":"graphic_figure","displayName":"Breast burns TBSA burn anterior and posterior trunk","title":"Total body surface area of anterior trunk including size of breast","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Total body surface area of anterior trunk including size of breast</div><div class=\"cntnt\"><img style=\"width:462px; height:349px;\" src=\"images/SURG/59647_Breast_burns.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The size of the breast is used to determine the percentage of total body surface area burned. The graph shows how the ratio of surface area of anterior to posterior trunk burns varies with bra cup size. The points represent the mean ratio for each cup size; the error bars represent the standard error at each point.</LI>&#xD;&#xA;<LI>Anterior/posterior trunk ratio = m(bra cup size) + c, where m = the gradient of the graph and c = a constant. For every increase in cup size, the surface area of a woman's anterior trunk increased by a factor of 0.1 relative to the posterior truncal surface area.</LI>&#xD;&#xA;<LI>This graph should be used in conjunction with the standard tables for estimating total body surface area burned in adults.</LI></UL></div><div class=\"graphic_reference\">Reproduced with permission from: Hidvegi N, Nduka C, Myers S, Dziewulski P. Estimation of breast burn size. Plast Reconstr Surg 2004; 113:1591. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59647 Version 10.0</div></div></div>"},"59648":{"type":"graphic_diagnosticimage","displayName":"Ultrasound lethal pulmonary hypoplasia","title":"Lethal pulmonary hypoplasia due to skeletal dysplasia","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Lethal pulmonary hypoplasia due to skeletal dysplasia</div><div class=\"cntnt\"><img style=\"width:505px; height:534px;\" src=\"images/OBGYN/59648_US_lethal_pulm_hypoplasia_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) Lethal pulmonary hypoplasia, subtype unknown, diagnosed at 13 weeks of gestation on the basis of a small chest circumference. The chest circumference (circle in A) is significantly smaller than the abdominal circumference (circle in B). Pathological diagnosis was dyssegmental dysplasia.<br />(A) Cross-section of the thorax.<br />(B) Cross-section of the abdomen.<br />(C and D) Lethal pulmonary hypoplasia on the basis of a small thorax.<br />(C) Thanatophoric dysplasia at 23 weeks. Sagittal ultrasound demonstrates the markedly narrow anteroposterior diameter of the thorax (between arrows). The heart fills almost the entire thorax. The abdomen appears relatively protuberant compared to the constricted thorax.<br />(D) Osteogenesis imperfecta type 2 at 21 weeks. Coronal ultrasound demonstrates the bell-shaped contour of the thorax and narrow transverse diameter relative to the abdomen.</div><div id=\"graphicVersion\">Graphic 59648 Version 7.0</div></div></div>"},"59650":{"type":"graphic_picture","displayName":"Endoscopic incision ring Endosc","title":"Transendoscopic electrocautery incision of an esophageal ring","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Transendoscopic electrocautery incision of an esophageal ring</div><div class=\"cntnt\"><img style=\"width:475px; height:215px;\" src=\"images/GAST/59650_Endoscopic_incision_ring_En.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy demonstrating a mucosal ring in the distal esophagus (left panel), which has been incised using a needle-knife papillotome (right panel).</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 59650 Version 2.0</div></div></div>"},"59651":{"type":"graphic_picture","displayName":"Gastric MZL B cell stain","title":"Extranodal marginal zone lymphoma of the stomach","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Extranodal marginal zone lymphoma of the stomach</div><div class=\"cntnt\"><img style=\"width:547px; height:180px;\" src=\"images/GAST/59651_Gastric_MALToma_B_cell_stai.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT). Left panel: Infiltrating lymphoma cells with loss of glands and a lymphoepithelial lesion. Right panel: Staining with the monoclonal B cell antibody CD-20 shows that most of the infiltrating cells show B cell reactivity.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 59651 Version 4.0</div></div></div>"},"59652":{"type":"graphic_table","displayName":"Sperm donor exclusion criteria","title":"Minimal sperm donor exclusion criteria based on sexual, social, and medical history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimal sperm donor exclusion criteria based on sexual, social, and medical history</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Sex with men</td> </tr> <tr> <td>Injected drug (non medical) use</td> </tr> <tr> <td>Sex for drugs and/or money</td> </tr> <tr> <td>Sexual relations in the past 12 months with a person who meets any of the above criteria</td> </tr> <tr> <td>Sexual relations within the past 12 months with an HIV or hepatitis infected person</td> </tr> <tr> <td>Exposure to HIV and/or hepatitis in the last 12 months (eg, open wound, mucous membranes)</td> </tr> <tr> <td>Incarceration for more than 72 hours</td> </tr> <tr> <td>Treatment fof syphilis or gonorrhea in the past 12 months</td> </tr> <tr> <td>Acupuncture, body piercing, and/or tattooing in the last 12 months in which it is not certain that sterile technique was used</td> </tr> <tr> <td>Recipients of human organ or tissue transplants or extracts</td> </tr> <tr> <td>Family history of transmissible spongiform encephalopathy</td> </tr> <tr> <td>Family history of transmissible Creutzfeldt-Jakob disease</td> </tr> <tr> <td>Changes in cognition, speech, or gait</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59652 Version 2.0</div></div></div>"},"59653":{"type":"graphic_diagnosticimage","displayName":"Distal radius greenstick fracture","title":"Distal radius greenstick fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal radius greenstick fracture</div><div class=\"cntnt\"><img style=\"width:182px; height:473px;\" src=\"images/PEDS/59653_Distal_radius_greenstick_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Greenstick fracture of the distal radius with 15° of apex volar angulation.</div><div class=\"graphic_reference\">Adapted with permission from: Eiff, MP, Hatch, RL, Calmbach, WL. Carpal Fractures: Fracture management for primary care. WB Saunders, Philadelphia, 2002. p.260. Copyright ©2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 59653 Version 3.0</div></div></div>"},"59654":{"type":"graphic_picture","displayName":"Exstrophy small bladder","title":"Exstrophy of a small bladder in male newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exstrophy of a small bladder in male newborn</div><div class=\"cntnt\"><img style=\"width:241px; height:321px;\" src=\"images/PEDS/59654_Exstrophy_small_bladder.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 59654 Version 3.0</div></div></div>"},"59656":{"type":"graphic_figure","displayName":"Chromosomal recombination","title":"Chromosomal recombination","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Chromosomal recombination</div><div class=\"cntnt\"><img style=\"width:475px; height:605px;\" src=\"images/PC/59656_Chromosomal_recombination.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59656 Version 2.0</div></div></div>"},"59657":{"type":"graphic_diagnosticimage","displayName":"RLL nodule CT","title":"Malignant solitary pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant solitary pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:305px; height:214px;\" src=\"images/PULM/59657_RLL_nodule_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with solitary pulmonary nodule in the right lower lobe, proven to represent a lung cancer. CT scan shows the solitary lesion in the superior segment of the right lower lobe.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59657 Version 3.0</div></div></div>"},"59658":{"type":"graphic_diagnosticimage","displayName":"Superior sulcus PA","title":"Superior sulcus tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior sulcus tumor</div><div class=\"cntnt\"><img style=\"width:372px; height:307px;\" src=\"images/PULM/59658_Superior_sulcus_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with superior sulcus tumor at the right apex. Chest radiograph shows a right upper lobe nodule with adjacent apical cap.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59658 Version 2.0</div></div></div>"},"59659":{"type":"graphic_diagnosticimage","displayName":"CT image halo","title":"CT image halo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT image halo</div><div class=\"cntnt\"><img style=\"width:432px; height:248px;\" src=\"images/ONC/59659_CT_image_halo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 77-year-old female patient with biopsy-proven 1.8 cm left lower lobe adenocarcinoma (stage IA NSCLC) who was not considered a surgical candidate due to chronic obstructive pulmonary disease and cardiac risk. Immediate post-procedure CT image with reactive \"halo\" of ground-glass parenchymal opacity (arrows) surrounding the treatment site.</div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Schirmang, T, MD and Dupuy, D, MD.</div><div id=\"graphicVersion\">Graphic 59659 Version 3.0</div></div></div>"},"59660":{"type":"graphic_figure","displayName":"Nomogram DSS resect gastric CA","title":"Nomogram for disease-specific survival (DSS) in patients with resected gastric cancer","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Nomogram for disease-specific survival (DSS) in patients with resected gastric cancer</div><div class=\"cntnt\"><img style=\"width:612px; height:546px;\" src=\"images/ONC/59660_Nomogram_DSS_resect_gastric.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nomogram predicting 5- and 10- year overall survival after D2 gastrectomy for gastric cancer. The nomogram is used by adding up the points identified on the points scale for each variable. The total points projected on the bottom scales indicate the probability of 5- and 10-year survival.</div><div class=\"graphic_footnotes\">LN: lymph nodes.</div><div class=\"graphic_reference\">From: Han DS, Suh YS, Kong SH, et al. Nomogram predicting long-term survival after D2 gastrectomy for gastric cancer. J Clin Oncol 2012; 30:3834. Reprinted with permission. Copyright © 2012 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 59660 Version 2.0</div></div></div>"},"59661":{"type":"graphic_table","displayName":"Cystic fibrosis antibiotics","title":"Antibiotics for treating exacerbations of cystic fibrosis lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotics for treating exacerbations of cystic fibrosis lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Bacteria</td> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Pediatric dose*</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><em>Staphylococcus aureus (</em>methicillin-sensitive)</td> <td>Cefazolin</td> <td>100 mg/kg per day in&nbsp;three or&nbsp;four divided doses</td> <td>1.5 g every 6 hours or 2 g every 8 hours</td> <td>Maximum 6 g per day.</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Nafcillin</td> <td>100 to 200 mg/kg per day in&nbsp;four or&nbsp;six divided doses</td> <td>2 g every 4 to 6 hours</td> <td>Maximum 12 g per day.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p><strong>Oral regimens </strong>(for mild exacerbations).<sup>&#182;</sup> One of the following, guided by susceptibility testing:</p> <ul> <li>Trimethoprim-sulfamethoxazole<sup>&#916;</sup> </li> <li>Doxycycline </li> <li>Amoxicillin-clavulanate </li> <li>Clindamycin (in the absence of inducible resistance) </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><em>S. aureus</em> (methicillin-resistant)</td> <td>Vancomycin<sup>&#9674;</sup></td> <td>60 mg/kg per day in&nbsp;three (or four) divided doses</td> <td>45 to 60 mg/kg per day in&nbsp;three divided doses</td> <td> <p>Maximum 1.25 g per dose initially.</p> Dose and frequency are adjusted based on serum concentrations to maintain a target serum trough level of 15 to 20 mcg/mL.</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Linezolid</td> <td> <p>Children &#60;12 years: 30 mg/kg per day IV or PO in&nbsp;three divided doses</p> Children &#8805;12 years: Use adult dose</td> <td>600 mg IV or PO every 12 hours</td> <td>Risk of myelosuppression (most commonly thrombocytopenia) with treatment &#62;14 days or when renal insufficiency is present.<sup>[1]</sup></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p><strong>Oral regimens</strong>.<sup>&#182;</sup> One of the following, guided by susceptibility testing:</p> <ul> <li>Trimethoprim-sulfamethoxazole<sup>&#916;</sup> (for mild exacerbations) </li> <li>Doxycycline (for mild exacerbations) </li> <li>Clindamycin (for mild exacerbations, in the absence of inducible resistance) </li> <li>Linezolid (for moderate or severe exacerbations)&nbsp; </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"17\"><em>Pseudomonas aeruginosa</em></td> <td class=\"sublist1_start\" colspan=\"4\"><strong>One of the following:</strong></td> </tr> <tr> <td class=\"sublist1\">Piperacillin-tazobactam<sup>&#167;&#165;</sup></td> <td class=\"sublist_other\">350 to 450 mg/kg<sup>&#135;</sup> per day in&nbsp;four divided doses</td> <td class=\"sublist_other\">4.5 g every 6 hours</td> <td class=\"sublist_other\">Maximum 16 g<sup>&#135;</sup> per day.</td> </tr> <tr> <td class=\"sublist1\">Ceftazidime<sup>&#167;</sup></td> <td class=\"sublist_other\">150 to 200 mg/kg per day in&nbsp;three or&nbsp;four divided doses</td> <td class=\"sublist_other\">2 g every 6 to 8 hours</td> <td class=\"sublist_other\">Maximum 8 g per day.</td> </tr> <tr> <td class=\"sublist1\">Cefepime</td> <td class=\"sublist_other\">150 mg/kg per day in&nbsp;three divided doses</td> <td class=\"sublist_other\">2 g every 8 hours</td> <td class=\"sublist_other\">Maximum 6 g per day.</td> </tr> <tr> <td class=\"sublist1\">Imipenem-cilastatin</td> <td class=\"sublist_other\">60 to 100 mg/kg per day in&nbsp;four divided doses</td> <td class=\"sublist_other\">0.5 to 1 g every 6 hours</td> <td class=\"sublist_other\">Maximum 4 g per day.</td> </tr> <tr> <td class=\"sublist1\">Meropenem</td> <td class=\"sublist_other\">120 mg/kg per day in&nbsp;three divided doses</td> <td class=\"sublist_other\">2 g every 8 hours</td> <td class=\"sublist_other\">Maximum 6 g per day.</td> </tr> <tr> <td class=\"sublist1\">Ticarcillin-clavulanate<sup>&#167;&#165;</sup>&nbsp;</td> <td class=\"sublist_other\">400 mg/kg&#134; per day in&nbsp;four or&nbsp;six divided doses&nbsp;</td> <td class=\"sublist_other\">3.1 g every 4 to 6 hours&nbsp;</td> <td class=\"sublist_other\">Maximum 18 g&#134; per day.</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"sublist1\">Ciprofloxacin</td> <td class=\"sublist_other\"> <p>PO: 40 mg/kg per day in&nbsp;two divided doses</p> IV: 30 mg/kg per day in&nbsp;three divided doses</td> <td class=\"sublist_other\"> <p>PO: 750 mg every 12 hours</p> IV: 400 mg every 8 to 12 hours</td> <td class=\"sublist_other\"> <p>Maximum dose:</p> <p>PO: 2 g per day in children; 1.5 g per day in adults.</p> <p>IV: 1.2 g per day.</p> Can be used in preference to aminoglycoside or colistin due to less toxicity, particularly when <em>Pseudomonas</em> is sensitive.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"4\"><strong>OR</strong></td> </tr> <tr> <td class=\"sublist1\">Levofloxacin&nbsp;</td> <td class=\"sublist_other\"> <p>PO and IV:</p> <p>6 months to 4 years old:&nbsp;16 to 20&nbsp;mg/kg per day in two divided doses</p> <p>5 to 16 years old:&nbsp;8 to 10&nbsp;mg/kg per day every 24 hours</p> </td> <td class=\"sublist_other\"> <p>PO and IV:</p> <p>750 mg every 24 hours</p> </td> <td class=\"sublist_other\"> <p>Maximum dose:</p> <p>PO and IV: 750 mg per day.</p> <p>Can&nbsp;be used in preference to an aminoglycoside or colistin, due to less toxicity, particularly when in vitro testing demonstrates that the<em>&nbsp;P. aeruginosa</em> is sensitive to levofloxacin.</p> </td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\"><strong>OR</strong></td> </tr> <tr> <td class=\"sublist1\">Tobramycin<sup>&#9674;</sup>**</td> <td class=\"sublist_other\">10 mg/kg every 24 hours</td> <td class=\"sublist_other\">10 mg/kg every 24 hours</td> <td class=\"sublist_other\" rowspan=\"3\">Refer to the UpToDate topic&nbsp;on treatment of acute pulmonary exacerbations&nbsp;for a discussion of serum concentration monitoring for aminoglycosides and for dose and interval adjustment for renal insufficiency. Dose and frequency from a previous course that achieved the therapeutic range may be considered for determining the initial dose.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td class=\"sublist1\">Amikacin<sup>&#9674;</sup>**</td> <td class=\"sublist_other\">30 to 35 mg/kg every 24 hours</td> <td class=\"sublist_other\">30 to 35 mg/kg every 24 hours</td> </tr> <tr> <td class=\"sublist2\" colspan=\"4\"><strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Colistin (colistimethate sodium)</td> <td class=\"sublist_other\"> <p>2.5 to 5 mg/kg<sup>&#182;&#182;</sup> (colistin base activity<sup>&#916;&#916;</sup>) per day in&nbsp;three divided doses</p> </td> <td class=\"sublist_other\"> <p>2.5 to 5 mg/kg<sup>&#182;&#182;</sup> (colistin-base activity<sup>&#916;&#916;</sup>) per day in&nbsp;three divided doses</p> </td> <td class=\"sublist_other\"> <p>Maximum 300 mg per day (colistin-base activity<sup>&#916;&#916;</sup>).</p> <p>Colistin is a second-line drug that may be useful when the <em>P. aeruginosa</em> demonstrates in vitro resistance to all aminoglycosides or when the patient fails to improve on an aminoglycoside-containing regimen.</p> <strong>IMPORTANT:</strong> Dose units and recommended dosing regimens vary by product and country. Doses shown here are specific to US-licensed information for Coly-Mycin M, which labels its product as units of \"colistin-base activity\".<sup>&#916;&#916;</sup> Consult local official product information for details before using this agent.</td> </tr> <tr class=\"divider_bottom\"> <td><em>S. aureus </em>(methicillin-sensitive) <strong>and</strong> <em>P. aeruginosa</em></td> <td colspan=\"3\">Same antibiotics shown above for <em>P. aeruginosa</em> alone, EXCEPT that ceftazidime should not be used because of poor activity against <em>S. aureus</em></td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"5\"><em>S. aureus </em>(methicillin-resistant) <strong>and</strong> <em>P. aeruginosa</em></td> <td colspan=\"3\">Same antibiotics shown above for <em>P. aeruginosa</em> alone</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\"><strong>PLUS</strong> one of the following <strong>(three antibiotics total)</strong>:</td> </tr> <tr> <td class=\"sublist1\">Vancomycin<sup>&#9674;</sup></td> <td class=\"sublist_other\">60 mg/kg per day in three (or four) divided doses</td> <td class=\"sublist_other\">45 to 60 mg/kg per day in&nbsp;three divided doses</td> <td class=\"sublist_other\"> <p>Maximum 1.25 g per dose initially.</p> Dose and frequency are adjusted based on serum concentrations to maintain a target serum trough level of 15 to 20 mcg/mL.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"4\"><strong>OR</strong></td> </tr> <tr> <td class=\"sublist1\">Linezolid</td> <td class=\"sublist_other\"> <p>Children &#60;12 years: 30 mg/kg per day IV or PO, in&nbsp;three divided doses</p> Children &#8805;12 years: Use adult dose</td> <td class=\"sublist_other\">600 mg IV or PO every 12 hours</td> <td class=\"sublist_other\">Risk of myelosuppression (most commonly thrombocytopenia) with treatment &#62;14 days or when renal insufficiency is present.<sup>[1]</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table contains recommended choices of antibiotics based on the type of bacteria isolated. The selection should be modified based on results of sensitivity testing and renal function. The doses given here are typical for patients with cystic fibrosis. Higher and/or more frequent dosing of some antibiotics is often required for&nbsp;cystic fibrosis&nbsp;patients as compared&nbsp;with patients without cystic fibrosis, and a wider range of dose requirements is to be expected. Note that these dosing recommendations do not apply to&nbsp;cystic fibrosis&nbsp;patients who have undergone lung transplantation. <br />For most of these antibiotics, dosing reflects recommendations from a comprehensive review of antipseudomonal antibiotics in cystic fibrosis.<SUP>[2] </SUP>For a few of the antibiotics (piperacillin-tazobactam, ticarcillin-clavulanate, and ceftazidime), the review recommends much higher doses for&nbsp;cystic fibrosis&nbsp;patients than are used for patients without cystic fibrosis. These are based primarily on pharmacokinetic and pharmacodynamic considerations, but clinical trial data for these very high doses is lacking. Therefore, we suggest intermediate doses for these drugs, as shown in the table above.</div><div class=\"graphic_footnotes\"><FONT color=black>IV: intravenous; PO: per os (by mouth).</FONT><br />* The dose given to children generally should not exceed the dose for adults.<br />¶&nbsp;The severity of an exacerbation is typically based upon changes in clinical symptoms and pulmonary function tests compared with the patient's own baseline.<br />Δ&nbsp;For trimethoprim-sulfamethoxazole,&nbsp;dosing for patients with&nbsp;cystic fibrosis&nbsp;may need to be higher than that recommended for non-cystic fibrosis&nbsp;patients (refer to the UpToDate topic on treatment of acute pulmonary exacerbations in cystic fibrosis).<br />◊&nbsp;Monitor aminoglycoside blood levels and creatinine&nbsp;to ensure efficacy and avoid toxicity. The dose and frequency from a previous course of treatment may be used initially if serum concentrations were in the target range and if creatinine clearance is not substantially changed, but drug levels should still be monitored.<br />§&nbsp;For piperacillin-tazobactam, ticarcillin-clavulanate, and ceftazidime, higher doses than those shown or extended infusions may be considered on a case-by-case basis to optimize pharmacodynamic targets in patients with multidrug-resistant pathogens and poor clinical response to initial treatment.<SUP innerHtml>[2] </SUP><FONT color=black>Ticarcillin-clavulanate is no longer available in the United States or Canada.</FONT><br />¥&nbsp;For treatment of <EM>P. aeruginosa</EM> without methicillin-sensitive <EM>S. aureus</EM> (MSSA), piperacillin without tazobactam or ticarcillin without clavulanate can be used where available (in combination with ciprofloxacin, an aminoglycoside, or colistin, depending on reported susceptibilities).<br />‡&nbsp;Of piperacillin component. Doses &gt;600 mg/kg/day may be considered on a case-by-case basis, but increased risk of toxicity is expected, including serum-sickness, anemias, and bone marrow suppression.<br />†&nbsp;Of ticarcillin component.<br />**&nbsp;If the patient is overweight, dose aminoglycoside initially using ideal body weight or dosing weight. A calculator for ideal body weight and dosing weight in adults is available in UpToDate.<br />¶¶&nbsp;If the patient is overweight, the initial dose of colistin should be based on ideal body weight. A calculator for ideal body weight in adults is available in UpToDate.<br />ΔΔ&nbsp;Conversions: 1 mg <STRONG>colistin-base activity</STRONG> (CBA; United States product) =&nbsp;30,000 international units of colistimethate sodium (CMS; European Union product).<br /></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hiraki Y, Tsuji Y, Matsumoto K, et al. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin. Am J Med Sci 2011; 342:456.</li>&#xD;&#xA;    <li>Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive Summary. Pediatric Pulmonology 2013.</li>&#xD;&#xA;</ol>&#xD;&#xA;Many but not all of the dosing recommendations in this table are reflected in the following source: Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive Summary. Pediatric Pulmonology 2013.</div><div id=\"graphicVersion\">Graphic 59661 Version 15.0</div></div></div>"},"59662":{"type":"graphic_table","displayName":"Glasgow Coma Scale and Pediatric Glasgow Coma Scale","title":"Glasgow Coma Scale and Pediatric Glasgow Coma Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glasgow Coma Scale and Pediatric Glasgow Coma Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Sign</td> <td class=\"subtitle1\">Glasgow Coma Scale<sup>[1]</sup></td> <td class=\"subtitle1\">Pediatric Glasgow Coma Scale<sup>[2]</sup></td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td rowspan=\"4\">Eye opening</td> <td>Spontaneous</td> <td>Spontaneous</td> <td>4</td> </tr> <tr> <td>To command</td> <td>To sound</td> <td>3</td> </tr> <tr> <td>To pain</td> <td>To pain</td> <td>2</td> </tr> <tr> <td>None</td> <td>None</td> <td>1</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Verbal response</td> <td>Oriented</td> <td>Age-appropriate vocalization, smile, or orientation to sound, interacts (coos, babbles), follows objects</td> <td>5</td> </tr> <tr> <td>Confused, disoriented</td> <td>Cries, irritable</td> <td>4</td> </tr> <tr> <td>Inappropriate words</td> <td>Cries to pain</td> <td>3</td> </tr> <tr> <td>Incomprehensible sounds</td> <td>Moans to pain</td> <td>2</td> </tr> <tr> <td>None</td> <td>None</td> <td>1</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Motor response</td> <td>Obeys commands</td> <td>Spontaneous movements (obeys verbal command)</td> <td>6</td> </tr> <tr> <td>Localizes pain</td> <td>Withdraws to touch (localizes pain)</td> <td>5</td> </tr> <tr> <td>Withdraws</td> <td>Withdraws to pain</td> <td>4</td> </tr> <tr> <td>Abnormal flexion to pain</td> <td>Abnormal flexion to pain (decorticate posture)</td> <td>3</td> </tr> <tr> <td>Abnormal extension to pain</td> <td>Abnormal extension to pain (decerebrate posture)</td> <td>2</td> </tr> <tr> <td>None</td> <td>None</td> <td>1</td> </tr> <tr class=\"divider_top\"> <td colspan=\"3\"><strong>Best total score</strong></td> <td><strong>15</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Glasgow Coma Scale (GCS) is scored between 3 and 15, 3 being the worst, and 15 the best. It is composed of three parameters: best eye response (E), best verbal response (V), and best motor response (M). The components of the GCS should be recorded individually; for example, E2V3M4 results in a GCS of 9. A score of 13 or higher correlates with mild brain injury, a score of 9 to 12 correlates with moderate injury, and a score of 8 or less represents severe brain injury. The pediatric Glasgow coma scale (PGCS) was validated in children&nbsp;two years of age or younger.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81. </LI>&#xD;&#xA;<LI>Holmes JF, Palchak MJ, MacFarlane T, Kuppermann N. Performance of the pediatric Glasgow coma scale in children with blunt head trauma. Acad Emerg Med 2005; 12:814. </LI></OL></div><div id=\"graphicVersion\">Graphic 59662 Version 12.0</div></div></div>"},"59663":{"type":"graphic_table","displayName":"Viral meningitis epidemiology","title":"Epidemiologic, clinical data, and pathogenesis of common viruses causing meningitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiologic, clinical data, and pathogenesis of common viruses causing meningitis in children</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Virus\n   </td>\n   <td  class=\"subtitle1\">\n   Transmission\n   </td>\n   <td  class=\"subtitle1\">\n   Age\n   </td>\n   <td  class=\"subtitle1\">\n   Season\n   </td>\n   <td  class=\"subtitle1\">\n   Associated syndromes\n   </td>\n   <td  class=\"subtitle1\">\n   Frequency\n   </td>\n   <td  class=\"subtitle1\">\n   Pathway to CNS\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Piconavirus-enterovirus\n   </td>\n   <td  rowspan=\"2\">\n   \t<p>Person to person:</p>\n\t<p>Oral-fecal</p>\n\t<p>Inhalation</p>\n   </td>\n   <td  rowspan=\"2\">\n   \t<p>All ages</p>\n\t<p>More common in children</p>\n   </td>\n   <td  rowspan=\"2\">\n   \t<p>Summer</p>\n\t<p>Fall</p>\n   </td>\n   <td  rowspan=\"2\">\n   \t<p>Encephalitis</p>\n\t<p>Myocarditis</p>\n\t<p>Neonatal sepsis</p>\n\t<p>Poliomyelitis</p>\n   </td>\n   <td  rowspan=\"2\">\n   Common\n   </td>\n   <td  rowspan=\"2\">\n   Blood\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   \t<p>Coxsackievirus</p>\n\t<p>Echovirus</p>\n   </td>\n   </tr>\n   <tr>\n   <td>Arboviruses</td>\n   <td>\t<p>Direct inoculation by vectors:</p>\n\t<p>Mosquitoes</p>\n\t<p>Ticks</p>\n</td>\n   <td>All ages</td>\n   <td>\t<p>Summer</p>\n\t<p>Fall</p>\n</td>\n   <td>Encephalitis</td>\n   <td>Common</td>\n   <td>Blood</td>\n   </tr>\n   <tr>\n   <td>Rabies</td>\n   <td>Direct population by bite of a rabid animal, transplant or inhalation</td>\n   <td>All ages</td>\n   <td>No seasonal pattern</td>\n   <td>&nbsp;</td>\n   <td>Rare</td>\n   <td>Neuronal</td>\n   </tr>\n   <tr>\n   <td>Influenza</td>\n   <td>\t<p>Person to person:</p>\n\t<p>Inhalation</p>\n</td>\n   <td>All ages</td>\n   <td>Winter</td>\n   <td>Encephalitis</td>\n   <td>Infrequent</td>\n   <td>Unknown</td>\n   </tr>\n   <tr>\n   <td>Herpesviridae</td>\n   <td>Person to person</td>\n   <td>&nbsp;</td>\n   <td>No seasonal pattern</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   </tr>\n   <tr>\n   <td>Herpes simplex</td>\n   <td>Vertical or horizontal</td>\n   <td>More common in neonates</td>\n   <td>&nbsp;</td>\n   <td>Meningo-encephalitis</td>\n   <td>Common</td>\n   <td>\t<p>Blood</p>\n\t<p>Neuronal</p>\n</td>\n   </tr>\n   <tr>\n   <td>Varicella-zoster</td>\n   <td>Respiratory</td>\n   <td>Any age following primary infection</td>\n   <td>&nbsp;</td>\n   <td>\t<p>Cerebellitus</p>\n\t<p>Encephalitis</p>\n\t<p>Myelitis</p>\n</td>\n   <td>Infrequent</td>\n   <td>&nbsp;</td>\n   </tr>\n   <tr>\n   <td>Epstein-Barr virus</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   <td>&nbsp;</td>\n   <td>\t<p>Encephalitis</p>\n\t<p>Myelitis</p>\n\t<p>Guillain-Barre</p>\n</td>\n   <td>Rare</td>\n   <td>&nbsp;</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Adenoviridae\n   </td>\n   <td  rowspan=\"2\">\n   Human\n   </td>\n   <td  rowspan=\"2\">\n   &nbsp;\n   </td>\n   <td  rowspan=\"2\">\n   No seasonal pattern\n   </td>\n   <td  rowspan=\"2\">\n   Encephalitis\n   </td>\n   <td  rowspan=\"2\">\n   Rare\n   </td>\n   <td  rowspan=\"2\">\n   Blood\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Adenovirus\n   </td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 59663 Version 2.0</div></div></div>"},"59664":{"type":"graphic_figure","displayName":"Extension olecranon injury","title":"Extension olecranon injury","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Extension olecranon injury</div><div class=\"cntnt\"><img style=\"width:526px; height:387px;\" src=\"images/EM/59664_Extensionolecranoninjury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Fracture with the elbow extended. If the elbow is extended when the direct blow occurs to the posterior aspect, an oblique or transverse fracture occurs (arrows).<br> (B) With the elbow extended, the initial failure is in the anterior articular surface (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Erickson M, Frick S. Fractures of the proximal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59664 Version 8.0</div></div></div>"},"59666":{"type":"graphic_table","displayName":"JCAHO protocol for surgical timeout","title":"JCAHO protocol for surgical timeout","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">JCAHO protocol for surgical timeout</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   1. Perform a preoperative verification process (ideally with the patient awake, aware and involved)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ensure that all relevant documents and studies are available prior to the start of the procedure. Identify the patient with at least two patient identifiers (eg, name, number, telephone number).</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ensure that this information has been reviewed and is internally consistent as well as consistent with the patient's expectations and with the surgical team's understanding of the intended patient, procedure, site and, as applicable, any implants.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Missing information or discrepancies must be addressed before starting surgery.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   2. Mark the operative site to unambiguously identify the intended procedure site\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>For procedures involving right/left distinction, multiple structures (such as fingers and toes), or multiple levels (as in spinal procedures), the intended site must be marked. Ideally the surgeon in charge will mark the site. A procedure must be defined for patients who refuse site marking.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>The mark must be unambiguous (eg, use initials or \"YES\" or a line representing the planned incision; \"X\" may be ambiguous). The mark must be visible after the patient has been prepped and draped (eg, use a permanent marker). Nonoperative sites should not be marked.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   3. The entire operating team takes a \"time out\" immediately before starting the procedure to conduct a final verification of the correct patient, procedure, site and, as applicable, implants.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>The procedure is not started until any questions or concerns are resolved and all members of the surgical/procedure team are in agreement. Identify the patient with at least two patient identifiers.</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) at www.jcaho.org/index.htm.</div><div id=\"graphicVersion\">Graphic 59666 Version 2.0</div></div></div>"},"59668":{"type":"graphic_figure","displayName":"Submucosal leiomyoma position","title":"Submucosal leiomyma position: European Society of Hysteroscopy classification","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Submucosal leiomyma position: European Society of Hysteroscopy classification</div><div class=\"cntnt\"><img style=\"width:533px; height:476px;\" src=\"images/OBGYN/59668_Submucosal_leiomyoma_posit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The European hysteroscopic classification of submucous leiomyomas.</div><div class=\"graphic_reference\">Reproduced with permission from: Baggish, MS, Valle, RF, Guedj, H. Hysteroscopy: Visual Perspectives of Uterine Anatomy, Physiology and Pathology. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59668 Version 1.0</div></div></div>"},"59669":{"type":"graphic_figure","displayName":"Symptoms in the last six months of life in cancer patients","title":"Prevalence of moderate to severe symptoms in the last six months of life in patients with terminal cancer","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Prevalence of moderate to severe symptoms in the last six months of life in patients with terminal cancer</div><div class=\"cntnt\"><img style=\"width:614px; height:382px;\" src=\"images/ONC/59669_Symptoms_last6.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Proportion of cohort reporting severe to moderate Edmonton Symptom Assessment System (ESAS) scores (ie, 4 to 10) over time. Number of assessments is the maximum number available among all nine symptoms. Missing ESAS values for a given symptom were not included when calculating the proportion.</div><div class=\"graphic_reference\">From: Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 2011; 29:1151. Reprinted with permission. Copyright &#169; 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 59669 Version 4.0</div></div></div>"},"59670":{"type":"graphic_picture","displayName":"Indirect immunofluorescence antiribosomal P autoantibodies","title":"Indirect immunofluorescence using the HEp-2 cell substrate and human serum containing antiribosomal P autoantibodies","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Indirect immunofluorescence using the HEp-2 cell substrate and human serum containing antiribosomal P autoantibodies</div><div class=\"cntnt\"><img style=\"width:504px; height:442px;\" src=\"images/RHEUM/59670_Indirect_immuno_antiribosom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The antibodies produce a finely speckled cytoplasmic staining pattern (green, panel A). DAPI staining in panel B (blue) indicates the location of nuclei. Merge of panels A and B is shown in panel C.</div><div class=\"graphic_reference\">Courtesy of Donald Bloch, MD.</div><div id=\"graphicVersion\">Graphic 59670 Version 3.0</div></div></div>"},"59671":{"type":"graphic_diagnosticimage","displayName":"FDG-PET scan diffuse metastatic paraganglioma","title":"FDG-PET scan showing diffuse metastatic paraganglioma","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">FDG-PET scan showing diffuse metastatic paraganglioma</div><div class=\"cntnt\"><img style=\"width:512px; height:483px;\" src=\"images/ENDO/59671_FDG_PET_metast_paragang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FDG-PET&nbsp;scan from a 28-year-old woman shows a diffuse metastatic paraganglioma (coronal image on right and sagittal image on left).</div><div class=\"graphic_footnotes\">FDG: fludeoxyglucose; PET: positron emission tomography.</div><div class=\"graphic_reference\">Courtesy of William F Young, Jr, MD.</div><div id=\"graphicVersion\">Graphic 59671 Version 3.0</div></div></div>"},"59677":{"type":"graphic_figure","displayName":"Comparison of survival of PD pts","title":"Comparison of survival of peritoneal dialysis patients with high- and low-transport characteristics","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comparison of survival of peritoneal dialysis patients with high- and low-transport characteristics</div><div class=\"cntnt\"><img style=\"width:418px; height:700px;\" src=\"images/NEPH/59677_Survival_on_PD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival on PD (patients censored at transplant or transfer to hemodialysis), according to transport category at the start of treatment in two cohorts commencing between (panel A) 1990 to 1997, n = 320,&nbsp;and (panel B) 1998 to 2005, n = 300. In the first cohort, transport category was significantly (p = 0.009) associated with survival, whereas, in the second, this was not the case due to an improvement in the survival of high-transport patients.</div><div class=\"graphic_footnotes\">PD: peritoneal dialysis.</div><div class=\"graphic_reference\">Reproduced with permission from: Davies SJ. Mitigating peritoneal membrane characteristics in modern peritoneal dialysis therapy. Kidney Int Suppl 2006; 70:S76. Copyright © 2006 Macmillan Publishers Ltd.</div><div id=\"graphicVersion\">Graphic 59677 Version 4.0</div></div></div>"},"59678":{"type":"graphic_figure","displayName":"Breech3","title":"Delivery of the upper limbs","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Delivery of the upper limbs</div><div class=\"cntnt\"><img style=\"width:541px; height:209px;\" src=\"images/OBGYN/59678_Breech3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A towel is wrapped around the fetus for better traction. When the scapulae appears under the symphysis, the operator reaches over the left shoulder, sweeps the arm across the chest (A), and delivers the arm (B).</div><div class=\"graphic_reference\">Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL (Eds). Obstetrics: Normal and Problem Pregnancies, 4th ed, Churchill Livingstone New York 2003. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 59678 Version 1.0</div></div></div>"},"59681":{"type":"graphic_picture","displayName":"Pedunculated polyp endloop","title":"Colonic polypectomy using an endoloop","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic polypectomy using an endoloop</div><div class=\"cntnt\"><img style=\"width:317px; height:331px;\" src=\"images/GAST/59681_Pedunculated_polyp_endloop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pedunculated polyp with a broad thick stalk; (B) Endoloop placed on the base of the polyp; (C) Polyp being transected with a snare placed above the endoloop.</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 59681 Version 2.0</div></div></div>"},"59682":{"type":"graphic_figure","displayName":"Midline incision of the abdominal wall","title":"Midline incision of the abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Midline incision of the abdominal wall</div><div class=\"cntnt\"><img style=\"width:508px; height:368px;\" src=\"images/SURG/59682_Midline_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The linea alba is incised and muscles separated in the midline. The peritoneum is opened at the cephalic pole of the incision. The peritoneal incision is expanded longitudinally, slightly off midline to avoid the urachus.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 59682 Version 3.0</div></div></div>"},"59683":{"type":"graphic_picture","displayName":"Normal blood smear","title":"Normal peripheral blood smear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"59684":{"type":"graphic_figure","displayName":"Adrenal blood supply","title":"Adrenal blood supply","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Adrenal blood supply</div><div class=\"cntnt\"><img style=\"width:591px; height:458px;\" src=\"images/SURG/59684_Adren_blood_supply_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic drawing showing the inferior vena cava, the aorta, the renal veins and arteries, and the relationship of these structures with the adrenal glands. Note the arterial and venous supply of the left adrenal gland. Only the vein of the right adrenal gland is shown.</div><div class=\"graphic_reference\">Reproduced with permission from: Uflacker, R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59684 Version 3.0</div></div></div>"},"59685":{"type":"graphic_waveform","displayName":"Atrial tachycardia with AV block","title":"Atrial tachycardia with AV block","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Atrial tachycardia with AV block</div><div class=\"cntnt\"><img style=\"width:453px; height:206px;\" src=\"images/PEDS/59685_Atrial_tachy_AV_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rapid atrial tachycardia with 2:1 atrioventricular conduction. Sweep speed is 25 mm/sec.</div><div class=\"graphic_footnotes\">P: P waves.</div><div id=\"graphicVersion\">Graphic 59685 Version 2.0</div></div></div>"},"59686":{"type":"graphic_picture","displayName":"Acute GVHD follicular","title":"Acute graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/59686_Acute_GVHD_follicular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small, erythematous, follicularly-based macules and papules are present on the distal lower extremities in this patient with acute graft-versus-host disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59686 Version 3.0</div></div></div>"},"59687":{"type":"graphic_figure","displayName":"Abdominal paracentesis sites","title":"Abdominal paracentesis sites","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Abdominal paracentesis sites</div><div class=\"cntnt\"><img style=\"width:490px; height:411px;\" src=\"images/GAST/59687_Abdominal-paracentesis-site.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal wall anatomy showing the author's preferred site for abdominal paracentesis and the inferior epigastric artery, which should be avoided.</div><div id=\"graphicVersion\">Graphic 59687 Version 2.0</div></div></div>"},"59688":{"type":"graphic_picture","displayName":"Dermoscopy vascular structures","title":"Morphology of vessels under dermoscopy","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Morphology of vessels under dermoscopy</div><div class=\"cntnt\"><img style=\"width:546px; height:405px;\" src=\"images/DERM/59688_Dermoscopy_vascular_struct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Dotted and glomerular vessels in string of pearls or serpiginous distribution in a clear cell acanthoma.<br> (B) Glomerular vessels focally present at the periphery of a squamous cell carcinoma.<br> (C) Polymorphous vessels in a malignant melanoma: dotted and serpentine vessels.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 59688 Version 6.0</div></div></div>"},"59690":{"type":"graphic_figure","displayName":"Extended cylinder life","title":"Cylinder life extended with conserving devices","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cylinder life extended with conserving devices</div><div class=\"cntnt\"><img style=\"width:392px; height:315px;\" src=\"images/PULM/59690_Ext_cylinder_life_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Calculated extended cylinder life using oxygen conserving devices of various delivery efficacies. The &quot;1X&quot; curve is the comparison curve without a conserving device. As the efficacy improves, the smallest oxygen cylinders become feasible for portable oxygen therapy.</div><div id=\"graphicVersion\">Graphic 59690 Version 3.0</div></div></div>"},"59691":{"type":"graphic_picture","displayName":"Portable hyperbaric chamber","title":"Portable hyperbaric chamber","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Portable hyperbaric chamber</div><div class=\"cntnt\"><img style=\"width:432px; height:260px;\" src=\"images/PULM/59691_Portable_hyperbaric_chamber.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Camp D'Altitude portable hyperbaric chamber.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 59691 Version 1.0</div></div></div>"},"59694":{"type":"graphic_figure","displayName":"Component separation technique","title":"Component separation technique","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Component separation technique</div><div class=\"cntnt\"><img style=\"width:528px; height:712px;\" src=\"images/SURG/59694_Componentseparation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Component separation involves the division of portions of the anterior and posterior rectus sheaths to gain adequate fascial coverage of the defect (A). The hernia sac is dissected from the surrounding tissues, and the hernia contents are reduced into the abdomen (B). The abdominal wall is then undermined, the external oblique is exposed, and the oblique fascia is divided, allowing the external oblique&nbsp;muscle to separate from the underlying internal oblique (B). The posterior rectus sheath can also be incised (C). These maneuvers add lateral length to the abdominal wall and will allow the fascial edges to be brought together without tension (D). Component separation allows advancement of the rectus abdominis muscle by as much as 20 cm. A larger defect can be bridged using this technique and mesh (E).<br /></div><div id=\"graphicVersion\">Graphic 59694 Version 4.0</div></div></div>"},"59696":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image omphalocele with extracorporeal liver","title":"Transverse section of the abdomen of a 28-week fetus with an omphalocele and extracorporeal liver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse section of the abdomen of a 28-week fetus with an omphalocele and extracorporeal liver</div><div class=\"cntnt\"><img style=\"width:303px; height:240px;\" src=\"images/OBGYN/59696_Ultrasound_of_an_omphalocel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow points to omphalocele sac containing fluid and fetal liver.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 59696 Version 4.0</div></div></div>"},"59698":{"type":"graphic_table","displayName":"Esophagectomysuperf esoph CA","title":"Esophagectomy outcomes in superficial esophageal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Esophagectomy outcomes in superficial esophageal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Author, year (accrual time)</td>\r\n            <td class=\"subtitle1\">Patients</td>\r\n            <td class=\"subtitle1\">Histology</td>\r\n            <td class=\"subtitle1\">Mortality rate, percent</td>\r\n            <td class=\"subtitle1\">Survival (5-yr), percent</td>\r\n            <td class=\"subtitle1\">Recurrence rate, percent</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Fujita H; 2001</p>\r\n            <p>(1981-1997)</p>\r\n            </td>\r\n            <td>113</td>\r\n            <td>Squam</td>\r\n            <td>8</td>\r\n            <td>\r\n            <p>71 M</p>\r\n            <p>74 SM-Rad</p>\r\n            <p>31 SM-Std</p>\r\n            </td>\r\n            <td>9</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Endo M; 2001</p>\r\n            <p>(1985-1997)</p>\r\n            </td>\r\n            <td>236</td>\r\n            <td>Squam</td>\r\n            <td>NR</td>\r\n            <td>67</td>\r\n            <td>13</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Rice T; 2001</p>\r\n            <p>(1985-1999)</p>\r\n            </td>\r\n            <td>122</td>\r\n            <td>Adeno</td>\r\n            <td>2.5</td>\r\n            <td>77</td>\r\n            <td>11</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Liu L; 2005</p>\r\n            <p>(1988-2003)</p>\r\n            </td>\r\n            <td>90</td>\r\n            <td>Adeno</td>\r\n            <td>NR</td>\r\n            <td>\r\n            <p>91 M</p>\r\n            <p>58 SM</p>\r\n            </td>\r\n            <td>10</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Westerterp M; 2005</p>\r\n            <p>(1980-1993)</p>\r\n            </td>\r\n            <td>120</td>\r\n            <td>Adeno</td>\r\n            <td>4</td>\r\n            <td>68</td>\r\n            <td>17</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Wang G; 2004</p>\r\n            <p>(1972-2003)</p>\r\n            </td>\r\n            <td>420</td>\r\n            <td>Squam</td>\r\n            <td>1</td>\r\n            <td>86</td>\r\n            <td>5</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Altorki N; 2008</p>\r\n            <p>(1994-2006)</p>\r\n            </td>\r\n            <td>75</td>\r\n            <td>\r\n            <p>Squam (15)</p>\r\n            <p>Adeno (60)</p>\r\n            </td>\r\n            <td>2.6</td>\r\n            <td>78 (87*)</td>\r\n            <td>8</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Pennathur A; 2009</p>\r\n            <p>(1995-2004)</p>\r\n            </td>\r\n            <td>100</td>\r\n            <td>\r\n            <p>Squam (9)</p>\r\n            <p>Adeno (91)</p>\r\n            </td>\r\n            <td>0</td>\r\n            <td>\r\n            <p>73 (T1a)</p>\r\n            <p>60 (T1b)</p>\r\n            </td>\r\n            <td>20</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Barbour A; 2010</p>\r\n            <p>(1991-2008)</p>\r\n            </td>\r\n            <td>85</td>\r\n            <td>Adeno</td>\r\n            <td>0</td>\r\n            <td>\r\n            <p>97 (T1a)</p>\r\n            <p>70 SM1</p>\r\n            <p>60 SM2</p>\r\n            <p>71 SM3</p>\r\n            </td>\r\n            <td>11</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Tanaka T; 2012</p>\r\n            <p>(1990-2008)&nbsp;</p>\r\n            </td>\r\n            <td>&nbsp;105</td>\r\n            <td>\r\n            <p>Squam (98)</p>\r\n            <p>Adeno (7)</p>\r\n            </td>\r\n            <td>2</td>\r\n            <td>74</td>\r\n            <td>21</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">Squam: squamous carcinoma; Adeno: adenocarcinoma; NR: not reported; M: mucosal; SM: submucosal; Rad: radical en-bloc esophagectomy; Std: standard esophagectomy.<br> * Disease specific survival.</div><div id=\"graphicVersion\">Graphic 59698 Version 5.0</div></div></div>"},"59700":{"type":"graphic_table","displayName":"Survival postsurgery IPHC DPAM","title":"Outcomes of radical surgery and intraperitoneal chemotherapy for disseminated peritoneal adenomucinosis (DPAM)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes of radical surgery and intraperitoneal chemotherapy for disseminated peritoneal adenomucinosis (DPAM)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author, year</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\" rowspan=\"2\">Median follow-up, months</td> <td class=\"subtitle1\" colspan=\"4\">Survival rate</td> </tr> <tr> <td class=\"subtitle2\">2 years</td> <td class=\"subtitle2\">3 years</td> <td class=\"subtitle2\">5 years</td> <td class=\"subtitle2\">10 years</td> </tr> <tr> <td>Ronnett BM; 2001</td> <td>65</td> <td>96</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>75</td> <td>68</td> </tr> <tr> <td>Smith JW; 1992</td> <td>17</td> <td>62</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>75</td> <td>60</td> </tr> <tr> <td>Sugarbaker P; 1993</td> <td>38</td> <td>NR</td> <td>&nbsp;</td> <td>90</td> <td>86*</td> <td>&nbsp;</td> </tr> <tr> <td>Sugarbaker P; 2001</td> <td>224</td> <td>38</td> <td>&nbsp;</td> <td>88</td> <td>86*</td> <td>&nbsp;</td> </tr> <tr> <td>van Ruth S; 2003</td> <td>38</td> <td>33</td> <td>95</td> <td>89</td> <td>70<sup>&#182;</sup></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patients with complete cytoreduction.<br />&para; 44 percent without evidence of disease at three years of follow-up.</div><div id=\"graphicVersion\">Graphic 59700 Version 3.0</div></div></div>"},"59701":{"type":"graphic_figure","displayName":"Bogalusa threshold girls","title":"Thresholds for defining cardiovascular risk in girls, Bogalusa Heart Study","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Thresholds for defining cardiovascular risk in girls, Bogalusa Heart Study</div><div class=\"cntnt\"><img style=\"width:544px; height:183px;\" src=\"images/PEDS/59701_Bogalusa_threshold_girls.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Smoothed body mass index (BMI) and waist circumference thresholds for predicting risk factor clustering among female children and adolescents in the Bogalusa Heart Study (1992-1994). Each curve defines the optimal&nbsp;BMI or waist circumference which predicts having three or more cardiovascular risk factors (high blood pressure; low high-density lipoprotein cholesterol concentration; or high low-density lipoprotein cholesterol, triglyceride, glucose, or insulin concentration, adjusted for age) at a given age.</div><div class=\"graphic_reference\">Data from: Katzmarzyk PT, Srinivasan SR, Chen W, et al. Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics 2004; 114:e198.</div><div id=\"graphicVersion\">Graphic 59701 Version 3.0</div></div></div>"},"59703":{"type":"graphic_diagnosticimage","displayName":"Clubfoot2","title":"Sonogram of fetal clubfoot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sonogram of fetal clubfoot</div><div class=\"cntnt\"><img style=\"width:390px; height:263px;\" src=\"images/OBGYN/59703_Clubfoot2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plantar surface of the entire fetal right foot can be seen in the same plane as the fibula and tibia.</div><div class=\"graphic_reference\">Courtesy of Urania Magriples, MD.</div><div id=\"graphicVersion\">Graphic 59703 Version 2.0</div></div></div>"},"59704":{"type":"graphic_figure","displayName":"Mean amniotic fluid volume by gestational age","title":"Mean amniotic fluid volume across normal pregnancy","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Mean amniotic fluid volume&nbsp;across normal pregnancy</div><div class=\"cntnt\"><img style=\"width:465px; height:333px;\" src=\"images/OBGYN/59704_Norm_amniotic_fluid_vol_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These values represent the 50<SUP>th</SUP> percentile. There is considerable variability around the mean. The 5<SUP>th</SUP>, 50<SUP>th</SUP>, and 95<SUP>th</SUP> percentiles at 33 weeks of gestation are approximately 300, 800, and 1900 mL, respectively.</div><div class=\"graphic_reference\">Data from: Brace RA, Wolf EJ. Normal amniotic fluid volume changes throughout pregnancy. Am J Obstet Gynecol 1989; 161:382.</div><div id=\"graphicVersion\">Graphic 59704 Version 6.0</div></div></div>"},"59705":{"type":"graphic_table","displayName":"Adjuvant vinorelbine plus cisplatin regimen for NSCLC","title":"Adjuvant vinorelbine plus cisplatin for resected early stage non-small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjuvant vinorelbine plus cisplatin for resected early stage non-small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Every 28 days, for four cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Vinorelbine</td> <td>25 mg/m<sup>2</sup> IV</td> <td>Dilute in normal saline (NS) to a final concentration between 0.5 and 2 mg/mL and administer over 6 to 10 minutes into the side port of a free-flowing IV infusion.</td> <td>Days 1, 8, 15, and 22</td> </tr> <tr class=\"divider_bottom\"> <td>Cisplatin</td> <td>50 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS and administer over two hours. Do not administer with aluminum needles or sets.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH: Days 1 and 8;<br /> MINIMAL: Days 15 and 22. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Vinorelbine is a vesicant and can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of febrile neutropenia is approximately 7%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of vinorelbine may be needed for patients with hepatic impairment. The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial.<sup>[1]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Basic metabolic panel (creatinine and electrolytes) prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Treatment with vinorelbine should be delayed until ANC is greater than 1500 cells/microL based on the manufacturer's guidelines. A dose reduction of 50% is recommended for patients with ANC 1000/microL to 1500/microL. If a patient's ANC is &#60;1000/microL, the weekly dose of vinorelbine should be held and blood counts should be rechecked in one week. For patients who develop febrile neutropenia or who have had two consecutive weekly doses held, the following dose adjustments will apply for subsequent doses of vinorelbine. For ANC &#8805;1500/microL, use a 25% dose reduction. For ANC 1000/microL to 1400/microL, use a 62.5% dose reduction. If ANC remains &#60;1000/microL, hold vinorelbine doses until count recovery and then follow above dosing guidelines.<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>The United States Prescribing Information recommends dose reduction for patients who develop hyperbilirubinemia during treatment with vinorelbine: <ul> <li>Serum bilirubin &#8804;2.0 mg/dL, give 100% of dose </li> <li>Serum bilirubin 2.1 to 3.0 mg/dL, give 50% of dose </li> <li>Serum bilirubin &#62;3.0 mg/dL, give 20% of dose </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Winton T, et al. N Engl J Med 2005; 352:2589.</LI>&#xD;&#xA;<LI>Vinorelbine injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 59705 Version 23.0</div></div></div>"},"59706":{"type":"graphic_table","displayName":"Hyperfractionated radiation therapy for diffuse pontine gliomas","title":"Hyperfractionated radiation therapy for diffuse intrinsic pontine gliomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hyperfractionated radiation therapy for diffuse intrinsic pontine gliomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Protocol [references]</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" rowspan=\"2\">Dose per fx/total dose</td> <td class=\"subtitle1\" rowspan=\"2\">TTP (mos)</td> <td class=\"subtitle1\" rowspan=\"2\">MST (mos)</td> <td class=\"subtitle1\" colspan=\"3\">Survival&nbsp;(percent)</td> </tr> <tr> <td class=\"subtitle2\">1 year</td> <td class=\"subtitle2\">2 years</td> <td class=\"subtitle2\">3 years</td> </tr> <tr> <td rowspan=\"3\">POG* <sup>[1, 2, 3]</sup></td> <td>38</td> <td>1.1 Gy/66 Gy</td> <td>6.5</td> <td>11</td> <td>48</td> <td>6</td> <td>3</td> </tr> <tr> <td>57</td> <td>1.17 Gy/70.2 Gy</td> <td>6 </td> <td>10</td> <td>40 </td> <td>23</td> <td>21</td> </tr> <tr> <td>39</td> <td>1.26 Gy/75.6 Gy</td> <td>7</td> <td>10</td> <td>39</td> <td>6</td> <td>6</td> </tr> <tr> <td rowspan=\"2\">CHOP/NYU <sup>[4]</sup></td> <td>16&nbsp;</td> <td>1.2 Gy/64.8 Gy</td> <td>7</td> <td>11</td> <td>48</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>35</td> <td>1 Gy/72 Gy</td> <td>8</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>28</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">CCG <sup>[5, 6, 7]</sup></td> <td>53</td> <td>1 Gy/72 Gy</td> <td>5.5</td> <td>9</td> <td>38</td> <td>14</td> <td>8</td> </tr> <tr> <td>66</td> <td>1 Gy/78 Gy</td> <td>8</td> <td>9.5</td> <td>35</td> <td>22</td> <td>11</td> </tr> <tr> <td rowspan=\"2\">UCSF <sup>[8, 9]</sup></td> <td>20</td> <td>1 Gy/72Gy</td> <td>9</td> <td>12</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>39</td> <td>1 Gy/78 Gy</td> <td>8.4</td> <td>10.8</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TTP: time to progression; MST: median survival time; POG: Pediatric Oncology Group; CHOP: Children's Hospital of Philadelphia; NYU: New York University; CCG: Children's Cancer Group; UCSF: University of California, San Francisco.</div><div class=\"graphic_reference\">1. Freeman CR, et al.&nbsp;Int J Radiat Oncol Biol Phys 1988; 15:311.<br />2. Freeman CR, et al. Cancer 1991; 68:474.<br />3. Freeman CR, et al.&nbsp;Int J Radiat Oncol Biol Phys 1993; 27:197.<br />4. Packer RJ, et al.&nbsp;Int J Radiat Oncol Biol Phys 1987; 13:1647.<br />5. Packer RJ, et al. Ann Neurol 1990; 27:167.<br />6. Packer RJ, et al. Cancer 1994; 74:1827. <br />7. Packer RJ, et al. Cancer 1993; 72:1414.<br />8. Edwards MS, et al. J Neurosurg 1989; 70:691.<br />9. Prados MD, et al.&nbsp;Int J Radiat Oncol Biol Phys 1995; 32:85.</div><div id=\"graphicVersion\">Graphic 59706 Version 2.0</div></div></div>"},"59709":{"type":"graphic_figure","displayName":"Placement of word catheter","title":"Placement of Word catheter in a Bartholin gland cyst cavity after drainage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Placement of Word catheter in a Bartholin gland cyst cavity after drainage</div><div class=\"cntnt\"><img style=\"width:443px; height:321px;\" src=\"images/OBGYN/59709_Placement_of_word_catheter.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59709 Version 2.0</div></div></div>"},"59710":{"type":"graphic_picture","displayName":"Two hand chest technique","title":"Two-handed chest compressions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-handed chest compressions</div><div class=\"cntnt\"><img style=\"width:308px; height:434px;\" src=\"images/EM/59710_Two_hand_chest_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For children (from one year until the start of puberty), chest compressions may be performed with two hands placed over the lower half of the sternum.</div><div id=\"graphicVersion\">Graphic 59710 Version 2.0</div></div></div>"},"59711":{"type":"graphic_picture","displayName":"HLA II expression in Graves","title":"HLA class II expression in Graves' disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HLA class II expression in Graves' disease</div><div class=\"cntnt\"><img style=\"width:334px; height:218px;\" src=\"images/ENDO/59711_HLA_II_expression_in_Graves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thyroid tissue from a patient with Graves' hyperthyroidism. The brown staining indicates the presence of HLA class II (DR) molecules which are not expressed in normal thyroid tissue.</div><div class=\"graphic_reference\">Courtesy of Terry F Davies, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 59711 Version 1.0</div></div></div>"},"59712":{"type":"graphic_table","displayName":"Treatment of PMS","title":"Therapies for the premenstrual syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapies for the premenstrual syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Treatments with demonstrated efficacy</td> </tr> <tr> <td class=\"indent1\">Serotonin reuptake inhibitors</td> </tr> <tr> <td class=\"indent1\">Oral contraceptives containing drospirenone</td> </tr> <tr> <td class=\"indent1\">Alprazolam</td> </tr> <tr> <td class=\"sublist2_start\">Agents that suppress ovulation</td> </tr> <tr> <td class=\"sublist2\">Continuous oral contraceptives (containing any progestin)</td> </tr> <tr> <td class=\"sublist2\">GnRH agonists</td> </tr> <tr> <td class=\"subtitle1_single\">Treatments with possible efficacy</td> </tr> <tr> <td class=\"indent1\">Cyclic oral contraceptives (not containing drospirenone)</td> </tr> <tr> <td class=\"indent1\">Exercise</td> </tr> <tr> <td class=\"subtitle1_single\">Ineffective treatments</td> </tr> <tr> <td class=\"indent1\">Progesterone</td> </tr> <tr> <td class=\"indent1\">Vitamin supplements</td> </tr> <tr> <td class=\"indent1\">Dietary restrictions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone.</div><div id=\"graphicVersion\">Graphic 59712 Version 6.0</div></div></div>"},"59713":{"type":"graphic_table","displayName":"Diagnosis of malabsorption","title":"Practical advice in the diagnosis of malabsorption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Practical advice in the diagnosis of malabsorption</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Stools may appear normal even when laden with excess fat.</td> </tr> <tr> <td>2. Patients with carbohydrate malabsorption may have watery diarrhea and complain of excess flatus and abdominal distension. Symptoms typically occur within 90 minutes of carbohydrate ingestion.</td> </tr> <tr> <td>3. Abdominal pain is unusual in malabsorption except in the case of chronic pancreatitis, Crohn disease, or intestinal&nbsp;pseudo-obstruction (eg, scleroderma).</td> </tr> <tr> <td>4. Patients with celiac disease often have a childhood history of ill health and a positive family history of gluten sensitivity or Crohn disease. A subtle presentation, such as anemia or mildly elevated liver enzymes, is commonly the sole initial indication of disease.</td> </tr> <tr> <td>5. The prevalence of celiac disease in patients with type 1 diabetes mellitus is higher than the general population.</td> </tr> <tr> <td>6. Always ask about previous surgery.</td> </tr> <tr> <td>7. Always ask about a history of recurrent peptic ulcer disease.</td> </tr> <tr> <td>8. Do a careful physical examination looking for signs of nutrient malabsorption.</td> </tr> <tr> <td>9. Do not forget to ask about alcohol consumption. It usually takes 10 to 20 years for pancreatic insufficiency to develop in alcoholics.</td> </tr> <tr> <td>10. A history of oil drops separated from the main stool mass, becoming whitish and firm after cooling (non-hydrolyzed triglycerides), strongly points toward pancreatic insufficiency as the cause.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59713 Version 2.0</div></div></div>"},"59715":{"type":"graphic_figure","displayName":"Pylorus preserving Whipple","title":"Pylorus preserving Whipple","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pylorus preserving Whipple</div><div class=\"cntnt\"><img style=\"width:432px; height:354px;\" src=\"images/GAST/59715_Pylorus_preserving_Whipple.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &#169; 2003 American Gastroenterological Association.</div><div id=\"graphicVersion\">Graphic 59715 Version 4.0</div></div></div>"},"59716":{"type":"graphic_figure","displayName":"Staging of patients who meet the definition of CKD","title":"Staging of patients who meet the definition of CKD","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Staging of patients who meet the definition of CKD</div><div class=\"cntnt\"><img style=\"width:598px; height:444px;\" src=\"images/NEPH/59716_Rel_risks_GFR_albuminuria.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">GFR and albuminuria grid to reflect the risk of progression by intensity of coloring (green, yellow, orange, red, deep red). The numbers in the boxes are a guide to the frequency of monitoring (number of times per year).</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Kidney International. KDIGO. Summary of recommendation statements. Kidney Int 2013; 3(Suppl):5. Copyright © 2013. <A href=\"http://www.nature.com/ki/index.html\" target=_blank>http://www.nature.com/ki/index.html</A>.</div><div id=\"graphicVersion\">Graphic 59716 Version 6.0</div></div></div>"},"59717":{"type":"graphic_picture","displayName":"Poison ivy fruit PI","title":"Poison ivy fruit","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Poison ivy fruit</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/59717_Poison_ivy_fruit_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cream-colored fruit of poison ivy.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59717 Version 5.0</div></div></div>"},"59718":{"type":"graphic_figure","displayName":"Pleural pressure volume curve in trapped lung and heart failure","title":"Pleural pressure volume curve in trapped lung and heart failure","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Pleural pressure volume curve in trapped lung and heart failure</div><div class=\"cntnt\"><img style=\"width:554px; height:412px;\" src=\"images/PULM/59718_Pl_press_vol_curv_lung_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure/volume curves are plotted in which the cause of the pleural effusion was attributed to a trapped lung resulting from different pleural insults with concomitant heart failure.<br> <br> The solid circles and solid triangles represent two separate patients with heart failure and trapped lung from uremic pleurisy; the solid squares represent a patient with heart failure and trapped lung following coronary artery bypass grafting (CABG).</div><div class=\"graphic_reference\">Reproduced with permission from the American College of Chest Physicians. Huggins JT, Sahn SA, Heidecker J, et al. Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT. Chest 2007; 131:206. Copyright © 2007.</div><div id=\"graphicVersion\">Graphic 59718 Version 4.0</div></div></div>"},"59720":{"type":"graphic_algorithm","displayName":"Pediatric algorithm for blunt chest trauma","title":"Blunt chest trauma in children ED management","html":"<div class=\"graphic\"><div style=\"width: 860px\" class=\"figure\"><div class=\"ttl\">Blunt chest trauma in children ED management</div><div class=\"cntnt\"><img style=\"width:840px; height:644px;\" src=\"images/EM/59720_Ped_algo_blunt_chest_trauma.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AP: anterior-posterior; CT: computed tomography; CXR: chest x-ray; ECG: electrocardiogram; ED: emergency department; FAST: Focused Assessment with Sonography in Trauma; OR: operating room; PA: posterior-anterior; PTX: pneumothorax; TEE: transesophageal echocardiography; US: ultrasound.</div><div id=\"graphicVersion\">Graphic 59720 Version 5.0</div></div></div>"},"59721":{"type":"graphic_figure","displayName":"Lateral airway anatomy","title":"Midsagittal view of the airway","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Midsagittal view of the airway</div><div class=\"cntnt\"><img style=\"width:479px; height:541px;\" src=\"images/EM/59721_Lateral_airway_anatomy_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59721 Version 4.0</div></div></div>"},"59722":{"type":"graphic_figure","displayName":"Multilumen catheter","title":"Multilumen catheter","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Multilumen catheter</div><div class=\"cntnt\"><img style=\"width:517px; height:463px;\" src=\"images/SURG/59722_Multilumen_catheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: SenoRX, Inc. Copyright &#169; 2010.</div><div id=\"graphicVersion\">Graphic 59722 Version 1.0</div></div></div>"},"59724":{"type":"graphic_table","displayName":"AIDS-defining conditions","title":"AIDS-defining conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AIDS-defining conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Bacterial infections, multiple or recurrent*</td> </tr> <tr> <td>Candidiasis of bronchi, trachea, or lungs</td> </tr> <tr> <td>Candidiasis of esophagus</td> </tr> <tr> <td>Cervical cancer, invasive<sup>&#182;</sup></td> </tr> <tr> <td>Coccidioidomycosis, disseminated or extrapulmonary</td> </tr> <tr> <td>Cryptococcosis, extrapulmonary</td> </tr> <tr> <td>Cryptosporidiosis, chronic intestinal (&#62;1 month's duration)</td> </tr> <tr> <td>Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age &#62;1 month</td> </tr> <tr> <td>Cytomegalovirus retinitis (with loss of vision)</td> </tr> <tr> <td>Encephalopathy, HIV related<sup>&#916;</sup></td> </tr> <tr> <td>Herpes simplex: chronic ulcers (&#62;1 month's duration) or bronchitis, pneumonitis, or esophagitis (onset at age &#62;1 month)</td> </tr> <tr> <td>Histoplasmosis, disseminated or extrapulmonary</td> </tr> <tr> <td>Isosporiasis, chronic intestinal (&#62;1 month's duration)</td> </tr> <tr> <td>Kaposi sarcoma</td> </tr> <tr> <td>Lymphoma, Burkitt (or equivalent term)</td> </tr> <tr> <td>Lymphoma, immunoblastic (or equivalent term)</td> </tr> <tr> <td>Lymphoma, primary, of brain</td> </tr> <tr> <td><em>Mycobacterium avium</em> complex (MAC) or <em>Mycobacterium kansasii</em>, disseminated or extrapulmonary</td> </tr> <tr> <td><em>Mycobacterium tuberculosis</em> of any site, pulmonary<sup>&#182;</sup>, disseminated, or extrapulmonary</td> </tr> <tr> <td><em>Mycobacterium</em>, other species or unidentified species, disseminated or extrapulmonary</td> </tr> <tr> <td><em>Pneumocystis jirovecii</em> (previously known as <em>\"Pneumocystis carinii\"</em>) pneumonia</td> </tr> <tr> <td>Pneumonia, recurrent<sup>&#182;</sup></td> </tr> <tr> <td>Progressive multifocal leukoencephalopathy</td> </tr> <tr> <td><em>Salmonella</em> septicemia, recurrent</td> </tr> <tr> <td>Toxoplasmosis of brain, onset at age &#62;1 month</td> </tr> <tr> <td>Wasting syndrome attributed to HIV<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus; MAC: mycobacterium avium complex.<br />* Only among children aged &lt;6 years.<br />¶ Only among children aged ≥6 years, adolescents, and adults.<br />Δ Suggested diagnostic criteria for these illnesses, which might be particularly important for HIV encephalopathy and HIV wasting syndrome, are described in <A href=\"http://www.cdc.gov/mmwr/PDF/rr/rr4312.pdf\" target=_blank>MMWR Recomm Rep 1994; 43 (No.12)</A> and <A href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm\" target=_blank>MMWR Recomm Rep 1992; 41 (No.17)</A>.</div><div class=\"graphic_reference\">Reproduced from: Selik RM, Mokotoff ED, Branson B, et al. Revised Surveillance Case Definition for HIV Infection - United States, 2014. MMWR Recomm Rep 2014; 63:1.</div><div id=\"graphicVersion\">Graphic 59724 Version 8.0</div></div></div>"},"59725":{"type":"graphic_diagnosticimage","displayName":"Transversus abdominis plane block ultrasound","title":"Transversus abdominis plane (TAP) block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Transversus abdominis plane (TAP) block ultrasound</div><div class=\"cntnt\"><img style=\"width:504px; height:250px;\" src=\"images/SURG/59725_Transverseabdomplane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided TAP block, the external oblique, internal oblique, transversalis muscle, and peritoneal cavity are visualized. Fascial planes appear hyperechoic relative to the adjacent hypoechoic muscle. The needle tip is visualized as it penetrates the fascial layer between the internal oblique and transversus abdominis, where a long-acting local anesthetic is injected. For further details, refer to the&nbsp;UpToDate topic on nerve blocks of the neck, scalp, and&nbsp;trunk.</div><div id=\"graphicVersion\">Graphic 59725 Version 6.0</div></div></div>"},"59726":{"type":"graphic_table","displayName":"Tips on taking medicines PI","title":"Tips on taking medicines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips on taking medicines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">To get the most out of your medicines, follow these tips:</td> </tr> <tr> <td>Take your medicines exactly as they have been prescribed for you.</td> </tr> <tr> <td>Use tools, such as a daily or weekly pill box, to organize your medicines.</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">Keep your medicine containers in a place you will see them every day.</span></td> </tr> <tr> <td>Create reminders for yourself to take your medicines. Try using a calendar, <span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">smart phone app</span>, a digital watch, or whatever method might work for you.</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">Read the prescription label and printed patient information that comes with each medicine.</span></td> </tr> <tr> <td>Do not skip pills, change doses, or take extra pills unless your doctor tells you to. <span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">The dose your doctor prescribes takes into account your age, weight, health problems, and other medicines you take. </span></td> </tr> <tr> <td>Learn <span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">the names of </span>each of your medicines<span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">, how each</span> works, and why you take it. People who understand their medicines are more likely to stay on them.</td> </tr> <tr> <td>Learn what each of your medicines looks like (shape, size, color). When you get a refill, you might get a new generic version that looks different from the last time. That is OK as long as the new medicine has the same ingredient as the one it is replacing. If you are worried about a refill looking different, talk to your pharmacist. </td> </tr> <tr> <td>Tell your doctor or nurse about any side effects you have. He or she might have ways to reduce or get rid of the side effects.</td> </tr> <tr> <td>Tell your doctor, nurse, or pharmacist if you can't afford your medicines. There are often ways to reduce costs.</td> </tr> <tr> <td>Make a list of all the medicines you take and keep one copy at home and one in your wallet.</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">Bring a bag containing <strong>all </strong>your medicines with you to your doctor's office. Have your doctor or nurse go over them with you.</span></td> </tr> <tr> <td>Talk to your doctor, nurse, or pharmacist <strong>before</strong> you take any cough, cold, allergy, pain, or other extra medicines. The same goes for supplements and herbal medicines. Over-the-counter and herbal medicines can interact with prescription medicines.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59726 Version 6.0</div></div></div>"},"59727":{"type":"graphic_table","displayName":"Diagnostic tests for adenovirus","title":"Diagnostic tests for adenovirus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic tests for adenovirus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Diagnostic test</td> <td class=\"subtitle1\">Appropriate samples</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td><strong>Viral culture</strong></td> <td> <ul> <li>Nasopharyngeal swabs or aspirates </li> <li>Throat swabs or washes </li> <li>Sputum, tracheal aspirates, or BAL fluid </li> <li>Conjunctival swabs or scrapings </li> <li>Stool or rectal swabs </li> <li>Urine </li> <li>Cerebrospinal fluid </li> <li>Tissue samples </li> </ul> </td> <td> <p>Samples should be placed in viral transport medium and transported on ice.</p> <p>Results available in 2 to 7 days for most serotypes, but up to 28 days for subgroup D serotypes (which cause epidemic keratoconjunctivitis).</p> <p>All adenovirus serotypes except 40 and 41 cause characteristic CPE in human epithelial cell lines and human embryonic kidney cells.</p> </td> </tr> <tr class=\"divider_top\"> <td><strong>Viral antigen assays</strong> (eg, adenovirus-specific enzyme-linked immunosorbent assay or immunofluorescence assay)</td> <td> <ul> <li>Nasopharyngeal swabs or aspirates </li> <li>Throat swabs or washes </li> <li>Tracheal aspirate or BAL material </li> <li>Conjunctival swabs or scrapings </li> <li>Stool or rectal swabs </li> </ul> </td> <td> <p>Results available in less than 30 minutes.</p> <p>Specific, but less sensitive than viral culture for respiratory secretions.</p> <p>Test of choice for adenovirus serotypes 40 and 41 (which cause infantile gastroenteritis); adjunct to viral culture for epidemic keratoconjunctivitis (more rapid results for subgroup D serotypes).</p> </td> </tr> <tr class=\"divider_top\"> <td><strong>Polymerase chain reaction</strong></td> <td> <ul> <li>Nasopharyngeal swabs or aspirates </li> <li>Throat swabs or washes </li> <li>Sputum, tracheal aspirates, or BAL fluid </li> <li>Blood </li> <li>Urine </li> <li>Stool </li> <li>Cerebrospinal fluid </li> <li>Biopsy specimens </li> <li>Fixed tissue </li> </ul> </td> <td>Rapid diagnosis of adenovirus infection in immunocompromised patients and other hospitalized patients.</td> </tr> <tr class=\"divider_top\"> <td><strong>Histopathologic studies</strong></td> <td> <ul> <li>Tissue </li> </ul> </td> <td> <p>Adenoviruses cause characteristic intranuclear inclusions; should be performed in conjunction with viral culture because histopathologic changes may be nonspecific, especially during the early stage of adenovirus infection.</p> <p>Immunohistochemistry, in situ hybridization, or electron microscopy can be used to definitively identify adenoviruses in tissue sections.</p> </td> </tr> <tr class=\"divider_top\"> <td><strong>Serology</strong></td> <td> <ul> <li>Blood </li> </ul> </td> <td>Adenovirus-specific IgM antibody suggests acute infection. Fourfold or greater rise in adenovirus-specific IgG antibodies confirms recent infection.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage; CPE: cytopathic effect.</div><div id=\"graphicVersion\">Graphic 59727 Version 5.0</div></div></div>"},"59732":{"type":"graphic_table","displayName":"Autoantibodies in scleroderma","title":"Serum autoantibodies in scleroderma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serum autoantibodies in scleroderma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antigen</td> <td class=\"subtitle1\">ANA staining pattern</td> <td class=\"subtitle1\">Approximate frequency in all patients (percent)</td> <td class=\"subtitle1\">Clinical associations</td> <td class=\"subtitle1\">Organ involvement</td> </tr> <tr> <td>Scl-70 (topoisomerase-1)</td> <td>Speckled</td> <td>10 to 40</td> <td>dcSSc</td> <td>Lung fibrosis, isolated pulmonary hypertension less likely</td> </tr> <tr> <td>Centromere</td> <td>Centromere (kinetochore)</td> <td>15 to 40</td> <td>lcSSc</td> <td>Pulmonary hypertension, esophageal disease, \"protection\" from lung fibrosis and renal disease</td> </tr> <tr> <td>RNA polymerase III</td> <td>Fine speckled nucleolar</td> <td>4 to 25</td> <td>dcSSc</td> <td>Renal, skin, malignancy</td> </tr> <tr> <td>U3 RNP (fibrillarin)</td> <td>Nucleolar</td> <td>1 to 5</td> <td>dcSSc, poor outcome black men</td> <td>Pulmonary hypertension, muscle</td> </tr> <tr> <td>PM-Scl</td> <td>Nucleolar</td> <td>3 to 6</td> <td>Overlap, mixed</td> <td>Muscle</td> </tr> <tr> <td>U1 RNP</td> <td>Speckled</td> <td>5 to 35</td> <td>lcSSc, blacks, polymyositis overlap</td> <td>Muscle</td> </tr> <tr> <td>Th/To</td> <td>Nucleolar</td> <td>1 to 7</td> <td>lcSsc</td> <td>Pulmonary hypertension, lung fibrosis, small bowel</td> </tr> <tr> <td>Anti-U11/U12</td> <td>Nucleolar</td> <td>1 to 5</td> <td>lcSSc and dcSSc</td> <td>Lung fibrosis</td> </tr> <tr> <td>Anti-Ku</td> <td>&nbsp;</td> <td>1 to 3</td> <td>Overlap SSc</td> <td>Muscle and joint involvement, SLE overlap</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Characteristics and clinical associations of the different autoantibodies that may be seen in scleroderma. dcSSc and lcSSc refer to diffuse and limited cutaneous systemic sclerosis, respectively.</div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematosus.</div><div class=\"graphic_reference\">Adapted from: Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6:112.</div><div id=\"graphicVersion\">Graphic 59732 Version 7.0</div></div></div>"},"59733":{"type":"graphic_table","displayName":"Myopathy and biochemical defect","title":"Correlation of metabolic myopathy symptoms and signs with specific biochemical defects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Correlation of metabolic myopathy symptoms and signs with specific biochemical defects</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Static symptoms and signs</td> </tr> <tr> <td>Acid maltase deficiency</td> </tr> <tr> <td>Branching enzyme deficiency</td> </tr> <tr> <td>Debranching enzyme deficiency</td> </tr> <tr> <td>Carnitine transport defect</td> </tr> <tr> <td>LCAD, VLCAD deficiencies</td> </tr> <tr> <td>Trifunctional enzyme deficiency</td> </tr> <tr> <td>Mitochondrial disorders</td> </tr> <tr> <td class=\"subtitle1_single\">Dynamic symptoms and signs</td> </tr> <tr> <td>Phosphorylase b kinase deficiency</td> </tr> <tr> <td>Myophosphorylase (PPL) deficiency</td> </tr> <tr> <td>Phosphofructokinase (PFK) deficiency</td> </tr> <tr> <td>Phosphoglycerate kinase (PGK) deficiency</td> </tr> <tr> <td>Lactate dehydrogenase (LDH) deficiency</td> </tr> <tr> <td>Carnitine palmitoyltransferase II (CPT II) deficiency</td> </tr> <tr> <td>Fatty acid oxidation/mitochondrial defects</td> </tr> <tr> <td class=\"subtitle1_single\">Static and dynamic symptoms and signs</td> </tr> <tr> <td>Myophosphorylase deficiency</td> </tr> <tr> <td>PFK, PPL b kinase deficiencies (plus fixed weakness)</td> </tr> <tr> <td>Debranching enzyme deficiency (plus dynamic symptoms)</td> </tr> <tr> <td>LCAD, VLCAD, SCHAD deficiencies</td> </tr> <tr> <td>Trifunctional enzyme deficiency</td> </tr> <tr> <td>Multiple mitochondrial DNA deletions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LCAD: long-chain acyl-CoA dehydrogenase; VLCAD: very long-chain acyl-CoA dehydrogenase; SCHAD: short-chain 3-hydroxyacyl-CoA dehydrogenase.</div><div id=\"graphicVersion\">Graphic 59733 Version 3.0</div></div></div>"},"59735":{"type":"graphic_picture","displayName":"Desquamation","title":"Desquamation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Desquamation</div><div class=\"cntnt\"><img style=\"width:504px; height:341px;\" src=\"images/ID/59735_Desquamation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Public Health Image Library (PHIL) http://phil.cdc.gov.</div><div id=\"graphicVersion\">Graphic 59735 Version 3.0</div></div></div>"},"59736":{"type":"graphic_table","displayName":"Postexposure prophylaxis hepatitis B vaccine","title":"Recommended postexposure prophylaxis for percutaneous or permucosal exposure to hepatitis B virus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended postexposure prophylaxis for percutaneous or permucosal exposure to hepatitis B virus</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td>\r\n                    <td class=\"subtitle1\" colspan=\"3\">Treatment when source is:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2\">HBsAg positive</td>\r\n                    <td class=\"subtitle2\">HBsAg negative</td>\r\n                    <td class=\"subtitle2\">Not tested or unknown</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle3_left\" colspan=\"4\">Vaccination and antibody response status of exposed person</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">Unvaccinated</td>\r\n                    <td>HBIG x 1; initiate HB vaccine series</td>\r\n                    <td>Initiate HB vaccine series</td>\r\n                    <td>Initiate HB vaccine series</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\" colspan=\"4\">Previously vaccinated</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent3\">Known responder</td>\r\n                    <td>No treatment</td>\r\n                    <td>No treatment</td>\r\n                    <td>No treatment</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent3\">Known non-responder</td>\r\n                    <td>HBIG x 2 or HBIG x 1 and initiate revaccination</td>\r\n                    <td>No treatment</td>\r\n                    <td>If known high-risk source, treat as if source were HBsAg positive</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent3\" rowspan=\"3\">Antibody response unknown</td>\r\n                    <td class=\"sublist1_start\">Test exposed person for anti-HBs</td>\r\n                    <td class=\"sublist_other_start\" rowspan=\"3\">No treatment</td>\r\n                    <td class=\"sublist1_start\">Test exposed person for anti-HBs</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">If adequate*, no treatment</td>\r\n                    <td class=\"sublist1\">If adequate*, no treatment</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">If inadequate*, HBIG x 1 and vaccine booster</td>\r\n                    <td class=\"sublist1\">If inadequate*, initiate revaccination</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_lgnd\">HBsAg: hepatitis B surface antigen; HBIG: hepatitis B immunoglobulin; HB vaccine series: hepatitis B vaccine; anti-HBs: antibody to hepatitis B surface antigen.<BR>For dosing information see \"Hepatitis B immune globulin: Drug information\" and \"Hepatitis B vaccine: Drug information\".</div><div class=\"graphic_footnotes\">* Responder is defined a person with adequate levels of serum antibody to hepatitis B surface antigen (ie, ≥10 mlU/mL); inadequate response to vaccination defined as serum anti-HBs &lt;10 mlU/mL.</div><div class=\"graphic_reference\">Courtesy of David Weber, MD, MPH.</div><div id=\"graphicVersion\">Graphic 59736 Version 3.0</div></div></div>"},"59738":{"type":"graphic_picture","displayName":"Epiglottitis - Direct visualization","title":"Epiglottitis: Direct visualization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epiglottitis: Direct visualization</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/EM/59738_Epiglottitis_visualization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A swollen, cherry-red epiglottis with an endotracheal tube passing posteriorly.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, MD, Ludwig W, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright ©2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59738 Version 2.0</div></div></div>"},"59739":{"type":"graphic_figure","displayName":"Factors affecting neonatal oxygen dissociation curve","title":"Factors that affect the neonatal oxygen-dissociation curve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Factors that affect the neonatal oxygen-dissociation curve</div><div class=\"cntnt\"><img style=\"width:404px; height:393px;\" src=\"images/PEDS/59739_Oxygen_dissociation_curve.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The oxygen-dissociation curve of human blood and the effects of changes in the H<SUP>+</SUP> ion concentration, Pco<SUB>2</SUB>, temperature, and level of 2,3-diposphoglycerate (2,3-DPG) are depicted above. For fetal hemoglobin, the normal curve (a) is shifted to the left (b).</div><div class=\"graphic_footnotes\">PCO<SUB>2</SUB>: partial pressure of carbon dioxide; PO<SUB>2</SUB>: partial pressure of oxygen; O<SUB>2</SUB>: oxygen.</div><div class=\"graphic_reference\">Reproduced with permission from: Levin AR. Management of the cyanotic newborn. Ped Ann 1981; 10:127. Copyright © 1981 SLACK, Inc.</div><div id=\"graphicVersion\">Graphic 59739 Version 5.0</div></div></div>"},"59741":{"type":"graphic_picture","displayName":"Erythema annulare centrifugum - dark skin","title":"Superficial erythema annulare centrifugum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial erythema annulare centrifugum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/59741_Eryth_ann_cent_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, annular plaques with \"trailing scale\" are classic features of superficial erythema annulare centrifugum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59741 Version 4.0</div></div></div>"},"59742":{"type":"graphic_picture","displayName":"Disseminated superficial actinic porokeratosis - legs","title":"Disseminated superficial actinic porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Disseminated superficial actinic porokeratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/59742_Dis_sup_actin_porokera_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous macules with peripheral keratotic rims are present on the lower legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59742 Version 3.0</div></div></div>"},"59744":{"type":"graphic_figure","displayName":"Intracapsular versus extracapsular hip fractures","title":"Intracapsular versus extracapsular hip fractures","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Intracapsular versus extracapsular hip fractures</div><div class=\"cntnt\"><img style=\"width:528px; height:349px;\" src=\"images/EM/59744_Hipfxcapsule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The prognosis of hip fractures varies by anatomic location. Intracapsular fractures are more likely to disrupt the blood supply to the femoral head, thereby increasing the risk of avascular necrosis, compared with extracapsular (or intertrochanteric) fractures. Femoral neck stress fractures are typically intracapsular. </div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright © 2009 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 59744 Version 4.0</div></div></div>"},"59746":{"type":"graphic_table","displayName":"Medications for treatment of constipation","title":"Medications for treatment of constipation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications for treatment of constipation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Usual adult dose</td> <td class=\"subtitle1\">Onset of action</td> <td class=\"subtitle1\">Side effects</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Bulk-forming laxatives*</td> </tr> <tr> <td class=\"indent1\">Psyllium</td> <td>Up to 1 tablespoon (&#8773;3.5 grams fiber) 3 times per day</td> <td>12 to 72 h</td> <td class=\"divider_bottom\" rowspan=\"4\">Impaction above strictures, fluid overload, gas and bloating</td> </tr> <tr> <td class=\"indent1\">Methylcellulose</td> <td>Up to 1 tablespoon (&#8773;2 grams fiber) or 4 caplets (500 mg fiber per caplet) 3 times per day</td> <td>12 to 72 h</td> </tr> <tr> <td class=\"indent1\">Polycarbophil</td> <td>2 to 4 tabs (500 mg fiber per tab) per day</td> <td>24 to 48 h</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Wheat dextrin<sup>&#182;</sup></td> <td>1 to 3 caplets (1 gram fiber per caplet) or 2 teaspoonsful (1.5 gram fiber per teaspoon) up to 3 times per daily</td> <td>24 to 48 h</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Surfactants (softeners)</td> </tr> <tr> <td class=\"indent1\">Docusate sodium</td> <td>100 mg 2 times per day</td> <td>24 to 72 hours</td> <td class=\"divider_bottom\" rowspan=\"2\">Well tolerated. Use lower dose if administered with another laxative. Contact dermatitis reported.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Docusate calcium</td> <td>240 mg 1 time per day</td> <td>24 to 72 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Osmotic agents</td> </tr> <tr> <td class=\"indent1\">Polyethylene glycol (macrogol)</td> <td>8.5 to 34 grams in 240 mL (8 ounces) liquids</td> <td>1 to 4 days</td> <td>Nausea, bloating, cramping</td> </tr> <tr> <td class=\"indent1\">Lactulose</td> <td>10 to 20 grams (15 to 30 mL) every other day. May increase up to 2 times per day.</td> <td>24 to 48 hours</td> <td>Abdominal bloating, flatulence</td> </tr> <tr> <td class=\"indent1\">Sorbitol</td> <td>30 grams (120 mL of 25 percent solution) 1 time per day</td> <td>24 to 48 hours</td> <td>Abdominal bloating, flatulence</td> </tr> <tr> <td class=\"indent1\">Glycerin (glycerol)</td> <td>One suppository (2 or 3 grams) per rectum for 15 minutes 1 time per day</td> <td>15 to 60 minutes</td> <td>Rectal irritation</td> </tr> <tr> <td class=\"indent1\">Magnesium sulfate</td> <td>One to two teaspoonsful (&#8773;5 to 10 grams) dissolved in 240 mL (8 ounces) water 1 time per day</td> <td>0.5 to 3 hours</td> <td class=\"divider_bottom\" rowspan=\"2\">Watery stools and urgency. Caution in renal insufficiency (magnesium toxicity).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Magnesium citrate</td> <td>200 mL (11.6 grams) 1 time per day</td> <td>0.5 to 3 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stimulant laxatives</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Bisacodyl</td> <td>10 to 30 mg as enteric coated tabs 1 time per day</td> <td>6 to 10 hours</td> <td>Gastric irritation</td> </tr> <tr> <td>10 mg suppository per rectum 1 time per day</td> <td>15 to 60 minutes</td> <td>Rectal irritation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Senna</td> <td>2 to 4 tabs (8.6 mg sennosides per tab) or 1 to 2 tabs (15 mg sennosides per tab) as a single daily dose or divided twice daily</td> <td>6 to 12 hours</td> <td>Melanosis coli</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Other</td> </tr> <tr> <td class=\"indent1\">Lubiprostone</td> <td>24 micrograms 2 times per day</td> <td>24 to 48 hours</td> <td>Nausea, diarrhea</td> </tr> <tr> <td class=\"indent1\">Linaclotide</td> <td>145 micrograms 1 time per day</td> <td>12 to 24 hours</td> <td>Diarrhea, bloating</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All doses shown are for oral administration unless otherwise noted. Phosphate containing laxatives are not recommended. Mineral oil (enema and oral liquid) laxatives are not generally recommended except as enema following disimpaction (see text).</div><div class=\"graphic_footnotes\">* Initiate at one-half or less of dose shown and gradually increase as needed to minimize gas and bloating. Administer with 180 to 360 mL (6 to 12 ounces) water or fruit juice. Do not administer within one hour of other medications. Fiber content per dose may vary. Consult individual product label.<br />&para; US trade name Benefiber&reg;.</div><div class=\"graphic_reference\">Courtesy of Arnold Wald, MD. Additional data from: Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 59746 Version 14.0</div></div></div>"},"59748":{"type":"graphic_figure","displayName":"LV diastolic pressure volume relationship ","title":"Left ventricular diastolic pressure-volume relationship in ischemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular diastolic pressure-volume relationship in ischemia</div><div class=\"cntnt\"><img style=\"width:323px; height:246px;\" src=\"images/CARD/59748_LV_pressure_vol_relation_2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left ventricular (LV) diastolic pressure as a function of the LV volume defines LV diastolic distensibility or compliance. With exercise and the provocation of ischemia, there is a shift of the pressure- volume curve upward, indicating a reduction in LV compliance. A relatively stiff, noncomplaint ventricle requires higher pressure to achieve filling of a given volume.</div><div class=\"graphic_reference\">Data from Carroll JD, Carroll EP. Herz 1991; 16:1.</div><div id=\"graphicVersion\">Graphic 59748 Version 3.0</div></div></div>"},"59749":{"type":"graphic_diagnosticimage","displayName":"Acute hypersensitivity pneumonitis CT","title":"Acute phase of hypersenstivity pneumonia (extrinsic allergic alveolitis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute phase of hypersenstivity pneumonia (extrinsic allergic alveolitis)</div><div class=\"cntnt\"><img style=\"width:343px; height:255px;\" src=\"images/PULM/59749_Acute_EAA_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows ground glass opacification of the lungs during the acute phase of hypersensitivity pneumonia (extrinsic allergic alveolitis). Several secondary pulmonary lobules are spared and appear as darker areas in both lower lobes. Lower attenuation secondary pulmonary lobules in both lower lobes are indicative of gas-trapping. The resulting pattern has been dubbed \"head-cheese sign.\" <br /></div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59749 Version 6.0</div></div></div>"},"59750":{"type":"graphic_figure","displayName":"Esophageal acid methacholine","title":"Esophageal acid increases methacholine responsiveness","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal acid increases methacholine responsiveness</div><div class=\"cntnt\"><img style=\"width:243px; height:314px;\" src=\"images/PULM/59750_Esophageal_acid_methacholin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Provocative doses of methacholine causing a 20 percent decrease in FEV<SUB>1</SUB> (PD20) in five asthmatics during esophageal infusion of NaCl and HCl infusion (open and closed symbols for patients without and with GE reflux, respectively). The change in PD20 is shown for each subject.</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: Forced expiratory volume in one second.</div><div class=\"graphic_reference\">Redrawn from Herve P, Denjean A, Jian R, et al. Am Rev Respir Dis 1986; 134:986.</div><div id=\"graphicVersion\">Graphic 59750 Version 3.0</div></div></div>"},"59751":{"type":"graphic_figure","displayName":"Ventilator trigger with COPD","title":"Ventilator triggering in presence of intrinsic positive end-expiratory pressure (PEEPi)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventilator triggering in presence of intrinsic positive end-expiratory pressure (PEEPi)</div><div class=\"cntnt\"><img style=\"width:324px; height:364px;\" src=\"images/PULM/59751_Ventilator_trigger_with_COP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recordings of tidal volume, flow, airway pressure (P<SUB>aw</SUB>), and esophageal pressure (P<SUB>es</SUB>) in a patient with chronic obstructive pulmonary disease receiving pressure support ventilation. Approximately half of the patient's inspiratory efforts do not succeed in triggering the ventilator. Triggering occurred only when the patient generated a P<SUB>es</SUB> ≤8 cm H<SUB>2</SUB>O (indicated by the horizontal line), which was equal in magnitude to the opposing elastic recoil pressure.</div><div class=\"graphic_reference\">Reproduced with permission from: Tobin MJ, Jubran A, Schweiz Med Wochenschr 1994; 124:2139.</div><div id=\"graphicVersion\">Graphic 59751 Version 2.0</div></div></div>"},"59755":{"type":"graphic_table","displayName":"Common side effects of antiseizure drugs","title":"Common side effects of antiseizure drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common side effects of antiseizure drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Systemic side effects</td> <td class=\"subtitle1\">Neurologic side effects</td> </tr> <tr> <td>Brivaracetam*&nbsp;</td> <td>Nausea, vomiting, constipation&nbsp;</td> <td>Headache, somnolence, dizziness, fatigue, ataxia, abnormal coordination, nystagmus&nbsp;</td> </tr> <tr> <td>Carbamazepine</td> <td>Nausea, vomiting, diarrhea, hyponatremia, rash, pruritus</td> <td>Drowsiness, dizziness, blurred or double vision, lethargy, headache</td> </tr> <tr> <td>Clobazam</td> <td>Increased salivation, nausea, vomiting, constipation</td> <td>Somnolence, aggression, irritability, ataxia, insomnia</td> </tr> <tr> <td>Eslicarbazepine&nbsp;</td> <td>Nausea, vomiting, diarrhea, fatigue, hyponatremia, rash&nbsp;</td> <td> <p>Dizziness, drowsiness, headache, diplopia, vertigo,&nbsp;ataxia, attention disturbance, blurred vision, tremor </p> <p>(Note: Dizziness, diplopia, and&nbsp;ataxia reported more frequently in combination with carbamazepine)</p> </td> </tr> <tr> <td>Ethosuximide</td> <td>Nausea, vomiting</td> <td>Sleep disturbance, drowsiness, hyperactivity</td> </tr> <tr> <td>Felbamate</td> <td>Nausea, vomiting, anorexia, weight loss</td> <td>Insomnia, dizziness, headache, ataxia</td> </tr> <tr> <td>Gabapentin</td> <td>Infrequent</td> <td>Somnolence, dizziness, ataxia</td> </tr> <tr> <td>Lacosamide</td> <td>Nausea, vomiting, fatigue</td> <td>Ataxia, dizziness, headache, diplopia</td> </tr> <tr> <td>Lamotrigine</td> <td>Rash, nausea</td> <td>Dizziness, tremor, diplopia</td> </tr> <tr> <td>Levetiracetam</td> <td>Infection</td> <td>Fatigue, somnolence, dizziness, agitation, anxiety, irritability, depression</td> </tr> <tr> <td>Oxcarbazepine</td> <td>Nausea, rash, hyponatremia</td> <td>Sedation, headache, dizziness, vertigo, ataxia, diplopia</td> </tr> <tr> <td>Perampanel</td> <td>Weight gain, fatigue, nausea</td> <td>Dizziness, somnolence, irritability, gait disturbance, falls, aggression, mood alteration</td> </tr> <tr> <td>Phenytoin</td> <td>Gingival hypertrophy, rash</td> <td>Confusion, slurred speech, double vision, ataxia</td> </tr> <tr> <td>Pregabalin</td> <td>Weight gain, peripheral edema, dry mouth</td> <td>Dizziness, somnolence, ataxia, tremor</td> </tr> <tr> <td>Primidone, phenobarbital</td> <td>Nausea, rash</td> <td>Alteration of sleep cycles, sedation, lethargy, behavioral changes, hyperactivity, ataxia, tolerance, dependence</td> </tr> <tr> <td>Rufinamide</td> <td>Nausea, vomiting, fatigue</td> <td>Dizziness, somnolence, headache</td> </tr> <tr> <td>Tiagabine</td> <td>Abdominal pain</td> <td>Dizziness, lack of energy, somnolence, nausea, nervousness, tremor, difficulty concentrating</td> </tr> <tr> <td>Topiramate</td> <td>Weight loss, paresthesias</td> <td>Fatigue, nervousness, difficulty concentrating, confusion, depression, anorexia, language problems, anxiety, mood problems, tremor</td> </tr> <tr> <td>Valproate</td> <td>Weight gain, nausea, vomiting, hair loss, easy bruising</td> <td>Tremor, dizziness</td> </tr> <tr> <td>Vigabatrin</td> <td>Vision loss</td> <td>Drowsiness, fatigue, dizziness</td> </tr> <tr> <td>Zonisamide</td> <td>Nausea, anorexia</td> <td>Somnolence, dizziness, ataxia, confusion, difficulty concentrating, depression</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based upon limited experience from preapproval clinical trials.</div><div id=\"graphicVersion\">Graphic 59755 Version 16.0</div></div></div>"},"59758":{"type":"graphic_picture","displayName":"Stretch marks in Cushings PI","title":"Stretch marks caused by Cushing's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stretch marks caused by Cushing's syndrome</div><div class=\"cntnt\"><img style=\"width:222px; height:324px;\" src=\"images/PI/59758_Striae_in_Cushings_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows reddish-purple stretch marks on the belly and under the arms in a person with Cushing's syndrome.</div><div class=\"graphic_reference\">Courtesy of David N Orth, MD.</div><div id=\"graphicVersion\">Graphic 59758 Version 3.0</div></div></div>"},"59759":{"type":"graphic_table","displayName":"Causes of venous thrombosis","title":"Risk factors (causes) for the development of venous thrombosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors (causes) for the development of venous thrombosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inherited thrombophilia</td> </tr> <tr> <td>Factor V Leiden mutation</td> </tr> <tr> <td>Prothrombin G20210A mutation</td> </tr> <tr> <td>Protein S deficiency</td> </tr> <tr> <td>Protein C deficiency</td> </tr> <tr> <td>Antithrombin (AT) deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Other disorders and risk factors</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td>Presence of a central venous catheter</td> </tr> <tr> <td>Surgery, especially orthopedic</td> </tr> <tr> <td>Trauma</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td>Oral contraceptives</td> </tr> <tr> <td>Hormone replacement therapy</td> </tr> <tr> <td>Certain cancer therapies (eg, tamoxifen, thalidomide, lenalidomide)</td> </tr> <tr> <td>Immobilization</td> </tr> <tr> <td>Heart&nbsp;failure</td> </tr> <tr> <td>Congenital heart disease</td> </tr> <tr> <td>Antiphospholipid syndrome</td> </tr> <tr> <td>Older age &#8805;65 years</td> </tr> <tr> <td>Obesity</td> </tr> <tr> <td class=\"sublist1_start\">Myeloproliferative neoplasms</td> </tr> <tr> <td class=\"sublist1\">Polycythemia vera</td> </tr> <tr> <td class=\"sublist1\">Essential thrombocythemia</td> </tr> <tr> <td>Paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Nephrotic syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59759 Version 9.0</div></div></div>"},"59760":{"type":"graphic_picture","displayName":"Syphilitic uveitis","title":"Syphilitic uveitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Syphilitic uveitis</div><div class=\"cntnt\"><img style=\"width:367px; height:276px;\" src=\"images/RHEUM/59760_Syphilitic_uveitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundus photograph from a patient with syphilitic uveitis. The retinal vessel has areas adjacent to it of focal inflammation, and the retina has become depigmented such that choroidal vessels beneath the retina can be seen.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum, MD.</div><div id=\"graphicVersion\">Graphic 59760 Version 2.0</div></div></div>"},"59761":{"type":"graphic_picture","displayName":"Open fracture of the lower extremity","title":"Open fracture of the lower extremity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open fracture of the lower extremity</div><div class=\"cntnt\"><img style=\"width:401px; height:504px;\" src=\"images/SURG/59761_Open_frac_lower_extremity.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59761 Version 1.0</div></div></div>"},"59762":{"type":"graphic_picture","displayName":"Bullous impetigo pediatric","title":"Bullous impetigo","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous impetigo</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/59762_Bullous_impetigo_pedia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>.&nbsp;Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59762 Version 3.0</div></div></div>"},"59765":{"type":"graphic_figure","displayName":"Cervical displacement due to endometriosis","title":"Endometriosis can be associated with lateral displacement of the cervix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endometriosis can be associated with lateral displacement of the cervix</div><div class=\"cntnt\"><img style=\"width:308px; height:492px;\" src=\"images/OBGYN/59765_Displaced_cx_in_endometrios.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral displacement of the cervix, which can be documented by visual examination of the cervix on speculum exam or by digital examination, is probably caused by the asymmetric involvement of one uterosacral ligament by endometriosis, causing one ligament to shorten and pull the cervix to that side of the body.</div><div class=\"graphic_reference\">Reproduced with permission from: Propst AM, Storti K, Barbieri RL. Lateral cervical displacement is associated with endometriosis. Fertil Steril 1998; 70:568. Copyright © 1998 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 59765 Version 3.0</div></div></div>"},"59766":{"type":"graphic_table","displayName":"Energy requirements premature","title":"Estimated daily energy requirements for growing premature infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated daily energy requirements for growing premature infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\">Kcal/kg</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Resting energy expenditure</td> <td class=\"centered\">50</td> <td>Resting metabolic rate</td> </tr> <tr> <td>Activity</td> <td class=\"centered\">15</td> <td>30 percent above resting</td> </tr> <tr> <td>Cold stress</td> <td class=\"centered\">10</td> <td>Thermoregulation</td> </tr> <tr> <td>Synthetic effect of feeding</td> <td class=\"centered\">8</td> <td>Dietary thermogenesis</td> </tr> <tr> <td>Fecal loss</td> <td class=\"centered\">12</td> <td>10 percent of intake</td> </tr> <tr class=\"divider_bottom\"> <td>Growth</td> <td class=\"centered\">25</td> <td>Calories stored</td> </tr> <tr> <td><strong>Total caloric requirement</strong></td> <td class=\"centered\"><strong>120</strong></td> <td><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Sinclair JC. Clin Obstet Gynecol 1971; 14:840.</div><div id=\"graphicVersion\">Graphic 59766 Version 4.0</div></div></div>"},"59767":{"type":"graphic_diagnosticimage","displayName":"LV aneurysm in midcavity HCM","title":"LV aneurysm in midcavity HCM","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LV aneurysm in midcavity HCM</div><div class=\"cntnt\"><img style=\"width:415px; height:308px;\" src=\"images/CARD/59767_LVaneurysminmidcavityHC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ventricular (LV)&nbsp;cineangiogram in a patient with midcavity LV obstruction (arrow) and an apical LV aneurysm. Atrial and right ventricular pacing leads of a dual-chamber pacing implanted to treat the midcavity obstruction are shown.</div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 59767 Version 4.0</div></div></div>"},"59769":{"type":"graphic_table","displayName":"Initial evaluation for common sources of sepsis","title":"Initial evaluation of common sources of sepsis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial evaluation of common sources of sepsis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Suspected site</td> <td class=\"subtitle1\">Symptoms/signs*</td> <td class=\"subtitle1\">Initial microbiologic evaluation<sup>&#182;</sup></td> </tr> <tr> <td>Upper respiratory tract</td> <td>Pharyngeal inflammation plus exudate &#177; swelling and lymphadenopathy</td> <td>Throat swab for aerobic culture</td> </tr> <tr> <td>Lower respiratory tract</td> <td>Productive cough, pleuritic chest pain, consolidative auscultatory findings</td> <td>Sputum of good quality, rapid influenza testing, urinary antigen testing (eg, pneumococcus, legionella; not recommended in children), quantitative culture of protected brush or bronchoalveolar lavage</td> </tr> <tr> <td>Urinary tract</td> <td>Urgency, dysuria, loin, or back&nbsp;pain</td> <td>Urine culture and microscopy showing pyuria</td> </tr> <tr> <td>Vascular catheters: arterial, central venous</td> <td>Redness or drainage at insertion site</td> <td>Culture of blood (from the catheter and a peripheral site), culture catheter tip (if removed)</td> </tr> <tr> <td>Indwelling pleural catheter</td> <td>Redness or drainage at insertion site</td> <td>Culture of pleural fluid (through catheter), culture of catheter tip (if removed)</td> </tr> <tr> <td>Wound or burn</td> <td>Inflammation, edema, erythema, discharge of pus</td> <td>Gram stain and culture of draining pus, wound culture not reliable</td> </tr> <tr> <td>Skin/soft tissue</td> <td>Erythema, edema, lymphangitis</td> <td>Culture blister fluid or draining pus; role of tissue aspirates not proven</td> </tr> <tr> <td>Central nervous system</td> <td>Signs of meningeal irritation</td> <td>CSF cell count, protein, glucose, Gram stain, and&nbsp;culture<sup>&#916;</sup></td> </tr> <tr> <td>Gastrointestinal</td> <td>Abdominal pain, distension, diarrhea, and vomiting</td> <td>Stool culture for Salmonella, Shigella, Campylobacter, and Clostridium difficile</td> </tr> <tr> <td>Intra-abdominal</td> <td>Specific abdominal symptoms/signs</td> <td>Aerobic and anaerobic culture of percutaneously or surgically drained abdominal fluid collections</td> </tr> <tr> <td>Peritoneal dialysis (PD) catheter</td> <td>Cloudy PD fluid, abdominal pain</td> <td>Cell count and culture of PD fluid</td> </tr> <tr> <td>Genital tract</td> <td> <p>Women: Low abdominal pain, vaginal discharge</p> Men: Dysuria, frequency, urgency, urge incontinence, cloudy urine, prostatic tenderness</td> <td> <p>Women: Endocervical and high vaginal swabs onto selective media</p> Men: Urine Gram stain and culture</td> </tr> <tr> <td>Bone&nbsp;</td> <td>Pain, warmth, swelling, decreased use</td> <td>Blood cultures, MRI, bone cultures at surgery or by interventional radiology&nbsp;</td> </tr> <tr> <td>Joint</td> <td>Pain, warmth, swelling, decreased range of motion</td> <td>Arthrocentesis with cell counts, Gram stain, and culture</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; PD: peritoneal dialysis; MRI: magnetic resonance imaging.<br />*Fever is frequently seen with all conditions.<br /><SUP>¶</SUP> Suggested initial tests are not considered to be comprehensive. Additional testing and infectious disease consultation may be warranted.<br /><SUP>Δ</SUP>Bacterial antigen and/or molecular testing may also be appropriate in selected patients. Refer to UpToDate topics on diagnostic testing for meningitis. </div><div class=\"graphic_reference\">Adapted from: Cohen J. Microbiologic requirements for studies of sepsis. In: Clinical Trials for the Treatment of Sepsis, Sibbald WJ, Vincent JL (eds), Springer-Verlag, Berlin 1995.</div><div id=\"graphicVersion\">Graphic 59769 Version 12.0</div></div></div>"},"59773":{"type":"graphic_diagnosticimage","displayName":"Dilated cardiomyopathy CXR","title":"Dilated cardiomyopathy chest radiograph","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dilated cardiomyopathy chest radiograph</div><div class=\"cntnt\"><img style=\"width:364px; height:316px;\" src=\"images/CARD/59773_Cardiomyopathy_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain frontal radiograph of the chest in a 51-year-old male demonstrates marked enlargement of the cardiac silhouette compatible with a dilated cardiomyopathy. Cardiomegaly is nonspecific and can be seen with any etiology of cardiomyopathy.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 59773 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"59777":{"type":"graphic_diagnosticimage","displayName":"Intracranial meningioma","title":"Intracranial meningioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracranial meningioma</div><div class=\"cntnt\"><img style=\"width:257px; height:422px;\" src=\"images/ONC/59777_Meningioma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 70-year-old woman presented with a several-week history of confusion. Panels (A, B): Non-contrast and contrast-enhanced head CT shows a large bifrontal lesion with calcifications and surrounding edema. Panels (C, D): Non-contrast and contrast-enhanced T1-weighted axial MR images of the head also demonstrate large flow voids representing blood vessels in the center of the tumor. Panel (E): Non-contrast T1-weighted sagittal MR image. Panel (F): Contrast-enhanced T1-weighted coronal MR image.</div><div class=\"graphic_footnotes\">CT: computed tomography; MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of John Park, MD, PhD.</div><div id=\"graphicVersion\">Graphic 59777 Version 5.0</div></div></div>"},"59779":{"type":"graphic_table","displayName":"The Chicago Classification of esophageal motility","title":"Esophageal motility classification on the basis of pressure topography criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Esophageal motility classification on the basis of pressure topography criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Normal</td> </tr> <tr> <td class=\"indent1\">CFV &#60;8 cm/s in &#62;90 percent of swallows</td> </tr> <tr> <td class=\"indent1\">DCI &#60;5000 mmHg s cm</td> </tr> <tr> <td class=\"indent1\">Normal EGJ pressure (10 to 35 mmHg) and deglutitive relaxation (eSleeve 4-s nadir &#60;15 mmHg)</td> </tr> <tr> <td class=\"subtitle1_single\">Peristaltic dysfunction</td> </tr> <tr> <td class=\"indent1\">Mild: &#8805;3 and &#60;7 swallows with either failed peristalsis or a &#8805;2-cm defect in the 30 mmHg isobaric contour of the distal esophageal segment</td> </tr> <tr> <td class=\"indent1\">Severe: &#8805;7 swallows with either failed peristalsis or a &#8805;2-cm defect in the 30 mmHg isobaric contour of the distal esophageal segment</td> </tr> <tr> <td class=\"subtitle1_single\">Aperistalsis</td> </tr> <tr> <td class=\"sublist2_start\">No continuous pressure domain above an isobaric contour of 30 mmHg in the distal esophageal segment in any swallow</td> </tr> <tr> <td class=\"sublist2\">- Scleroderma pattern: no continuous pressure domain above an isobaric contour of 30 mmHg in the distal esophageal segment in any swallow and a mean LES pressure &#60;10 mmHg</td> </tr> <tr> <td class=\"subtitle1_single\">Hypertensive peristalsis</td> </tr> <tr> <td class=\"indent1\">CFV &#60;8 cm/s in &#62;90 percent of swallows</td> </tr> <tr> <td class=\"sublist2_start\">Mean DCI: &#62;5000 mmHg s cm</td> </tr> <tr> <td class=\"sublist2\">- Nutcracker: mean DCI &#62;5000 and &#60;8000 mmHg s cm</td> </tr> <tr> <td class=\"sublist2\">- Segmental Nutcracker: mean DCI &#62;5000 with only one segmental focus of hypertensive contraction (&#62;180 mmHg)</td> </tr> <tr> <td class=\"sublist2\">- Spastic Nutcracker: mean DCI &#62;8000 mmHg s cm</td> </tr> <tr> <td class=\"sublist2\">- Nutcracker LES: mean DCI &#62;5000 mmHg s cm with the focus of hypertensive contraction (&#62;180 mmHg) limited to the LES after-contraction</td> </tr> <tr> <td class=\"subtitle1_single\">Rapidly propagated pressurization</td> </tr> <tr> <td class=\"sublist2_start\">CFV &#62;8 cm/s in &#8805;20 percent of swallows</td> </tr> <tr> <td class=\"sublist2\">- Spasm (increased CFV attributable to rapid contractile wavefront); distal latency &#60;4.5 seconds</td> </tr> <tr> <td class=\"sublist2\">- Compartmentalized pressurization (increased CFV attributable to distal compartmentalized esophageal pressurization)</td> </tr> <tr> <td class=\"subtitle1_single\">Abnormal LES tone (end expiratory)</td> </tr> <tr> <td class=\"indent1\">Hypotensive: mean &#60;10 mmHg with normal peristaltic function</td> </tr> <tr> <td class=\"indent1\">Hypertensive: mean &#62;35 mmHg with normal peristaltic function and EGJ relaxation</td> </tr> <tr> <td class=\"subtitle1_single\">Achalasia</td> </tr> <tr> <td class=\"indent1\">Impaired deglutitive EGJ relaxation</td> </tr> <tr> <td class=\"sublist2_start\">Aperistalsis</td> </tr> <tr> <td class=\"sublist2\">- Classic: aperistalsis or pan-esophageal pressurization with no identifiable segmental contractile activity with all swallows</td> </tr> <tr> <td class=\"sublist2\">- Vigorous: with distal spasm</td> </tr> <tr> <td class=\"subtitle1_single\">Functional obstruction</td> </tr> <tr> <td class=\"sublist2_start\">Impaired deglutitive EGJ relaxation</td> </tr> <tr> <td class=\"sublist2\">- Mild: CFV &#60;8 cm/s in &#62;90 percent of swallows with a mild elevation (15 to 30 mmHg) of distal esophageal pressurization</td> </tr> <tr> <td class=\"sublist2\">- Severe: CFV &#62;8 cm/s in &#8805;20 percent of swallows with compartmentalized pressurization</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CFV: contractile front velocity, cm/second; DCI: distal contractile integral (quantifies the strength of the contractions in the distal esophagus by integrating the length, contractile amplitude, and duration of a contraction), mmHg sec cm; EGJ: esophagogastric junction; LES: lower esophageal sphincter.</div><div class=\"graphic_reference\">Reproduced with permission from: Kahrilas PJ, Ghosh SK, Pandolfino JE. Esophageal motility disorders in terms of pressure topography: The Chicago Classification. J Clin Gastroenterol 2008; 42:627. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59779 Version 16.0</div></div></div>"},"59780":{"type":"graphic_picture","displayName":"Thumb spica cast 5","title":"Thumb spica cast: Step 5","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thumb spica cast: Step 5</div><div class=\"cntnt\"><img style=\"width:432px; height:317px;\" src=\"images/EM/59780_Thumb_spica_cast_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extend the underlayment to or just beyond the metacarpophalangeal joints such that there will be adequate padding at the rim of the cast once the underlayment is folded. Wrap the the forearm, hand, and thumb in webril or similar material. Try to make the wrap as smooth and evenly distributed as possible. Wrap the webril so each layer overlaps the previous layer by about three-fourths of its width. Additional material may be needed over bony prominences.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 59780 Version 7.0</div></div></div>"},"59781":{"type":"graphic_diagnosticimage","displayName":"Echocardiography of hypoplastic left heart syndrome","title":"Echocardiography of hypoplastic left heart syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiography of hypoplastic left heart syndrome</div><div class=\"cntnt\"><img style=\"width:369px; height:583px;\" src=\"images/PEDS/59781_EchocardhypoplasticLHS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal short-axis views in a patient with hypoplastic left heart syndrome. In (A) the right ventricle (RV) is enlarged with a smaller, hypertrophied left ventricle (LV). Scanning more superiorly from a parasternal short-axis view (B), the larger main pulmonary artery (MPA) and patent ductus arteriosus (arrow) are seen connecting to the descending aorta. No brachiocephalic vessels are seen arising from the ductal arch, a key finding in differentiating the ductal arch from the true aortic arch.</div><div class=\"graphic_footnotes\">Ao: aorta.</div><div class=\"graphic_reference\">Reproduced with permission from: Tweddell J, Hoffman G, Ghanayem N, et al. Hypoplastic left heart syndrome. In: Moss and Adams' Heart Disease in Infants, Children and Adolescents: Including the Fetus and Young Adult, 7<SUP>th</SUP> ed, Allen H, Driscoll D, Shaddy R, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59781 Version 9.0</div></div></div>"},"59782":{"type":"graphic_diagnosticimage","displayName":"Drug packets abdominal plain radiograph","title":"Drug packets on plain abdominal radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Drug packets on plain abdominal radiograph</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/EM/59782_Drug_pack_abd_plain_radiogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph shows the typical appearance of drug packets in the bowel overlying the pelvis. Note the rim of air around some packages, which helps in their detection.</div><div class=\"graphic_reference\">Courtesy of Robert Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 59782 Version 1.0</div></div></div>"},"59784":{"type":"graphic_algorithm","displayName":"Algorithm for CRC screening","title":"Algorithm for CRC screening and surveillance in average-risk and increased-risk populations","html":"<div class=\"graphic\"><div style=\"width: 832px\" class=\"figure\"><div class=\"ttl\">Algorithm for CRC screening and surveillance in average-risk and increased-risk populations</div><div class=\"cntnt\"><img style=\"width:812px; height:610px;\" src=\"images/GAST/59784_Algo_for_CRC_screening_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease; CRC: colorectal cancer; FDR: first-degree relative; SDR: second-degree relative; CTC: computed tomographic colonography; FAP: familiar adenomatous polyposis; HNPCC: hereditary nonpolyposis colorectal cancer; gFOBT: guaiac fecal occult blood test; FIT: fecal immunochemical test; flex sig: flexible sigmoidoscopy; sDNA: stool DNA test.</div><div id=\"graphicVersion\">Graphic 59784 Version 6.0</div></div></div>"},"59785":{"type":"graphic_figure","displayName":"Survival by tumor size HCC","title":"Effect of tumor size on survival in patients with a single hepatocellular cancer without vascular invasion","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Effect of tumor size on survival in patients with a single hepatocellular cancer without vascular invasion</div><div class=\"cntnt\"><img style=\"width:471px; height:412px;\" src=\"images/ONC/59785_Survival_by_tumor_size_HCC.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Vauthey, J, Lauwers, GY, Esnaola, NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527. Copyright &#169; 2002 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 59785 Version 1.0</div></div></div>"},"59786":{"type":"graphic_figure","displayName":"Severe breathing trouble PI","title":"Signs of severe trouble breathing (retractions)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Signs of severe trouble breathing (retractions)</div><div class=\"cntnt\"><img style=\"width:446px; height:664px;\" src=\"images/PI/59786_Severe_breathing_trouble_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When a child is having a lot of trouble breathing, the skin and muscles between the child's ribs or below the child's ribcage look like they are caving in.</div><div id=\"graphicVersion\">Graphic 59786 Version 2.0</div></div></div>"},"59791":{"type":"graphic_picture","displayName":"Diphyllobothrium latum egg","title":"Egg of <em>Diphyllobothrium latum</em>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Egg of <em>Diphyllobothrium latum</em></div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/ID/59791_Diphyllobothrium_latum_egg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These eggs are oval or ellipsoidal, with an operculum at one end that can be inconspicuous. At the opposite (abopercular) end is a small knob that can be barely discernible. The eggs are passed in the stool unembryonated. Size range: 58 to 76 mcm by 40 to 51 mcm.</div><div class=\"graphic_reference\">http://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/Diphyllobrothiasis_il.html (Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Parasitic Diseases. Public domain).</div><div id=\"graphicVersion\">Graphic 59791 Version 2.0</div></div></div>"},"59792":{"type":"graphic_table","displayName":"Pretransplant lab evaluation SOT","title":"The pretransplant laboratory evaluation for solid organ transplant candidates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The pretransplant laboratory evaluation for solid organ transplant candidates</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Tests to obtain in all transplant candidates</td> </tr> <tr> <td class=\"subtitle2_single\">Serologies</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> </tr> <tr> <td class=\"indent1\">Varicella-zoster virus</td> </tr> <tr> <td class=\"indent1\">Epstein Barr virus</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Hepatitis B virus: HBsAg, HBsAb, HBcAb<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Hepatitis C virus<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\"><em>Treponema pallidum</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Toxoplasma gondii</em> (in heart transplant candidates)</td> </tr> <tr> <td class=\"subtitle2_single\">Other tests</td> </tr> <tr> <td class=\"indent1\">Urinalysis</td> </tr> <tr> <td class=\"indent1\">Urine culture</td> </tr> <tr> <td class=\"indent1\">Tuberculin skin test or interferon-gamma release assay<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Chest radiograph</td> </tr> <tr> <td class=\"indent1\">Sputum stains and cultures for bacteria, mycobacteria, and fungi (in lung transplant candidates)</td> </tr> <tr> <td class=\"indent1\">Microbiologic studies for colonization patterns of antimicrobial resistance</td> </tr> <tr> <td class=\"subtitle1_single\">Tests to obtain from transplant candidates with exposures in endemic areas<sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Serologies</td> </tr> <tr> <td class=\"indent1\"><em>Strongyloides stercoralis</em> (empiric therapy for all patients with risk factors is an alternate approach to screening)</td> </tr> <tr> <td class=\"indent1\"><em>Leishmania</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma capsulatum</em></td> </tr> <tr> <td class=\"indent1\"><em>Coccidioides </em>spp</td> </tr> <tr> <td class=\"indent1\"><em>Trypanosoma cruzi</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HTLV1 and 2 (available screening platforms are suboptimal in low-prevalence areas)</td> </tr> <tr> <td class=\"subtitle2_single\">Other tests</td> </tr> <tr> <td class=\"indent1\">Stool ova and parasites for <em>Strongyloides stercoralis</em></td> </tr> <tr> <td class=\"indent1\">Urine ova and parasites (and cystoscopy) for <em>Schistosoma</em> spp (for&nbsp;renal transplants)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HBsAg: hepatitis B surface antigen; HBsAb: hepatitis B surface antibody; HBcAb: hepatitis B core antibody; HTLV: human T-lymphotropic virus.<br />* The preferred serologic test for HIV-1 and -2 is a fourth-generation antigen/antibody combination HIV-1/2 immunoassay plus a confirmatory HIV-1/HIV-2 antibody differentiation immunoassay.<br />¶ For individuals with known infection or at increased risk for infection (based on risk factors detected in the medical and/or social history), quantitative nucleic acid testing should also be performed.<br />Δ&nbsp;Refer to the UpToDate topic on tuberculosis in solid organ transplant candidates and recipients for detailed recommendations about the appropriate screening test for latent tuberculosis, which depends in part upon the patient's type and degree of organ dysfunction.<br />§ Consider other assays based on individual exposures.</div><div id=\"graphicVersion\">Graphic 59792 Version 11.0</div></div></div>"},"59794":{"type":"graphic_figure","displayName":"Diagram showing AV graft for hemodialysis PI","title":"Diagram showing AV graft for hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram showing AV graft for hemodialysis</div><div class=\"cntnt\"><img style=\"width:298px; height:616px;\" src=\"images/PI/59794_Bridge_graft_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows an AV graft in a person's arm. A graft is under the skin. A doctor makes a graft by doing surgery. He or she uses a flexible rubber tube to connect an artery to a vein. During hemodialysis,&nbsp;two needles are put into the graft to remove and return blood to the body.</div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\">AV: arteriovenous (this means involving an artery and a vein).</SPAN></div><div id=\"graphicVersion\">Graphic 59794 Version 10.0</div></div></div>"},"59795":{"type":"graphic_figure","displayName":"Rotation mentum posterior to anterior","title":"Mechanism of labor for right mentoposterior position with subsequent rotation to mentum anterior and delivery","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Mechanism of labor for right mentoposterior position with subsequent rotation to mentum anterior and delivery</div><div class=\"cntnt\"><img style=\"width:511px; height:626px;\" src=\"images/OBGYN/59795_Rotation_mentum_posterior_to_anterior.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mechanism of labor for right mentoposterior position with subsequent rotation of the mentum anteriorly followed by delivery.</div><div id=\"graphicVersion\">Graphic 59795 Version 9.0</div></div></div>"},"59796":{"type":"graphic_table","displayName":"Complic salvage surg prostat CA","title":"Early and late complications in three contemporary series of salvage prostatectomy after definitive RT for clinically localized prostate cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Early and late complications in three contemporary series of salvage prostatectomy after definitive RT for clinically localized prostate cancer</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Author, year</td>\n<td class=\"subtitle1\">Year of treatment</td>\n<td class=\"subtitle1\">n</td>\n<td class=\"subtitle1\">Early perioperative complications, percent</td>\n<td class=\"subtitle1\">Late rectal injury, percent</td>\n<td class=\"subtitle1\">Late urinary continence, percent</td>\n<td class=\"subtitle1\">Late anastomotic stricture, percent</td>\n</tr>\n<tr>\n<td>Ward, J; 2005</td>\n<td>1990-2000</td>\n<td>89</td>\n<td>27</td>\n<td>3</td>\n<td>56</td>\n<td>23</td>\n</tr>\n<tr>\n<td>Stephenson, A; 2004</td>\n<td>1993-2003</td>\n<td>60</td>\n<td>13</td>\n<td>2</td>\n<td>68</td>\n<td>32</td>\n</tr>\n<tr>\n<td>Gheiler, E; 1998</td>\n<td>1992-97</td>\n<td>30</td>\n<td>17</td>\n<td>3</td>\n<td>50</td>\n<td>17</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 59796 Version 1.0</div></div></div>"},"59797":{"type":"graphic_table","displayName":"ACC AHA HRS sinus dys","title":"ACC/AHA/HRS: Indications for permanent pacing in sinus node dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/HRS: Indications for permanent pacing in sinus node dysfunction</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class I - There is evidence and/or general agreement that permanent pacing is indicated in patients with sinus node dysfunction in the following settings:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Documented symptomatic bradycardia, including frequent sinus pauses that produce symptoms. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Symptomatic chronotropic incompetence. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Symptomatic sinus bradycardia that results from required drug therapy for medical conditions. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class IIa - The weight of evidence or opinion is in favor of the usefulness of permanent pacing in patients with sinus node dysfunction in the following settings:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Heart rate &#60;40 beats per minute when a clear association between significant symptoms consistent with bradycardia and the actual presence of bradycardia has not been documented. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Syncope of unexplained origin when clinically significant abnormalities of sinus node function are discovered or provoked in electrophysiological studies. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class IIb - The evidence or opinion is less well established that permanent pacing in sinus node dysfunction is beneficial in the following setting:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Minimally symptomatic patients with chronic heart rate &#60;40 beats per minute while awake. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Class III - There is evidence that permanent pacing in sinus node dysfunction is not useful and may be harmful in the following settings:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Asymptomatic patients. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Patients for whom the symptoms suggestive of bradycardia have been clearly documented to occur in the absence of bradycardia. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Symptomatic bradycardia due to nonessential drug therapy. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.</div><div id=\"graphicVersion\">Graphic 59797 Version 2.0</div></div></div>"},"59798":{"type":"graphic_diagnosticimage","displayName":"Trapezoid edema T2 axial MRI","title":"Trapezoid edema with T2 axial MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trapezoid edema with T2 axial MRI</div><div class=\"cntnt\"><img style=\"width:324px; height:201px;\" src=\"images/EM/59798_Trapezoid_edema_MRI_T2_axia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This T2-weighted, axial magnetic resonance image of the wrist shows increased signal in the trapezoid compared to the marrow signal from the adjacent bones. This appearance of the trapezoid showing edema consistent with microtrabecular injury.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 59798 Version 3.0</div></div></div>"},"59799":{"type":"graphic_picture","displayName":"Nevus depigmentosus - abdomen","title":"Nevus depigmentosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nevus depigmentosus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/59799_Nevusdepigmentabd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 6-year-old boy was noted to have a well-demarcated hypopigmented patch on the abdomen at birth. The lesion is consistent with nevus depigmentosus.</div><div class=\"graphic_reference\">Copyright © Mary Tonsager, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 59799 Version 5.0</div></div></div>"},"59801":{"type":"graphic_table","displayName":"Causes of amenorrhea","title":"Major causes of primary and secondary amenorrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of primary and secondary amenorrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Abnormality</td> <td class=\"subtitle1\" colspan=\"2\">Causes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pregnancy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Anatomic abnormalities</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Congenital abnormality in m&#252;llerian development*</td> <td colspan=\"2\">Isolated defect</td> </tr> <tr> <td colspan=\"2\">Androgen insensitivity syndrome</td> </tr> <tr> <td colspan=\"2\">5-alpha-reductase deficiency</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Congenital defect of urogenital sinus development*</td> <td colspan=\"2\">Agenesis of lower vagina</td> </tr> <tr> <td colspan=\"2\">Imperforate hymen</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Intrauterine adhesions</td> <td colspan=\"2\">Asherman syndrome </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Tuberculous endometritis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Disorders of the hypothalamic-pituitary-ovarian axis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Hypothalamic dysfunction</td> <td class=\"indent1\">&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Pituitary dysfunction</td> <td class=\"indent1\">&nbsp;</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\" colspan=\"2\">Ovarian dysfunction</td> <td class=\"sublist1_start\">Gonadal dysgenesis (Turner syndrome, 46,XY*)</td> </tr> <tr> <td class=\"sublist1_start\">Other causes of primary ovarian insufficiency</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Other</td> <td class=\"indent1\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Present as primary amenorrhea only.<br />¶ Refer to UpToDate graphics&nbsp;on the multiple causes of hormonal dysfunction.</div><div id=\"graphicVersion\">Graphic 59801 Version 8.0</div></div></div>"},"59803":{"type":"graphic_picture","displayName":"Ischemic colitis on colonoscopy","title":"Ischemic colitis on colonoscopy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ischemic colitis on colonoscopy</div><div class=\"cntnt\"><img style=\"width:368px; height:183px;\" src=\"images/GAST/59803_Ischemic_colitis_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy of ischemic colitis may reveal continuous necrosis and mucosal friability that resembles ulcerative colitis (left panel); discrete ulcers with surrounding edema may also be seen (right panel).</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 59803 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal sigmoid colon</div><div class=\"cntnt\"><img style=\"width:216px; height:216px;\" src=\"images/GAST/55563_Normal_sigmoid_colon_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 55563 Version 1.0</div></div></div>"},"59804":{"type":"graphic_picture","displayName":"Medullary carcinoma of the breast","title":"Medullary carcinoma of the breast","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Medullary carcinoma of the breast</div><div class=\"cntnt\"><img style=\"width:590px; height:243px;\" src=\"images/ONC/59804_Medullary_breast_ca_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Low power view of a medullary breast carcinoma shows that the tumor has a well circumscribed border.<br />(Panel B) High power view demonstrates that the tumor cells grow in a syncytial pattern and have marked nuclear atypia. A prominent lymphoplasmacytic infiltrate is also present.</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 59804 Version 3.0</div></div></div>"},"59806":{"type":"graphic_diagnosticimage","displayName":"SVC syndrome mediast lymphoma","title":"Superior vena cava syndrome in a patient with lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior vena cava syndrome in a patient with lymphoma</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/ONC/59806_SVC_syndrome_mediast_lympho.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scan image of a patient with non-Hodgkin's lymphoma and massive mediastinal lymph node enlargement. The superior vena cava is occluded and kept open by a Porta-A Cath (arrow). The lymphomatous mass encases the aortic arch (arrowhead), and displaces the trachea posteriorly. The azygos vein (dashed arrow) and the left lateral thoracic veins are dilated and enhancing. A right pleural effusion is visible. Of note, ring-like dystrophic calcifications are seen in the lymphomatous mass.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59806 Version 3.0</div></div></div>"},"59807":{"type":"graphic_picture","displayName":"Lichen planus","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:387px; height:252px;\" src=\"images/PC/59807_Lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichen planus is characterized by flat-topped, violaceous papules.</div><div class=\"graphic_reference\">Courtesy of Andrew Samel, MD.</div><div id=\"graphicVersion\">Graphic 59807 Version 1.0</div></div></div>"},"59808":{"type":"graphic_table","displayName":"AAT deficiency and ANCA","title":"Alpha-1 antitrypsin phenotypes in anti-PR3 (C-ANCA) positive vasculitic disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alpha-1 antitrypsin phenotypes in anti-PR3 (C-ANCA) positive vasculitic disorders</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">&nbsp;</td>\r\n                    <td class=\"subtitle1\">France</td>\r\n                    <td class=\"subtitle1\">Sweden</td>\r\n                    <td class=\"subtitle1\">Austria</td>\r\n                    <td class=\"subtitle1\">Australia</td>\r\n                    <td class=\"subtitle1\">UK</td>\r\n                    <td class=\"subtitle1\">Denmark</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Number&nbsp;of patients</td>\r\n                    <td>37</td>\r\n                    <td>105</td>\r\n                    <td>32</td>\r\n                    <td>31</td>\r\n                    <td>99</td>\r\n                    <td>44</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>PI*ZZ</td>\r\n                    <td>3</td>\r\n                    <td>1</td>\r\n                    <td>2</td>\r\n                    <td>1</td>\r\n                    <td>1</td>\r\n                    <td>0</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Z allele frequency</td>\r\n                    <td>17.6</td>\r\n                    <td>9</td>\r\n                    <td>10.9</td>\r\n                    <td>6.5</td>\r\n                    <td>5.6</td>\r\n                    <td>9.1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Z allele in controls</td>\r\n                    <td>1.9</td>\r\n                    <td>2.4</td>\r\n                    <td>1.4</td>\r\n                    <td>0.9</td>\r\n                    <td>1.8</td>\r\n                    <td>2.4</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">anti-PR3: antibody to proteinase 3; C-ANCA: cytoplasmic staining pattern of antineutrophil cytoplasmic antibodies; PI: protease inhibitor; PI*ZZ: homozygosity of protease inhibitor allele (Z) that is most commonly associated with alpha-1 antitrypsin deficiency.</div><div class=\"graphic_reference\">Data from: Esnault VL, Testa A, Audrain M, et al. Alpha-1 antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993; 43:1329.<BR>Reproduced with permission from: American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818. Official Journal of the American Thoracic Society. Copyright &#169; 2003 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 59808 Version 2.0</div></div></div>"},"59809":{"type":"graphic_table","displayName":"Eur study preg result asthma","title":"Odds ratios (95 percent CI) for outcomes of pregnancy in asthmatic vs control women in a large population based study","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Odds ratios (95 percent CI) for outcomes of pregnancy in asthmatic vs control women in a large population based study</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n<tbody>\r\n\r\n<tr>\r\n<td class=\"subtitle1\">Outcome</td>\r\n<td class=\"subtitle1\">All subjects, n = 36,985</td>\r\n<td class=\"subtitle1\">Asthma most severe, n = 1,396</td>\r\n</tr>\r\n<tr>\r\n<td>Perinatal mortality</td>\r\n<td>1.21 (1.08-1.35)</td>\r\n<td>1.28 (0.76-2.17)</td>\r\n</tr>\r\n<tr>\r\n<td>Preeclampsia</td>\r\n<td>1.15 (1.08-1.23)</td>\r\n<td>1.42 (1.09-1.86)</td>\r\n</tr>\r\n<tr>\r\n<td>Preterm birth (&#60;37 weeks)</td>\r\n<td>1.15 (1.09-1.21)</td>\r\n<td>1.56 (1.27-1.90)</td>\r\n</tr>\r\n<tr>\r\n<td>Low birth weight (&#60;2500 gm)</td>\r\n<td>1.21 (1.14-1.29)</td>\r\n<td>1.98 (1.52-2.59)</td>\r\n</tr>\r\n<tr>\r\n<td>Congenital malformations</td>\r\n<td>1.05 (0.99-1.10)</td>\r\n<td>1.08 (0.83-1.40)</td>\r\n</tr>\r\n</tbody>\r\n</table></div><div class=\"graphic_reference\">From Kallen, B, Rydhstroem, H, Aberg, A. Asthma during pregnancy - a population based study. Eur J Epidem 2000; 16:167.</div><div id=\"graphicVersion\">Graphic 59809 Version 1.0</div></div></div>"},"59811":{"type":"graphic_picture","displayName":"Granular casts","title":"Granular and waxy casts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granular and waxy casts</div><div class=\"cntnt\"><img style=\"width:375px; height:251px;\" src=\"images/NEPH/59811_Granular_casts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing waxy and fine and coarse (arrow) granular casts. The broader casts are thought to form when there is stasis (due to advanced renal failure) in the wider collecting tubules into which many nephrons drain.</div><div class=\"graphic_reference\">Courtesy of Harvard Medical School.</div><div id=\"graphicVersion\">Graphic 59811 Version 1.0</div></div></div>"},"59814":{"type":"graphic_table","displayName":"Urine exfoliated cells analysis for bladder cancer ","title":"Urinary tests for the detection of bladder cancer that analyze exfoliated cells","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urinary tests for the detection of bladder cancer that analyze exfoliated cells</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Target</td> <td class=\"subtitle1\">Sensitivity</td> <td class=\"subtitle1\">Specificity</td> <td class=\"subtitle1\">False positive in</td> </tr> <tr> <td>Nuclear morphology abnormalities</td> <td>59 to 69 percent</td> <td>73 to 93 percent</td> <td>&nbsp;</td> </tr> <tr> <td>Cytokeratin 20</td> <td>78 to 87 percent</td> <td>55 to 80 percent</td> <td>Urinary tract infection, calculi, post-BCG</td> </tr> <tr> <td>Telomerase</td> <td>70 to 100 percent</td> <td>60 to 70 percent</td> <td>Infection</td> </tr> <tr> <td>Microsatellite DNA</td> <td>72 to 97 percent</td> <td>80 to 100 percent</td> <td>BPH, inflammation</td> </tr> <tr> <td>Chromosomal abnormalities (chromosomes 3, 7, 17, and 9p21)</td> <td>69 to 87 percent</td> <td>89 to 96 percent</td> <td>BPH, inflammation, hematuria</td> </tr> <tr> <td>Carcinoembryonic antigen (CEA), mucoproteins</td> <td>70 to 80 percent</td> <td>60 to 70 percent</td> <td>BPH, inflammation, hematuria</td> </tr> <tr> <td>DD23 antibody</td> <td>70 to 87 percent</td> <td>60 percent</td> <td>&nbsp;</td> </tr> <tr> <td>Lewis X antigen</td> <td>80 to 85 percent</td> <td>80 to 85 percent</td> <td>BPH</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59814 Version 2.0</div></div></div>"},"59815":{"type":"graphic_picture","displayName":"Rosacea with papules","title":"Rosacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rosacea</div><div class=\"cntnt\"><img style=\"width:396px; height:271px;\" src=\"images/PC/59815_Rosaceapapulopustular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rosacea manifesting as inflammatory papules and pustules and telangiectasias located on the central third of the face. Comedones are absent.</div><div class=\"graphic_reference\">Reproduced with permission: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59815 Version 4.0</div></div></div>"},"59818":{"type":"graphic_table","displayName":"Lung allocation score","title":"Lung allocation score for candidates age 12 and older","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lung allocation score for candidates age 12 and older</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Step 1: The transplant center enters the factors in part 1 below on the UNet web site. A Cox proportional hazards model is used to derive an estimate of the number of days a recipient would be expected to live during the first year post transplant. This is the <strong>post transplant survival measure</strong>.</td> </tr> <tr> <td>Step 2: The transplant center enters the factors in part 2 below on the UNet web site. A Cox proportional hazards model is used to derive an estimate of the expected number of days a candidate would live without a transplant during an additional year on the waitlist. This is the <strong>waitlist survival measure</strong>.</td> </tr> <tr> <td> <p>Step 3: Using the values derived in steps 1 and 2, the transplant benefit measure is calculated:</p> <p>Transplant benefit = post transplant survival (days) - waitlist survival (days).</p> </td> </tr> <tr> <td>Step 4: The <strong>raw allocation score</strong> = transplant benefit (days) - waitlist survival (days).</td> </tr> <tr> <td>Step 5: The <strong>lung allocation score</strong> is derived by normalizing the raw allocation score to a range of 0 to 100. The higher the score the higher the priority.</td> </tr> <tr> <td class=\"subtitle1_single\">Part 1 Post transplant survival measure: </td> </tr> <tr> <td>1. FVC (Group B, D)</td> </tr> <tr> <td>2. PCW pressure &#8805;20 (Group D)</td> </tr> <tr> <td>3. Continuous mechanical ventilation</td> </tr> <tr> <td>4. Age</td> </tr> <tr> <td>5. Serum creatinine</td> </tr> <tr> <td>6. Functional Status (NYHA class)</td> </tr> <tr> <td>7. Diagnosis</td> </tr> <tr> <td class=\"subtitle1_single\">Part 2 Waiting list urgency measure: </td> </tr> <tr> <td>1. Forced vital capacity (FVC)</td> </tr> <tr> <td>2. Pulmonary artery systolic pressure (Group A, C, D)*</td> </tr> <tr> <td>3. Pulmonary artery mean pressure&nbsp;</td> </tr> <tr> <td>4. Pulmonary capillary wedge pressure</td> </tr> <tr> <td>5. Supplemental O<sub>2</sub> required at rest (Group A, C, D)*</td> </tr> <tr> <td>6. Age</td> </tr> <tr> <td>7. Body mass index (BMI)</td> </tr> <tr> <td>8. Diabetes</td> </tr> <tr> <td>9. Functional status</td> </tr> <tr> <td>10. Six-minute walk distance</td> </tr> <tr> <td>11. Continuous mechanical ventilation</td> </tr> <tr> <td>12. Diagnosis</td> </tr> <tr> <td>13. pCO<sub>2<sup></sup></sub><sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Group A: COPD, alpha-1-antitrypsin, emphysema, lymphangioleiomyomatosis, bronchiectasis, sarcoidosis with a mean PA pressure ≤30 mmHg.<br />Group B: Pulmonary hypertension (IPAH, Eisenmenger's syndrome, etc).<br />Group C: Cystic fibrosis, immunodeficiency disorders (eg, Hypogammaglobulinemia).<br />Group D: IPF, other causes of pulmonary fibrosis, sarcoidosis with PA &gt;30 mmHg, obliterative bronchiolitis (non-retransplant).<br />¶&nbsp;pCO2 may be taken from arterial, capillary or venous measurement. If venous, 6 mmHg will be subtracted to produce an equivalent arterial value. This a adjusted for any change in value over time that is greater than 15 percent.</div><div class=\"graphic_reference\">Data from:http://optnpilot.unos.org/converge/resources/allocationcalculators.asp?index=88.</div><div id=\"graphicVersion\">Graphic 59818 Version 2.0</div></div></div>"},"59819":{"type":"graphic_diagnosticimage","displayName":"Pulmonary vein velocities","title":"Pulmonary vein velocities","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Pulmonary vein velocities</div><div class=\"cntnt\"><img style=\"width:534px; height:315px;\" src=\"images/CARD/59819_Pulm_vein_vel.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Sherif F Nagueh.</div><div id=\"graphicVersion\">Graphic 59819 Version 4.0</div></div></div>"},"59820":{"type":"graphic_figure","displayName":"Irradiance formula","title":"Irradiance","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Irradiance</div><div class=\"cntnt\"><img style=\"width:463px; height:188px;\" src=\"images/DERM/59820_Irradiance_formula.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59820 Version 1.0</div></div></div>"},"59821":{"type":"graphic_diagnosticimage","displayName":"VSD malalignment of long axis 2D still frame","title":"VSD malalignment of long axis 2D still frame","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">VSD malalignment of long axis 2D still frame</div><div class=\"cntnt\"><img style=\"width:550px; height:415px;\" src=\"images/CARD/59821_VSD_malalignment_long_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This parasternal long axis view demonstrates anterior malalignment of the conal septum (CS) when compared with the plane of the trabecular septum (IVS), resulting in aortic override and subpulmonary stenosis in this patient with Tetralogy of Fallot.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; AO: aorta; LA: left atrium; CS: conal septum; IVS: trabecular portion of interventricular septum; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 59821 Version 3.0</div></div></div>"},"59822":{"type":"graphic_algorithm","displayName":"Hyperglycemia treatment for hospitalized patients NPO","title":"Hyperglycemia treatment for hospitalized patients receiving nothing by mouth","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Hyperglycemia treatment for hospitalized patients receiving nothing by mouth</div><div class=\"cntnt\"><img style=\"width:460px; height:566px;\" src=\"images/ENDO/59822_Hyperglyc_tx_hosp_pat_NPO.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proposed algorithm for management of diabetes and hyperglycemia in the noncritical care setting.</div><div class=\"graphic_footnotes\">NPO: nil per os (nothing by mouth); DM: diabetes mellitus: GLP-1: glucagon-like peptide-1; BG: blood glucose; IV: intravenous.<br />* Adjusted based on current degree of hyperglycemia; consider modest (20-25%) dose reduction if tightly controlled on admission, to be conservative.</div><div class=\"graphic_reference\">Reproduced with permission from: Inzucchi SE. Diabetes facts and guidelines. Yale Diabetes Center, 2011. Copyright &copy; 2011.</div><div id=\"graphicVersion\">Graphic 59822 Version 4.0</div></div></div>"},"59829":{"type":"graphic_picture","displayName":"Nipple vasoconstriction","title":"Vasoconstriction of the nipple","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Vasoconstriction of the nipple</div><div class=\"cntnt\"><img style=\"width:528px; height:194px;\" src=\"images/PEDS/59829_Nipple_vasoconstriction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cycles from blanched white to deep red and back again at a frequency of approximately one minute.</div><div id=\"graphicVersion\">Graphic 59829 Version 1.0</div></div></div>"},"59830":{"type":"graphic_figure","displayName":"Schematic of echo findings in EMF","title":"Schematic of echo findings in EMF","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Schematic of echo findings in EMF</div><div class=\"cntnt\"><img style=\"width:550px; height:418px;\" src=\"images/CARD/59830_Schematic_echo_findings_EMF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic of the two-dimensional, four-chamber apical view findings in 10 patients with endmyocardial disease. Numbers on the right and left indicate the number of patients with each finding.</div><div class=\"graphic_footnotes\">IVC: inferior vena cava; MOT: preserved or increased inward motion of the obliterative process; OBL: obliteration; RFL: increased reflectance of the obliterative surface; THICK: increased thickening of the basal inflow tract papillary muscle and/or posterior atrioventricular valve.</div><div class=\"graphic_reference\">Reproduced with permission from: Acquatella H, Schiller NB, Puigbo JJ, et al. Value of two-dimensional echocardiography in the endomyocardial disease with and without eosinophilia. A clinical and pathologic study. Circulation 1983; 67:1219. Copyright © 1983 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59830 Version 9.0</div></div></div>"},"59831":{"type":"graphic_figure","displayName":"Vaginal delivery PI","title":"Vaginal delivery (childbirth)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vaginal delivery (childbirth)</div><div class=\"cntnt\"><img style=\"width:323px; height:411px;\" src=\"images/PI/59831_Vaginal_delivery_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a vaginal delivery, a woman pushes her baby out of her vagina.</div><div class=\"graphic_reference\">Reproduced from: U.S. Department of Health and Human Services Office on Women's Health. Pregnancy: Labor and birth. Available at: <A spellcheck=true href=\"http://www.womenshealth.gov/pregnancy/childbirth-beyond/labor-birth.html\" target=_blank>http://www.womenshealth.gov/pregnancy/childbirth-beyond/labor-birth.html</A> (Accessed on November 11, 2011).</div><div id=\"graphicVersion\">Graphic 59831 Version 2.0</div></div></div>"},"59832":{"type":"graphic_table","displayName":"Amsterdam II criteria","title":"Amsterdam II criteria for Lynch syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amsterdam II criteria for Lynch syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>There should be at least three relatives with any Lynch syndrome-associated cancer (colorectal cancer, cancer of the endometrium, small bowel, ureter, or renal pelvis)</td> </tr> <tr> <td>One should be a first-degree relative of the other two</td> </tr> <tr> <td>At least two successive generations should be affected</td> </tr> <tr> <td>At least&nbsp;one should be diagnosed before age 50</td> </tr> <tr> <td>Familial adenomatous polyposis should be excluded in the colorectal cancer case(s), if any</td> </tr> <tr> <td>Tumors should be verified by pathological examination</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Vasen HF, Watson P, Mecklin JP, et al. Gastroenterology 1999; 116:1453.</div><div id=\"graphicVersion\">Graphic 59832 Version 6.0</div></div></div>"},"59833":{"type":"graphic_diagnosticimage","displayName":"Sagittal MRI Sturge-Weber","title":"Sturge-Weber syndrome sagittal MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sturge-Weber syndrome sagittal MRI</div><div class=\"cntnt\"><img style=\"width:440px; height:231px;\" src=\"images/PEDS/59833_Sagittal_MRI_Sturge-Weber.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal MRI of the brain with contrast from a 13-year-old subject with Sturge-Weber syndrome showing a large meningeal capillary-venous malformation (angioma) involving the left hemisphere. Note the contrast enhancement of the gyral pattern and the enlargement of the deep venous system secondary to the increased flow through the extensive lesion.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of John Bodensteiner, MD.</div><div id=\"graphicVersion\">Graphic 59833 Version 5.0</div></div></div>"},"59834":{"type":"graphic_figure","displayName":"Risk of colon cancer assoc w fam history","title":"Risk of colon cancer associated with a family history","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Risk of colon cancer associated with a family history</div><div class=\"cntnt\"><img style=\"width:441px; height:280px;\" src=\"images/PC/59834_Risk_colon_cancer_fam_hist.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The highest risk is in people with multiple first-degree relatives or relatives who have developed CRC at a relatively young age.</div><div class=\"graphic_footnotes\">FH: family history; CRC: colorectal cancer; dx: diagnosis.</div><div class=\"graphic_reference\">Data from: Johns LE, Houlston RS. Am J Gastroenterol 2001; 96:2992.</div><div id=\"graphicVersion\">Graphic 59834 Version 5.0</div></div></div>"},"59835":{"type":"graphic_picture","displayName":"Lobectomy specimen","title":"Intralobar sequestration with recurrent left lower lobe pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intralobar sequestration with recurrent left lower lobe pneumonia</div><div class=\"cntnt\"><img style=\"width:390px; height:480px;\" src=\"images/PULM/59835_Lobectomy_specimen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A left lower lobe lobectomy specimen shows multiple cysts permeating the left lower lobe, basal segments.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59835 Version 3.0</div></div></div>"},"59836":{"type":"graphic_diagnosticimage","displayName":"Fracture of the hook of the hamate","title":"Fracture of the hook of the hamate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fracture of the hook of the hamate</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/EM/59836_Hook_of_hamate_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The carpal tunnel or 45 degree supination oblique view was used in this radiograph of the wrist in order to isolate the image of the hook of the hamate from the shadows of other carpal bones. In this view, a fracture of the hook of the hamate is easily seen (arrow).</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 59836 Version 5.0</div></div></div>"},"59838":{"type":"graphic_table","displayName":"Respiratory virus prevalence in lung transplant recipients","title":"Prevalence of community respiratory viruses in lung transplant recipients in studies that used molecular methods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of community respiratory viruses in lung transplant recipients in studies that used molecular methods</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Study:</td> <td class=\"subtitle1\">Milstone<sup>[1]</sup></td> <td class=\"subtitle1\">Gottlieb<sup>[2]</sup></td> <td class=\"subtitle1\">Liu<sup>[3]</sup></td> <td class=\"subtitle1\">Kumar<sup>[4]</sup></td> <td class=\"subtitle1\">Soccal<sup>[5]</sup></td> <td class=\"subtitle1\">Weinberg<sup>[6]</sup></td> </tr> <tr> <td class=\"subtitle2\">Population:</td> <td class=\"subtitle2\"> <p>50 adults</p> 17 (34 percent) with infection</td> <td class=\"subtitle2\"> <p>384 adults</p> 30 (7.8 percent) with infection</td> <td class=\"subtitle2\"> <p>576 children</p> 79 (13.8 percent) with infection</td> <td class=\"subtitle2\"> <p>93 adults</p> 48 (51.6 percent) with infection</td> <td class=\"subtitle2\"> <p>77 adults and children*</p> 13 (17.2 percent) with infection<sup>&#182;</sup></td> <td class=\"subtitle2\"> <p>60 adults</p> 51 (85 percent) with symptoms</td> </tr> <tr> <td>Influenza</td> <td>10 (52.6 percent)</td> <td>1 (2.9 percent)</td> <td>9 (8.9 percent)</td> <td>4 (4.9 percent)</td> <td>1 (1.7 percent)</td> <td>16 (25 percent)</td> </tr> <tr> <td>Respiratory syncytial virus</td> <td>8 (42.1 percent)</td> <td>7 (20.5 percent)</td> <td>21 (20.8 percent)</td> <td>4 (4.9 percent)</td> <td>7 (11.9 percent)</td> <td>13 (20.3 percent)</td> </tr> <tr> <td>Human metapneumovirus</td> <td>-</td> <td>6 (17.6 percent)</td> <td>-</td> <td>-</td> <td>3 (5.1 percent)</td> <td>7 (10.9 percent)</td> </tr> <tr> <td>Parainfluenza virus</td> <td>1 (5.3 percent)</td> <td>12 (35.3 percent)</td> <td>19 (18.9 percent)</td> <td>17 (21.0 percent)</td> <td>13 (22 percent)</td> <td>19 (29.7 percent)</td> </tr> <tr> <td>Rhinovirus</td> <td>-</td> <td>3 (6.6 percent)</td> <td>22 (21.7 percent)</td> <td>46 (56.8 percent)</td> <td>22 (37.3 percent)</td> <td>9 (14.1 percent)</td> </tr> <tr> <td>Enterovirus</td> <td>-</td> <td>-</td> <td>4 (3.9 percent)</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Coronavirus</td> <td>-</td> <td>5 (17.1 percent)</td> <td>-</td> <td>11 (12.4 percent)</td> <td>17 (28.8 percent)</td> <td>-</td> </tr> <tr> <td>Adenovirus</td> <td>-</td> <td>-</td> <td>25 (25.8 percent)</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Majority were adults.<br />¶ Positive from bronchoalveolar fluid only.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Milstone, AP, Brumble, LM, Barnes, J, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006; 28:131.</LI>&#xD;&#xA;<LI>Gottlieb, J, Schulz, TF, Welte, T, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009; 87:1530.&nbsp;</LI>&#xD;&#xA;<LI>Liu, M, Worley, S, Arrigain, S, et al. Respiratory viral infections within one year after pediatric lung transplant. Transpl Infect Dis 2009; 11:304.</LI>&#xD;&#xA;<LI>Kumar, D, Husain, S, Chen, MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89:1028.</LI>&#xD;&#xA;<LI>Soccal, PM, Aubert, JD, Bridevaux, PO, et al. Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients. Clin Infect Dis 2010; 51:163. </LI>&#xD;&#xA;<LI>Weinberg, A, Lyu, DM, Li, S, et al. Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis 2010; 12:330.</LI></OL></div><div id=\"graphicVersion\">Graphic 59838 Version 2.0</div></div></div>"},"59839":{"type":"graphic_picture","displayName":"HIV nephropathy EM","title":"Electron micrograph showing tubuloreticular structures in HIV nephropathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph showing tubuloreticular structures in HIV nephropathy</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/59839_HIV_nephropathy_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in HIV-induced focal collapsing glomerulosclerosis shows numerous intraendothelial (End) tubuloreticular structures (arrow). These structures are not seen in the idiopathic form of the disease. The epithelial cell (Ep) has no discrete foot processes, a reflection of primary epithelial cell injury.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 59839 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"59842":{"type":"graphic_picture","displayName":"Lamellar ichthyosis","title":"Lamellar ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lamellar ichthyosis</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/PEDS/59842_Lamellar_ichthyosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lamellar ichthyosis: abdomen, child.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169;2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59842 Version 1.0</div></div></div>"},"59845":{"type":"graphic_figure","displayName":"Forest plot","title":"Forest plot of meta-analysis of randomized controlled trials of the effect of chromium supplementation on fasting glucose in participants with normal glucose tolerance","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">Forest plot of meta-analysis of randomized controlled trials of the effect of chromium supplementation on fasting glucose in participants with normal glucose tolerance</div><div class=\"cntnt\"><img style=\"width:619px; height:571px;\" src=\"images/PC/59845_Forest_plot_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The point estimates of the net changes (change in chromium arm minus change in control arm) and the corresponding 95% CI for individual studies are indicated by circles and bars. The random effects model summary estimates are indicated by squares and bars. Black squares indicate summary estimate of all studies; white squares indicate subanalyses, as indicated. Studies are arranged by chromium formulation (Cr Form), then dose, and then number of participants consuming Cr (N). Total numbers refer only to studies included in the meta-analyses.</div><div class=\"graphic_footnotes\">BrY: brewer's yeast; Cr: chromium; CrCl: chromium chloride; CrNic: chromium nicotinate; CrPic: chromium picolinate; nd: no data; Ind: industry; Non-ind: non-industry; S.A: Saudia Arabia.<br> * Study participants taking a &quot;medication with hyperglycemic potential&quot;.<br> <span class=bullet>&#8226;</span> Study participants not taking a &quot;medication with hyperglycemic potential&quot;.<br> &#916; One participant had type 2 diabetes, and the remaining participants had normal glucose tolerance.<br> <span class=lozenge>&#9674;</span> Only point estimate reported (not included in meta-analyses).</div><div class=\"graphic_reference\">Reproduced with permission from: Balk EM, Tatsioni A, Lichtenstein A, et al. Effect of chromium supplementation on glucose metabolism and lipids. Diabetes Care 2007; 30:2154. Copyright &#169; 2007 American Diabetes Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 59845 Version 2.0</div></div></div>"},"59846":{"type":"graphic_diagnosticimage","displayName":"Acromioclavicular injury Type III","title":"Acromioclavicular injury Type III","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular injury Type III</div><div class=\"cntnt\"><img style=\"width:590px; height:406px;\" src=\"images/EM/59846_AC_type_III_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type III AC injuries represent complete rupture of both the AC and CC ligaments. This radiograph clearly shows the clavicle elevated above the normal plane of the AC joint (arrow) and an increase in the coracoclavicular distance (arrowhead).</div><div class=\"graphic_footnotes\">AC: acromioclavicular; CC: coracoclavicular.</div><div class=\"graphic_reference\">Courtesy of Scott M. Koehler, MD.</div><div id=\"graphicVersion\">Graphic 59846 Version 5.0</div></div></div>"},"59847":{"type":"graphic_picture","displayName":"Splinting material","title":"Splinting material","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Splinting material</div><div class=\"cntnt\"><img style=\"width:498px; height:513px;\" src=\"images/EM/59847_Splinting_material.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common splinting materials include cotton padding (eg, Webril&#174;), plaster, and stockinette (A). Layers of plaster are placed between layers of padding (B). Padding between the skin and plaster must be thick enough to prevent excessive pressure and injury but thin enough to allow adequate immobilization. Usually four layers is sufficient. A stockinette may be placed over the splint (C and D).</div><div class=\"graphic_reference\">Courtesy of Richard Derby, MD.</div><div id=\"graphicVersion\">Graphic 59847 Version 1.0</div></div></div>"},"59848":{"type":"graphic_table","displayName":"Dyspareunia differential dx1","title":"Differential diagnoses for physical causes of dyspareunia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnoses for physical causes of dyspareunia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Location affected</td> <td class=\"subtitle1\">Specific condition</td> <td class=\"subtitle1\">Important history</td> <td class=\"subtitle1\">Physical source of dyspareunia</td> <td class=\"subtitle1\">Comments and caveats</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\">Vulva and vestibule</td> <td>Dermatitis (eczema)</td> <td>Atopic history, other eczema</td> <td>Erythema, scaling, fissuring</td> <td>Look for <em>Candida</em> also</td> </tr> <tr> <td>Dermatosis: lichen sclerosus</td> <td>Itching, recent or lifelong, soreness, possibly no symptoms</td> <td>Fissures, ulceration, scarring</td> <td>Look for <em>Candida</em> also</td> </tr> <tr> <td>Dermatosis: lichen planus</td> <td>Itching, irritation, burning</td> <td>Erosions, ulcers, scarring</td> <td>Hydrochlorothiazide and nonsteroidal antiinflammatory drugs exacerbate lichen planus</td> </tr> <tr> <td>Ulcerative disease: herpes simplex or zoster, chancroid, Crohn disease, aphthae, Beh&#231;et syndrome</td> <td>Episodic outbreaks</td> <td>Ulceration varying in size, tenderness</td> <td>Beh&#231;et syndrome&nbsp;very rare, involves oral ulcers, uveitis, other systems</td> </tr> <tr> <td>Labial hypertrophy</td> <td>Irritation w/physical activity</td> <td>Elongation of labia</td> <td>Need to distinguish physical symptoms from body image issues</td> </tr> <tr> <td>Female circumcision</td> <td>Ethnicity and country of origin</td> <td>Absence of clitoris and prepuce, labial fusion</td> <td>&nbsp;</td> </tr> <tr> <td>Generalized unprovoked vulvodynia</td> <td>Episodic or virtually constant burning, stinging, soreness irritation, rawness</td> <td>Often no findings; or erythema and edema, areas of hyper or hypoesthesia</td> <td>Long history of unsuccessful urinary tract, yeast, bacterial vaginosis treatments</td> </tr> <tr class=\"divider_bottom\"> <td>Radiation</td> <td>History of gynecologic or urinary tumor</td> <td>Pallor, alopecia, loss of elasticity</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"3\">Urethra and bladder</td> <td>Urinary tract infection</td> <td>Dysuria, frequency, urgency</td> <td>Tenderness over bladder</td> <td>Negative cultures suggests vulvodynia</td> </tr> <tr> <td>Urethral diverticulum</td> <td>Dysuria, dribbling, pain with penetration</td> <td>Urethral tenderness, mass</td> <td>&nbsp;</td> </tr> <tr> <td>Interstitial cystitis/bladder pain syndrome</td> <td>Pelvic pain, dysuria, urgency, frequency, nocturia</td> <td>Tenderness over bladder, along anterior vaginal wall</td> <td>Look for localized provoked vulvodynia and pelvic floor dysfunction</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Elizabeth Gunther Stewart, MD.</div><div id=\"graphicVersion\">Graphic 59848 Version 4.0</div></div></div>"},"59849":{"type":"graphic_figure","displayName":"Hepatic drug metabolism","title":"Hepatic drug metabolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic drug metabolism</div><div class=\"cntnt\"><img style=\"width:429px; height:240px;\" src=\"images/GAST/59849_Hepatic_drug_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phase I reactions are catalyzed by cytochrome P450. Phase II reactions are catalyzed by one of several enzymes, such as UDP-glucuronyltransferase, sulfotransferases, and glutathione S-transferases. Active metabolites can lead to hepatic injury.</div><div id=\"graphicVersion\">Graphic 59849 Version 1.0</div></div></div>"},"59850":{"type":"graphic_figure","displayName":"Epileptic visual hallucination","title":"Drawing by a patient with epileptic visual hallucinations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Drawing by a patient with epileptic visual hallucinations</div><div class=\"cntnt\"><img style=\"width:418px; height:418px;\" src=\"images/NEURO/59850_Epileptic_vis_hallu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient had occipital seizures with this stereotyped hallucination for approximately 12 years without a diagnosis. He described a bright red circle that flickered with what looked like moving flames coming out of it. The hallucination typically lasted for seconds and was usually followed by subtle mental status changes, headache, and nausea.</div><div id=\"graphicVersion\">Graphic 59850 Version 2.0</div></div></div>"},"59851":{"type":"graphic_table","displayName":"C-S rate by Bishop score ","title":"Cesarean delivery rate (percent) for failed induction by Bishop score and parity, circa 1985 (prior to availability of prostaglandins)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cesarean delivery rate (percent) for failed induction by Bishop score and parity, circa 1985 (prior to availability of prostaglandins)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Bishop score</td>\n<td class=\"subtitle1\">Nullipara</td>\n<td class=\"subtitle1\">Multipara</td>\n</tr>\n<tr>\n<td>0-3</td>\n<td>45</td>\n<td>7.7</td>\n</tr>\n<tr>\n<td>4-6</td>\n<td>10</td>\n<td>3.9</td>\n</tr>\n<tr>\n<td>7-10</td>\n<td>1.4</td>\n<td>0.9</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=42099&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>C-S_rate_by_Bishop_score_no.htm</title></head></div><div class=\"graphic_reference\">Adapted from: Arulkumaran S, Gibb DM, TambyRaja RL, et al. Failed induction of labour. Aust N Z J Obstet Gynaecol 1985; 25:190.</div><div id=\"graphicVersion\">Graphic 59851 Version 3.0</div></div></div>"},"59853":{"type":"graphic_diagnosticimage","displayName":"SIP free air cross tab xray","title":"Cross-table lateral view demonstrating pneumoperitoneum in an infant with spontaneous intestinal perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cross-table lateral view demonstrating pneumoperitoneum in an infant with spontaneous intestinal perforation</div><div class=\"cntnt\"><img style=\"width:378px; height:234px;\" src=\"images/PEDS/59853_SIP_free_air_cross_tab_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mary Brandt, MD.</div><div id=\"graphicVersion\">Graphic 59853 Version 2.0</div></div></div>"},"59854":{"type":"graphic_table","displayName":"Pediatric ambulance equipment for advanced life support","title":"Pediatric equipment and supplies for advanced life support (ALS) ambulances in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric equipment and supplies for advanced life support (ALS) ambulances in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">ALS ambulances</td> </tr> <tr> <td class=\"subtitle2_single\">Required*<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle3_single\">Airway and ventilation</td> </tr> <tr> <td class=\"indent2\">Laryngoscope handle, extra batteries and bulbs</td> </tr> <tr> <td class=\"indent2\">Laryngoscope blades: straight (Miller) sizes 0-4; curved (MacIntosh) sizes 2-4</td> </tr> <tr> <td class=\"indent2\">Endotracheal tubes: cuffed and/or uncuffed sizes 2.5-5.5 mm; cuffed 6-8 mm (1 of each size and type)</td> </tr> <tr> <td class=\"indent2\">10-mL non-Luerlock syringes</td> </tr> <tr> <td class=\"indent2\">Stylettes for endotracheal tubes: adult and pediatric</td> </tr> <tr> <td class=\"indent2\">Magill (Rovenstein) forceps, adult and pediatric</td> </tr> <tr> <td class=\"indent2\">Lubricating jelly (water soluble)</td> </tr> <tr> <td class=\"indent2\">End-tidal CO<sub>2 </sub>detector (adult and pediatric colorimetric or quantitative capnometry)</td> </tr> <tr> <td class=\"subtitle3_single\">Vascular access</td> </tr> <tr> <td class=\"indent2\">Intravenous catheters, 14 to 24 gauge</td> </tr> <tr> <td class=\"indent2\">Intraosseous needles or devices appropriate for children</td> </tr> <tr> <td class=\"indent2\">Pediatric intravenous arm boards</td> </tr> <tr> <td class=\"subtitle3_single\">Monitoring and defibrillation</td> </tr> <tr> <td class=\"indent2\">Portable, battery-operated monitor/defibrillator with tape write-out/recorder, defibrillator pads, quick-look paddles or electrodes or hands-free patches, ECG leads, adult and pediatric chest attachment electrodes, adult and pediatric paddles</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Transcutaneous cardiac pacemaker with pediatric pads and cables (standalone or integrated into monitor/defibrillator)</td> </tr> <tr> <td class=\"subtitle2_single\">Optional advanced equipment</td> </tr> <tr> <td class=\"indent1\">Respirator (volume-cycled, on/off operation, 100 percent oxygen, 40-50 psi pressure (child/infant capabilities))</td> </tr> <tr> <td class=\"indent1\">Pediatric blood sample tubes</td> </tr> <tr> <td class=\"indent1\">Nasogastric tubes, pediatric feeding tube sizes 5 F and 8 F, sump tube sizes 8 F-16 F</td> </tr> <tr> <td class=\"indent1\">Pediatric laryngoscope handles</td> </tr> <tr> <td class=\"indent1\">Size 1 curved (MacIntosh) laryngoscope blades</td> </tr> <tr> <td class=\"indent1\">Rescue airway devices for children (eg, laryngeal mask airways in pediatric sizes)</td> </tr> <tr> <td class=\"indent1\">Needle cricothyrotomy capability</td> </tr> <tr> <td class=\"indent1\">Atomizers for administration of intranasal medications</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CO<SUB>2</SUB>: carbon dioxide; ECG: electrocardiogram; psi: pounds per square inch; F: French.<br />* In addition to the standard equipment and supplies as determined by state and local regulations.<br />¶ In addition to items for basic life support ambulances.</div><div class=\"graphic_reference\">Data from: Joint policy statement--Equipment for ground ambulances. American Academy of Pediatrics, American College of Emergency Physicians, American College of Surgeons Committee on Trauma, Emergency Medical Services for Children, Emergency Nurses Association, National Association of EMS Physicians, National Association of State EMS Officials. Prehosp Emerg Care 2014; 18:92.</div><div id=\"graphicVersion\">Graphic 59854 Version 4.0</div></div></div>"},"59855":{"type":"graphic_picture","displayName":"Hyphema 100 percent","title":"Hyphema, 100 percent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyphema, 100 percent</div><div class=\"cntnt\"><img style=\"width:312px; height:324px;\" src=\"images/EM/59855_Hyphema100percent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 17-year-old boy with Sturge-Weber syndrome has his entire pupil obscured by blood and massive subconjunctival hemorrhage.</div><div class=\"graphic_reference\">Reproduced with permission from: Trauma: Head and Neck. In: Atlas of Pediatric Emergency Medicine. Fleisher GR, Ludwig S, Baskin MN (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59855 Version 9.0</div></div></div>"},"59856":{"type":"graphic_figure","displayName":"Carpal tunnel syndrome structures","title":"Structures involved with carpal tunnel syndrome","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Structures involved with carpal tunnel syndrome</div><div class=\"cntnt\"><img style=\"width:503px; height:601px;\" src=\"images/EM/59856_Structures_involved_with_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a depiction of the volar surface of the right hand showing the relationship of the median nerve to the transverse carpal ligament (flexor retinaculum). The&nbsp;ligament attaches to the carpal bones, including the hamate, pisiform, trapezium, and scaphoid tuberosity (navicular).</div><div id=\"graphicVersion\">Graphic 59856 Version 4.0</div></div></div>"},"59857":{"type":"graphic_table","displayName":"Platelet function tests","title":"List of established platelet function tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">List of established platelet function tests</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Platelet function test</td>\n\n      <td class=\"subtitle1\">Aspects of platelet function measured</td>\n\n      <td class=\"subtitle1\">Advantages</td>\n\n      <td class=\"subtitle1\">Disadvantages</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bleeding Time</td>\n\n      <td>In vivo screening test</td>\n\n      <td>Physiological</td>\n\n      <td>Insensitive, Invasive &#38; high inter-operator variability</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Aggregometry -&nbsp;Turbidometric methods</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Responsiveness to Panel of Agonists</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Diagnostic</td>\n\n      <td>Labor intensive</td>\n\n    </tr>\n\n    <tr>\n      \n      \n      \n      <td>Non-Physiological</td>\n    </tr>\n    <tr>\n\n      <td>Aggregometry -&nbsp;impedance methods</td>\n\n      <td>Responsiveness to Panel of Agonists</td>\n\n      <td>Whole blood test</td>\n\n      <td>Insensitive</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aggregometry and luminescence</td>\n\n      <td>Combined aggregation and ADP release</td>\n\n      <td>More information</td>\n\n      <td>Semi-quantitative</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Adenine Nucleotides</td>\n\n      <td>Stored and Released ADP</td>\n\n      <td>Sensitive</td>\n\n      <td>Specialized equipment</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Thromboelastography (TEG)</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Global Haemostasis</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Predicts bleeding</td>\n\n      <td>Measures Clot properties only</td>\n\n    </tr>\n\n    <tr>\n      \n      \n      \n      <td>Insensitive to aspirin</td>\n    </tr>\n    <tr>\n\n      <td>Glass Filterometer</td>\n\n      <td>High shear platelet function</td>\n\n      <td>Simple</td>\n\n      <td>Requires blood counter</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Platelet Release Markers eg. BetaTG PF4</td>\n\n      <td>In vivo platelet activation markers</td>\n\n      <td>Simple, systemic measure of platelet</td>\n\n      <td>Prone to artifact</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">4/17/2001 -perm requested - jm\r\n4/25/2001 -refaxed to UK office -jm\r\n6/26/2001- perm granted, gave to chris &amp;amp; lisa  -jm\r\n\r\n7/15/2008--�116.00 converted into $232.96, then divided by two figures (JD).\r\n\r\n The total fee of $&amp;quot;116.48&amp;quot;was originally charged to\r\nPlatelet_function_tests\r\nNewer_platelet_function_tests</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26268&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Platelet_function_tests.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Harrison P. Progress in the Assessment of Platelet Function. Br J Haematol 2000; 111:733. Copyright © 2000 Blackwell Science. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 59857 Version 2.0</div></div></div>"},"59858":{"type":"graphic_diagnosticimage","displayName":"AV fistula after renal bx Angio","title":"Renal AV fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal AV fistula</div><div class=\"cntnt\"><img style=\"width:308px; height:288px;\" src=\"images/NEPH/59858_AV_fistula_after_renal_bx_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arteriovenous (AV) fistula following biopsy of a transplanted kidney. Following injection of contrast material into the right common iliac artery (arrow), there is prompt filling of the iliac vein (arrowhead) with poor perfusion of the transplanted kidney.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 59858 Version 4.0</div></div></div>"},"59862":{"type":"graphic_table","displayName":"Morphology prost CA needle bx","title":"Morphologic features associated with malignancy on needle biopsy of the prostate","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Morphologic features associated with malignancy on needle biopsy of the prostate</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Morphologic feature</td>\n\n      <td class=\"subtitle1\">Malignant lesions, percent (n = 100)</td>\n\n      <td class=\"subtitle1\">Benign lesions, percent (n = 150)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prominent nucleoli</td>\n\n      <td>94</td>\n\n      <td>25</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Marginated nucleoli</td>\n\n      <td>88</td>\n\n      <td>7</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Multiple nucleoli</td>\n\n      <td>64</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Blue-tinged mucinous secretions</td>\n\n      <td>52</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intraluminal crystalloids </td>\n\n      <td>41</td>\n\n      <td>1</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Intraluminal amorphous eosinophilic material</td>\n\n      <td>87</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Collagenous micronodules </td>\n\n      <td>2</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Glomerulations</td>\n\n      <td>15</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Perineural invasion</td>\n\n      <td>22</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Retraction clefting</td>\n\n      <td>39</td>\n\n      <td>7</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Invasion of fat</td>\n\n      <td>0.7</td>\n\n      <td>0</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=47076&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Morphology_prost_CA_needle.htm</title></head></div><div class=\"graphic_reference\">Modified from Varma M, Lee MW, Tamboli P, et al. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. Arch Pathol Lab Med 2002; 126:554.</div><div id=\"graphicVersion\">Graphic 59862 Version 2.0</div></div></div>"},"59863":{"type":"graphic_diagnosticimage","displayName":"Right upper lobe atelectasis B","title":"Right upper lobe atelectasis in an adolescent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right upper lobe atelectasis in an adolescent</div><div class=\"cntnt\"><img style=\"width:270px; height:378px;\" src=\"images/PEDS/59863_Right_upper_lobe_atelecta1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Portable supine radiograph of a 12-year-old following intubation. There are focal opacities within the right upper lung and retrocardiac left lower lobe. The curvilinear inferior margin of the right-sided opacity represents a significantly elevated minor fissure, consistent with right upper lobe collapse; the left lower lobe opacity is less specific.</div><div id=\"graphicVersion\">Graphic 59863 Version 3.0</div></div></div>"},"59868":{"type":"graphic_picture","displayName":"Plaque sarcoidosis - annular","title":"Plaque sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plaque sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/59868_Plaque_sarcoidosis_annular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular sarcoidosis. Erythematous, indurated, ring-like plaques with central clearing are present on the back.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.</div><div id=\"graphicVersion\">Graphic 59868 Version 4.0</div></div></div>"},"59869":{"type":"graphic_table","displayName":"Features of hypereosinophilic syndrome (HES) variants","title":"Features of hypereosinophilic syndrome (HES) variants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of hypereosinophilic syndrome (HES) variants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Terminology for HES variants</td> <td class=\"subtitle1\">Subtypes/identified abnormalities/examples</td> <td class=\"subtitle1\">Clinical and laboratory features&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Myeloid variants</td> <td> <p><em>PDGFRB</em> and <em>FGFR1</em> rearrangements</p> <p><em>JAK2</em> point mutation and translocation</p> Chronic eosinophilic leukemia, not otherwise specified, on the basis of blast count in peripheral blood and/or bone marrow or of a clonal cytogenetic abnormality</td> <td>&#8593; Serum B12 <p>Anemia and/or thrombocytopenia</p> <p>Hepatomegaly and/or splenomegaly</p> Circulating leukocyte precursors</td> </tr> <tr> <td>Deletion on 4q12 &#8594; <em>FIP1L1-PDGFRA</em> fusion</td> <td>May show &#8593; serum tryptase + mast cell abnormalities</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>PDGFRA or PDGFRB rearrangement-associated disease occurs almost exclusively in males</td> </tr> <tr class=\"divider_bottom\"> <td>T cell lymphocytic variants (L-HES)</td> <td> <p>Aberrant IL-5-producing T cells</p> <p>Example: CD3-CD4+ T cell-associated disease</p> </td> <td>Prominent skin findings (including plaques, erythroderma, urticaria) <p>Polyclonal hypergammaglobulinemia</p> Usually a benign lymphoproliferative disorder, but may progress to T cell lymphoma</td> </tr> <tr class=\"divider_bottom\"> <td>Familial HES</td> <td>Mapped to 5q 31-33</td> <td> <p>Asymptomatic eosinophilia from birth, autosomal dominant</p> <p>Progression to other forms of HES may occur</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Idiopathic HES</td> <td>&nbsp;</td> <td>Multisystem involvement with varied signs/symptoms</td> </tr> <tr class=\"divider_bottom\"> <td>Organ-restricted HES</td> <td>Examples include eosinophilic gastrointestinal disease, chronic eosinophilic pneumonia, and others</td> <td>Peripheral blood eosinophilia associated with eosinophilic infiltration and associated signs/symptoms in a single organ</td> </tr> <tr> <td>Specific/defined syndromes associated with hypereosinophilia</td> <td>Examples include episodic angioedema with eosinophilia, eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss), other disorders associated with immune dysregulation</td> <td>Marked eosinophilia in the setting of an underlying disorder associated with eosinophilia; the precise role of eosinophils in the disease manifestations remains uncertain</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HES: hypereosinophilic syndromes; PDGFRB: platelet-derived growth factor receptor beta; FGFR1: fibroblast growth factor receptor 1; JAK2: Janus kinase 2; FIP1L1: Fip1-like1; PDGFRA: platelet-derived growth factor receptor alpha; L-HES: lymphocytic variant HES; IL-5: interleukin-5.</div><div id=\"graphicVersion\">Graphic 59869 Version 13.0</div></div></div>"},"59870":{"type":"graphic_table","displayName":"Immunohistochemical differential diagnosis of JXG","title":"Immunohistochemical differential diagnosis of juvenile xanthogranuloma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunohistochemical differential diagnosis of juvenile xanthogranuloma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">JXG</td> <td class=\"subtitle1\">LCH</td> <td class=\"subtitle1\">XD</td> <td class=\"subtitle1\">PX</td> <td class=\"subtitle1\">BCH&nbsp;</td> </tr> <tr> <td>CD68</td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;+</td> </tr> <tr> <td>CD1a</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">&nbsp;-</td> </tr> <tr> <td>CD163</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>S100</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">&nbsp;-</td> </tr> <tr> <td>Factor XIIIa</td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td class=\"centered\">&nbsp;+</td> </tr> <tr> <td>Fascin</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;+</td> </tr> <tr> <td>Langerin (CD207)</td> <td class=\"centered\">-</td> <td class=\"centered\">+</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">&nbsp;-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">JXG: juvenile xanthogranuloma; LCH: Langerhans cell histiocytosis; XD: xanthoma disseminatum; PX: papular xanthoma; BCH: benign cephalic histiocytosis.</div><div id=\"graphicVersion\">Graphic 59870 Version 4.0</div></div></div>"},"59871":{"type":"graphic_figure","displayName":"Pelvic veins","title":"Veins of the pelvis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Veins of the pelvis</div><div class=\"cntnt\"><img style=\"width:410px; height:593px;\" src=\"images/EM/59871_Pelvicveins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patterns of the portal and systemic (vena caval) venous systems of the abdominopelvic cavity are shown. Venous drainage from pelvic organs flows mainly to the caval system via the internal iliac veins. The upper rectum normally drains into the portal system, although the superior rectal veins anastomose with the middle and inferior rectal veins, which are tributaries of the internal iliac veins.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59871 Version 11.0</div></div></div>"},"59872":{"type":"graphic_picture","displayName":"Plasmodium vivax thin smear","title":"<EM>Plasmodium vivax</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Plasmodium vivax</EM></div><div class=\"cntnt\"><img style=\"width:359px; height:238px;\" src=\"images/ID/59872_Plasmodiumvivaxthinsmear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Giemsa-stained thin smear of blood (x1000) shows a ring trophozoite of <EM>Plasmodium vivax</EM>. Red blood cells infected by <EM>P. vivax </EM>are enlarged and contain Schüffner's dots.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 59872 Version 2.0</div></div></div>"},"59875":{"type":"graphic_table","displayName":"Clinical group rhabdomyosarcoma","title":"Clinical grouping of rhabdomyosarcoma by the intergroup rhabdomyosarcoma study group (IRSG)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical grouping of rhabdomyosarcoma by the intergroup rhabdomyosarcoma study group (IRSG)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical group</td> <td class=\"subtitle1\">Extent of disease/surgical result</td> </tr> <tr> <td rowspan=\"2\">I</td> <td>A Localized tumor, confined to site of origin, completely resected</td> </tr> <tr> <td>B Localized tumor, infiltrating beyond site of origin, completely resected</td> </tr> <tr> <td rowspan=\"3\">II</td> <td>A Localized tumor, gross total resection, but with microscopic residual disease</td> </tr> <tr> <td>B Locally extensive tumor (spread to regional lymph nodes), completely resected</td> </tr> <tr> <td>C Locally extensive tumor (spread to regional lymph nodes), gross total resection, but microscopic residual disease</td> </tr> <tr> <td rowspan=\"2\">III</td> <td>A Localized or locally extensive tumor, gross residual disease after biopsy only</td> </tr> <tr> <td>B Localized or locally extensive tumor, gross residual disease after major resection (&#8805;50 percent&nbsp;debulking)</td> </tr> <tr> <td>IV*</td> <td>Any size primary tumor, with or without regional lymph node involvement, with distant metastases, irrespective of surgical approach to primary tumor</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Although current Children's Oncology Group (COG) trials include all patients with metastatic disease in the high-risk category, selected patients with favorable site, histology/molecular features&nbsp;(embryonal or alveolar, and<EM> FOXO1</EM> fusion-negative), and age (under age 10) with limited metastases may have better outcomes with VAC therapy (vincristine, actinomycin D, and cyclophosphamide) or intensified treatments such as those in the completed ARST0431 protocol.</div><div class=\"graphic_reference\">Modified from Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13:610; and Crist W, Garnsey L, Beltangady M, et al. Prognosis in children with rhabdomyosarcoma: A report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol 1990; 8:443.</div><div id=\"graphicVersion\">Graphic 59875 Version 5.0</div></div></div>"},"59876":{"type":"graphic_figure","displayName":"Structure of ER","title":"Structure of estrogen receptor (ER)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of estrogen receptor (ER)</div><div class=\"cntnt\"><img style=\"width:434px; height:164px;\" src=\"images/ONC/59876_Structure_of_ER.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A to F represent different domains of the ER. Numbers represent amino acids from amino to carboxy termini.</div><div class=\"graphic_reference\">Reproduced with permission from: Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Diseases of the Breast, 2nd ed, Harris JR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2000. Copyright © 2000 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 59876 Version 10.0</div></div></div>"},"59877":{"type":"graphic_diagnosticimage","displayName":"Barium enema in Hirschsprung disease","title":"Barium enema in Hirschsprung disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barium enema in Hirschsprung disease</div><div class=\"cntnt\"><img style=\"width:280px; height:350px;\" src=\"images/PEDS/59877_Hirschsprung_dz_barium_enem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium enema of an infant with Hirschsprung disease, showing the transition zone (arrow) between the lower aganglionic bowel and the normal colon above.</div><div class=\"graphic_reference\">Courtesy of George D Ferry, MD.</div><div id=\"graphicVersion\">Graphic 59877 Version 5.0</div></div></div>"},"59878":{"type":"graphic_picture","displayName":"Nodular acne - face","title":"Nodular acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular acne</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/59878_Nodular_acne_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules, pustules, and nodules are present on the face. This patient also has postinflammatory hyperpigmentation and scarring.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59878 Version 3.0</div></div></div>"},"59879":{"type":"graphic_figure","displayName":"Surgical treatment of pulp space infection","title":"Surgical treatment of pulp space infection","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Surgical treatment of pulp space infection</div><div class=\"cntnt\"><img style=\"width:512px; height:595px;\" src=\"images/SURG/59879_Surg_tx_pulp_space_infect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most patients with a pulp abscess require surgical intervention because the infection may be more extensive than the symptoms and clinical appearance suggest.<br />(A) The incisions used to drain a pulp abscess. Left: Lateral incision. Right: Palmar incision. <br />(B) The surgical approach to the pulp abscess cavity. The lateral incision enters the abscess cavity dorsal to the neurovascular bundle and palmar to the palmar cortex of the distal phalanx. The palmar incision enters the abscess cavity directly from the palmar aspect.</div><div class=\"graphic_footnotes\">DIPJ: distal interphalangeal joint. </div><div id=\"graphicVersion\">Graphic 59879 Version 4.0</div></div></div>"},"59880":{"type":"graphic_figure","displayName":"Right colectomy - transecting the ileum and colon","title":"Right colectomy - transecting the ileum and colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right colectomy - transecting the ileum and colon</div><div class=\"cntnt\"><img style=\"width:363px; height:357px;\" src=\"images/SURG/59880_Right-hemi-transect-ileum-colon.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59880 Version 2.0</div></div></div>"},"59882":{"type":"graphic_picture","displayName":"Serous cystadenoma Light III","title":"Pancreatic serous cystadenoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pancreatic serous cystadenoma</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/GAST/59882_Serous_cystadenoma_Light_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of biopsy obtained with an EUS-guided trucut needle showing a pancreatic serous cystadenoma.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 59882 Version 1.0</div></div></div>"},"59883":{"type":"graphic_diagnosticimage","displayName":"Abnormal mammogram","title":"Abnormal mammogram","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Abnormal mammogram</div><div class=\"cntnt\"><img style=\"width:470px; height:380px;\" src=\"images/PC/59883_Abnormal_mammogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an abnormal mammogram showing a mass, caused by breast cancer.</div><div class=\"graphic_reference\">Copyright © Yale University, 2006. All rights reserved.</div><div id=\"graphicVersion\">Graphic 59883 Version 2.0</div></div></div>"},"59884":{"type":"graphic_diagnosticimage","displayName":"EGPA (Churg-Strauss) lateral","title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) lateral chest radiograph","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) lateral chest radiograph</div><div class=\"cntnt\"><img style=\"width:237px; height:289px;\" src=\"images/PULM/59884_Churg_Strauss_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral chest radiograph of a patient with&nbsp;eosinophilic granulomatosis with polyangiitis (Churg-Strauss) demonstrating prominent consolidative opacities.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 59884 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lateral chest radiograph</div><div class=\"cntnt\"><img style=\"width:252px; height:368px;\" src=\"images/PULM/57909_Normal_chest_film_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 57909 Version 1.0</div></div></div>"},"59885":{"type":"graphic_diagnosticimage","displayName":"Malignant mesothelioma III MRI","title":"Malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:323px; height:320px;\" src=\"images/PULM/59885_Malignant_mesothelioma_II1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI scan, coronal, T1 weighted spin-echo sequence, shows circumferential encasement of the left lung with loss of volume and ipsilateral shift of the mediastinum to the left. The aortic arch and the descending aorta are encased by tumor.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59885 Version 4.0</div></div></div>"},"59887":{"type":"graphic_figure","displayName":"Diameters of the vertex brow and face presentation","title":"Diameters of the vertex, brow, and face presentation","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Diameters of the vertex, brow, and face presentation</div><div class=\"cntnt\"><img style=\"width:515px; height:254px;\" src=\"images/OBGYN/59887_Diameters-of-the-vertex-brow-and-face-presentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;Occipital presentation with widest diameter suboccipitobregmatic, mean length 11.9 cm.<br />(B) Brow presentation with widest diameter mentoparietal, mean length 13.4 cm.<br />(C) Face presentation with widest diameter trachelobregmatic or trachelpariaetal, mean length 12.6.</div><div class=\"graphic_reference\">Data from: Borell, U, Fernstrom, I. The mechanism of labour in face and brow presentation. Acta Obst et Gynec Scandinav 1960; 39:626.</div><div id=\"graphicVersion\">Graphic 59887 Version 4.0</div></div></div>"},"59888":{"type":"graphic_figure","displayName":"Saphenous nerve","title":"Saphenous nerve","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Saphenous nerve</div><div class=\"cntnt\"><img style=\"width:493px; height:289px;\" src=\"images/SURG/59888_Saphenous_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The saphenous nerve is the largest cutaneous branch of the femoral nerve. It exits the adductor canal traveling deep to the sartorius muscle emerging medially between the tendons of the sartorius and gracilis muscles at the knee to become superficial. It travels distally adjacent the great saphenous vein. The saphenous nerve provides sensory innervation to the medial aspect of the leg.</div><div id=\"graphicVersion\">Graphic 59888 Version 3.0</div></div></div>"},"59890":{"type":"graphic_picture","displayName":"Alpha hemolysis","title":"Optochin disk test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optochin disk test</div><div class=\"cntnt\"><img style=\"width:339px; height:240px;\" src=\"images/ID/59890_Alpha_hemolysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Optochin disk test to differentiate alpha-hemolytic (green) streptococci. <EM>Streptococcus pneumoniae</EM> is susceptible to optochin as shown by the zone of inhibition around the disk of the culture on the right. Other alpha-hemolytic streptococci (example on left) are resistant to this compound.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 59890 Version 3.0</div></div></div>"},"59892":{"type":"graphic_figure","displayName":"Albumin in nephrosis and CAPD","title":"Plasma albumin in nephrotic syndrome and CAPD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma albumin in nephrotic syndrome and CAPD</div><div class=\"cntnt\"><img style=\"width:350px; height:252px;\" src=\"images/NEPH/59892_Albumin_in_nephrosis_and_CA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between total albumin loss and the plasma albumin concentration in patients undergoing continuous ambulatory peritoneal dialysis (CAPD), in which albumin is primarily lost in the dialysate fluid, and those with the nephrotic syndrome. At any level of albumin loss, the plasma albumin concentration is approximately 1 g/dL (10 g/L) lower in patients with the nephrotic syndrome, suggesting that some factor in addition to urinary albumin excretion must be involved.</div><div class=\"graphic_reference\">Data from Kaysen, GA, Schoenfeld, PY, Kidney Int 1984; 25:107.</div><div id=\"graphicVersion\">Graphic 59892 Version 1.0</div></div></div>"},"59893":{"type":"graphic_table","displayName":"Causes of delirium and confusion","title":"Common causes of delirium and confusional states","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of delirium and confusional states</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Drugs and toxins</td> </tr> <tr> <td class=\"indent1\">Prescription medications (eg, opioids, sedative-hypnotics, antipsychotics, lithium, skeletal muscle relaxers, polypharmacy)</td> </tr> <tr> <td class=\"indent1\">Nonprescription medications (eg, antihistamines)</td> </tr> <tr> <td class=\"indent1\">Drugs of abuse (eg, ethanol, heroin, hallucinogens, nonmedicinal use of prescription medications)</td> </tr> <tr> <td class=\"indent1\">Withdrawal states (eg, ethanol, benzodiazepines)</td> </tr> <tr> <td class=\"indent1\">Medication side effects (eg, hyperammonemia from valproic acid, confusion from quinolones, serotonin syndrome)</td> </tr> <tr> <td class=\"sublist2_start\">Poisons:</td> </tr> <tr> <td class=\"sublist2\">Atypical alcohols (ethylene glycol, methanol)</td> </tr> <tr> <td class=\"sublist2\">Inhaled toxins (carbon monoxide, cyanide, hydrogen sulfide)</td> </tr> <tr> <td class=\"sublist2\">Plant-derived (eg, Jimson weed, Salvia)</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> </tr> <tr> <td class=\"indent1\">Systemic infections; fever-related delirium</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic derangements</td> </tr> <tr> <td class=\"indent1\">Electrolyte disturbance (elevated or depressed): sodium, calcium, magnesium, phosphate</td> </tr> <tr> <td class=\"indent1\">Endocrine disturbance (depressed or increased): thyroid, parathyroid, pancreas, pituitary, adrenal</td> </tr> <tr> <td class=\"indent1\">Hypercarbia</td> </tr> <tr> <td class=\"indent1\">Hyperglycemia and hypoglycemia</td> </tr> <tr> <td class=\"indent1\">Hyperosmolar and hypoosmolar states</td> </tr> <tr> <td class=\"indent1\">Hypoxemia</td> </tr> <tr> <td class=\"indent1\">Inborn errors of metabolism: porphyria, Wilson disease, etc</td> </tr> <tr> <td class=\"indent1\">Nutritional: Wernicke encephalopathy, vitamin B12 deficiency, possibly folate and niacin deficiencies</td> </tr> <tr> <td class=\"subtitle1_single\">Brain disorders</td> </tr> <tr> <td class=\"indent1\">CNS infections: encephalitis, meningitis, brain or epidural abscess</td> </tr> <tr> <td class=\"indent1\">Epileptic seizures, especially nonconvulsive status epilepticus*</td> </tr> <tr> <td class=\"indent1\">Head injury*</td> </tr> <tr> <td class=\"indent1\">Hypertensive encephalopathy</td> </tr> <tr> <td class=\"indent1\">Psychiatric disorders*</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic organ failure</td> </tr> <tr> <td class=\"indent1\">Cardiac failure</td> </tr> <tr> <td class=\"indent1\">Hematologic: thrombocytosis, hypereosinophilia, leukemic blast cell crisis, polycythemia</td> </tr> <tr> <td class=\"indent1\">Liver failure: acute, chronic</td> </tr> <tr> <td class=\"indent1\">Pulmonary disease, including hypercarbia and hypoxemia</td> </tr> <tr> <td class=\"indent1\">Renal failure: acute, chronic</td> </tr> <tr> <td class=\"subtitle1_single\">Physical disorders</td> </tr> <tr> <td class=\"indent1\">Burns</td> </tr> <tr> <td class=\"indent1\">Electrocution</td> </tr> <tr> <td class=\"indent1\">Hyperthermia</td> </tr> <tr> <td class=\"indent1\">Hypothermia</td> </tr> <tr> <td class=\"indent1\">Trauma: with systemic inflammatory response syndrome, head injury*, fat embolism</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br />* Disorders that, while not truly systemic or \"medical,\" may produce the clinical picture of delirium or confusional state in all other aspects.</div><div id=\"graphicVersion\">Graphic 59893 Version 5.0</div></div></div>"},"59894":{"type":"graphic_picture","displayName":"Severe fetal vascular malperfusion","title":"Severe fetal vascular malperfusion (fetal thrombotic vasculopathy)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe fetal vascular malperfusion (fetal thrombotic vasculopathy)</div><div class=\"cntnt\"><img style=\"width:396px; height:298px;\" src=\"images/OBGYN/59894_Fetalthrombvasculardis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large portion of the villous tree (&gt;15 villi/slide) shows loss of fetal vessels and hyaline fibrosis secondary to upstream vascular occlusion.</div><div class=\"graphic_reference\">Courtesy of Raymond W. Redline, MD.</div><div id=\"graphicVersion\">Graphic 59894 Version 3.0</div></div></div>"},"59895":{"type":"graphic_diagnosticimage","displayName":"Rectal cancer node EUS","title":"Rectal cancer seen on endoscopic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rectal cancer seen on endoscopic ultrasound</div><div class=\"cntnt\"><img style=\"width:374px; height:273px;\" src=\"images/GAST/59895_Rectal_cancer_node_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound image of a rectal cancer with involvement of perirectal lymph node (arrow).</div><div class=\"graphic_reference\">Courtesy of Gavin C Harewood, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 59895 Version 3.0</div></div></div>"},"59897":{"type":"graphic_picture","displayName":"MDS abnormal megakaryocytes","title":"Myelodysplastic syndrome with abnormal megakaryocytic maturation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myelodysplastic syndrome with abnormal megakaryocytic maturation</div><div class=\"cntnt\"><img style=\"width:430px; height:288px;\" src=\"images/HEME/59897_MDS_abnormal_megakaryocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with myelodysplastic syndrome. The megakaryocytes are abnormal, with multiple small lobes seemingly disconnected from each other (&quot;Pawn ball&quot; changes, arrows). (Wright-Giemsa).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 59897 Version 1.0</div></div></div>"},"59898":{"type":"graphic_figure","displayName":"NHL distribution by ART use and CD4 count","title":"Distribution of non-Hodgkin lymphomas (NHLs) by use of ART and CD4 cell count at diagnosis","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Distribution of non-Hodgkin lymphomas (NHLs) by use of ART and CD4 cell count at diagnosis</div><div class=\"cntnt\"><img style=\"width:526px; height:400px;\" src=\"images/HEME/59898_NHL_distr_HAART_CD4_count.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution of 347 NHLs by use of ART and CD4 cell count at NHL diagnosis. CD4 cell count at diagnosis was not available for 82 NHLs.</div><div class=\"graphic_footnotes\">ART: antiretroviral therapy.</div><div class=\"graphic_reference\">Reproduced with permission from: Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008; 22:301. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59898 Version 9.0</div></div></div>"},"59899":{"type":"graphic_table","displayName":"AHA recs for exercise and diet counseling","title":"American Heart Association (AHA) recommendations for counseling to promote dietary and physical activity changes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Heart Association (AHA) recommendations for counseling to promote dietary and physical activity changes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cognitive-behavioral strategies for promoting behavior change</td> </tr> <tr> <td class=\"subtitle2_left\">Class I</td> </tr> <tr> <td class=\"indent1\">Design interventions to target dietary and physical activity behaviors with specific, proximal goals. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">Provide feedback on progress toward goals. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">Provide strategies for self-monitoring. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">Establish a plan for frequency and duration of follow-up contacts (eg, in-person, oral, written, electronic) in accordance with individual needs to assess and reinforce progress toward goal achievement. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">Utilize motivational interviewing strategies, particularly when an individual is resistant or ambivalent about dietary and physical activity behavior change. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">Provide for direct or peer-based long-term support and follow-up, such as referral to ongoing community-based programs, to offset the common occurrence of declining adherence that typically begins at&nbsp;four to six&nbsp;months in most behavior change programs. (Level of evidence: B)</td> </tr> <tr> <td class=\"indent1\">Incorporate strategies to build self-efficacy into the intervention. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">Use a combination of&nbsp;two of the above strategies (eg, goal-setting, feedback, self-monitoring, follow-up, motivational interviewing, self-efficacy) in an intervention. (Level of evidence: A)</td> </tr> <tr> <td class=\"subtitle2_left\">Class II</td> </tr> <tr> <td class=\"indent1\">Use incentives, modeling, and problem-solving strategies. (Level of evidence: B)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\">Intervention processes and/or delivery strategies</td> </tr> <tr> <td class=\"subtitle2_left\">Class I</td> </tr> <tr> <td class=\"indent1\">Use individual- or group-based strategies. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">Use individual-oriented sessions to assess where the individual is in relation to behavior change, to jointly identify the goals for risk reduction or improved cardiovascular health, and to develop a personalized plan to achieve it. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">Use group sessions with cognitive-behavioral strategies to teach skills to modify the diet and develop a physical activity program, to provide role modeling and positive observational learning, and to maximize the benefits of peer support and group problem-solving. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">For appropriate target populations, use Internet- and computer-based programs to target dietary and physical activity change; adding a form of electronic-counseling improves outcomes. (Level of evidence: B)</td> </tr> <tr> <td class=\"subtitle2_left\">Class IIa</td> </tr> <tr> <td class=\"indent1\">Use individualized rather than non-individualized print- or media-only delivery strategies. (Level of evidence: A)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\">Addressing cultural and social context variables that influence behavioral change</td> </tr> <tr> <td class=\"subtitle2_left\">Class IIa</td> </tr> <tr> <td class=\"indent1\">Utilize church, community, work, or clinic settings for delivery of interventions. (Level of evidence: B)</td> </tr> <tr> <td class=\"indent1\">Use a multiple-component delivery strategy that includes a group component rather than individual- or group-only approaches. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">Use culturally adapted strategies, including use of peer or lay health advisors to increase trust; tailor health messages and counseling strategies to be sensitive to the cultural beliefs, values, language, literacy, and customs of the target population. (Level of evidence: A)</td> </tr> <tr> <td class=\"indent1\">Use problem-solving to address barriers to physical activity and dietary change, such as transportation barriers, poor local safety, and lack of access to affordable healthier foods and physical activity. (Level of evidence: B)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Class I: evidence of effectiveness; Class II: conflicting evidence; Class IIa: weight of evidence in favor; Level of evidence A: data derived from multiple randomized clinical trials; Level of evidence B: data derived from a single randomized trial or nonrandomized studies; Level of evidence C: expert opinion or case studies.</div><div class=\"graphic_reference\">Reprinted with permission from: Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 2010; 122:406. Copyright © 2010 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 59899 Version 12.0</div></div></div>"},"59900":{"type":"graphic_picture","displayName":"Proptosis and chemosis","title":"Proptosis and chemosis in a direct, high-flow, right carotid cavernous fistula following trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proptosis and chemosis in a direct, high-flow, right carotid cavernous fistula following trauma</div><div class=\"cntnt\"><img style=\"width:432px; height:294px;\" src=\"images/NEURO/59900_Propto_chemosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">With permission from: Norman J Schatz, MD. Reproduced from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001.</div><div id=\"graphicVersion\">Graphic 59900 Version 1.0</div></div></div>"},"59901":{"type":"graphic_picture","displayName":"Linear IgA bullous dermatosis close view","title":"Linear IgA bullous dermatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear IgA bullous dermatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/59901_Linear_IgA_bull_derm_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense bullae and erosions are present on the extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59901 Version 3.0</div></div></div>"},"59902":{"type":"graphic_figure","displayName":"VE VCO2 and survival in HF","title":"Ventilatory response to exercise predicts survival in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventilatory response to exercise predicts survival in heart failure</div><div class=\"cntnt\"><img style=\"width:444px; height:299px;\" src=\"images/CARD/59902_VEVCO2andsurvivalinHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival curves for an 18 month follow-up of patients with heart failure show a significant increase in survival in patients with a normal ventilatory response to exercise compared&nbsp;with those with a VE/V<SUB>CO2</SUB> ratio (the ratio of minute ventilation and carbon dioxide production) above 34.</div><div class=\"graphic_reference\">Data from: Chua TP, Ponikowski P, Harrington D, et al. J Am Coll Cardiol 1997; 29:1585.</div><div id=\"graphicVersion\">Graphic 59902 Version 2.0</div></div></div>"},"59903":{"type":"graphic_diagnosticimage","displayName":"Balloon dilation PD stricture","title":"Balloon dilation of pancreatic duct stricture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balloon dilation of pancreatic duct stricture</div><div class=\"cntnt\"><img style=\"width:256px; height:358px;\" src=\"images/GAST/59903_Balloon_dilation_PD_strictu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows a balloon that has been inflated within a stricture in the main pancreatic duct.</div><div class=\"graphic_reference\">Courtesy of Marc Catalano, MD.</div><div id=\"graphicVersion\">Graphic 59903 Version 3.0</div></div></div>"},"59906":{"type":"graphic_table","displayName":"Screening tests","title":"Screening instruments for late-life depression for use in primary care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening instruments for late-life depression for use in primary care</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Sensitivity percent</td> <td class=\"subtitle1\">Specificity percent</td> <td class=\"subtitle1\">Inpatient</td> <td class=\"subtitle1\">Outpatient</td> <td class=\"subtitle1\">Physically ill</td> <td class=\"subtitle1\">Cognitively impaired</td> </tr> <tr> <td>Two-question screen</td> <td>97</td> <td>67</td> <td>Unknown</td> <td>Yes</td> <td>Unknown</td> <td>No</td> </tr> <tr> <td>Geriatric Depression Scale (5-item)</td> <td>94</td> <td>81</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Unknown</td> </tr> <tr> <td>Patient Health Questionnaire-9 (9-item)</td> <td>88</td> <td>88</td> <td>Unknown</td> <td>Yes</td> <td>Yes</td> <td>Unknown</td> </tr> <tr> <td>Cornell Scale for Depression in Dementia (19-item)</td> <td>90</td> <td>75</td> <td>Yes</td> <td>Yes</td> <td>Unknown</td> <td>Yes</td> </tr> <tr> <td>Center for Epidemiologic Studies - Depression Scale (20-item)</td> <td>93</td> <td>73</td> <td>No</td> <td>Yes</td> <td>Unknown</td> <td>No</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59906 Version 2.0</div></div></div>"},"59908":{"type":"graphic_table","displayName":"Functional capacity in RA","title":"Classification of functional capacity in rheumatoid arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of functional capacity in rheumatoid arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class I: Complete</td> </tr> <tr> <td>&nbsp;Ability to carry on all usual duties without handicaps</td> </tr> <tr> <td class=\"subtitle1_single\">Class II: Adequate for normal activities</td> </tr> <tr> <td>&nbsp;Despite handicap of discomfort or limited motion at one or more joints</td> </tr> <tr> <td class=\"subtitle1_single\">Class III: Limited</td> </tr> <tr> <td>&nbsp;Only to little or none of duties of usual occupation or self-care</td> </tr> <tr> <td class=\"subtitle1_single\">Class IV: Incapacitated, largely or wholly</td> </tr> <tr> <td>&nbsp;Bedridden or confined to wheelchairs; little or no self-care</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59908 Version 2.0</div></div></div>"},"59910":{"type":"graphic_figure","displayName":"Cross section of the eye","title":"Horizontal section of the eyeball","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Horizontal section of the eyeball</div><div class=\"cntnt\"><img style=\"width:515px; height:532px;\" src=\"images/ID/59910_Cross_section_eye_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representation of a horizontal section of the eyeball reveals its three coats: (1) external or fibrous coat (sclera and cornea); (2) middle or vascular coat (choroid, ciliary body, and iris); and (3) internal or retinal layer. The four refractive media are the cornea, the aqueous humor in the anterior chamber, the lens, and the vitreous body.</div><div id=\"graphicVersion\">Graphic 59910 Version 3.0</div></div></div>"},"59911":{"type":"graphic_picture","displayName":"Hypopyon in endophthalmitis","title":"Hypopyon in endophthalmitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hypopyon in endophthalmitis</div><div class=\"cntnt\"><img style=\"width:540px; height:363px;\" src=\"images/ID/59911_Hypopyon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A postoperative eye showing endophthalmitis with conjunctival injection and&nbsp;a hypopyon, the layering of white blood cells in the anterior chamber.</div><div class=\"graphic_reference\">Reproduced with permission from the department of Ophthalmology and Vision Science, University of Toronto.</div><div id=\"graphicVersion\">Graphic 59911 Version 4.0</div></div></div>"},"59915":{"type":"graphic_waveform","displayName":"Chagas heart disease ECG","title":"Chagas' heart disease","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Chagas' heart disease</div><div class=\"cntnt\"><img style=\"width:517px; height:236px;\" src=\"images/CARD/59915_Chagas_heart_disease_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram from a patient with chronic Chagas' disease without evidence of heart failure. The 12 lead ECG shows sinus bradycardia, first degree heart block, and the typical combination of right bundle branch block and left anterior hemiblock. Poor R wave progression and abnormal Q wave in V4 suggest the presence of anterior-apical necrosis.</div><div id=\"graphicVersion\">Graphic 59915 Version 2.0</div></div></div>"},"59920":{"type":"graphic_table","displayName":"Rx protocol acute CVS","title":"Sample treatment protocol order sheet for a child having an acute attack of CVS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample treatment protocol order sheet for a child having an acute attack of CVS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">In Emergency Department and in-hospital settings, an example of a regimen would include:</td> </tr> <tr> <td>Darkened, quiet room, take vital signs every 4-6 hours</td> </tr> <tr> <td>If child is dehydrated, rehydrate with initial intravenous fluid bolus of 10 mL/kg normal 0.9% saline and repeat as clinically necessary</td> </tr> <tr> <td>Infuse 10% dextrose 0.45% (half normal) saline solution with potassium chloride as appropriate at 1.5 times maintenance rates</td> </tr> <tr> <td>Intravenous ondansetron 0.3 mg/kg/dose every 6 hours x 24 hours (maximum 20 mg per dose)</td> </tr> <tr> <td>Intravenous lorazepam 0.05 mg/kg/dose every 6 hours x 24 hours (maximum 2 mg per dose)</td> </tr> <tr> <td>If child has moderate to severe abdominal pain, intravenous ketorolac 0.5 to 1 mg/kg/dose (maximum 30 mg per dose) every 6 hours x 24 hours (avoid in renal insufficiency or prior to hydration if dehydrated)</td> </tr> <tr> <td>Admit child if &#62;5 percent dehydrated, no urine output &#62;12 hours, Na<sup>+</sup> &#60;130 mEq/L, anion gap &#62;18 mEq/L, or inability to stop emesis</td> </tr> <tr> <td>Allow oral fluid intake</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Adapted from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 59920 Version 10.0</div></div></div>"},"59921":{"type":"graphic_diagnosticimage","displayName":"RT portal paraaortic nodes","title":"Extended field radiation therapy (EFRT) for cervical or endometrial cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extended field radiation therapy (EFRT) for cervical or endometrial cancer</div><div class=\"cntnt\"><img style=\"width:407px; height:424px;\" src=\"images/OBGYN/59921_EFRT_cervical_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extended field anteroposterior (AP) radiation portal covering the para-aortic nodes.</div><div class=\"graphic_reference\">Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.</div><div id=\"graphicVersion\">Graphic 59921 Version 2.0</div></div></div>"},"59922":{"type":"graphic_picture","displayName":"Central squamous CA gross","title":"Centrally located squamous cell carcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Centrally located squamous cell carcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:319px; height:347px;\" src=\"images/PULM/59922_Central_squamous_CA_gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilobectomy specimen showing a centrally located endobronchial squamous cell carcinoma. There is associated post-obstructive bronchiectasis.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 59922 Version 1.0</div></div></div>"},"59924":{"type":"graphic_table","displayName":"Antibiotic doses for pneumococcal pneumonia in children","title":"Doses of drugs used in the treatment of <em>Streptococcus pneumoniae</em> pneumonia in children >3 months","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doses of drugs used in the treatment of <em>Streptococcus pneumoniae</em> pneumonia in children &gt;3 months</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Maximum daily dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Intravenous&nbsp;therapy</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Ampicillin*</td> <td><strong>Penicillin susceptible (MIC &#8804;2 mcg/mL):</strong><br /> 150 to 200 mg/kg per day divided in 4 doses</td> <td>6 g/day</td> </tr> <tr> <td><strong>Penicillin resistant or intermediate (MIC &#62;2 mcg/mL):</strong><br /> 300 to 400&nbsp;mg/kg per day divided in 4 doses</td> <td>12 g/day</td> </tr> <tr> <td class=\"indent1\">Cefotaxime<sup>&#182;</sup></td> <td>150 mg/kg per day divided in 3 doses</td> <td>6&nbsp;g/day</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Ceftaroline&nbsp;</td> <td> <p><strong>2 through 23 </strong><strong>months:</strong></p> <p>24 mg/kg per day divided in 3 doses</p> </td> <td rowspan=\"3\">1.2 g/day</td> </tr> <tr> <td> <p><strong>2 through 17 years:</strong></p> <ul> <li>&#8804;33 kg: 36 mg/kg per day divided in 3 doses </li> <li>&#62;33 kg:&nbsp;1.2 g&nbsp;per day divided in 2 or 3 doses </li> </ul> </td> </tr> <tr> <td> <p><strong>&#8805;18 years:</strong></p> <p>1.2 g per day divided in 2 doses</p> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Ceftriaxone<sup>&#182;</sup></td> <td><strong>Penicillin susceptible (MIC &#8804;2 mcg/mL):</strong><br /> 50 to 100 mg/kg per day divided in 1 or 2 doses</td> <td>2&nbsp;g/day</td> </tr> <tr> <td><strong>Penicillin resistant (MIC &#8805;4 mcg/mL):</strong><br /> 100 mg/kg per day divided in 1 or 2 doses</td> <td>4 g/day</td> </tr> <tr> <td class=\"indent1\">Clindamycin<sup>&#916;</sup> (if susceptible)</td> <td>40 mg/kg per day divided in 3 or 4 doses</td> <td>2.7 g/day</td> </tr> <tr> <td class=\"indent1\">Penicillin G*</td> <td>200,000 to 250,000 units/kg per day divided in 4 or 6 doses</td> <td>24 million units/day</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Levofloxacin<sup>&#916;</sup> (if susceptible)</td> <td><strong>6 months to 5 years:</strong><br /> 16 to 20 mg/kg per day divided in 2 doses</td> <td rowspan=\"2\">750 mg/day</td> </tr> <tr> <td><strong>5 to 16 years:</strong><br /> 8 to 10 mg/kg once daily</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Linezolid</td> <td><strong>&#60;12 years:</strong><br /> 30 mg/kg per day divided in 3 doses</td> <td>1.8 g/day</td> </tr> <tr> <td><strong>&#8805;12 years:</strong><br /> 20 mg/kg per day divided in 2 doses</td> <td>1.2 g/day</td> </tr> <tr> <td class=\"indent1\">Vancomycin<sup>&#916;</sup></td> <td>40 to 60 mg/kg per day divided in 3 or 4 doses<sup>&#9674;</sup></td> <td>4 g/day<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oral therapy (for mild infection or completion of a course of therapy initiated intravenously)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Amoxicillin*</td> <td>90 mg/kg per day divided in 2 doses</td> <td>4 g/day</td> </tr> <tr> <td>45 mg/kg per day divided in 3 doses</td> <td>4 g/day</td> </tr> <tr> <td class=\"indent1\">Cefpodoxime</td> <td>10 mg/kg per day divided in 2 doses</td> <td>400 mg/day</td> </tr> <tr> <td class=\"indent1\">Cefprozil</td> <td>15 to 30 mg/kg per day divided in 2 doses</td> <td>1 g/day</td> </tr> <tr> <td class=\"indent1\">Cefuroxime</td> <td>20 to 30 mg/kg per day divided in 2 doses</td> <td>1&nbsp;g/day</td> </tr> <tr> <td class=\"indent1\">Clindamycin<sup>&#916;</sup> (if susceptible)</td> <td>30 to 40 mg/kg per day divided in 3 doses</td> <td>1.8 g/day</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Levofloxacin<sup>&#182;</sup><br /> (if susceptible)</td> <td><strong>6 months to 5 years:</strong><br /> 16 to 20 mg/kg per day divided in 2 doses</td> <td rowspan=\"2\">750 mg/day</td> </tr> <tr> <td><strong>5 to 16 years:</strong><br /> 8 to 10 mg/kg once daily</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Linezolid<sup>&#182;</sup></td> <td><strong>&#60;12 years:</strong><br /> 30 mg/kg per day divided in 3 doses</td> <td>1.8 g/day</td> </tr> <tr> <td><strong>&#8805;12 years:</strong><br /> 20 mg/kg per day divided in 2 doses</td> <td>1.2 g/day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency<br />* Preferred agents for penicillin susceptible <EM>S. pneumoniae</EM>.<br />¶ Preferred agents for penicillin nonsusceptible <EM>S. pneumoniae</EM>.<br />∆ Alternative agents for children with severe allergic reactions to beta-lactam antibiotics. <br />◊ 60 mg/kg per day is recommended for children with serious infections (eg, toxic-appearing or have evidence of complications such as empyema). Adjustment of dose and frequency may be necessary based upon serum concentration monitoring. <br /></div><div class=\"graphic_reference\">Adapted from: Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.</div><div id=\"graphicVersion\">Graphic 59924 Version 13.0</div></div></div>"},"59925":{"type":"graphic_table","displayName":"Causes of FUO in older adults","title":"Causes of FUO in older adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of FUO in older adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Major causes of FUO</td> <td class=\"subtitle1\">Percent*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Infections</td> </tr> <tr> <td class=\"indent1\">Intra-abdominal abscess</td> <td>12</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Infective endocarditis</td> <td>7</td> </tr> <tr> <td class=\"indent1\">Other</td> <td>6</td> </tr> <tr> <td class=\"indent1\">Total</td> <td><strong>35</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Collagen vascular disorders</td> </tr> <tr> <td class=\"indent1\">Giant cell arteritis plus polymyalgia rheumatica</td> <td>19</td> </tr> <tr> <td class=\"indent1\">Polyarteritis nodosa</td> <td>6</td> </tr> <tr> <td class=\"indent1\">Others</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Total</td> <td><strong>28</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Lymphoma plus other hematologic disorders</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Solid tumors (usually with liver involvement)</td> <td>9</td> </tr> <tr> <td class=\"indent1\">Total</td> <td><strong>19</strong></td> </tr> <tr> <td><strong>Miscellaneous</strong> (eg, pulmonary emboli/venous thrombosis, drug fever)</td> <td><strong>8</strong></td> </tr> <tr> <td><strong>No diagnosis</strong></td> <td><strong>9</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FUO: fever of unknown origin.<br> * Data pooled from three trials of FUO in older adults (see below).</div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Knockaert, et al. Fever of unknown origin in elderly patients. J Am Geriatr Soc 1993; 41:1187. </li> <li>Expositio, et al. Fever of unknown origin in the elderly. J Am Geriatr Soc 1978; 26:498. </li> <li>Barrier, et al. Les fievres prolonguées inexpliquées chez les personnes agées. Concours Med 1982; 104:4679. </li> </ol></div><div id=\"graphicVersion\">Graphic 59925 Version 2.0</div></div></div>"},"59926":{"type":"graphic_picture","displayName":"High-resolution manometry - Vigorous achalasia","title":"High-resolution manometry - Vigorous achalasia","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">High-resolution manometry - Vigorous achalasia</div><div class=\"cntnt\"><img style=\"width:538px; height:327px;\" src=\"images/SURG/59926_High_res_mano_vigor_achal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts the high amplitude simultaneous contractions and no lower esophageal sphincter (LES) contractions of vigorous achalasia.</div><div id=\"graphicVersion\">Graphic 59926 Version 1.0</div></div></div>"},"59927":{"type":"graphic_table","displayName":"Management of premenopausal osteoporosis","title":"Management of premenopausal osteoporosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of premenopausal osteoporosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Calcium 1000 mg daily</td> </tr> <tr> <td>Vitamin D 600&nbsp;international units&nbsp;daily</td> </tr> <tr> <td>Weightbearing exercise</td> </tr> <tr> <td>Changes in habits (avoidance of smoking, excess alcohol, poor nutrition)</td> </tr> <tr> <td>Treatment of secondary causes</td> </tr> <tr> <td>Pharmacologic treatment in selected cases</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Carolyn Becker, MD and Adi Cohen, MD.</div><div id=\"graphicVersion\">Graphic 59927 Version 6.0</div></div></div>"},"59928":{"type":"graphic_picture","displayName":"Hyperacute rejection IF fibrin","title":"Renal allograft biopsy showing hyperacute rejection with fibrin by immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal allograft biopsy showing hyperacute rejection with fibrin by immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/NEPH/59928_Hyperacute_rejection_IF_Fib.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy in hyperacute rejection showing extensive fibrin deposition in a glomerulus (right) and in the vascular wall and lumen of an artery (left). The arterial lumen is markedly narrowed due to intraluminal fibrin deposition.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 59928 Version 3.0</div></div></div>"},"59931":{"type":"graphic_table","displayName":"AAP followup schedule CDH","title":"Recommended schedule of follow-up for infants with congenital diaphragmatic hernia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended schedule of follow-up for infants with congenital diaphragmatic hernia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"6\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Before discharge</td> <td class=\"subtitle1\">1 to 3 months after birth</td> <td class=\"subtitle1\">4 to 6 months after birth</td> <td class=\"subtitle1\">9 to 12 months after birth</td> <td class=\"subtitle1\">15 to 18 months after birth</td> <td class=\"subtitle1\">Annual through 16 years</td> </tr> <tr> <td><strong>Weight, length, occipital-frontal circumference</strong></td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td><strong>Chest radiograph</strong></td> <td>X</td> <td>If patched</td> <td>If patched</td> <td>If patched</td> <td>If patched</td> <td>If patched</td> </tr> <tr> <td><strong>Pulmonary function testing</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>If indicated</td> <td>&nbsp;</td> <td>If indicated</td> <td>If indicated</td> </tr> <tr> <td><strong>Childhood immunizations</strong></td> <td>As indicated throughout childhood</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td><strong>RSV prophylaxis</strong></td> <td>RSV season during first two years after birth (if evidence of chronic lung disease)</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td><strong>Echocardiogram and cardiology follow-up</strong></td> <td>X</td> <td>If previously abnormal or if on supplemental oxygen</td> <td>If previously abnormal or if on supplemental oxygen</td> <td>If previously abnormal or if on supplemental oxygen</td> <td>If previously abnormal or if on supplemental oxygen</td> <td>If previously abnormal or if on supplemental oxygen</td> </tr> <tr> <td><strong>Head computed tomography or MRI</strong></td> <td>If (1) abnormal finding on head ultrasound; (2) seizures/abnormal neurologic findings*; or (3) ECMO or patch repair</td> <td>As indicated</td> <td>As indicated</td> <td>As indicated</td> <td>As indicated</td> <td>As indicated</td> </tr> <tr> <td><strong>Hearing evaluation</strong></td> <td>Auditory brainstem evoked response or otoacoustic emissions screen</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>Every six months to age three years, then annually to age five years</td> </tr> <tr> <td><strong>Developmental screening evaluation</strong></td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>Annually to age five years</td> </tr> <tr> <td><strong>Neurodevelopmental evaluation</strong></td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>Annually to age five years</td> </tr> <tr> <td><strong>Assessment for oral feeding problems</strong></td> <td>X</td> <td>X</td> <td>If oral feeding problems</td> <td>If oral feeding problems</td> <td>If oral feeding problems</td> <td>If oral feeding problems</td> </tr> <tr> <td><strong>Upper gastrointestinal study, pH probe, and/or gastric scintiscan</strong></td> <td>Consider for all patients</td> <td>If symptoms</td> <td>If symptoms</td> <td>Consider for all patients</td> <td>If symptoms</td> <td>If symptoms</td> </tr> <tr> <td><strong>Esophagoscopy</strong></td> <td>&nbsp;</td> <td>If symptoms</td> <td>If symptoms</td> <td>If symptoms or if abnormal gastrointestinal evaluations</td> <td>If symptoms</td> <td>If symptoms</td> </tr> <tr> <td><strong>Scoliosis and chest wall deformity screening (physical examination, chest radiograph, and/or computed tomography of the chest)</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>X</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The neurosensory tests performed and frequency of surveillance may differ among infants with CDH because of variability in neurologic, developmental, and physiologic impairments. Follow-up should be tailored to each infant.</div><div class=\"graphic_footnotes\">RSV: respiratory syncytial virus; ECMO: extracorporeal membrane oxygenation.<br />* Muscle weakness, hypotonia, hypertonia, or other abnormal neurologic sign or symptom.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol 121, Pages 627-32, Copyright © 2008 by the AAP.</div><div id=\"graphicVersion\">Graphic 59931 Version 17.0</div></div></div>"},"59933":{"type":"graphic_figure","displayName":"Major deflections on ECG","title":"Formation of the major deflections on the ECG","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Formation of the major deflections on the ECG</div><div class=\"cntnt\"><img style=\"width:498px; height:472px;\" src=\"images/CARD/59933_Major_deflections_on_ECG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The electrical impulse is initiated in the sinus node and then activates the right and left atria, generating the P wave. Impulse conduction through the atrioventricular (AV) node and bundle of His, which are small structures, does not generate any ECG activity; this period of \"electrical silence\" is the PR interval. The first part of the ventricle to be depolarized is the left side of the interventricular septum, producing a small septal Q wave, followed by depolarization of the remainder of the ventricular myocardium, generating the full QRS complex. The T wave represents ventricular repolarization. A U wave may be present, representing repolarization of the His Purkinje system.</div><div id=\"graphicVersion\">Graphic 59933 Version 2.0</div></div></div>"},"59934":{"type":"graphic_picture","displayName":"Antimicrobial gradient method","title":"Antimicrobial gradient method","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Antimicrobial gradient method</div><div class=\"cntnt\"><img style=\"width:323px; height:318px;\" src=\"images/ID/59934_E-test_MIC_determination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A commercially prepared strip containing a graded concentration of a specific antimicrobial is placed on a lawn of a standardized inoculum of bacteria. After incubation, the minimum inhibitory concentration is determined by identifying the intersection of the elliptical zone of growth inhibition with the strip.</div><div class=\"graphic_reference\">Courtesy of Mary Jane Ferraro, PhD, MPH.</div><div id=\"graphicVersion\">Graphic 59934 Version 4.0</div></div></div>"},"59935":{"type":"graphic_diagnosticimage","displayName":"Ictal SPECT scan","title":"Ictal spect hyperperfusion","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Ictal spect hyperperfusion</div><div class=\"cntnt\"><img style=\"width:453px; height:241px;\" src=\"images/NEURO/59935_Ictal_SPECT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ictal SPECT scan showing hyperperfusion at a likely seizure focus in the left temporal region (see boxed area).</div><div class=\"graphic_footnotes\">SPECT: single-photon emission computed tomography.</div><div class=\"graphic_reference\">Figure courtesy of Hiba Arif, MD and Lawrence J Hirsch, MD.</div><div id=\"graphicVersion\">Graphic 59935 Version 5.0</div></div></div>"},"59936":{"type":"graphic_table","displayName":"VNS settings","title":"Vagus nerve stimulator: adjustable parameters and initial settings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vagus nerve stimulator: adjustable parameters and initial settings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Initial settings</td> <td class=\"subtitle1\">Adjusted settings</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>On time</td> <td>30 seconds</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Off time</td> <td>5 minutes</td> <td>5, 3, 1.8, 1.1 minutes</td> <td>Decreasing off time, (increasing the duty cycle) may improve efficacy, but may decrease tolerability and battery life</td> </tr> <tr> <td>Output current</td> <td>0.25 mA</td> <td>0.25 mA to 3.5 mA</td> <td>Increased current may improve efficacy, but may decrease tolerability</td> </tr> <tr> <td>Frequency</td> <td>30 Hz</td> <td>20 to 30 Hz</td> <td>Decreasing frequency may improve tolerability without affecting efficacy</td> </tr> <tr> <td>Pulse width</td> <td>500 microseconds</td> <td>250, 500 microseconds</td> <td>Decreasing pulse width may improve tolerability without affecting efficacy</td> </tr> <tr> <td>Magnet current</td> <td>0.5 mA</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Magnet duration</td> <td>60 seconds</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Magnet pulse width</td> <td>500 microseconds</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59936 Version 2.0</div></div></div>"},"59937":{"type":"graphic_picture","displayName":"Early congenital cholesteatoma","title":"Early congenital cholesteatoma","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Early congenital cholesteatoma</div><div class=\"cntnt\"><img style=\"width:501px; height:249px;\" src=\"images/ALLRG/59937_Earlycholesteatoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Early in the course, the cholesteatoma is hard to appreciate. It may appear as a subtle whitish discoloration behind a normal tympanic membrane. As the lesion grows, it makes contact with the underside of the tympanic membrane and becomes more obvious.<br />(B) The eardrum is reflected downward to reveal a white spherical lesion.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 120, Pages 603-8, Copyright © 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 59937 Version 19.0</div></div></div>"},"59938":{"type":"graphic_diagnosticimage","displayName":"VCUG PUV dilated post ureth","title":"Voiding cystourethrogram of a patient with posterior urethral valves","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Voiding cystourethrogram of a patient with posterior urethral valves</div><div class=\"cntnt\"><img style=\"width:288px; height:321px;\" src=\"images/PEDS/59938_VCUG_PUV_dilated_post_ureth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Voiding cystourethrogram of patient with posterior urethral valves noted by arrows with dilated posterior urethra. Small capacity bladder with vesicoureteral reflux (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Nicholas Holmes, MD.</div><div id=\"graphicVersion\">Graphic 59938 Version 5.0</div></div></div>"},"59939":{"type":"graphic_figure","displayName":"Audiogram conductive loss","title":"Audiogram conductive loss","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Audiogram conductive loss</div><div class=\"cntnt\"><img style=\"width:560px; height:741px;\" src=\"images/PC/59939_Audiogram_conductive_loss.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59939 Version 1.0</div></div></div>"},"59940":{"type":"graphic_table","displayName":"Knee anterior pain ddx","title":"Differential diagnosis of anterior knee pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of anterior knee pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Bone</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Patellofemoral osteoarthritis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Bone tumors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>OsGood Schlatter's disease</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Sinding Larsen Johansson syndrome</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Symptomatic bipartite patella</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Osteochondritis dissecans</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Synovium</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Pigmented villonodular synovitis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Plica</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Retinaculum</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Patellar instability</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Skin/bursa</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Prepatellar bursitis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Pes anserine bursitis </td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Illiotibial band syndrome</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hoffa's disease</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Nerve</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Saphenous neuritis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Neuroma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Muscle/tendon</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Quadriceps tendinopathy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Patellar tendinopathy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Referred pain</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\">Lumbar spine</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Discogenic disease</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\">Hip</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Slipped capital femoral epiphysis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Legg calve perthes disease</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 59940 Version 1.0</div></div></div>"},"59943":{"type":"graphic_table","displayName":"Differential diagnosis of postoperative delirium","title":"Differential diagnosis of postoperative delirium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of postoperative delirium</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td>Myocardial ischemia or infarction</td> </tr> <tr> <td>Arrhythmias</td> </tr> <tr> <td>Hypertension</td> </tr> <tr> <td>Hypotension</td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td>Amantadine</td> </tr> <tr> <td>Amoxapine</td> </tr> <tr> <td>Anticholinergics</td> </tr> <tr> <td>Antidepressants</td> </tr> <tr> <td>Antipsychotics</td> </tr> <tr> <td>Benzodiazepines</td> </tr> <tr> <td>Beta-blockers</td> </tr> <tr> <td>Cimetidine</td> </tr> <tr> <td>Corticosteroids</td> </tr> <tr> <td>Digoxin</td> </tr> <tr> <td>Insulin</td> </tr> <tr> <td>Narcotic analgesics</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine</td> </tr> <tr> <td>Thyrotoxicosis</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td>Adrenalcortical dysfunction</td> </tr> <tr> <td>Hypoglycemia</td> </tr> <tr> <td>Diabetic ketoacidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td>Septicemia</td> </tr> <tr> <td>Meningitis</td> </tr> <tr> <td>Encephalitis</td> </tr> <tr> <td>Pneumonia</td> </tr> <tr> <td>Urinary tract</td> </tr> <tr> <td>Wound</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td>Hyponatremia</td> </tr> <tr> <td>Hypomagnesemia</td> </tr> <tr> <td>Hypercalcemia</td> </tr> <tr> <td>Acid-base disorders</td> </tr> <tr> <td>Renal failure</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td>Subdural hematoma</td> </tr> <tr> <td>Subarachnoid hemorrhage</td> </tr> <tr> <td>Intracranial bleeding</td> </tr> <tr> <td>Cerebrovascular accident</td> </tr> <tr> <td>Seizure</td> </tr> <tr> <td class=\"subtitle1_single\">Oncologic</td> </tr> <tr> <td>Neoplasm</td> </tr> <tr> <td>Paraneoplastic syndromes</td> </tr> <tr> <td class=\"subtitle1_single\">Psychiatric</td> </tr> <tr> <td>Pain</td> </tr> <tr> <td>Sensory deprivation or overload</td> </tr> <tr> <td>Depression</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary</td> </tr> <tr> <td>Hypoxia</td> </tr> <tr> <td>Hypercapnia</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Chang PH, Steinberg MB. Alcohol withdrawal. Med Clin North Am 2001; 85:1191. Copyright © 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 59943 Version 2.0</div></div></div>"},"59944":{"type":"graphic_figure","displayName":"Lipids and premature CHD","title":"Lipoproteins and premature coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lipoproteins and premature coronary heart disease</div><div class=\"cntnt\"><img style=\"width:350px; height:250px;\" src=\"images/CARD/59944_Lipids_and_premature_CHD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of different lipid abnormalities in men with premature coronary disease (&lt;60 years of age). Patients with more than one disturbance (eg, low HDL plus hypertriglyceridemia) are noted in the combined group. Only 12.5 percent of subjects were normal in this study versus 58.5 percent of age-matched controls without coronary disease.</div><div class=\"graphic_reference\">Data from Genest JJ, McNamara JR, Ordovas JM, et al. J Am Coll Cardiol 1992; 19:792.</div><div id=\"graphicVersion\">Graphic 59944 Version 4.0</div></div></div>"},"59947":{"type":"graphic_picture","displayName":"Oral candidiasis in a patient with CMCC","title":"Oral candidiasis (thrush) in a patient with chronic mucocutaneous candidiasis (CMCC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral candidiasis (thrush) in a patient with chronic mucocutaneous candidiasis (CMCC)</div><div class=\"cntnt\"><img style=\"width:298px; height:215px;\" src=\"images/ALLRG/59947_Oral_onychomycosis_in_a_patient_with_CMCC.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59947 Version 1.0</div></div></div>"},"59949":{"type":"graphic_table","displayName":"Treatment of Lyme disease","title":"Treatment of Lyme disease*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of Lyme disease*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Adult dosage</td> <td class=\"subtitle1\">Pediatric dosage</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Erythema migrans (early disease)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">&nbsp;</td> <td>Doxycycline<sup>&#916;</sup><sup>&#9674;</sup></td> <td>100 mg PO bid x 10 to 21 d</td> <td>&#8805;8 years: 2 mg/kg PO bid (maximum 100 mg per dose) x 10 to 21 d</td> </tr> <tr> <td><strong>or</strong> Amoxicillin</td> <td>500 mg PO tid x 14 to 21 d</td> <td>50 mg/kg/day divided tid PO (maximum 500 mg per dose) x 14 to 21 d</td> </tr> <tr class=\"divider_bottom\"> <td><strong>or</strong> Cefuroxime axetil</td> <td>500 mg PO bid x 14 to 21 d</td> <td>30 mg/kg/day divided bid PO (maximum 500 mg per dose) x 14 to 21 d</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Neurologic disease</td> </tr> <tr> <td class=\"indent1\">Isolated facial nerve palsy (early disseminated disease)</td> <td>Doxycycline<sup>&#916;</sup><sup>&#167;</sup></td> <td>100 mg PO bid x 14 to 28 d</td> <td>&#8805;8 years: 2 mg/kg PO bid (maximum 100 mg per dose) x 14 to 28 d</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">More serious disease<sup>&#165;</sup> (eg, meningitis, radiculopathy, encephalitis) (early or late disseminated disease)</td> <td>Ceftriaxone<sup>&#135;</sup><sup>&#134;</sup></td> <td>2 g IV once daily x 28 d (range 10 to 28 days)</td> <td>50-75 mg/kg IV once daily (maximum 2 g per dose) x 28 d (range 10 to 28 days)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Carditis**</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Mild (first-degree atrioventricular block with PR interval &#60;300 milliseconds)</td> <td>Doxycycline<sup>&#916;</sup></td> <td>100 mg PO bid x 21 d (range 14 to 21 days)</td> <td>&#8805;8 years: 2 mg/kg PO bid (maximum 100 mg per dose) x 21 d (range 14 to 21 days)</td> </tr> <tr> <td><strong>or</strong> Amoxicillin</td> <td>500 mg PO tid x 21 d (range 14 to 21 days)</td> <td>50 mg/kg/day divided tid PO (maximum 500 mg per dose) x 21 d (range 14 to 21 days)</td> </tr> <tr> <td><strong>or</strong> Cefuroxime axetil</td> <td>500 mg PO bid x 21 d (range 14 to 21 days)</td> <td>30 mg/kg/day divided bid PO (maximum 500 mg per dose) x 21 d (range 14 to 21 days)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">More serious disease (symptomatic, second- or third-degree atrioventricular block, first-degree atrioventricular block with PR interval &#62;/=300 milliseconds)<sup>&#182;&#182;</sup></td> <td>Ceftriaxone<sup>&#135;</sup>**</td> <td>2 g once/day IV x 21 to 28 d</td> <td>50-75 mg/kg once/day IV (maximum 2 g per dose) x 21 to 28 d</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Arthritis<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Arthritis without neurologic disease</td> <td>Doxycycline<sup>&#916;</sup></td> <td>100 mg PO bid x 28 d</td> <td>&#8805;8 years: 2 mg/kg PO bid (maximum 100 mg per dose) x 28 d</td> </tr> <tr> <td><strong>or</strong> Amoxicillin<sup>&#916;&#916;</sup></td> <td>500 mg PO tid x 28 d</td> <td>50 mg/kg/day divided tid PO (maximum 500 mg per dose) x 28 d</td> </tr> <tr> <td class=\"indent1\">Arthritis with neurologic disease</td> <td>Ceftriaxone<sup>&#135;</sup></td> <td>2 g IV once/day x 28 d</td> <td>50-75 mg/kg once/day IV (maximum 2 g per dose) x 28 d</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Recurrent arthritis (despite adequate prior oral therapy)</td> <td>Ceftriaxone<sup>&#135;</sup></td> <td>2 g IV once/day x 14 to 28 d</td> <td>50-75 mg/kg once/day IV (maximum 2 g per dose) x 14 to 28 d</td> </tr> <tr> <td><strong>or</strong> Doxycycline<sup>&#916;</sup></td> <td>100 mg PO bid x 28 d</td> <td>&#8805;8 years: 2 mg/kg PO bid (maximum 100 mg per dose) x 28 d</td> </tr> <tr class=\"divider_bottom\"> <td><strong>or</strong> Amoxicillin<sup>&#916;&#916;</sup></td> <td>500 mg PO tid x 28 d</td> <td>50 mg/kg/day divided tid PO (maximum 500 mg per dose) x 28 d</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Acrodermatitis chronica atrophicans</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">&nbsp;</td> <td>Doxycycline<sup>&#916;</sup></td> <td>100 mg PO bid x 21 d</td> <td>&#8805;8 years: 2 mg/kg PO bid (maximum 100 mg per dose) x 21 d</td> </tr> <tr> <td><strong>or</strong> Amoxicillin</td> <td>500 mg PO tid x 21 d</td> <td>50 mg/kg/day divided tid PO (maximum 500 mg per dose) x 21 d</td> </tr> <tr> <td><strong>or</strong> Cefuroxime</td> <td>500 mg PO bid x 21 d</td> <td>30 mg/kg/day divided bid PO (maximum 500 mg per dose) x 21 d</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">bid: twice daily; tid: three times daily; PO: oral; IV: intravenous.<br />* Regardless of the clinical manifestation of Lyme disease, complete response to treatment may be delayed beyond the treatment duration. Relapse has occurred with all of these regimens; patients with objective signs of relapse may need a second course of treatment.<br />&para; Alternative but less effective therapy for patients unable to tolerate preferred regimens, azithromycin in adults: 500 mg once daily, in children: 10 mg/kg per day x 7-10 days or clarithromycin in adults: 500 mg twice daily, in children: 7.5 mg/kg twice per day x 14-21 days, or erythromycin in adults: 500 mg four times daily, in children: 12.5 mg/kg four times daily x 14-21 days.<br />&Delta; Should not be used for children younger than eight years old or for pregnant or lactating women.<br /><span class=\"lozenge\">&loz;</span> Doxycycline also has activity against Anaplasma phagocytophilum and Bartonella henselae (which causes cat scratch disease) but not against Babesia microti.<br />&sect; Amoxicillin or cefuroxime are alternatives in patients with contraindications to doxycycline.<br />&yen; In late disease, the response to treatment may be delayed for several weeks or months.<br />&Dagger; Or cefotaxime 2 g IV q 8 hours x 14-28 days for adults and 150-200 mg/kg/day in 3 divided doses (maximum 6 g per day) for children or penicillin G 18 to 24 million U per day divided into doses given every 4 hours in adults and 200,000 to 400,000 U/kg per day divided every 4 hours (maximum 18-24 million U per day) in children.<br />&dagger; In nonpregnant adult patients intolerant of beta-lactam antibiotics, doxycycline 200 to 400 mg per day orally or intravenously in two divided doses. In children &ge;8 years of age, doxycycline 4 to 8 mg/kg per day in two divided doses to a maximum daily dosage of 200 to 400 mg.<br />** A parenteral antibiotic regimen is recommended for initiation of treatment for hospitalized patients. IV antibiotics should be continued until high-grade AV block has resolved and the PR interval has become less than 300 milliseconds. The patient may then be switched to oral therapy to complete a 21 to 28 day course.<br />&para;&para; A temporary pacemaker may be necessary.<br />&Delta;&Delta; Cefuroxime may be used as an alternative in patients with contraindications to doxycycline and amoxicillin, although it has not been assessed in clinical studies for this indication.</div><div class=\"graphic_reference\">Adapted with permission from: Wormser GP, Dattwyler RJ, Shapiro ED, et al. The Clinical Assessment, Treatment, and Prevention of Lyme disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.</div><div id=\"graphicVersion\">Graphic 59949 Version 7.0</div></div></div>"},"59950":{"type":"graphic_diagnosticimage","displayName":"Chronic hydronephrosis","title":"Chronic hydronephrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic hydronephrosis</div><div class=\"cntnt\"><img style=\"width:396px; height:381px;\" src=\"images/NEPH/59950_Chronic_hydronephrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal sonogram of the right kidney showing calyces (C) that extend almost to the renal capsule (arrows), indicating severe thinning of the parencyma.</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 59950 Version 2.0</div></div></div>"},"59951":{"type":"graphic_picture","displayName":"Low grade muc cys neo","title":"Histologic appearance of mucinous cystic neoplasm, low grade","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of mucinous cystic neoplasm, low grade</div><div class=\"cntnt\"><img style=\"width:432px; height:274px;\" src=\"images/ONC/59951_Low_grade_muc_cys_neo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-grade mucinous cystic neoplasm of the pancreas The cellular (ovarian) stroma lies immediately below the mucinous epithelium lining the cyst, and a dense collagenous capsule is visible at the bottom of the field. Hematoxylin and eosin-stained section.</div><div class=\"graphic_reference\">Courtesy of Daniel S Longnecker, MD.</div><div id=\"graphicVersion\">Graphic 59951 Version 3.0</div></div></div>"},"59954":{"type":"graphic_algorithm","displayName":"Evaluation for hyperandrogenism risk factors","title":"Initial evaluation for the presence of hyperandrogenism","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Initial evaluation for the presence of hyperandrogenism</div><div class=\"cntnt\"><img style=\"width:571px; height:689px;\" src=\"images/PEDS/59954_Evalhyperandrrisks.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Suggested algorithm for the initial evaluation of young women for hyperandrogenism, based on The Endocrine Society clinical practice guidelines for the evaluation of hirsutism. Risk assessment includes more than the degree of hirsutism. Focal hirsutism that is not accompanied by hyperandrogenism risk factors does not require an endocrine workup. If hirsutism is of an abnormal degree (Ferriman-Gallwey score &ge;8 in the general US population) or if a risk factor assessment suggests an underlying disorder, elevated androgen levels should be ruled out. Disorders to be considered, as shown, include neoplasm and various endocrinopathies, of which PCOS is the most common; if an abdominal or pelvic mass is palpable, a prompt screening ultrasound is advisable. Drugs that cause hirsutism include anabolic or androgenic steroids (consider in athletes), most of which are not detected by testosterone assays, and valproic acid (consider in neurologic disorders), which elevates serum testosterone. Serum testosterone is best assessed by an analytically specific method, such as mass spectrometry, preferably in the early morning. Females with mild hirsutism (score 8 to 15 in the general US population), normal total testosterone level, and no risk factors probably have idiopathic hirsutism, which may be responsive to oral contraceptive therapy. The calculated free testosterone level is the most clinically sensitive marker of androgen excess and should be assayed in a reference laboratory if the total testosterone is normal in the presence of risk factors or if signs or symptoms progress on therapy. Simultaneous assay of 17-hydroxyprogesterone may be indicated in subjects at risk for congenital adrenal hyperplasia, eg, Ashkenazi Jews.</div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome; SHBG: sex hormone binding globulin.<br />* The free testosterone level in blood is ordinarily calculated as the product of the total testosterone level and the percent free testosterone, which may be computed from the SHBG level. Norms are standardized for early morning in the early follicular phase (days 4 to 10) of the menstrual cycle.<br />&para; Progression of hyperandrogenism in the presence of a normal serum free testosterone is very unusual. Such patients should be thoroughly re-evaluated.</div><div class=\"graphic_reference\">Adapted and expanded from: Martin KA, Change J, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.</div><div id=\"graphicVersion\">Graphic 59954 Version 8.0</div></div></div>"},"59955":{"type":"graphic_picture","displayName":"Female condom PI","title":"Female condom","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female condom</div><div class=\"cntnt\"><img style=\"width:432px; height:201px;\" src=\"images/PI/59955_Female_condom_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One of the rings of the female condom rests inside the woman's vagina. The other ring, which is open, rests outside.</div><div id=\"graphicVersion\">Graphic 59955 Version 4.0</div></div></div>"},"59956":{"type":"graphic_picture","displayName":"Lateral canthal rhytides","title":"Lateral canthal rhytides","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Lateral canthal rhytides</div><div class=\"cntnt\"><img style=\"width:505px; height:335px;\" src=\"images/DERM/59956_Lat_canthal_rhytides_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple wrinkles are present lateral to the eye (left). The wrinkles are more prominent during smiling (right).</div><div id=\"graphicVersion\">Graphic 59956 Version 2.0</div></div></div>"},"59957":{"type":"graphic_figure","displayName":"Kidney transplant PI","title":"Kidney transplant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kidney transplant</div><div class=\"cntnt\"><img style=\"width:363px; height:389px;\" src=\"images/PI/59957_Kidney_transpl_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a person who has had a kidney transplant. The new kidney is put in the lower part of the belly.&nbsp;The kidney's&nbsp;ureter (the tube that carries urine from the kidney to the bladder) is connected to the person's bladder. In many cases, the diseased kidneys are left in place.</div><div class=\"graphic_reference\">Reproduced from: Treatment Methods for Kidney Failure: Transplantation. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Additional information available at: <A spellcheck=true href=\"https://www.niddk.nih.gov/health-information/health-topics/kidney-disease/treatment-methods-for-kidney-failure-transplantation/Pages/facts.aspx\"target=_blank>https://www.niddk.nih.gov/health-information/health-topics/kidney-disease/treatment-methods-for-kidney-failure-transplantation/Pages/facts.aspx</A> (Accessed on August 3, 2016).</div><div id=\"graphicVersion\">Graphic 59957 Version 3.0</div></div></div>"},"59958":{"type":"graphic_diagnosticimage","displayName":"Retained sponge of the breast on ultrasound","title":"Retained sponge of the breast on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Retained sponge of the breast on ultrasound</div><div class=\"cntnt\"><img style=\"width:576px; height:439px;\" src=\"images/SURG/59958_Retained_sponge_breast_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast sonogram shows hypoechoic mass with linear echogenic foci (arrows).</div><div class=\"graphic_reference\">From: Manzella A, Filho PB, Albuquerque E, et al. Imaging of gossypibomas: pictorial review. AJR Am J Roentgenol 2009; 193:S94. Reprinted with permission from the American Journal of Roentgenology. Copyright © 2009 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 59958 Version 9.0</div></div></div>"},"59959":{"type":"graphic_picture","displayName":"Chronic irritant contact dermatitis 2","title":"Chronic irritant contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Chronic irritant contact dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/59959_chronirrconderm2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema, fissuring, and scaling resulting from repeated exposure to irritants.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59959 Version 5.0</div></div></div>"},"59963":{"type":"graphic_table","displayName":"Yin Yang symptoms","title":"Yin/Yang symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Yin/Yang symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Yin</td> <td class=\"subtitle1\">Yang</td> </tr> <tr> <td>Fatigue, drowsiness</td> <td>Restless, throws off covers</td> </tr> <tr> <td>Facial pallor</td> <td>Flushed complexion</td> </tr> <tr> <td>Desires heat</td> <td>Likes cold</td> </tr> <tr> <td>Diarrhea/watery stools</td> <td>Constipation</td> </tr> <tr> <td>Likes quiet, no desire to talk</td> <td>Noisy, loudmouthed</td> </tr> <tr> <td>Copious clear urine</td> <td>Dark, scanty urine</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59963 Version 2.0</div></div></div>"},"59964":{"type":"graphic_figure","displayName":"MID CABG incisions","title":"Surgical incisions used for minimally invasive CABG","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgical incisions used for minimally invasive CABG</div><div class=\"cntnt\"><img style=\"width:343px; height:327px;\" src=\"images/CARD/59964_MID_CABG_incisions_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conventional CABG uses a long median sternotomy incision (A), while the incisions for minimally invasive CABG are small (5 to 7 cm) and include transternal (B), right parasternal (C) extending over the fourth and fifth costal cartilages, left parasternal (D) extending over the third and fourth costal cartilages, and limited thoracotomy (E).</div><div class=\"graphic_reference\">Adapted from: Stanbridge RD, Hadjinikolaou LK, Cohen AS, et al. Ann Thorc Surg 1997; 65 (6 Suppl):S53.</div><div id=\"graphicVersion\">Graphic 59964 Version 6.0</div></div></div>"},"59965":{"type":"graphic_table","displayName":"Causes of alveolar proteinosis","title":"Causes of alveolar proteinosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of alveolar proteinosis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Pulmonary alveolar proteinosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute silicosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Aluminum dust</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Titanium exposure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Infections\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Viral\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Bacterial (eg, Nocardia)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Mycobacterial\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Fungal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Pneumocystis jirovecii pneumonia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Leukemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Following allogeneic bone marrow transplantation</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 59965 Version 1.0</div></div></div>"},"59966":{"type":"graphic_diagnosticimage","displayName":"Pleural lymphoma I CT","title":"Lymphoblastic lymphoma with pleural involvement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoblastic lymphoma with pleural involvement</div><div class=\"cntnt\"><img style=\"width:360px; height:285px;\" src=\"images/PULM/59966_Pleural_lymphoma_I_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows extensive right sided pleural involvement with circumferential nodular thickening of the parietal and the diaphragmatic pleura.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 59966 Version 4.0</div></div></div>"},"59967":{"type":"graphic_table","displayName":"Pediatric headache examination","title":"Important aspects of the examination of a child with headache","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the examination of a child with headache</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Examination feature</td> <td class=\"subtitle1\">Possible significance</td> </tr> <tr> <td>General appearance</td> <td>Altered mental status may indicate meningitis, encephalitis, intracranial hemorrhage, elevated intracranial pressure, hypertensive encephalopathy.</td> </tr> <tr> <td>Vital signs</td> <td> <ul> <li>Hypertension may cause headache or be a response to increased intracranial pressure </li> <li>Fever suggests infection (most commonly upper respiratory infection) but may occur with intracranial hemorrhage or central nervous system malignancy </li> </ul> </td> </tr> <tr> <td>Head circumference</td> <td>Macrocephaly may indicate slowly progressive increases in intracranial pressure.</td> </tr> <tr> <td>Height and weight trajectories</td> <td>Abnormal or altered trajectories may indicate intracranial pathology.</td> </tr> <tr> <td>Auscultation of the neck, eyes, and head for bruit</td> <td>Bruit may indicate arteriovenous malformation.</td> </tr> <tr> <td>Palpation of the head and neck</td> <td> <ul> <li>Localized scalp tenderness may occur in migraine and tension-type headaches </li> <li>Scalp swelling may indicate head trauma </li> <li>Sinus tenderness may indicate sinusitis </li> <li>Temporomandibular joint (TMJ) and/or masseter tenderness suggests TMJ dysfunction </li> <li>Nuchal rigidity may indicate meningitis </li> <li>Posterior neck pain may indicate an anatomic abnormality (eg, Chiari malformation) </li> <li>Thyromegaly may indicate thyroid dysfunction </li> </ul> </td> </tr> <tr> <td>Visual fields</td> <td>Visual field abnormalities may indicate increased intracranial pressure and/or a space-occupying lesion.</td> </tr> <tr> <td>Funduscopy</td> <td> <ul> <li>Papilledema may indicate increased intracranial pressure </li> <li><span style=\"color: black;\">Funduscopic examination is normal in primary headache</span> </li> </ul> </td> </tr> <tr> <td>Otoscopy</td> <td>May demonstrate otitis media; hemotympanum may indicate trauma.</td> </tr> <tr> <td>Oropharynx</td> <td>Signs of pharyngitis? Dental decay or abscess?</td> </tr> <tr> <td>Neurologic examination (see text for details)</td> <td>Abnormal neurologic examination (particularly mental status, eye movements, papilledema, asymmetry, coordination disturbance, abnormal deep tendon reflexes) may indicate intracranial pathology but also may occur with migraine headache.</td> </tr> <tr> <td>Skin examination</td> <td>Signs of neurocutaneous disorders (eg, neurofibromatosis, tuberous sclerosis complex, which are associated with intracranial neoplasms) or trauma (bruises, abrasions, etc).</td> </tr> <tr> <td>Spine</td> <td>Signs of occult spinal dysraphism (eg, midline vascular of pigment changes), which may be associated with structural abnormalities (eg, Chiari malformation).</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Great Ormond Street Hospital for Children Clinical Guideline. Headache. www.gosh.nhs.uk/clinical_information/clinical_guidelines/cmg_guideline_00045. Accessed on March 29, 2011. </li>&#xD;&#xA;    <li>Lewis DW, Koch T. Headache evaluation in children and adolescents: When to worry? When to scan? Pediatr Ann 2010; 39:399. </li>&#xD;&#xA;    <li>Newton RW. Childhood headache. Arch Dis Child Educ Pract Ed 2008; 93:105. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 59967 Version 8.0</div></div></div>"},"59968":{"type":"graphic_figure","displayName":"Liver microcirculation","title":"Microcirculation of the liver","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Microcirculation of the liver</div><div class=\"cntnt\"><img style=\"width:514px; height:558px;\" src=\"images/GAST/59968_Liver_microcirculation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram depicting the hepatic acinus and lobule. The &quot;lobule&quot; model considers the terminal hepatic venules to be the center of the hepatic microcirculation while the &quot;acinar&quot; model (also known as the Rappaport classification) considers it to represent the periphery.</div><div id=\"graphicVersion\">Graphic 59968 Version 2.0</div></div></div>"},"59969":{"type":"graphic_picture","displayName":"FSGS IF","title":"IgM in focal glomerulosclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">IgM in focal glomerulosclerosis</div><div class=\"cntnt\"><img style=\"width:394px; height:255px;\" src=\"images/NEPH/59969_FGS_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy in focal segmental glomerulosclerosis is usually negative, except for probably nonspecific deposition of IgM in sclerotic area at the bottom of the glomerulus.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 59969 Version 2.0</div></div></div>"},"59970":{"type":"graphic_picture","displayName":"Preeclampsia electron micrograph","title":"Preeclampsia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Preeclampsia</div><div class=\"cntnt\"><img style=\"width:429px; height:275px;\" src=\"images/NEPH/59970_Preeclampsia_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in preeclampsia showing narrowing of the capillary lumen due to expansion of the mesangium, swelling of the endothelial (Endo) cell cytoplasm (arrow), and subendothelial deposition of hyaline (Hy) material which represents large macromolecules such as immunoglobulin M. The damaged endothelial cell has become partially separated (*) from the glomerular basement membrane (GBM).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 59970 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"59974":{"type":"graphic_diagnosticimage","displayName":"PA pseudoaneurysm CT","title":"Right middle lobe pulmonary artery pseudoaneurysm","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Right middle lobe pulmonary artery pseudoaneurysm</div><div class=\"cntnt\"><img style=\"width:485px; height:466px;\" src=\"images/PULM/59974_PA_pseudoaneurysm_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomographic scan obtained in a patient who developed hemoptysis following pulmonary artery catheterization. Arrow indicates area of PA pseudoaneurysm; arrowhead shows halo of associated hemorrhage. Right middle lobectomy was required to control hemoptysis.</div><div class=\"graphic_reference\">Courtesy of Jess Mandel, MD.</div><div id=\"graphicVersion\">Graphic 59974 Version 3.0</div></div></div>"},"59975":{"type":"graphic_figure","displayName":"Proarrhythmia with class Ic antiarrhythmic drugs in CAST","title":"Encainide and flecainide increase cardiac mortality","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Encainide and flecainide increase cardiac mortality</div><div class=\"cntnt\"><img style=\"width:520px; height:238px;\" src=\"images/CARD/59975_Proarrhythmia_in_CAST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of the Cardiac Arrhythmia Suppression Trial (CAST) in patients with ventricular premature beats after myocardial infarction. Patients receiving encainide or flecainide had, when compared to those receiving placebo, a significantly lower rate of avoiding a cardiac event (death or resuscitated cardiac arrest) (left panel, p = 0.001) and a lower overall survival (right panel, p = 0.0006). The cause of death was arrhythmia or cardiac arrest.</div><div class=\"graphic_reference\">Data from Echt DS, Liebson PR, Mitchell B, et al. N Engl J Med 1991; 324:781.</div><div id=\"graphicVersion\">Graphic 59975 Version 3.0</div></div></div>"},"59976":{"type":"graphic_figure","displayName":"Anatomy of the biceps brachii muscle","title":"Anatomy of the biceps brachii muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the biceps brachii muscle</div><div class=\"cntnt\"><img style=\"width:428px; height:566px;\" src=\"images/EM/59976_Biceps_tendon_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 59976 Version 3.0</div></div></div>"},"59977":{"type":"graphic_table","displayName":"Complication fetal ovarian cyst","title":"Complications from fetal/neonatal ovarian cysts reported in case reports","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications from fetal/neonatal ovarian cysts reported in case reports</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Torsion with potential loss of ovarian tissue and impaired fertility</td>\n   </tr>\n   <tr>\n   <td>Hemorrhage within the cyst or peritoneum, sometimes leading to hemorrhagic shock</td>\n   </tr>\n   <tr>\n   <td>Rupture leading to peritonitis, adhesion formation, and bowel obstruction</td>\n   </tr>\n   <tr>\n   <td>Renal compression</td>\n   </tr>\n   <tr>\n   <td>Pulmonary hypoplasia</td>\n   </tr>\n   <tr>\n   <td>Urinary tract obstruction</td>\n   </tr>\n   <tr>\n   <td>Aortocaval shunting</td>\n   </tr>\n   <tr>\n   <td>Incarceration in an inguinal hernia</td>\n   </tr>\n   <tr>\n   <td>Difficult delivery</td>\n   </tr>\n   <tr>\n   <td>Respiratory distress after birth</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 59977 Version 1.0</div></div></div>"},"59978":{"type":"graphic_table","displayName":"Classification of NHL","title":"WHO classification of the non-Hodgkin lymphomas (subclassified according to clinical aggressiveness*)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO classification of the non-Hodgkin lymphomas (subclassified according to clinical aggressiveness*)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">The indolent lymphomas</td> </tr> <tr> <td class=\"subtitle2_single\">B-cell neoplasms</td> </tr> <tr> <td class=\"indent1\">Small lymphocytic lymphoma/B-cell chronic lymphocytic leukemia</td> </tr> <tr> <td class=\"indent1\">Lymphoplasmacytic lymphoma (&#177; Waldenstrom's macroglobulinemia)</td> </tr> <tr> <td class=\"indent1\">Plasma cell myeloma/plasmacytoma</td> </tr> <tr> <td class=\"indent1\">Hairy cell leukemia</td> </tr> <tr> <td class=\"indent1\">Follicular lymphoma (grade I and II)</td> </tr> <tr> <td class=\"indent1\">Marginal zone B-cell lymphoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mantle cell lymphoma<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">T-cell neoplasms</td> </tr> <tr> <td class=\"indent1\">T-cell large granular lymphocyte leukemia</td> </tr> <tr> <td class=\"indent1\">Mycosis fungoides</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T-cell prolymphocytic leukemia</td> </tr> <tr> <td class=\"subtitle2_single\">Natural killer cell neoplasms</td> </tr> <tr> <td class=\"indent1\">Natural killer cell large granular lymphocyte leukemia</td> </tr> <tr> <td class=\"subtitle1_single\">The aggressive lymphomas</td> </tr> <tr> <td class=\"subtitle2_single\">B-cell neoplasms</td> </tr> <tr> <td class=\"indent1\">Follicular lymphoma (grade III)</td> </tr> <tr> <td class=\"indent1\">Diffuse large B-cell lymphoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mantle cell lymphoma<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">T-cell neoplasms</td> </tr> <tr> <td class=\"indent1\">Peripheral T-cell lymphoma</td> </tr> <tr> <td class=\"indent1\">Anaplastic large cell lymphoma, T/null cell</td> </tr> <tr> <td class=\"subtitle1_single\">The highly aggressive lymphomas</td> </tr> <tr> <td class=\"subtitle2_single\">B-cell neoplasms</td> </tr> <tr> <td class=\"indent1\">Burkitt's lymphoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Precursor B lymphoblastic leukemia/lymphoma</td> </tr> <tr> <td class=\"subtitle2_single\">T-cell neoplasms</td> </tr> <tr> <td class=\"indent1\">Adult T-cell lymphoma/leukemia</td> </tr> <tr> <td class=\"indent1\">Precursor T lymphoblastic leukemia/lymphoma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Editor's note: The WHO classification system of non-Hodgkin lymphoma (NHL) is presented here, subclassified according to the degree of clinical aggressiveness (ie, indolent, aggressive, highly aggressive) shown by each variant.<br />&para; Mantle cell lymphoma can behave clinically as either an indolent or an aggressive disorder.</div><div class=\"graphic_reference\">Adapted from Harris, NL, Jaffe, ES, Diebold, J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.</div><div id=\"graphicVersion\">Graphic 59978 Version 3.0</div></div></div>"},"59980":{"type":"graphic_figure","displayName":"Dietary modification in hypertension","title":"Efficacy of dietary modification in mild hypertension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efficacy of dietary modification in mild hypertension</div><div class=\"cntnt\"><img style=\"width:320px; height:253px;\" src=\"images/NEPH/59980_Dietary_modification_in_HTN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ability of combined nutritional intervention - weight loss, salt restriction, and avoidance of excess alcohol (squares) - to maintain normotension as compared&nbsp;with a control group without dietary modification (circles) after cessation of previously successful antihypertensive therapy. Hypertension recurred in over 90 percent of control patients, but in only 60 percent with dietary modification.</div><div class=\"graphic_reference\">Data from Stamler R, Stamler J, Grimm R, et al.&nbsp;Nutritional therapy for high&nbsp;blood pressure. Final report for a four-year randomized controlled trial--the Hypertension Control Program.&nbsp;JAMA 1987; 257:1484.</div><div id=\"graphicVersion\">Graphic 59980 Version 2.0</div></div></div>"},"59981":{"type":"graphic_table","displayName":"Helminths with prolonged eos","title":"Helminthic parasitic diseases causing eosinophilia of years duration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Helminthic parasitic diseases causing eosinophilia of years duration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Parasite</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td>Hookworm infection</td> <td>Common cause of low-grade eosinophilia</td> </tr> <tr> <td>Strongyloidiasis</td> <td>Self-perpetuating, auto-infection cycle; may last &#62;50 years</td> </tr> <tr> <td>Cysticercosis</td> <td>&nbsp;</td> </tr> <tr> <td>Echinococcosis</td> <td>&nbsp;</td> </tr> <tr> <td>Gnathostomiasis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Filariases</td> </tr> <tr> <td class=\"sublist1\">Tropical pulmonary eosinophilia</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Loiasis</td> <td class=\"sublist_other\">Especially in expatriates</td> </tr> <tr> <td class=\"sublist1\">Onchocerciasis</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Mansonelliasis</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Flukes</td> </tr> <tr> <td class=\"sublist1\">Schistosomiasis</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Fas<span class=\"sublist1\">c</span>ioliasis</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Clonorchiasis</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Paragonimiasis</td> <td class=\"sublist_other\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Weller, PF. Med Clin North America 1992; 76:1413.</div><div id=\"graphicVersion\">Graphic 59981 Version 2.0</div></div></div>"},"59982":{"type":"graphic_picture","displayName":"Subconjunctival petechiae in IE","title":"Subconjunctival petechiae in infective endocarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subconjunctival petechiae in infective endocarditis</div><div class=\"cntnt\"><img style=\"width:380px; height:252px;\" src=\"images/ID/59982_Subconjunctival_petechiae_i.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subconjunctival petechiae are prominent in this case of bacterial endocarditis caused by <EM>Staphylococcus aureus</EM>.</div><div class=\"graphic_reference\">Courtesy of Jan V Hirschmann. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 59982 Version 6.0</div></div></div>"},"59985":{"type":"graphic_table","displayName":"Tumor markers breast CA","title":"Percentage of breast cancer patients with elevated tumor markers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percentage of breast cancer patients with elevated tumor markers</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Stage</td>\n\n      <td class=\"subtitle1\">CEA, percent</td>\n\n      <td class=\"subtitle1\">CA15-3, percent</td>\n\n      <td class=\"subtitle1\">CA27-29, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>I</td>\n\n      <td>10</td>\n\n      <td>9</td>\n\n      <td>29</td>\n\n    </tr>\n\n    <tr>\n\n      <td>II</td>\n\n      <td>19</td>\n\n      <td>19</td>\n\n      <td>36</td>\n\n    </tr>\n\n    <tr>\n\n      <td>III</td>\n\n      <td>31</td>\n\n      <td>38</td>\n\n      <td>55</td>\n\n    </tr>\n\n    <tr>\n\n      <td>IV</td>\n\n      <td>64</td>\n\n      <td>75</td>\n\n      <td>81</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol 2003; 30:338. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 59985 Version 2.0</div></div></div>"},"59987":{"type":"graphic_diagnosticimage","displayName":"Common bile duct stone on ERCP","title":"Common bile duct stone on endoscopic retrograde cholangiopancreatography (ERCP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common bile duct stone on endoscopic retrograde cholangiopancreatography (ERCP)</div><div class=\"cntnt\"><img style=\"width:432px; height:441px;\" src=\"images/GAST/59987_Common_bile_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram showing large (2 cm) common bile duct stone (arrow).</div><div class=\"graphic_reference\">Courtesy of Martin L. Freeman, MD.</div><div id=\"graphicVersion\">Graphic 59987 Version 5.0</div></div></div>"},"59989":{"type":"graphic_table","displayName":"Techniques of the middle phase of Interpersonal Psychotherapy","title":"Techniques of the middle phase of Interpersonal Psychotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Techniques of the middle phase of Interpersonal Psychotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Technique</td> <td class=\"subtitle1\">Strategy</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Review depressive symptoms</td> <td>Examine the results of the standardized, self-report depression rating instrument at each session.</td> <td>Patients learn the symptoms of depression as the instrument is reviewed each week. This complements the psychoeducation.</td> </tr> <tr> <td>Relate mood to current life events and/or relationships</td> <td>Begin each session with the question, \"How have you been since we last met?\"</td> <td>The clinician directs the patient's attention to a specific time frame (past week) and elicits material about mood and interpersonal life.</td> </tr> <tr> <td>Focus on interpersonal problem area</td> <td>Maintain focus on selected problem area.</td> <td>If the clinician has chosen the correct problem area, the relevant material will readily emerge during the session. However, the clinician should explicitly redirect the patient to the problem area as needed.</td> </tr> <tr> <td>Build social support</td> <td>Encourage the patient to socialize and connect with positive individuals.</td> <td>Pointing out improvement in mood following socialization often provides the incentive needed to take risks associated with expanding social network.</td> </tr> <tr> <td>Provide psychoeducation</td> <td>Utilize the medical model to explore how depression has interfered with effective communication and interpersonal relationships.</td> <td>The clinician blames the depression (rather than the patient) for failures in interpersonal relationships.</td> </tr> <tr> <td>Improve communication skills</td> <td>Scrutinize the patient's communication with others and coach her to improve maladaptive patterns.</td> <td>Role play and rehearsals for upcoming interactions can help patients learn more adaptive communication styles.</td> </tr> <tr> <td>Explore options</td> <td>Ask the patient what she wants in a given situation.</td> <td>Depressed patients may have difficulty imagining that options exist, thus the clinician may initially need to be active and suggest options.</td> </tr> <tr> <td>Behavioral activation</td> <td>Encourage socializing and activity.</td> <td>Socialization and pleasurable activities are inherently antidepressant.</td> </tr> <tr> <td>Maintain the therapeutic alliance</td> <td>The clinician encourages the patient to express affect in sessions, is supportive and encouraging, and addresses ruptures in the therapeutic alliance.</td> <td>Although IPT is not a transference focused therapy, the clinician may observe transference reactions that arise in the course of IPT and use this material to inform treatment. It is not discussed explicitly with the patient.</td> </tr> <tr> <td>Support and highlight therapeutic gains</td> <td>The clinician explicitly encourages and praises treatment gains and progress.</td> <td>The clinician's optimism and encouragement are used to counteract the depressed patient's negative thoughts and feelings, and support her emerging sense of self-efficacy.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 59989 Version 1.0</div></div></div>"},"59990":{"type":"graphic_figure","displayName":"Division of liver tissue","title":"Division of liver tissue","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Division of liver tissue</div><div class=\"cntnt\"><img style=\"width:451px; height:442px;\" src=\"images/SURG/59990_Division-of-uninjured-liver-tissue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The liver is gently 'finger fractured' to fully expose any vessels or biliary radicals asociated with liver injury. These are then clipped or tied.</div><div id=\"graphicVersion\">Graphic 59990 Version 4.0</div></div></div>"},"59991":{"type":"graphic_picture","displayName":"Sunburn on face","title":"Sunburn","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sunburn</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/59991_Sunburn_on_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and scale are present on the sun exposed areas of the skin. Note the relative sparing in the shadow areas of the nasolabial folds and infranasal skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 59991 Version 3.0</div></div></div>"},"59992":{"type":"graphic_diagnosticimage","displayName":"Buckle fracture","title":"Buckle fracture","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Buckle fracture</div><div class=\"cntnt\"><img style=\"width:505px; height:274px;\" src=\"images/EM/59992_Buckle_fracture_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AP and oblique views of the left forearm. Buckle (torus) fracture of the dorsolateral cortex of the distal radial metaphysis (arrows). No displacement or angulation.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of David Mathison, MD and Dewesh Agrawal, MD.</div><div id=\"graphicVersion\">Graphic 59992 Version 4.0</div></div></div>"},"59996":{"type":"graphic_figure","displayName":"Shoulder strength exercises","title":"Strengthening exercises for the rotator cuff tendons","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strengthening exercises for the rotator cuff tendons</div><div class=\"cntnt\"><img style=\"width:233px; height:492px;\" src=\"images/PC/59996_Shoulder_strength_exercises.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Part A: The inward rotation isometric exercise is performed by holding the elbow at 90 degrees, close to the side. The rubber band is hooked onto a door handle and grasped with the hand. The forearm is slowly moved towards the body two to three inches and held for five seconds. The hand should not rotate as the forearm moves.<br />Part B: The outward rotation isometric exercise is performed with the elbows at 90 degrees, close to the sides. The rubber band is grasped with the hands. The forearms are moved outward two to three inches and held for five seconds. Sets of 15 to 20 exercises, each held for five seconds, should be performed daily.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 59996 Version 3.0</div></div></div>"},"59997":{"type":"graphic_algorithm","displayName":"Jet ventilator settings","title":"Initial jet ventilator settings","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Initial jet ventilator settings</div><div class=\"cntnt\"><img style=\"width:546px; height:427px;\" src=\"images/PULM/59997_Jet_ventilator_settings.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* If the patient was hypoxic with controlled mechanical ventilation, driving pressure should be adjusted as necessary to achieve a mean airway pressure equal to that present during controlled mechanical ventilation. If minute ventilation under those conditions is not at least equal to that present during controlled mechanical ventilation, driving pressure should be further increased until this condition is met before obtaining arterial blood gas levels. If the patient was hypercapnic with controlled mechanical ventilation, driving pressure should be adjusted as necessary to achieve a minute ventilation two times that present during controlled mechanical ventilation. If mean airway pressure exceeds 110 percent of that present during controlled mechanical ventilation before obtaining that minute ventilation, arterial blood gas levels should be obtained at that point before further increasing driving pressure. In individual patients, changes in rate may have opposite effects on PaCO2.<br> • Careful monitoring of peak, mean, and end-expiratory airway pressure as well as minute ventilation and oximetry should be performed when any change is made in ventilatory parameters. Only experienced personnel should use high-frequency jet ventilation. </div><div class=\"graphic_reference\">Redrawn from: Standiford, TJ, Morganroth, ML, Chest 1989; 96:1383.</div><div id=\"graphicVersion\">Graphic 59997 Version 2.0</div></div></div>"},"59998":{"type":"graphic_table","displayName":"Physical examination in musculoskeletal chest pain","title":"Physical examination in musculoskeletal chest pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical examination in musculoskeletal chest pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General examination</td> </tr> <tr> <td>Heart, lungs, abdomen (to rule out visceral source)</td> </tr> <tr> <td>Skin lesions (clue to psoriatic arthritis or SCCH syndrome)</td> </tr> <tr> <td>Ocular exam (uveitis, conjunctivitis suggestive of spondyloarthropathy)</td> </tr> <tr> <td class=\"subtitle1_single\">Musculoskeletal examination</td> </tr> <tr> <td>Cervical spine</td> </tr> <tr> <td>Shoulders</td> </tr> <tr> <td class=\"sublist1_start\">Thoracic spine</td> </tr> <tr> <td class=\"sublist1\">Localized tenderness</td> </tr> <tr> <td class=\"sublist1\">Mobility</td> </tr> <tr> <td class=\"sublist1\">Chest expansion</td> </tr> <tr> <td class=\"sublist1_start\">Lumbar spine</td> </tr> <tr> <td class=\"sublist1\">Forward flexion</td> </tr> <tr> <td class=\"sublist1\">Sacroiliac tenderness to compression</td> </tr> <tr> <td class=\"sublist1_start\">Tender points</td> </tr> <tr> <td class=\"subtitle1_single\">Chest wall examination</td> </tr> <tr> <td class=\"sublist1_start\">Observation</td> </tr> <tr> <td class=\"sublist1\">Localized swelling, particularly costochondral junctions</td> </tr> <tr> <td class=\"sublist1_start\">Palpation</td> </tr> <tr> <td class=\"sublist1\">Acromioclavicular and sternoclavicular joints</td> </tr> <tr> <td class=\"sublist1\">Sternum and xiphoid costochondral junctions</td> </tr> <tr> <td class=\"sublist1\">Costovertebral joints</td> </tr> <tr> <td class=\"sublist1_start\">Maneuvers</td> </tr> <tr> <td class=\"sublist1\">Crowing rooster maneuver</td> </tr> <tr> <td class=\"sublist1\">Horizontal arm flexion</td> </tr> <tr> <td class=\"sublist1\">Hooking maneuver</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SCCH: sternocostoclavicular hyperostosis.</div><div id=\"graphicVersion\">Graphic 59998 Version 2.0</div></div></div>"},"59999":{"type":"graphic_picture","displayName":"Histopathology rabies","title":"Histopathological findings in a patient with rabies","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Histopathological findings in a patient with rabies</div><div class=\"cntnt\"><img style=\"width:514px; height:194px;\" src=\"images/ID/59999_Histopathology_rabies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathologic examination of CNS tissue from autopsy showing neuronal cytoplasmic inclusions (Negri bodies) after hematoxylin and eosin staining (left) and rabies virus antigen (red) after immunohistochemical staining (right).</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. Human Rabies---Kentucky/Indiana, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:393.</div><div id=\"graphicVersion\">Graphic 59999 Version 1.0</div></div></div>"}};